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ABSTRACT 
Tuberculosis (TB) caused by Mycobacterium tuberculosis remains one of the major global 
health threats. The disease is responsible for significant morbidity and mortality, with an 
estimated one third of the world’s population having latent TB infections (LTBI). Reactivation 
of LTBI occurs in immunocompromised individuals. Diabetes mellitus (DM) is a condition that 
impairs host defence, leading to higher morbidity and mortality in individuals with TB. The 
global burden of DM is unprecedented with 425 million people living with diabetes in 2017 
and 4 million diabetes-associated deaths. Type 2 diabetes (T2D) comprises more than 90% of 
the global diabetes incidence and is attributed to genetic, environment and life style factors. 
Obesity, caused mostly by a combination of sedentary life style and consumption of an energy-
dense diet rich in refined carbohydrate and fat, is considered a leading cause of the global 
increase of T2D. The resurgent interest in TB-T2D co-morbidity is due to the slow reduction 
in global TB incidence and the rapid escalation of T2D particularly in TB endemic areas. 
Epidemiological studies have found a strong correlation of T2D with increased TB 
susceptibility, reactivation of LTBI and treatment failure, however the underlying mechanisms 
for this are unclear. Non-tuberculous mycobacterial (NTM) infections are also increasing in 
individuals with diabetes in comparison to the general population. Among the NTM species, 
Mycobacterium fortuitum is a leading cause of skin and soft tissue infections and capable of 
causing severe pulmonary infections. There is no data available on T2D-M. fortuitum co-morbid 
conditions.  
A few studies have investigated the reason for increased TB susceptibility in diabetics although 
the findings are often contradictory. Animal model studies designed to investigate immune 
dysregulation in diabetes/mycobacterium co-morbidity have typically used streptozotocin 
induced type 1 diabetic murine models rather than models of T2D. Hence, characterisation of 
a T2D murine model that incorporates the Western diet and accurately models the clinical 
features of human T2D is highly desirable. Such a model is also required to investigate the 
immunological dysfunction in host-mycobacterial co-morbid infections and thus allow the 
development of therapeutic and preventative strategies.  
The first Aim of this study was to characterise a diet-induced diabetic mouse model of T2D for 
subsequent mycobacterial infection studies. Male C57BL/6 mice were used for all experiments 
with groups receiving either an energy-dense diet (EDD) for a period of 30 weeks to induce 
diabetes or a standard rodent diet (SRD) for the same time period. The metabolic and 
biochemical parameters including body weight, fasting blood glucose (FBG) level, glucose 
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tolerance test (GTT), glycated haemoglobin (HbA1c) level, urine albumin, creatinine and 
albumin creatinine ratio (ACR) were assessed after 25 and 30 weeks. Visceral adipose tissue, 
liver, pancreas and kidney from mice were analysed using a variety of histological stains and 
image analysis techniques. Body weight gain was increased in EDD fed mice compared to SRD 
fed control animals. After both 25 and 30 weeks, EDD fed mice had a significantly higher FBG 
levels, glucose intolerance and HbA1c levels compared to controls. Analysis of urine 
biochemical parameters demonstrated higher microalbumin, lower creatinine and higher ACR 
in EDD fed mice compared to controls. Histological examination of visceral adipose tissue, 
liver and pancreas revealed adipocyte hypertrophy, hepatic steatosis and a compensatory 
pancreatic islet hyperplasia, respectively in mice fed the EDD compared to controls. Mesangial 
matrix thickening within the glomeruli, thickening of the Bowman’s capsules and glomerular 
size were increased in the kidneys of EDD fed mice compared to controls. These results 
suggested that feeding an EDD for 30 weeks can induce a T2D phenotype in mice. The 
metabolic, biochemical and histological findings demonstrated a chronic hyperglycaemic state 
due to insulin resistance. The urine biochemical parameters together with histological 
observations also confirmed renal damage which is one of the common complications of 
diabetes in humans.    
The second Aim of this research was to investigate macrophage phagocytic function in vitro. 
In initial experiments, peritoneal exudate macrophages (PEM), resident peritoneal macrophages 
(RPM) and alveolar macrophages (AM) isolated from diabetic and control mice were assessed 
for the respective abilities to phagocytose mycolic acid coated beads and induce cytokines. 
Subsequently, the phagocytic uptake, bacterial killing capacity and cytokine secretion of these 
macrophages was assessed by co-culture with M. fortuitum, M. bovis (BCG) and M. 
tuberculosis (H37Rv). Results demonstrated that uptake of the mycolic acid coated beads was 
reduced significantly in PEM, RPM and AM from diabetic mice compared to controls. There 
were no significant differences in the production of cytokines from these cells following co-
culture with the beads. However, there was a significant reduction in mycobacterial uptake and 
killing in both RPM and AM from the diabetic mice compared to controls. Furthermore, there 
was a reduction in TNF-α, MCP-1, IL-6 and IL-1β production by both RPM and AM from 
diabetic mice compared to controls during co-culture. These findings indicated that the uptake, 
killing and cytokine production were impaired in macrophages from diabetic mice compared to 
controls.   
The final Aim of this study was to investigate the susceptibility of diabetic and control mice to 
M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) infections by evaluating animal 
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survival, organ bacterial loads, tissue pathology and organ cytokine levels during the course of 
high- or low-dose intravenous infections. Diabetic mice showed higher mortality compared to 
controls following challenge with a high-dose of all mycobacteria. Following low-dose 
challenge with all mycobacteria species, the bacillary burden was higher in spleen, liver and 
lungs of diabetic mice compared to controls at 14 and 30/35 days post infection. Estimation of 
the number and size of inflammatory granuloma-like lesions in the liver, revealed increased 
inflammation, with higher loads of acid-fast bacilli in diabetic mice compared to controls. 
Furthermore, the total area of inflammation observed in the lungs of diabetic mice was 
significantly higher than controls. Assessment of tissue cytokines demonstrated an overall 
lower production of TNF-α, MCP-1, IL-6 and IL-1β in the liver and lungs of diabetic mice 
compared to controls although an opposite trend was observed in the spleen. The overall 
production of IL-12, IL-2 and IFN-γ was reduced in the spleen, liver and lungs of diabetic mice 
compared to controls.   
In summary, this thesis describes the influence of an EDD on the induction of diabetes in a 
mouse model and the increased susceptibility of these diabetic animals to mycobacterial 
infection. It was found that the EDD has the potential to induce overt clinical features of T2D 
in mice that closely mirror the pathology observed in human T2D patients. Investigation of 
antimycobacterial immune responses (in vitro and in vivo) showed that the uptake, killing and 
cytokine production (TNF-α, MCP-1, IL-6 and IL-1β) by macrophages was impaired in T2D. 
A higher bacterial load and high numbers of inflammatory lesions were observed in the organs 
of diabetic mice which is also indicative of impairment of macrophage phagocytic function. 
Decreased production of pro-inflammatory cytokines including IL-12, IL-2 and IFN-γ in 
diabetic mice indicated that T helper 1 cells mediated responses in mycobacterial infections 
maybe delayed or impaired. This immune defect in diabetics may ultimately lead to delayed or 
defective granuloma formation. Our results also suggest the possibility of a breakdown of the 
granuloma due to the persistent hyperglycaemia that occurs in diabetes. The current study has 
demonstrated that antimycobacterial immunity was dysregulated in T2D mice which is one of 
the key reasons for increased mycobacterial susceptibility. Moreover, the diet-induced murine 
model of T2D that we have developed can be used for future in depth studies of host-
mycobacterial susceptibility. The model can also be used to investigate other infections that are 
exacerbated by diabetes. 
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1 CHAPTER 1  
GENERAL INTRODUCTION 
 
The global burden of non-communicable diseases (NCD) has increased dramatically in recent 
decades and is now the leading cause of death globally killing more individuals than all other 
causes combined. With the exception of human immunodeficiency virus (HIV) disease, 
mortality from communicable diseases has decreased in recent years (Boutayeb, 2006, Capizzi 
et al., 2015, Jakovljevic and Milovanovic, 2015). The implications of the growing NCD burden 
on infectious disease risk are immense, with Tuberculosis (TB) at the forefront of this growing 
epidemic. Tuberculosis is a deadly communicable disease caused by the acid-fast bacteria; 
Mycobacterium tuberculosis. It typically affects the lungs but can disseminate to other parts of 
the body. The organism spreads via air droplets released during coughing, sneezing or via other 
respiratory fluids from individuals with active disease (Frieden et al., 2003). It is the number 
one leading cause of death from an infectious disease after HIV infection and remains a major 
cause of global mortality (WHO., 2017). While M. tuberculosis is responsible for the majority 
of mycobacterial infections, there are more than 150 non-tuberculous mycobacterial (NTM) 
species that are capable of causing a wide spectrum of diseases (Orme and Ordway, 2014). The 
NTM species are widely distributed in the environment able to cause diseases affecting a variety 
of tissues including lungs, lymph nodes, skin, soft and skeletal tissues. Some of these species 
can also cause respiratory disease (De Groote and Huitt, 2006, Jackson et al., 2007, Hoefsloot 
et al., 2013). The rapid escalation of immune suppressing NCD has contributed to the growing 
risk of TB and NTM infections. Diabetes is one of the NCD conditions considered a major risk 
factor for increased TB and NTM susceptibility (Jeon and Murray, 2008, Martinez and 
Kornfeld, 2014, Bridson et al., 2016). 
Diabetes mellitus (DM), in particular, type 2 diabetes (T2D) is a multifactorial metabolic 
disease. It is characterised by a hyperglycaemic state due to insulin resistance in peripheral 
tissues or inadequate secretion of insulin from the pancreatic β-cells (Weyer et al., 1999, ADA., 
2010). The key factors that contribute to the development of T2D include dietary factors, 
sedentary lifestyle, obesity, smoking, generous consumption of alcohol, older age, stress, 
ethnicity, prior history of glucose intolerance (genetic) and gestational diabetes (Hu et al., 2001, 
Smyth and Heron, 2006, Sobngwi et al., 2008). Obesity is considered one of the foremost risk 
factors for developing T2D (Walley et al., 2006). The principal cause behind the rapid rise in 
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global obesity is the nutritional shift towards an energy-dense diet (EDD) with excess 
consumption of refined carbohydrate and increased fat (Popkin and Nielsen, 2003, Morris et 
al., 2016). The high glycaemic index diet associated with persistent hyperglycaemia results in 
the deposition of advanced glycation end products in tissues and cells, leading to oxidative 
stress, chronic inflammation, immune defects and microvascular (e.g. retinopathy, nephropathy 
and neuropathy) and macrovascular complications (e.g. atherosclerosis, cardiovascular 
diseases) (Shah and Hux, 2003, Leutholtz and Ripoll, 2011). The disease also increases 
susceptibility to infections resulting in a higher morbidity and mortality in diabetic individuals 
(Martinez and Kornfeld, 2014, Hodgson et al., 2015).  
The global burden of TB and T2D is alarming. An estimated one-third of the world’s population 
is infected with Mtb. New infections occur in about 1% of the population each year (WHO., 
2015). In 2016, there were an estimated 10.4 million people with active TB (including 10% TB-
HIV patients). TB killed an estimated 1.3 million people (without TB-HIV related mortality) 
of those afflicted in 2016. Furthermore, there are 2 billion latent TB infections with 5-10% 
reactivating every year (WHO., 2017). In contrast, the global burden of T2D has increased 
markedly over the past 50 years. In 2017, approximately 425 million people were living with 
the disease compared to around 30 million in 1985 (Smyth and Heron, 2006, IDF., 2017). The 
disease is predicted to afflict 629 million people by 2045 (IDF., 2017). The association between 
these two diseases has co-existed for many thousands of years (Kapur et al., 2013). The 
resurgent interest in this co-morbidity is due to the sluggish reduction of global TB incidence 
(2.2% reduction annually) (WHO., 2013a) along with the worldwide rapid escalation of T2D 
in TB affected people (Hodgson et al., 2015, Workneh et al., 2017). Several epidemiological 
studies have shown that T2D is one of the strongest risk factors for TB susceptibility or its 
reactivation. Particularly, in low-income countries, malnutrition and diabetes are key factors 
impeding the reduction of the global TB burden. T2D confers a three-eight times higher 
susceptibility for developing active TB in comparison to non-diabetics (Restrepo et al., 2007, 
Jeon and Murray, 2008). There is also growing evidence of an increased prevalence of NTM 
infections in immunocompromised HIV and diabetic patients (Tortoli et al., 1995, Piersimoni 
et al., 1997, Gholizadeh et al., 1998, Uslan et al., 2006, Orme and Ordway, 2014, Bridson et 
al., 2016, Xu et al., 2016). A recent retrospective review of 20 years Townsville (Australia) 
hospital data showed that NTM infections in diabetic patients were three times over-represented 
in comparison to the general population (Bridson et al., 2016). According to the available 
epidemiological data relating to NTM, 16.7% of patients with soft tissue infection with M. 
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fortuitum had co-morbid diabetes (Uslan et al., 2006). Despite the high TB burden and rising 
incidence of NTM infections such as M. fortuitum, the underlying mechanisms for the increased 
susceptibility of T2D patients is still not clear. In order to develop strategies to prevent TB and 
other NTM infections in individuals affected by T2D, research is required to explore the reasons 
for increased mycobacterial susceptibility in these individuals.  
Previous studies have demonstrated increased mortality in TB-DM comorbid patients (Oursler 
et al., 2002, Lindoso et al., 2008, Dooley et al., 2009, Wang et al., 2009). Patients with TB-DM 
co-morbid infections have increased bacterial burden in sputum and bacterial clearance requires 
a significantly longer treatment period than in non-diabetic TB patients (Restrepo et al., 2008b, 
Dooley et al., 2009, Wang et al., 2009). The few studies that investigated cellular immunity in 
TB-DM co-morbid infections have shown depressed cellular immunity (Goonetilleke et al., 
2003, Niazi and Kalra, 2012). Fewer T lymphocytes with reduced production of IFN-γ, TNF-
α, IL-1β and IL-6 were also seen among people with concomitant diabetes and TB compared 
to non-diabetic individuals (Tsukaguchi et al., 1997, Geerlings and Hoepelman, 1999, 
Stalenhoef et al., 2008). However, conflicting reports have suggested that there is either no 
difference (Zhang et al., 2012), or even higher production (Legesse et al., 2013) of T helper 1 
(Th1) cells specific IFN-γ in diabetic compared to non-diabetic TB patients. Kumar and 
colleagues (2013) reported that there was the heightened production of type 1 (IFN-γ, IL-2, 
TNF-α), type 2 (IL-5), type 17 (IL-17A) and other pro-inflammatory cytokines (IL-1 β, IL-6, 
IL-18) in chronic TB-DM patients. The few studies that have evaluated phagocytic functions in 
peripheral blood mononuclear cells (PBMCs), observed reduced phagocytosis and killing (Hill 
et al., 1983, Glass et al., 1987, Chang and Shaio, 1995, Geerlings and Hoepelman, 1999, 
Restrepo et al., 2008a, Lecube et al., 2011, Tan et al., 2012). To our knowledge, there have been 
no studies assessing cellular immunity in T2D-M. fortuitum infections.  
Several previous studies have used streptozotocin (STZ)/STZ+NA (Nicotinamide)-induced 
type 1 diabetes (T1D) animal models to explore the mechanisms underlying the increased TB 
susceptibility seen in diabetics (Saiki et al., 1980, Sugawara et al., 2004, Yamashiro et al., 2005, 
Martens et al., 2007, Vallerskog et al., 2010, Podell et al., 2014, Cheekatla et al., 2016). Saiki 
and colleagues (1980) first reported increased mortality in STZ-induced T1D mice following 
M. tuberculosis infection and proposed that functional alterations in macrophages was one 
explanation for increased mortality. Martens and colleagues (2007) reported M. tuberculosis 
defence was impaired in chronic diabetic mice (16 weeks post-infection) after an aerosol 
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infection in T1D mice. Others reported reduced production of IL-12, IFN-γ as well as impaired 
development of Th1 cells responses as a reason of impaired host resistance against M. 
tuberculosis infection in diabetic mice (Yamashiro et al., 2005, Vallerskog et al., 2010). A 
recent study observed increased levels of IFN-γ, TNF-α, IL-1β, IL-6 and MCP-1 (monocyte 
chemoattractant protein-1) in the lungs of STZ+NA-induced diabetic mice 6 months after 
aerosol infection with M. tuberculosis, although the opposite trend was found earlier in 
infection (Cheekatla et al., 2016). The previous animal model studies provided no information 
as to the impact of diabetes on the phagocytic functions of macrophages particularly the alveolar 
macrophages (AM). AM are amongst the first immune cells to interact with bacteria in infected 
host (Cooper, 2009). However, several previous studies in STZ/STZ+NA-induced diabetic 
animal models mentioned above evaluated antimycobacterial immunity in chronic M. 
tuberculosis infection. These studies observed a higher bacterial burden, increased 
inflammatory lesions and heightened production/expression of various pro-inflammatory 
cytokines in diabetics than controls. Although these studies provided substantial information 
on the effect of hyperglycaemia on chronic TB susceptibility, there is lack of information of 
how T2D impairs antimycobacterial immunity during early mycobacterial infections.  
The first section of this thesis describes the development and characterisation of a diet-induced 
diabetic (DID) murine model of T2D. Hodgson and colleagues (2013a) first described the 
suitability of a 10 weeks energy-dense diet (EDD, 23% fat, 19% protein, 50.5% dextrose, 7.5% 
fibre) for the induction of diabetes in mice. In the current study, we extended these findings to 
discover the biochemical, metabolic, pathological consequences of this diet and propose that 
this model accurately mimics many of the overt biochemical and clinical features of T2D. In 
the subsequent chapters of this thesis, this murine diabetes model is used to investigate 
antimycobacterial immunity in vitro and in vivo during M. fortuitum, M. bovis (Bacillus 
Calmette–Guérin; BCG) and M. tuberculosis (H37Rv) infections.  
The broad Aims investigated in this thesis are: 
1. To investigate whether an energy-dense diet can induce T2D in mice (Chapter 4) 
2. To determine the phagocytic function of macrophages from T2D mice infected with 
M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) in vitro (Chapter 5) 
3. To evaluate whether antimycobacterial immunity is dysregulated in T2D mice 
infected with M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) in vivo 
(Chapter 6, 7 and 8) 
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2 CHAPTER 2  
LITERATURE REVIEW 
 
 Overview of mycobacterial infections 
 Tuberculosis: The disease 
Tuberculosis (TB) is an often fatal infectious disease caused by various strains of mycobacteria, 
usually Mycobacterium tuberculosis (Mtb) (Kumar, 2007). The disease most commonly affects 
the lungs (about 90% of cases) and is known as pulmonary TB (PTB). In 15-20% of cases of 
active PTB, the organism may spread to other parts of the body and is known as extrapulmonary 
TB. This is more common in immunosuppressed individuals (e.g. HIV patients) and children 
(Golden and Vikram, 2005, Lawn and Zumla, 2011). The symptoms of active TB include 
chronic cough (lasting more than 2 weeks), haemoptysis, fever, night sweats, weight loss. Most 
infections with Mtb do not produce any clinical signs and are termed latent TB infection (LTBI). 
Diagnosis can be made based on clinical history, radiological findings and microbial assays 
(McFadden, 1982). Latent infection can be confirmed by immunological tests, including the 
tuberculin skin test (TST) and interferon-γ release assay (IGRA) (Al-Orainey, 2009). The 
therapeutic regimen comprises the use of several antibiotics for 3 to 6 months or longer. The 
only recommended vaccine for TB protection is the Mycobacterium bovis Bacillus Calmette–
Guérin (BCG) vaccine (Andersen and Kaufmann, 2014). 
 The bacterium  
Mycobacterium tuberculosis (Mtb) is in the family Mycobacteriaceae and was discovered by 
Robert Koch in 1882. The bacterium measures around 1-4 µm long and 0.3-0.6 µm in diameter 
(Ducati et al., 2006). It does not have a flagellum or a capsule (Figure 2.1 A). Mtb can be grown 
on simple media composed of inorganic salts, asparagine and glycerol. It is an obligate aerobe 
and strictly mesophilic showing little or no growth below 300C or higher than 390C. The 
bacterium is a very slow grower and cell division takes 12 to 20 hours. Culturing the bacterium 
requires a prolonged period of 2 to 6 weeks. Several different colony morphologies may be seen 
on solid media, including smooth or rough and opaque or transparent colonies (Figure 2.1 B). 
In liquid media, the cells clump and float to the surface unless a detergent is added (McFadden, 
1982, Kassim, 2004). 
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Figure 2.1 Morphology of Mycobacterium tuberculosis 
Figure illustrates the morphology of Mycobacterium tuberculosis under the electron 
microscope (A) and an example of colony morphology (e.g. rough) on solid media (B) (Kubica, 
1976, Jabado and Gros, 2005). 
 
M. tuberculosis is a member of the M. tuberculosis complex. This group also comprises M. 
bovis, M. canetti, M. africanum, M. microti and M. pinnipedii as well as M. caprae which is 
considered a variant of M. bovis. M. tuberculosis was believed to have evolved from M. bovis 
during the domestication of cattle (Stead et al., 1995). Genomic data of M. bovis (BCG) and M. 
tuberculosis has shown that M. bovis (BCG) has 99.95% homogeneity with M. tuberculosis 
species with several DNA deletions known as the regions of difference (RD) (Brosch et al., 
2002). Furthermore, a whole genome study has also suggested that member of the M. 
tuberculosis complex originated from M. canetti, also referred to as M. prototuberculosis 
(Gutierrez et al., 2005).  
 Cell wall of Mycobacterium tuberculosis  
The cell wall of Mtb uniquely consists of a thick layer of mycolic acids (Figure 2.2). This waxy 
layer is found at the external portion of the cell wall and is linked with arabinogalactan, which 
is further lined with a peptidoglycan layer. Additionally, the cell wall also possesses several 
lipoglycans comprising lipoarabinomannan (LAM), lipomannan (LM) and phosphatidyl-myo-
inositol mannosides (PIM). All these structures are attached non-covalently to the plasma 
membrane (Briken et al., 2004, Ducati et al., 2006). Lipoarabinomannan consists of a 
phosphatidyl-myo-inositol anchor, D-mannan polymer (attached to the inositol ring), D-
arabinose chains and capping motifs at the end of the arabinose residues (Vergne et al., 2003). 
A) B) 
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This lipoglycans acts as a virulence factor and inhibits of macrophage functions, particularly 
phagosomal maturation. It also interferes with cell signalling and alters cytokine responses from 
pro- to anti-inflammatory (Nigou et al., 2001, Briken et al., 2004, Pathak et al., 2005, Vergne 
et al., 2005a). In addition, all slow growing pathogenic mycobacteria including Mtb also possess 
a heterogenous lipoglycan structure termed ‘mannose-capped LAM (ManLAM) in their cell 
wall. Rapidly growing mycobacteria contain non-capped AraLAM or phospho-myo-inositol-
capped LAM (PILAM) which can initiate immunostimulatory effects (Dao et al., 2004). 
Phosphatidyl-myo-inositol mannosides are divided into two groups depending on the mannose 
content that determine immunogenic effects. These structures may also be present on the cell 
surface as mannoglycoproteins which are secreted during growth (Villeneuve et al., 2005, 
Torrelles et al., 2009).  
.  
 
 
 
 
 
 
 
Figure 2.2 Schematic representation of the cell wall of Mycobacterium tuberculosis (Park 
and Bendelac, 2000)  
 Transmission and outcomes of Mycobacterium tuberculosis infection 
Tuberculosis is transmitted by the inhalation of droplet nuclei (1-5 µm in diameter) containing 
a small number of organisms (as few as 10 bacilli). These droplet nuclei are released by a person 
with active TB during coughing, sneezing, singing or talking. A cough can release 3000 droplet 
nuclei, whereas a sneezing can generate as many as 40,000 droplet nuclei (Frieden et al., 2003, 
Nicas et al., 2005). These minute droplet nuclei can remain suspended in the air for several 
minutes to an hour allowing spread to other persons (Frieden et al., 2003, Ahmed and Hasnain, 
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2011). The spread of Mtb from an individual within a community depends on several factors 
such as the number of droplet nuclei inhaled, extent of exposure to the infected patients, 
crowding, weather conditions and the immune status of the individual (Frieden et al., 2003, 
Ahmed and Hasnain, 2011). A person with active but untreated TB reportedly may infect 10-
15 (or more) other people per year (WHO., 2013a). Fortunately, the infected person with 
nonresistant active TB cannot be a source of infection within 2 weeks following the 
commencement of an effective treatment (Ahmed and Hasnain, 2011).  
Transmission of Mtb leads to one of three possible consequences for an individual. Firstly, 
bacteria can be eliminated with no disease state. Secondly, bacteria continuously multiply and 
the disease progresses actively with clinical manifestations of active TB (Madigan, 2002). The 
third and final possibility is the dormant state of the TB or latent tuberculosis infection (LTBI), 
where viable bacilli are present in the host but do not cause active disease (Flynn and Chan, 
2001b, Ahmad, 2011). The latent infection might be the result of an effective immune response 
of the host with granuloma formation or use of an effective chemotherapeutic regimen. 
Moreover, primary infection by Mtb has been reported to be eradicated in only 10% people 
upon treatment, with the remaining 90% unable to completely clear the bacteria resulting in 
LTBI (Richard, 2011). Annually, 5-10% of LTBI can be reactivated, particularly in 
immunosuppressed individuals to cause active disease (Flynn and Chan, 2001b).  
 Immunopathogenesis of tuberculosis 
 Innate immunity and host defence  
The innate immune response plays an important role in the protection against Mtb infections. 
This response provides the first line of defence against the invading pathogens and is successful 
in clearing the infection if it is activated properly. The response initially clears the bacilli by 
receptor mediated phagocytosis and triggers the adaptive immune responses for effective 
control of the infection. However, the cells of the innate immune system are also a prerequisite 
for mycobacterial pathogenesis as the bacterium has the ability to manipulate macrophage 
functions, enabling survival and replication in the host cells. 
2.1.1.5.1 Entry of the organism  
Mtb infections start with the inhalation of aerosol droplet nuclei containing tubercle bacilli from 
an infected individual (Sakamoto, 2012). The inhaled bacilli travel to the lungs’ alveoli, where 
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the primary encounter is initiated by alveolar macrophages (AM) (Dheda et al., 2010). 
Following the initial encounter, cells such as dendritic cells and monocyte-derived 
macrophages also participate in the phagocytic process (Henderson et al., 1997, Thurnher et al., 
1997). These initial host-pathogen interactions lead to activation of adaptive immune responses 
and determine whether the infection will become localised (within a granuloma) or continue to 
spread (Lawn and Zumla, 2011, Natarajan et al., 2011).  
2.1.1.5.2 Immune recognition of Mycobacterium tuberculosis  
The interactions between mycobacterial components and host cells are important for mounting 
effective immune responses. The process of recognition of Mtb by the host cells plays a central 
role in initiation and coordination of the innate immune system (Akira et al., 2006). These 
interactions not only activate innate immune mechanisms, but also assist in the development of 
antigen specific adaptive immunity. After the entry of Mtb, the recognition of the bacilli begins 
via pattern recognition receptors (PRRs) of alveolar macrophages (AM). These PRRs recognise 
the pathogen associated molecular patterns (PAMP) such as outer coat mannosylated 
lipoarabinomannan (ManLAM), trehalose dimycolate and N-glycolymuramyl dipeptide. The 
Mtb components are also recognised by the other host receptors comprising Toll like receptors 
(TLRs), nucleotide-binding oligomerisation domain (NOD) like receptors (NLRs) and C-type 
lectins (Ahmad, 2011). C-type lectins include mannose receptors (CD207), dendritic cell 
specific intracellular adhesion molecule grabbing nonintegrin (DC-SIGN) and Dectin (Jo, 2008, 
Harding and Boom, 2010). 
Toll like receptors (TLRs) are important molecules for initiating effective innate immune 
responses during Mtb infections (Jo, 2008, Harding and Boom, 2010). They are essential for 
microbial recognition by macrophages and dendritic cells (Belvin and Anderson, 1996, 
Medzhitov et al., 1997, Visintin et al., 2001). To date, 10 human TLRs have been identified, of 
these, TLR2, TLR4, TLR9 and possibly TLR8 are involved in recognising Mtb. The dimer of 
TLR2 in combination with either TLR1 or TLR6 can recognise the mycobacterial cell wall’s 
glycolipids including LAM, LM, 19 kDa and 38 kDa glycoprotein, phosphatidylinositol 
mannoside (PIM) and triacylated (TLR2/TLR1) or diacylated (TLR2/TLR6) lipoproteins 
(Jones et al., 2001, Means et al., 2001, Thoma-Uszynski et al., 2001). The interaction of Mtb 
components with TLRs eventually activates nuclear transcription factors kappa B (NF-kB) 
which stimulates the cells to produce pro-inflammatory cytokines, chemokines and nitric oxide 
through MyD88 dependent (myeloid differentiation primary response protein 88) or 
10 
 
independent pathways (Garcia-Perez et al., 2003, Yamamoto et al., 2003, Jo, 2008). For 
example, TLR2 activates macrophages to produce TNF-α (Underhill et al., 1999, Bafica et al., 
2005) and IL-12 (Pompei et al., 2007). Furthermore, activation of TLR2 and TLR6 can also 
stimulate macrophages to secrete IL-1β (Kleinnijenhuis et al., 2009). An in vitro study 
demonstrated that TLR2 activation can directly lead to the killing of intracellular Mtb in AM 
(Thoma-Uszynski et al., 2001). However, excessive TLR induced pro-inflammatory cytokine 
responses are harmful for the host and can be mitigated by tyrosine kinases termed 
Tyro3/As/Mer (TAM). TAM provides a negative feedback to TLRs to suppress pro-
inflammatory cytokine production (Hernandez-Pando et al., 2000). Further, the 19 kDa 
lipoprotein of Mtb is also a potential agonist of TLR2 which can modulate innate immunity by 
interfering with antigen presenting cell function (Noss et al., 2001). Interestingly, mycobacterial 
infection and pro-inflammatory cytokine release increases surface expression of TLR2 (Wang 
et al., 2000). Studies have shown binding of TLR2 by the mycobacterial lipoproteins (19-kDa) may 
inhibit antigen processing by macrophages and expression of Major Histocompatibility Complex 
(MHC) II (Fulton et al., 2004, Pai et al., 2004b). Consequently, infected macrophages fail to 
present Mtb antigens to T cells (CD4+ or CD8+ T cells) resulting in an opportunity for the 
organism to survive (Noss et al., 2001, Jo, 2008).  
C-type lectins of PRRs are involved in the recognition of polysaccharide structures of Mtb. The 
mannose receptor (MR; CD206) is highly expressed on AM (Gordon, 2003). It interacts with 
ManLAM of the cell wall component of Mtb. Endocytosis of Mtb bacilli by the macrophage 
via the stimulation of the MR leads to the production of anti-inflammatory cytokines (IL-4 and 
IL-13) which interfere with phagosome-lysosome fusion (Hernandez-Pando et al., 2000, Nigou 
et al., 2001, Hmama et al., 2004, Kang et al., 2005). Further, ManLAM can also inhibit MR 
dependent IL-12 production which is essential for T cells priming. These inhibited macrophage 
responses result in failure to control the infection. As a result, the organism is able to survive 
in the macrophage (Nigou et al., 2001, Kang et al., 2005).  
Dendritic cell specific intracellular adhesion molecule grabbing nonintegrin (DC-SIGN) is 
another membrane bound PRR which plays an important role in Mtb-dendritic cells 
interactions. It is predominantly expressed on dendritic cells and influences cell migration and 
T cell interactions (Geijtenbeek et al., 2000a, Geijtenbeek et al., 2000b). After interaction with 
Mtb components, DC-SIGN initiates an anti-inflammatory immune response stimulating the 
secretion of IL-10 following the maturation of infected dendritic cells (Geijtenbeek et al., 2003).  
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Dectin-1 is another PRR which is mainly expressed on macrophages, dendritic cells, 
neutrophils and a subset of T cells suggesting that it may also play a significant role in Mtb 
recognition (Dinadayala et al., 2004). Moreover, dectin-1 has been observed to stimulate bone 
marrow-derived macrophages of mice to produce TNF-α and IL-6 in a dectin-1-independent or 
dectin-1-dependent manner, respectively (Yadav and Schorey, 2006). It has also been shown to 
trigger IL-12 production (Rothfuchs et al., 2007).  
Another group of intracellular PRRs are the NOD like receptors (NLRs), which bind bacterial 
cell wall muramyl-dipeptides and initiate the secretion of TNF-α, IL-1β, IL-6 and bactericidal 
IL-37 (Brooks et al., 2011, Juarez et al., 2012). Other receptors such as complement receptors, 
scavenger receptors, surfactant protein A receptors (Sp-A) and cholesterol receptors are also 
required for optimal Mtb recognition resulting in effective phagocytosis of the bacteria (El-Etr 
and Cirillo, 2001).  
2.1.1.5.3 Role of innate immune cells 
Apart from macrophages and dendritic cells, neutrophils and natural killer (NK) cells have also 
participated in the immune defence against Mtb infections (Natarajan et al., 2011). 
 Macrophage: receptor mediated phagocytosis 
Macrophages play numerous important roles during host-Mtb interactions. These cells are 
primarily involved in phagocytosis and killing of the mycobacteria. They also initiate adaptive 
T cell mediated immunity to protect against Mtb infections (Kleinnijenhuis, 2011). 
Phagocytosis of Mtb bacilli involves different receptors such as complement receptors (CR), 
mannose receptors (MR), scavenger receptors and Fcγ receptors (FcγR) (Schlesinger et al., 
1990, Roecklein et al., 1992, Hirsch et al., 1994). Receptor mediated phagocytosis of bacilli 
occurs either by opsonisation (CR with antibodies) or by a non-opsonisation mechanism. This 
determines the subsequent events in cells as well as the ultimate fate of infections in the host 
(Pieters, 2008). Macrophage-Mtb interactions during phagocytosis involve several receptors 
(Ernst, 1998) some of which are presented here.  
2.1.1.5.3.1.1 Complement receptors 
In general, the complement system is activated by antibody complexes or microbes. These 
complement proteins have roles in opsonising the invading pathogens, chemotaxis, clumping 
of antigens and lysis of microbial cells. There are several receptors present on the cell surface 
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of macrophages including CR1 (binds with C3b and C4b), CR3 and CR4 (binds with C3bi and 
glucan) which facilitate the recognition of complement-opsonised and occasionally un-
opsonised pathogens (Ernst, 1998). Macrophage-Mtb interactions activate the alternative 
pathway of the complement system and initiate opsonisation with subsequent C3b and C3bi 
mediated uptake. Mtb can recruit opsonically active C3b without triggering the complement 
cascade or non-opsonically by binding with C3bi or β-glucan binding domain of CR3 
(Schlesinger, 1993, Hirsch et al., 1994, Cywes et al., 1996, Cywes et al., 1997). An in vitro 
study has shown that CR3 mediates approximately 80% of complement-opsonised Mtb 
phagocytosis (Schlesinger et al., 1990). In contrast, non-opsonic phagocytosis occurs during 
primary infection in the lungs as complement factors are mostly absent in the alveolar space 
(Schluger, 2001).  
2.1.1.5.3.1.2 Mannose receptors 
Fully differentiated macrophages carry the mannose receptor (MR) for phagocytosis of Mtb. 
The MR binds with glycosylated molecules with terminal mannose, fucose or N-
acetylglucosamine motifs of Mtb which initiate uptake of bacilli either by phagocytosis or 
pinocytosis. One study showed that the MR alone was not sufficient for phagocytosis, 
suggesting that other receptors are also required for effective phagocytosis (Le Cabec et al., 
2005). Furthermore, signalling events for ligation of MR with the bacilli are poorly 
characterised, but phagocytosis is mediated by reactive oxygen species (ROS) production upon 
ligation. This MR ligation can be downregulated by a high level of IFN-γ. Therefore, this 
receptor is believed to function effectively immediately after the infection, before the onset of 
T helper 1 (Th1) cells mediated adaptive immune responses (Ernst, 1998, van Crevel et al., 
2002). However, this receptor mediated phagocytosis is essential particularly for virulent Mtb 
strains because the bacilli carry mannose-capped ManLAM on their surface to interact with MR 
(Schlesinger, 1993, Kang and Schlesinger, 1998, Kang et al., 2005).  
2.1.1.5.3.1.3 Fcγ receptors 
Fcγ receptor mediated phagocytosis particularly occurs during the humoral immune responses. 
This receptor on the macrophages binds with IgG-opsonised Mtb leading to a higher level of 
phagolysosomal fusion in macrophages (Armstrong and Hart, 1975) and rapid (10-12 minutes) 
acidification (pH 5) of the phagosome to provide for effective killing of bacilli (Divangahi et 
al., 2008). Furthermore, FcγR-mediated phagocytosis can also lead to reactive oxygen species 
(ROS) production and initiate pro-inflammatory responses, suggesting that this pathway is 
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beneficial for the host in mounting effective macrophage responses against Mtb (Caron and 
Hall, 1998, de Valliere et al., 2005).  
2.1.1.5.3.1.4 Additional receptors  
In addition to these three major receptors (described above), other receptors or proteins are also 
present on the macrophage surface for interaction with the Mtb. Surfactant proteins in the lungs 
can coat the bacilli and facilitate either recognition by the surfactant protein receptors on the 
macrophage (Pasula et al., 1997) or alteration of the uptake mechanism (Gaynor et al., 1995) 
and thus interfere with MR activity (Berrington and Hawn, 2007). Scavenger receptors on 
macrophages can bind to sulpholipids and CD14 with LAM of Mtb leading to recognition of 
bacilli for phagocytosis (Ernst, 1998, Berrington and Hawn, 2007).  
2.1.1.5.3.1.5 Cytokine and chemokine response of macrophages  
Macrophage-Mtb interactions result in the secretion of various cytokines and chemokines 
(Table 2.1). Macrophage polarisation determines the outcomes of the host responses and 
subsequent elimination of Mtb (Benoit et al., 2008). The classically activated macrophage (M1) 
stimulated by the microbial products or IFN-γ leads to the production of pro-inflammatory 
cytokines (e.g. TNF-α, IL- 1β, IL-12, IL-15, IL-23, IFN-γ) (Doherty et al., 1996, Wang et al., 
1999, Verreck et al., 2004, Verreck et al., 2006). In contrast, the non-classically activated 
macrophage (M2) lacks antimicrobial activity and fails to produce IL-12. The later subsets have 
a poor antigen presenting capability and also suppress cellular immunity by producing anti-
inflammatory cytokines (e.g. IL-10, IL-6, IL-4, TGF-β) (VanHeyningen et al., 1997, Guyot-
Revol et al., 2006, Verreck et al., 2006). In addition to the cytokine response, chemokines 
comprising MCP-1 (monocyte chemoattractant protein-1), MCP-3, MCP-5, RANTES 
(regulated on activation, normal T cells expressed and secreted) and IFN-γ induced protein 10 
kDa from macrophages are crucial for protection against Mtb infections (Flynn and Chan, 
2001a, Raja, 2004). The specific role of major pro- and anti-inflammatory cytokines and 
chemokines produced by macrophages (also by other cells) in Mtb infection are presented in 
Table 2.1.  
 Neutrophils 
Neutrophils are one of the first cells to arrive at the site of infection after the initial attack of 
Mtb by AM (Korbel et al., 2008). They can kill the Mtb pathogens using a wide range of 
antimicrobial molecules present in the granules including defensins, lactoferrin, cathelicidin 
14 
 
and lysozyme. These substances are transferred into the phagosome upon fusion (Faurschou 
and Borregaard, 2003, Martineau et al., 2007, Korbel et al., 2008) allowing the cells to 
efficiently kill the bacilli in the phagosome using an assembly of NADPH (nicotinamide 
adenine dinucleotide phosphate) oxidase. This process leads to the production of superoxide 
and ROS (Faurschou and Borregaard, 2003). Neutrophils subsequently activate macrophages 
through the release of granule protein (Tan et al., 2006) and heat shock protein 72 (Hsp72). The 
Hsp72 from apoptotic neutrophils is able to activate macrophages, even though the protein has 
an inflammation resolving role (Persson et al., 2008). Several studies have documented 
contradictory evidence suggesting that neutrophils have either protective or tissue-damaging 
effects during Mtb infections (Martineau et al., 2007, Korbel et al., 2008, Persson et al., 2008). 
 Natural Killer cells 
Natural killer cells are granular lymphocytes that have cytotoxic functions. These cells carry 
out their functions through granules containing perforin and granzyme or granulysin (Korbel et 
al., 2008) and activate macrophages through IFN-γ secretion during Mtb infections (Junqueira-
Kipnis et al., 2003, Ducati et al., 2006). These cells can directly lyse the Mtb infected 
macrophages and restrict Mtb growth by mounting pro-inflammatory responses (Korbel et al., 
2008). One study reported that NK cells can kill regulatory T cells (Treg) that can dampen the 
immune responses to Mtb infections (Roy et al., 2008). However, the exact role of NK cells in 
TB defence is still imprecise. Prior study has shown that NK cells defects in TB patients were 
found to be effective (Raja, 2004).  
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Table 2.1 Cytokine and chemokine production in Mycobacterium tuberculosis infection 
Pro-inflammatory cytokines 
Cytokines Source/Cells Functions 
TNF-α 
Monocytes, macrophages, 
dendritic cells (Valone et 
al., 1988), CD4+ T cells 
(Silva Miranda et al., 
2012) 
-Pro-inflammatory responses 
-Activation of macrophagess and neutrophil (Orme 
and Cooper, 1999, Tsenova et al., 1999, Gan et al., 
2005) 
-Organises granuloma formation (Kindler et al., 
1989, Flynn et al., 1995, Senaldi et al., 1996) 
-Containment of latent infections in granuloma 
(Mohan et al., 2001) 
-Lack of TNF-α increases susceptibility to 
infection resulting higher organ bacterial load 
(Benoit et al., 2008) 
IL-1β 
Monocytes, macrophages 
and dendritic cells (Roach 
et al., 1993, Dahl et al., 
1996) 
-Granuloma formation (Fantuzzi and Dinarello, 
1996, Juffermans et al., 2000) 
-Stimulates macrophages to produce TNF-α, IL-6 
(Toossi et al., 1990) and IFN-γ (Juffermans et al., 
2000) 
 
IL-12 
Macrophages, dendritic 
cells (Bermudez et al., 
1992, Ladel et al., 1997b) 
-Differentiation of Th1 cells for IFN-γ production 
(Sieling et al., 1994, Cooper et al., 1995, 
Trinchieri, 1995, O'Neill and Greene, 1998) 
-Increases proliferation of cytotoxic T (Tc) cells 
and NK cells (Bertagnolli et al., 1992)  
IL-18 
Peripheral blood 
mononuclear cells 
(Vankayalapati et al., 
2000) 
-Induces IFN-γ, synergise with IL-12 (O'Neill and 
Greene, 1998, Sugawara et al., 1999) 
IL-15 (IL-2) 
 
Monocytes, macrophages, 
CD4 T cells (Jullien et 
al., 1997) 
-Stimulates T cells and NK cells proliferation and 
activation (Doherty et al., 1996, Kennedy and Park, 
1996) 
IFN-γ 
CD4+ T cells (Th1), 
CD8+ T cells, NKT cells 
(Martinez et al., 2009), 
alveolar macrophages 
(Wang et al., 1999), NK 
cells in response to IL-12 
and IL-18 (Iho et al., 
1999) 
-Initiates antigen specific cellular immunity 
(Andersen, 1997) 
-Activate macrophages and increases expression of 
MHC class II molecules (Fulton et al., 2004, 
Herbst et al., 2011) 
-Induction of reactive oxygen species and nitric 
oxide synthase for bacterial killing (Martinez et al., 
2009)  
IL-17 
Lymphocytes γ/δ, CD4+ 
T cells (Th17) (Ouyang et 
al., 2008) 
-Involved in the recruitment of leucocytes and 
initial granuloma formation (Ouyang et al., 2008) 
-Stimulates neutrophils to produce IL-6, IL-8 and 
granulocyte-macrophage colony-stimulating factor 
(GM-CSF) (Fossiez et al., 1996) 
- Acts synergistically with TNF-α (Ruddy et al., 
2004) and produces IL-17A, IL-17F, IL-21 and IL-
22 (Diveu et al., 2008, Dong, 2008) 
Anti-inflammatory cytokines 
IL-10 
 
Macrophages (Shaw et 
al., 2000), Treg cells, 
alternatively activated 
-Anti-inflammatory responses 
-Suppresses Th1 cells responses (Hirsch et al., 
1999a) 
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macrophage (AAM), 
reactive T cells (Barnes et 
al., 1993, Boussiotis et 
al., 2000)  
-Downregulation of IFN-γ, TNF-α and IL-12 
production (Gong et al., 1996, Fulton et al., 1998, 
Hirsch et al., 1999a)  
TGF-β 
Monocytes, dendritic 
cells (Toossi et al., 1995), 
Treg cells, AAM (Guyot-
Revol et al., 2006) 
-Anti-inflammatory responses 
-Suppresses T cells to produce IFN-γ (Hirsch et al., 
1999a) 
-In macrophages, it antagonises antigen 
presentation, pro-inflammatory cytokine 
production and cellular activation (Toossi and 
Ellner, 1998) 
-Involved with tissue damage and fibrosis 
(Hernandez-Pando et al., 2004) 
-Acts synergistically with IL-10 to suppress IFN-γ 
production (Othieno et al., 1999) 
IL-6 
Macrophages 
(VanHeyningen et al., 
1997) 
-Pro and anti-inflammatory responses 
(VanHeyningen et al., 1997)  
-Inhibits the production of TNF-α and IL-1β 
(Schindler et al., 1990, Denis and Gregg, 1991, 
Bermudez et al., 1992) 
-Suppresses T cells proliferation and IL-2 
production (VanHeyningen et al., 1997) 
IL-4 
AAM (Verreck et al., 
2006) 
-Suppresses of IFN-γ production by 
downregulation of Th1 cells responses (Powrie and 
Coffman, 1993, Lucey et al., 1996, Biedermann et 
al., 2001) 
-Inhibits macrophage activation (Appelberg et al., 
1992, de Waal Malefyt et al., 1993) 
-Overexpression of it involves with tissue 
damage/cavitation (Lukacs et al., 1997, van Crevel 
et al., 2000) 
Chemokines 
IL-8 (CXCL8) 
AM, 
epithelia cells of the lungs 
(Zhang et al., 1995, 
Juffermans et al., 1999)  
-Recruits neutrophils (Zhang et al., 1995, 
Juffermans et al., 1999) 
(MCP-1) 
/CCL2 
Monocytes, macrophages 
(Kasahara et al., 1994) 
- Recruits macrophages and other immune cells 
(Peters et al., 2001) 
-Required for granuloma formation (Lu et al., 
1998) 
-Suppressed Th1 type cytokine production (Boring 
et al., 1997) 
RANTES 
/CCL5 
Wide variety of cells and 
macrophages 
 (Chensue et al., 1999)  
-Recruits macrophages and other immune cells 
- Associated with granuloma formation (Floto et 
al., 2006) 
CXCL9, 
CXCL10 (IP-
10) CXCL11 
Bronchial epithelial cells 
(Silva Miranda et al., 
2012) 
-Recruits immune cells (Silva Miranda et al., 2012) 
CCL19/CCL21 
Stromal cells of lymph 
node 
(Silva Miranda et al., 
2012) 
-Recruitment and priming of IFN-γ producing T 
cells  
-Migration of DC from lung to draining LN (Silva 
Miranda et al., 2012) 
17 
 
 Adaptive immunity and host defence 
2.1.1.6.1 Initiation of adaptive immunity  
Initiation of adaptive immunity largely depends on innate immune responses. The innate 
immune cells, particularly macrophages and dendritic cells play central roles in initiating 
adaptive immune responses. The initiation of adaptive and in particular, cell mediated immunity 
in Mtb infections is underpinned by three processes: antigen presentation, costimulation and 
cytokine production by the immune cells (van Crevel et al., 2002). 
 Antigen presentation 
Antigen presentation plays an important role in activating subsequent adaptive immune 
responses. Presentation of exogenous Mtb pathogens is achieved following uptake by the 
antigen presenting cells (APC), particularly macrophages and dendritic cells. The Mtb antigens 
are processed in phagolysosomal compartments of the APC before being presented to T cells 
(Figure 2.3) (van Crevel et al., 2002). During this process of antigen presentation, Mtb antigens, 
in conjunction with MHC class II molecules, are presented to the antigen specific CD4+ T cells, 
leading to activation of cellular and/or humoral immune responses. MHC class I molecules are 
able to present mycobacterial antigens to antigen specific CD8+ T cells. The role of MHC class 
I mediated antigen presentation has been documented both in murine models (Peters et al., 
1991, Sousa et al., 2000) and TB patients (Cho et al., 2000, Geluk et al., 2000). This pathway 
of presentation is important to kill the infected cells by Tc cells (Peters et al., 1991, 
Weerdenburg et al., 2010). In addition, nonpolymorphic MHC class I molecules such as type I 
CD1 (-a,-b and -c) molecules can present Mtb lipoproteins to CD1-restricted T cells. This 
pathway of presentation is usually activated before the development of antigen specificity 
(Lewinsohn et al., 1998). Moreover, the expression of antigen presentation in Mtb infections 
can also be regulated by the cytokines (Figure 2.3). During host-Mtb interactions, expression 
of antigen presenting molecules in macrophages is enhanced by pro-inflammatory cytokines, 
whereas their expression is inhibited by anti-inflammatory cytokines (Pancholi et al., 1993, 
Gercken et al., 1994).  
 Costimulation 
Costimulatory signals are essential for T cell stimulation during antigen presentation. The most 
well described costimulatory signals for T cell stimulation are B-7.1 (CD80) and B-7.2 (CD86). 
These molecules are expressed primarily on macrophages and dendritic cells which bind to 
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CD28 and CTLA-4 (cytotoxic T lymphocyte antigen 4) on T cells. Studies have shown that 
during Mtb infection B-7.1 (CD80) expression on monocytes is decreased (Saha et al., 1994) 
whereas dendritic cells show higher expression of B7.1, CD40 and intracellular adhesion 
molecule-1 (ICAM-1) (Henderson et al., 1997). Furthermore, lack of costimulatory signals 
during presentation of Mtb antigens increased T cell apoptosis followed by T cells 
hyporesponsiveness (Hirsch et al., 1999b, Hirsch et al., 2001). 
 Cytokine production 
Several cytokines produced by activated macrophages and dendritic cells are crucial for T cells 
stimulation (van Crevel et al., 2002) (details in Table 2.1 and Figure 2.3). Macrophages and 
dendritic cells produce type 1 cytokines (IL-12, IL-18 and IL-23) for T cell stimulation 
(Oppmann et al., 2000). Studies documented that functional mutation of gene encoding for IL-
12p40 (Frucht and Holland, 1996, Altare et al., 1998b), IL-12Rβ1 (de Jong et al., 1998, Othieno 
et al., 1999), IFN-γ receptor 1 (Jouanguy et al., 1996, Holland et al., 1998) and IFN-γ receptor 
2 (Dorman and Holland, 1998) in chronic or recurrent TB patients suggesting the failure of 
IFN-γ receptors signalling in macrophages and dendritic cells. Further, IL-1 and TNF-α have 
important T cell stimulatory properties (Dinarello, 1996, Tsenova et al., 1999). Decreased 
production of such pro-inflammatory cytokines delayed T cell stimulation followed by poor T 
cell mediated immunity. Anti-inflammatory cytokines like IL-10, TGF-β have antagonistic 
roles in T cell stimulation during antigen presentation (Table 2.1) (Hirsch et al., 1997, 
Boussiotis et al., 2000).  
2.1.1.6.2 Role of T cells  
A wide range of immune cells of the adaptive immune system is involved in mounting effective 
cell mediated immune responses against Mtb infections. These cells comprise CD4+ T cells, 
CD8+ T cells, Treg cells, CD1 restricted T cells and γδ T cells.  
The CD4+ T cells are thought to play a major role in Mtb protection following infection (Figure 
2.3). These cells can produce a stronger IFN-γ response than other T cells to mount effective 
immunity against Mtb infections (Schaible et al., 2003, Ngai et al., 2007). The functional role 
of CD4+ T cells is diverse. One of the significant functions of these cells is the production of 
cytokines such as IFN-γ, IL-2 and TNF-α. Among the cytokines, IFN-γ plays the central role 
in controlling Mtb infections. Defects in IFN-γ or IFN-γ receptor gene in humans and animals 
were reported to be the cause of increased susceptibility to Mtb infections (Flynn et al., 1993, 
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Chan and Flynn, 2004, Cooper, 2009). IFN-γ synergises the function of TNF-α to kill Mtb 
through the activation of macrophages and increasing expression of inducible nitric oxide 
synthase (iNOS) (Scanga et al., 2001, Chan and Flynn, 2004, Cooper, 2009). This crucial 
cytokine also enhances antigen presentation, recruitment of more CD4+ T cells or cytotoxic 
CD8+ T cells for killing the bacilli as well as preventing exhaustion of memory T cells (Chan 
and Flynn, 2004, Russell et al., 2009). Furthermore, it increases gene expression in 
macrophages for MHC class II molecule expression as well as the production of antimicrobial 
components (Scanga et al., 2001, Chan and Flynn, 2004, Cooper, 2009). TNF-α (also produced 
from macrophages and dendritic cells) also has a protective role in TB defence (Bean et al., 
1999, Keane, 2005). Studies in mouse models documented that TNF-α or TNF-α receptor 
deficiency increased Mtb infections (Keane, 2005). It also initiates cell migration for granuloma 
formation as well as its maintenance. In addition, depletion of TNF-α results in overgrowth of 
Mtb (Flynn et al., 1993, Chan and Flynn, 2004). Secondary functions of CD4+ T cells are 
confinement of bacilli within the granuloma, apoptosis of infected macrophages, induction of 
macrophages and dendritic cells to produce cytokines (IL-10, IL-12, IL-15) and activation of 
macrophages through CD40 ligand binding (Flynn et al., 1993, Cella et al., 1996, Oddo et al., 
1998, Chan and Flynn, 2004). CD4+ T cells also regulate the function of cytotoxic CD8+ T 
cells. Studies have documented that inhibition of CD4+ T cells in apoptosis of macrophages 
affects the activation of CD8+ T cells (Serbina et al., 2001, Cooper, 2009). In contrast, depletion 
of CD4+ T cells leads to reactivation of latent infections followed by extensive tissue pathology 
and mortality in mice even though there are higher IFN-γ levels due to CD8+ T cells responses 
(Scanga et al., 2001). Delayed dissemination of CD8+ T cells from the draining lymph nodes 
to other organs occurs due to lack of CD4+ T cells, causing impairment of immune protection 
(Wang et al., 2004). These cells also control the intracellular growth of Mtb by a nitric oxide 
dependent mechanism (Cowley and Elkins, 2003, Cooper, 2009).  
CD8+ T cells take part in Mtb protection by secreting IFN-γ (Figure 2.3). These cells can 
directly kill the Mtb through a perforin and granulysin-mediated pathway and facilitate the 
control of both acute and chronic infections (Grotzke and Lewinsohn, 2005, Cooper, 2009). 
CD8+ T cells kill the infected macrophages directly or by induction of apoptosis via Fas ligand 
(Woodworth et al., 2008, Dheda et al., 2010). CD8+ T cells also have a protective role in the 
control of LTBI. Depletion of CD8+ T cells has been reported to initiate the reactivation of 
latent infections (van Pinxteren et al., 2000) and defective function of CD8+ T cells is also 
documented in chronic TB patients (Brighenti and Andersson, 2010).  
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Figure 2.3 Antigen presenting cell and T cell interactions, and the cytokine networks 
required for mounting an adaptive immune responses during Mycobacterium tuberculosis 
infections 
Figure illustrates the antigen presentation by antigen presenting cells (APC) to T cell for 
mounting adaptive immune responses in M. tuberculosis infection. The infected APC 
(macrophages and dendritic cells) secrete various cytokines including IL-12 and TNF-α to 
present antigen to T cell populations; CD4+ T cells (MHC class II), CD8+ T cells (MHC class 
I). Immediately after antigen presentation, CD4+Th1 cells proliferate to produce effector T cells 
(Teff) and memory T cells (TM) responses. These cells then produce multiple cytokines such as 
IFN-γ and TNF-α for further activation of macrophages for effective killing of the bacilli 
through the secretion antimycobacterial compounds (e.g. ROS and iNOS). In addition, CD8+ 
cytotoxic T cells can kill the bacilli through granulysin and perforin-mediated pathways. 
Another major subset of CD4+ T cells is CD4+ Th2 cells and CD4+CD25+FoxP3+ Treg cells 
which dampen down the Th1 cells through the secretion of anti-inflammatory cytokines (e.g. 
IL-4, IL-10, TGF-β). Interestingly, Th2 cells also secrete B cells stimulating factors (e.g. IL-4, 
IL-5, IL-10, IL-13) for antibody production. Th 17 cells, a distinct subset of CD4+Th cell which 
produced in the presence of IL-23 are able to modulate the inflammatory responses and recall 
memory responses through the production of IL-17. The Th17 cell population can recruit 
neutrophils and monocytes and IFN-γ-producing CD4+ T cells and stimulate chemokine 
responses. Figure adapted and modified from Dheda et al., (2010). 
 
Treg cells have an influence in TB defence as these cells modulate Th1, Th2 and Th17 cells. 
Natural Treg subsets (CD4+CD25+FoxP3+) can produce either TGF-β and IL-10 to 
downregulate CD4+ T cells (Figure 2.3) (Kursar et al., 2007, Kaufmann and Parida, 2008, 
Dorhoi and Kaufmann, 2009, Rahman et al., 2009, Sharma et al., 2009) leading to suppression 
of immunity and clinical manifestation of TB. Furthermore, CD4+ Treg cells subsets and CD8+ 
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Treg cells can alter cytokine production and inhibition of T cells proliferation (Scott-Browne et 
al., 2007), resulting in immune suppression and bacillary dissemination (Rahman et al., 2009, 
Sharma et al., 2009). It was observed that a high percentage of Treg cells (CD4+ 
CD25highCD39+) were found in patients with active TB. Attenuation of these Treg cells has a 
positive impact on Mtb vaccine efficacy (Bayry et al., 2008, Jaron et al., 2008). However, 
unconventional T cells such as CD1 restricted T cells, γδ T cells also have a protective role in 
TB defence (Kaufmann, 2004, Barral and Brenner, 2007, Beetz et al., 2008). 
2.1.1.6.3 Role of B cells  
The role of B lymphocytes and the humoral immune response for protection against TB is not 
clear. A study using a mouse model found that B cells were required for optimal protection 
against Mtb infections (Maglione and Chan, 2009). It was also observed that low-dose aerosol 
infection with Mtb in B cell deficient mice showed no difference in susceptibility to infection 
(Johnson et al., 1997, Bosio et al., 2000, Taylor et al., 2005), however high-dose intravenous 
challenge increased the susceptibility as well as severity of lesion formation (Vordermeier et 
al., 1996). Another study reported that granulomas comprise a large population of B cells, 
particularly B220+ cells, suggesting that these cells have a protective role in TB defence 
(Kahnert et al., 2007). It has been suggested that the antibody response that occurs during Mtb 
infections can modulate cell mediated immunity through cytokine signalling, triggering the 
complement system and also promoting antibody-dependent cellular cytotoxicity (de Valliere 
et al., 2005, Abebe and Bjune, 2009, Maglione and Chan, 2009).  
 Granuloma formation  
The granuloma is a hallmark of Mtb infections (Silva Miranda et al., 2012). It prevents bacterial 
dissemination as well as reactivation of bacilli (Ehlers, 2009). Formation of the granuloma 
results from effective innate and adaptive immune responses (discussed above) (Saunders and 
Cooper, 2000, Saunders and Britton, 2007, Korbel et al., 2008). Furthermore, the cellular 
aggregation for the formation of the granuloma occurrs in response to different cytokines and 
chemokines resulting from both innate and adaptive immune cells (Table 2.1). The balance 
between pro- and anti-inflammatory cytokines is crucial for the establishment of an effective 
granuloma in Mtb infection.  
Macrophages are one of the principal cells found in the granuloma (Jo et al., 2007, Cooper et 
al., 2011). The granuloma is mainly composed of centrally infected macrophages surrounded 
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by epithelioid cells, foamy macrophages, multinucleated giant cells of Langhans type with 
peripherally by T lymphocytes (CD4+, CD8+ T cells) (Gonzalez-Juarrero and Orme, 2001, 
Puissegur et al., 2004). A mature granuloma is compact, highly stratified, becomes vascularised 
and develops a fibrotic capsule around it (Russell, 2007). 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Schematic diagram of tuberculosis granuloma (Ramakrishnan, 2012) 
In the granuloma, there is no or little multiplication of confined bacteria (Ducati et al., 2006). 
The environment is considered hypoxic which is important for Mtb metabolism and 
antimycobacterial therapy (Adams, 1989, Aly et al., 2006). Prior studies demonstrated that Mtb 
bacilli adapted to the hypoxic environment of the granuloma by producing a thickened cell wall 
and also altering the transcription of various proteins (Cunningham and Spreadbury, 1998, 
Rosenkrands et al., 2002). It provides a microenvironment in which the bacilli can survive for 
a longer period of time as latent TB infection (LTBI) (Adams, 1976, Sandor et al., 2003). It was 
also assumed that secondary granuloma formation or reactivation of LTBI can result due to 
drainage of non-replicating bacilli into the airways to the upper lobes of the lungs (Saunders 
and Britton, 2007, Cardona, 2009, Cardona, 2010).  
Reactivation of LTBI occurs most commonly in the lungs (80% of the cases), whereas in 20% 
of cases, it reactivates at other tissue sites (e.g. pleural space, lymph nodes, bone, kidney, etc.) 
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(Frieden et al., 2003). It is assumed that reactivation of TB from LTBI occurs due to immune 
compromised status (e.g diabetes, HIV infection) of the hosts (Martens et al., 2007, Hodgson 
et al., 2015). Previous research has shown that in immunocompetent individuals with TB 
infection, granulomas are small, compact and characterised by the presence of a signfiicant 
number of IFN-γ producing CD4 T cells. In contrast, in immunodeficient individuals, the TB 
granuloma is larger in size, rich in activated macrophages and with few surrounding 
lymphocytes. These granulomas are unable to effectively control and confine the infection 
(Ulrichs et al., 2005).  
 Vaccines against tuberculosis 
2.1.1.8.1 Current vaccine for tuberculosis protection 
Bacillus Calmette-Guérin (BCG) is currently the only recommended vaccine against TB 
(Andersen and Kaufmann, 2014). The vaccine was developed by Albert Calmette and Camille 
Guérin following 230 in vitro passages of a Mycobacterium bovis strain over a 13 year period 
(Calmette, 1927, Calmette and Plotz, 1929). Subsequent comparative genome analyses have 
shown that the M. bovis BCG vaccine strain lacks several gene segments cluster into regions of 
difference (RD). The RD1 encodes the important virulence factors and T cell antigens early 
secretary antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP10) (Behr et al., 
1999). Clinical use of the vaccine began in 1930. Vaccination through the Expanded Program 
on Immunisation, commenced in the early 1970s and has been successful in preventing infant 
mortality (Hatherill, 2011, WHO., 2013a) because the vaccine can prevent extra-pulmonary TB 
(miliary TB or TB meningitis) in children (Andersen and Kaufmann, 2014)  
The most controversial aspect of the BCG vaccine is the level of protection. The efficacy of the 
vaccination is influenced by geography, genetics and the nutritional status of the host, 
concurrent bacterial infections and condition of the laboratory where the vaccine was produced 
including genetic differences in the strain, media used for growth etc., (Sutherland and 
Springett, 1987, Janaszek, 1991, Fine, 1995, Venkataswamy et al., 2012). Studies have shown 
that vaccination efficacy (based on the occurrence of TB in vaccinated group) is 60-80% in UK 
populations (Sutherland and Springett, 1987) and as low as 0% in south Indian populations 
(Indian Council of Medical Research., 2013). A systematic study documented that this vaccine 
reduces the overall risk of getting TB by approximately 50% (Colditz et al., 1994). Another 
systemic review has demonstrated that BCG vaccine reduces the infection by 19-27% and 
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reduce the progression of the active disease by 71% (Roy et al., 2014). The duration of 
protection offered by the vaccine is also controversial. A study of a native American population 
reported that protection (based on the reactivity of tuberculin skin test) remained for 50-60 years 
(Fine, 1995, Aronson et al., 2004). Whereas another study showed that the level of protection 
waned to 59% after 15 years and to nearly zero after 20 years (Styblo and Meijer, 1976).  
2.1.1.8.2 Future vaccines for tuberculosis  
To overcome the limitation of the current BCG vaccine and to face the global challenge of 
increasing TB incidence, several vaccines have been developed that are now under clinical 
assessment (Table 2.2). These vaccines have been developed based on three immunisation 
strategies: (i) prime; (ii) prime boost; and (iii) immunotherapeutic (Frick, 2013). These vaccines 
either boost the current BCG or replace BCG (Montagnani et al., 2014). Several preexposure 
vaccines have been designed for infants which could be used to boost the level of protection 
afforded by the current BCG vaccine (Kaufmann, 2012). Postexposure vaccines are formulated 
to be administered to adolescents and adults with LTBI. These vaccines are again designed to 
boost BCG or replace BCG given at infancy. The third strategy of future vaccines are for 
therapeutic purposes to reduce the chemotherapy requirements of active TB patients, drug-
resistant TB patients (Frick, 2013, Prabowo et al., 2013) as well as HIV patients suffering from 
miliary TB (von Reyn et al., 2010).   
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Table 2.2 Overview of tuberculosis vaccines currently under clinical trial  
Vaccine name Target indication 
Antigen name 
or Rv number 
Delivery system Descriptive notes Phase Reference 
MTBVAC Preventive N/A Live Mtb 
Attenuated Mtb with PhoP and 
FadD26 gene deletions 
I Arbues et al. (2013) 
VPM 
Preventive 
 
N/A 
Live rBCG strain 
expressing isteriolysin, 
urease deleted 
Improved antigenicity due to 
perforation of phagosome 
membrane 
IIa 
Grode et al. (2013) Grode et 
al. (2005) 
Ad5 Ag85A Preventive Ag85A Adenovirus 5 vector 
Replication-deficient viral 
delivery system 
I Smaill et al. (2013) 
Ad35/ MVA85A 
Preventive 
 
Ag85A, Ag85B 
TB10.4 
Adenovirus 35 and 
modified vaccinia 
Ankara vector 
Prime boost combination of 
two viral delivery systems 
I 
Abel et al. (2010) Radosevic 
et al. (2007) 
H4/IC31 Preventive Ag85B TB10.4 IC31 
Formulation of cationic 
peptide and a synthetic TLR-9 
agonist 
II 
Dietrich et al. (2005), 
Aagaard et al. (2009), 
Billeskov et al. (2012) 
MVA85A 
 
Preventive Ag85A 
Modified vaccinia 
Ankara 
 
Replication-deficient viral 
delivery system 
IIb 
Tameris et al. (2013) 
Beveridge et al. (2007), 
Verreck et al. (2009), White 
et al. (2013) 
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M72 
Preventive 
/ Postexposure 
 
Rv1196 
Rv0125 
 
AS01E 
Liposomes incorporating the 
TLR-4 agonist 
monophosphoryl lipid A 
 
IIa 
Leroux-Roels et al. (2013) 
Reed et al. (2009) 
ID93 
Preventive/ 
/Postexposure 
/Therapeutic 
Rv2608 
Rv3619 
Rv3620 
Rv1813 
GLA-SE 
Synthetic TLR-4 agonist in oil-
inwater emulsion 
I 
Coler et al. (2013) Bertholet 
et al. (2010) 
H1/H56/IC31 
Preventive 
/Postexposure 
/Therapeutic 
Ag85B ESAT-
6 Rv2660c 
IC31 
Formulation of cationic 
peptide and a synthetic TLR-9 
agonist 
II 
van Dissel et al. (2010), 
Aagaard et al. (2011) 
Weinrich Olsen et al. (2001) 
RUTI Therapeutic N/A Whole fragmented Mtb - I Cardona (2006) 
Mycobacterium 
vaccae 
Therapeutic N/A Whole killed Mtb - III 
Yang et al. (2010) 
von Reyn et al. (2010) 
de Bruyn and Garner (2003) 
Mycobacterium 
indicus pranii 
Therapeutic N/A Whole killed Mtb - III Gupta et al. (2012) 
N/A; Not applicable, Adapted and modified from (Andersen and Kaufmann, 2014) 
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 Diagnosis of tuberculosis 
2.1.1.9.1 Active tuberculosis 
The presumptive diagnosis of active tuberculosis is based on a variety of clinical features. 
Productive, persistent cough (lasting more than two weeks), haemoptysis and chest pain are 
also considered. Other common manifestations include low grade fever, night sweats, chills, 
inappetence, fatigue and shortness of breath. (Frieden et al., 2003, Kumar, 2007). Further, 
medical history including history of previous exposure to an infected individual provides 
important diagnostic clues. Disease in these patients is usually confirmed with chest X-ray, 
microscopy of sputum smear and culture of Mtb. In many developing countries, diagnostic 
algorithms and point scoring systems are often used to get a better diagnostic yield (Hesseling 
et al., 2002). Biomarkers in the peripheral blood such as anaemia and pancytopenia may also 
be seen in TB patients with bone marrow involvement (Cameron, 1974). Inflammatory markers 
such as acute phase protein, C-reactive protein (CRP) also considered in the diagnosis of active 
TB (Breen et al., 2008). 
 Microscopy  
Early TB diagnosis is crucial for its control. The most common method of TB diagnosis, 
particularly in the poorest parts of the world where disease burden is high, is microscopy (Zumla 
et al., 2013). Microscopy of a sputum sample is usually performed either by light microscopy 
with Ziehl-Neelsen/Kinyoun stain or fluorescent microscopy with a stain such as auramine-O. 
Sputum smear microscopy is considered an easy, cheap and rapid test for diagnosis of TB in a 
limited resource setting (CDC, 2000). Fluorescent microscopy is more sensitive than 
conventional microscopy, but requires an expensive fluorescent microscope. In 2009, WHO 
endorsed low-cost fluorescent LED (light emitting diodes) technology to overcome the use of 
expensive traditional fluorescence microscopes (Mizuno et al., 2009, WHO., 2009). However, 
the sensitivity of this diagnostic assay is influenced by the number of samples and sampling 
time. Ulukanligil and colleagues (2000) documented that early morning samples contained 
more bacilli and repeated sampling increased the sensitivity. The sensitivity of Ziehl-Neelsen 
and fluorescence microscopy was reported to be 61% and 83%, respectively, when a single 
sample was considered, whereas sensitivity increased to 80% and 92%, respectively, when three 
or more sample was submitted.  
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 Culture 
Culture is considered as the gold-standard for the diagnosis of TB (Zumla et al., 2013). The 
sensitivity of culture is higher than traditional microscopy, as it can detect as few as 10 bacilli 
per millilitre of respiratory samples (Yeager et al., 1967). Culturing should be performed in 
both solid (e.g. egg based Lowenstein-Jensen medium or agar based Middlebrook 7H10/7H11) 
and liquid media (Middlebrook 7H9, 7H12 or Kirshners) because the former allows the 
examination of colony morphology for identification and the later enables more rapid diagnosis 
of TB (Frieden et al., 2003). 
A recent advance in culturing is the use of automated liquid culture systems such as MB/BacT 
system (bioMerieux, France) and the MGIT 960 (Becton Dickinson, New Jersey, USA). Both 
culture systems increase the sensitivity and reduce detection time and have a 10% greater yield 
than solid media (Palomino et al., 2008, Muyoyeta et al., 2009, Parrish et al., 2009). The 
MB/BacT system uses a modified Middlebrook 7H9 broth with a pH indicator for detecting pH 
changes in the presence of CO2. The MGIT 960 culture system utilises the same broth and 
detects the release of a fluorophore that is produced after utilisation of oxygen by the bacilli. 
The MGIT 960 method has been reported to be better over solid culture because it can recover 
more organisms from extra-pulmonary samples (Hillemann et al., 2007). However in 2007, 
WHO endorsed the automated liquid culture system as the gold standard for TB diagnosis, 
although the higher cost and contamination issues limit the use of this method in many low and 
middle income countries (Zumla et al., 2013).  
 Imaging  
Imaging is an important tool for diagnosing active PTB. Radiographic lesions indicate 
infiltration or consolidations and/or cavities or tree-in-bud sign (airway obstruction) in the 
upper lobes of the lungs. This can be with or without the involvement of mediastinal or hilar 
lymphadenopathy, although lesions may be found anywhere in the lungs (Rossi et al., 2005). A 
multivariate analysis has also documented that lesions are mostly restricted to the upper lobes 
upon chest X-ray and they were positively associated with culture proven TB (Wisnivesky et 
al., 2000). Furthermore, tiny nodules throughout the lungs are also common in disseminated 
forms of the disease (miliary TB). Moreover, chest radiographs cannot detect all cases of PTB. 
Pepper et al. (2008) reported that 9% of patients with culture-confirmed PTB had a normal chest 
X-ray. In this regard, a computed tomography (CT) scan can assist the diagnosis of both 
pulmonary and extra-pulmonary TB.  
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 Nucleic acid amplification test  
Several molecular tools have been introduced over the last two decades for the rapid diagnosis 
of TB. Popular molecular tools based on nucleic acid amplification are Qiagen Artus TB PCR 
(Crawley, UK), Roche COBAS TaqMan Mtb assays (Indianapolis, USA) and strand 
displacement amplification (SDA) assay (Becton Dickinson, New Jersey, USA). These 
techniques use various molecular targets to amplify Mtb DNA. For example, Qiagen Artus TB 
PCR and Roche COBAS TaqMan Mtb assay use the 16S rDNA gene, whereas the insertion 
sequence; IS6110 is the target for the SDA assay. Higher sensitivity (93%) and specificity 
(92%) were documented in SDA based assays (McHugh et al., 2004). The insertion sequence 
IS6110 is an excellent target for diagnosis of TB as most of the Mtb bacilli possess multiple 
copies of it. However, the specificity of this assay may reduce due to cross reactivity with many 
other non-tuberculous mycobacterial species, as many of these possess a similar insertion 
sequence (McHugh et al., 1997). Recently, a new molecular diagnostic test was introduced, 
Cepheid GeneXpert (Xpert® MTB/RIF) which can identify concurrently Mtb specific DNA and 
the rifampicin resistance mutation. The sensitivity of this assay reportedly was similar to the 
SDA assay and higher than the Roche Assay (Boehme et al., 2010).  
2.1.1.9.2 Drug resistant tuberculosis 
The diagnosis of drug resistant tuberculosis remains a challenge. The current standard for 
detecting first-line drug-susceptibility/resistance is an automated liquid culture system. In 2008, 
WHO recommended the molecular technique, line probe assays (LPAs) for the rapid detection 
(within 24 hours) of drug resistance in smear-positive specimens or cultured samples (Ling et 
al., 2008, WHO., 2010, O'Grady et al., 2011). The WHO also endorsed the use of Xpert 
MTB/RIF and at the same time also recommended other standard drug-susceptibility tests to 
confirm rifampicin and other drug resistance (WHO., 2011a). Other molecular assays such as 
the automated nucleic acid amplification test, loop-mediated isothermal amplification and 
oligonucleotide microarray are used for drug screening. Microscopic observation direct 
susceptibility (MODS) assay, light-emitting diode microscopy, multi drug and extremely drug 
resistant (MDR-XDR)-TB colour test, colorimetric assays and phage amplification are also 
used as non-molecular assays (Wilson, 2013) for drug susceptibility testing. Unfortunately, 
most of these methods are not currently available in many TB endemic countries, as the tests 
require technical expertise and have higher associated costs. An estimated 10% of potential 
MDR-TB are currently diagnosed globally and only half of such patients receive proper 
treatment (WHO., 2011b, Zignol et al., 2012).  
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2.1.1.9.3 Latent tuberculosis 
Latent tuberculosis infection (LTBI) is a subclinical form of Mtb infection and therefore shows 
no clinical features or radiological findings (Al-Orainey, 2009). The recommended test for the 
diagnosis of LTBI is the Mantoux tuberculin skin test (TST). The test is based on a delayed-
type hypersensitivity (DTH) response following intradermal injection with purified protein 
derivative (PPD). The test is interpreted based on the development of a cutaneous induration at 
the site of injection after 48-72 hours. A positive test suggests previous exposure to Mtb or other 
related mycobacterial species or BCG vaccination (Comstock, 1975, Huebner et al., 1993, 
Wang et al., 2002). The test result may be affected by the dose of PPD, the reader, repetition of 
the dose, as well as the immune status of the individual (Magnus and Edwards, 1955, Chaparas 
et al., 1985, Markowitz et al., 1993, Stuart et al., 2000). A study has shown that a low-dose of 
PPD may give false negative reactions, whereas a high-dose may show false positive reactions 
(Stuart et al., 2000). Further, it was observed that cutaneous indurations can reach greater than 
10 mm after 12 weeks of BCG vaccination in the first year of infancy (Lifschitz, 1965) and test 
reactivity may last up to 5 years (Horwitz and Bunch-Christensen, 1972). In some instances, 
the TST reactivity may continue for up to 15 years post vaccination (Wang et al., 2002). 
Furthermore, the test also gives false positive reactions in immune suppressed patients (e.g. 
HIV patients) with impaired T cell responses (Markowitz et al., 1993). Repeated skin tests 
particularly in health workers, also give strong skin reactions (Magnus and Edwards, 1955). 
The test cannot differentiate between exposure or infection with Mtb and other mycobacterial 
infections (Frieden et al., 2003). The poor sensitivity and specificity of the test limit its use in 
immunosuppressed patients as well as diagnosis of LTBI (Markowitz et al., 1993), but it has 
been used widely because there was no better alternative (Al-Orainey, 2009).  
Recently, a more sensitive and specific test, interferon-gamma (IFN-γ) release assay (IGRA), 
has been developed to diagnose LTBI. The test detects IFN-γ release through stimulation of T 
cells with two Mtb antigens; ESAT-6 and CFP-10 (Brock et al., 2001, Pai et al., 2004a, Whalen, 
2005). The IGRA has excellent specificity as the antigens used in this assay are absent in the 
BCG vaccine (Mahairas et al., 1996, Behr et al., 1999, Pai et al., 2004a). The two commercially 
available diagnostic IGRAs are the whole blood ELISA based “QuantiFERON (QFN)-TB Gold 
assay” (Cellestis Ltd., Carnegie, Australia) and Enzyme linked immunospot (ELISPOT) 
technology based “T-SPOT®TB” using peripheral blood mononuclear cells (PMBC) (Oxford 
Immunotec, Oxford, UK) (Anonymous, 2014, OIL, 2014). Improvements have been made these 
original tests and a newer version of QFN-TB Gold assay is the QuantiFERON-TB-Gold-In-
Tube that uses TB7.7 peptide along with ESAT-6 and CFP-10 peptides (Cole et al., 1998). The 
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latest version of T-SPOT-TB also uses specific peptides of ESAT-6 and CFP-10 rather than 
using whole antigens. Studies have shown that IGRA is more specific and sensitive for the 
diagnosis of LTBI than the TST (Lalvani et al., 2001, Pathan et al., 2001, Chapman et al., 2002, 
Menzies et al., 2007). Pai and co-workers (2008) documented that they cannot differentiate 
latent and active Mtb infections in immunosuppressed individuals. To date, IGRA is considered 
the most effective diagnostic tool for the diagnosis of LTBI but extensive research is required 
to further improve the test, particularly in immune compromised individuals.  
 Non-tuberculous mycobacteria: Classification 
Non-tuberculous mycobacteria (NTM) or atypical mycobacteria comprises all mycobacterial 
species other than M. tuberculosis, M. bovis and M. leprae (Jarzembowski and Young, 2008). 
According to the Runyon classification, NTM were classified based on pigmentation and 
growth rates into four groups (Table 2.3). These microbes share many common properties, such 
as acid-fastness and the ability to cause pulmonary and extrapulmonary granulomatous 
disorders (Jarzembowski and Young, 2008).  
Table 2.3 Runyon classification of non-tuberculosis mycobacteria  
Runyon 
class 
Growth Description 
Pigment 
production 
Species 
I 
Slow 
Photochomogens 
Yellow-orange 
(with light) 
Mycobacterium kansaii*, 
M. marinum* 
II Scotochromogens 
Yellow-orange 
(with or without 
light) 
M. scrofulaceum*, 
M. gordonae*, M. szulgai 
III Nonchromogens None 
M. avium-intracellulare*, 
M. xenopi, M. terrae 
IV 
 
Rapid 
 
Rapid growers None 
M. fortuitum* 
M. peregrinum, 
M abscessus*, M 
cheonae* 
*clinically important species  
 Clinical importance of Mycobacterium fortuitum 
While M. tuberculosis mainly contributes to the majority of mycobacterial infections, there are 
more than 150 non-tuberculous mycobacterial (NTM) species, which are capable of causing a 
wide spectrum of infections (Orme and Ordway, 2014). Among the species of rapidly growing 
mycobacteria, M. fortuitum is one of the most clinically important pathogenic species. They are 
widely distributed in the environment and are able to cause a range of diseases affecting a 
variety of tissues including lungs, lymph nodes, skin, soft and skeletal tissues. The bacteria can 
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cause severe pulmonary infections in addition to osteomyelitis and peritonitis, (Wallace, 1989, 
Lessing and Walker, 1993, Sangwan et al., 2013). According to the available epidemiological 
data on NTM, 16.7% of the patients with soft tissue infections due to M. fortuitum, had 
comorbid diabetes (Uslan et al., 2006). Furthermore, M. fortuitum (43.1%) was the leading 
cause of oedematous lesions in diabetic patients reported in Australian population (O'Brien et 
al., 2014). The rapid escalation of immune suppressing co-morbidities has contributed not only 
to an increased incidence of TB, but also NTM infections (e.g. M. fortuitum infection). 
 Virulence factors of non-tuberculous mycobacteria 
Host immune response to M. tuberculosis and non-tuberculous mycobacterial (NTM) infection 
varies in many aspects. In both Mtb and NTM, the most recognised virulence factor is the 
hydrophobic cell wall, which has various immune-modifying capabilities depending on its 
composition and ability to interact with host cells. The glycopeptidiolipids (GPL) of the cell 
wall are mainly produced by NTM but absent in M. tuberculosis. The GPL extract of M. avium 
complex reduced the production of IFN-γ and TNF-α (Pourshafie et al., 1999), which are crucial 
for NTM infections. Non-specific GPL (nsGPL) of M. avium stimulated macrophages to secrete 
immunosuppressive chemical as prostaglandin E2 resulting in higher intracellular survival 
(Barrow et al., 1993), whereas the absence of the same structure in M. abscessus enhanced 
intracellular survival (Sweet and Schorey, 2006). Moreover, phagocytosis, inhibition of 
phagosome-lysosome fusion and cytokine production in macrophages also influenced by 
serotype specific GPL (ssGPL) (Takegaki, 2000). Such as, ssGPL from serovar 2 of M. avium 
enabled macrophages invasion, reduced TNF-α production and increased intracellular survival, 
whereas serovar 8 can survive in macrophages regardless of marked pro-inflammatory 
responses (Cebula et al., 2012). In addition to GPL, lipoglycans as lipoarabinomannans (LAM) 
considered another important virulent factor in mycobacterial pathogenesis. The structural 
domain of LAM has similarity and dissimilarity with Mtb. ManLAM; a structural domain of 
LAM present in M. avium which is similar to Mtb. M. fortuitum and M. smegmatis possesses 
phosphatidylinositol-LAM (PILAM) (Chatterjee and Khoo, 1998). Research has shown that 
Purified PILAM from NTM enhances the secretion of IL-12, TNF-α and IL-8 in macrophages 
(Maeda et al., 2003). Whereas purified AraLAM (arabinose-capped LAM) from M. smegmatis 
able to trigger an acute inflammatory response (increase TNF-α, IL-6 and IL-1β production) 
with numerus neutrophil influx for the clearance of the bacteria. The authors also showed that 
TLR2 is the signaling receptor for purified AraLAM and lack of it delayed the bacterial 
clearance from the lungs (Wieland et al., 2004). Furthermore, the interaction between Mtb and 
host dendritic cells (DCs) is thought to be critical for mounting protective antimycobacterial 
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immune responses. Prior research demonstrated that Dendritic Cell Specific Intracellular 
Adhesion Molecule (DC-SIGN) strongly bind to ManLAM of Mtb, whereas ManLAM of M. 
avium bind poorly with same pattern recognition receptor indicating that host recognition of 
NTM infection is different to Mtb (Maeda et al., 2003). It is obvious that multiple factors are 
necessary for the pathogenesis of NTM infections, which differs based on species specific 
mycobacterial virulence factors, host susceptibility factors, route of infection etc. Further 
investigations using the purified NTM-derived cell wall components along with species itself 
are crucial in understanding the underlying immune responses in host-pathogen interaction. 
 Immune responses to Mycobacterium fortuitum  
Few studies have investigated the in vitro performance of macrophages during M. fortuitum 
infections (Parti et al., 2005, Helguera-Repetto et al., 2014). Unlike Mtb infection, M. fortuitum 
(and other many fast-growing mycobacteria) behave differently in terms of growth within the 
macrophages (Orme and Ordway, 2014). An in vitro study of macrophages infected with slow 
growing (M. tuberculosis and M. celatum) and fast growing mycobacteria (M. fortuitum and M. 
abscessus) reported a lower number of infected cells with a higher survival and proliferation of 
fast growers within the infected macrophages, compared to slow growers (Helguera-Repetto et 
al., 2014). A similar observation was also documented by Parti and colleagues (2005) using M. 
fortuitum infected macrophages. A previous study demonstrated that virulent M. fortuitum 
survive within the macrophages by restricting the IFN-γ driven nitric oxide (NO) production 
and by limiting the phagosome fusion with lysosomes (Da Silva et al., 2002). Higher survival 
of the mycobacteria is not associated with fatal infections, as the M. fortuitum infected 
macrophages produce more antimycobacterial compounds (reactive oxygen species; ROS) and 
induce rapid apoptosis of the infected cell (Helguera-Repetto et al., 2014). Prior studies have 
also reported that the inability of less virulent M. fortuitum failed to cause disease despite their 
higher survival in macrophages due to the rapid induction of host cell apoptosis, as this leads 
to direct killing of intracellular mycobacteria (Molloy et al., 1994, Keane et al., 2002, Bohsali 
et al., 2010). Cytokine production during in vitro culture of mycobacteria was also found to 
assist with controlling survival of the M. fortuitum. A higher production of TNF-α and IL-1β 
was observed in M. fortuitum infected macrophages compared to Mtb infected macrophages 
following culture (Helguera-Repetto et al., 2014). The difference in the production of TNF-α 
was explained by the variations in the lipoarabinomannan (LAM) structure on the cell wall 
(Chatterjee et al., 1992a, Singh and Goyal, 2013). Less pathogenic mycobacteria (e.g. M. 
fortuitum) possess extensive arabinose side-chains on LAM which is a potential inducer of 
cytokines. Whereas pathogenic mycobacteria such as Mtb, comprise the short mannan chain 
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which extensively masks the arabinose side chain (Chatterjee et al., 1991, Chatterjee et al., 
1992a). Another possible mechanism for greater TNF-α induction by the less pathogenic 
bacteria is the differences in phagolysosome fusion. Phagolysosome fusion is a pre-requisite to 
enhance the production of cytokines. Phosphatidylinositol 3-phosphate (PI3P) is a membrane 
trafficking regulatory lipid which is important for the phagosomal acquisition of lysosomal 
contents (Vergne et al., 2005b). Virulent mycobacteria secrete an acid phosphatase known as 
SapM which is required to hydrolyse PI3P, resulting in inhibition of the phagolysosomal fusion. 
Less or non-pathogenic mycobacteria do not produce SapM, thus no inhibition of phagosome 
with endosome occurs, resulting in more cytokine production (Saleh and Belisle, 2000).  
 
There are few studies investigating the pathogenesis of M. fortuitum infection in animal models 
(Saito and Tasaka, 1969, Da Silva et al., 2002, Parti et al., 2005, Silva et al., 2010). M. fortuitum 
caused disseminated infection when mice were infected intravenously (Parti et al., 2005, Silva 
et al., 2010). Parti and co-workers (2005) observed a 1000-fold higher bacillary burden in the 
kidneys of M. fortuitum infected mice compared to the bacillary load in the spleen and lungs at 
10 days post-infection (dpi). The authors also demonstrated that after 45 and 60 dpi, the 
bacillary load in spleen and lungs was minimal although a trend of higher bacterial load was 
maintained in the kidney at the same timepoint. The bacillary burden in the liver was high 
immediately following infection, although it dropped dramatically after 10 dpi. Silva and co-
workers (2010) observed a similar pattern of bacterial burden in the spleen and liver of M. 
fortuitum infected mice. Similar to Mtb infections, a granulomatous response in M. fortuitum 
infection is crucial for controlling and confining the infection (Parti et al., 2005, Silva et al., 
2010). Granuloma formation is driven by the Th1 cells mediated responses as seen in Mtb 
infection (Flynn et al., 2011). During M. fortuitum infection, macrophages and CD4+ T cells 
are the main components of the granuloma. It was observed that granuloma formation is 
accelerated by the antigen specific CD4+T cells and is largely dependent on TNF-α and IFN-γ 
(Appelberg et al., 1994a). Parti and co-workers (2005) reported a higher production of IFN-γ 
production from the CD4+ T cells compared to CD8+ T cells following infection with M. 
fortuitum. A higher production of IFN-γ by the previous reports confirmed that a Th1 cell 
response is essential in the control of M. fortuitum infection.  
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 Overview of diabetes 
 Diabetes 
Diabetes mellitus (DM) or diabetes is a group of metabolic diseases. They are characterised by 
high blood sugar either because the pancreas becomes unable to secrete sufficient insulin 
(insulin deficiency) or the peripheral cells do not respond to insulin (insulin resistance). This 
hyperglycaemic condition in diabetic patients produces classical symptoms of polyuria 
(frequent urination), polydipsia (increased thirst) and polyphagia (increased hunger) (WHO., 
2006, Cooke and Plotnick, 2008, Gardner and Shoback, 2011). 
The disease is considered one of the oldest human diseases. It was first documented in Egyptian 
manuscripts about 3000 years ago (Leutholtz and Ripoll, 2011). In 1936, type 1 diabetes (T1D) 
(insulin dependent) and type 2 diabetes (T2D) (non-insulin dependent) appeared as two distinct 
types of diabetes (Himsworth, 1936) but T2D was first stated as a component of metabolic 
syndrome in 1988 (Patlak, 2002). T2D is the most common form of DM (Weyer et al., 1999) 
accounting for about 90% of cases (ADA., 2010).  
 Types of diabetes 
There are three main types of DM; T1D, T2D and gestational diabetes. Type 1 diabetes or 
insulin-dependent diabetes mellitus (IDDM) results from insulin deficiency due to pancreatic 
defects. It is mainly mediated by the loss of insulin-producing β (beta) cells of the islets of 
Langerhans (Rother, 2007). The cause of β-cell defects can either be idiopathic or the result of 
T cell mediated autoimmune responses, which are characterised by the presence of auto-
antibodies in the pancreas (e.g. islet cell antibodies, anti-glutamic acid decarboxylase 
antibodies, or protein tyrosine phosphatase-like protein IA-2 antibodies) (Zimmet et al., 2004). 
Most affected people have good health with normal sensitivity and responsiveness to insulin 
during the time of onset. Later, the affected individual becomes absolutely insulin deficient and 
requires additional administration of insulin to prevent severe consequences like ketoacidosis, 
coma or death (Rabinovitch and Suarez-Pinzon, 1998, Zimmet et al., 2004, WHO., 2006). The 
risk of developing T1D is mainly influenced by genetics and environmental factors. Genetic 
factors include human leucocyte antigen markers (e.g. HLA-A, HL-B, HLA-DPβ1) of the host 
(Barnett et al., 1981, Akerblom et al., 2002). Whereas environmental factors include bacterial 
or viral infections, or nutritional factors that trigger the autoimmune process (McNally et al., 
2006). This type of diabetes mostly affects children but is also found in adults; therefore, it was 
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traditionally called "juvenile diabetes". There are no effective preventive measures against T1D 
(WHO., 2016a).  
Type 2 diabetes or noninsulin-dependent diabetes mellitus (NIDDM) results from insulin 
resistance by the peripheral tissue or inadequate secretion of insulin from the pancreas (Weyer 
et al., 1999, ADA., 2010). The risk factors for developing T2D are many, including older age, 
dietary intake, sedentary lifestyle, obesity, ethnicity, prior history of glucose intolerance 
(genetic) or gestational diabetes and other environmental factors as found in T1D (Zimmet et 
al., 2004, Sobngwi et al., 2008). This type of diabetes is common in adults; therefore, it is also 
occasionally termed as "adult-onset diabetes". At the early stages of T2D, the defective 
responsiveness of the body tissues is believed to involve impairment of cell-associated insulin 
receptors to respond to insulin (i.e. insulin resistance) (Kumar, 2007). In individuals with T2D, 
there is no auto-immune degeneration of the pancreatic β-cell as is seen T1D patients (Zimmet 
et al., 2004). However more recently it has become clear that auto-reactive B and T cells may 
be activated following excessive inflammation of adipose tissue (Winer et al., 2011). The 
resulting hyperglycaemia due to relative insulin deficiency can be reversed by dietary 
interventions and medications for improving insulin sensitivity or limiting glucose production 
by the liver. Sometimes relative insulin deficiency may convert to absolute insulin deficiency 
requiring external supplementation of insulin (Gardner and Shoback, 2011).  
The third form of diabetes is gestational diabetes mellitus (GDM). This form usually occurs 
around the 24th week of pregnancy, due to transient resistance to insulin. The condition arises 
because action of insulin is inhibited, probably by hormones produced by the placenta. Women 
who have the GDM are at a high risk of developing the condition in subsequent pregnancies. 
GDM may also lead to the development of T2D in later life (Vijan, 2010). Babies born to 
mothers with GDM also have a higher lifetime risk of developing T2D (WHO., 2016b). Other 
forms of DM include congenital diabetes, cystic fibrosis-related diabetes, steroid diabetes and 
several forms of monogenic diabetes. 
 Criteria for classification and diagnosis of diabetes  
The classical symptoms of diabetes include polyuria (frequent urination), polydipsia (increased 
thirst) and polyphagia (increased hunger) (Cooke and Plotnick, 2008). Several other signs may 
be seen during the onset of diabetes such as weight loss, blurry vision and headache, weakness 
and delayed healing, but these are not specific to the disease. Symptoms usually develop rapidly 
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in T1D (within weeks or months) whereas manifestations of T2D occur slowly and remain 
asymptomatic (Zimmet et al., 2004). 
The World Health Organisation (WHO) and American Diabetic Association (ADA) has  
provided the updated diagnostic criteria (Table 2.4) for diabetes (ADA., 2010, WHO., 2016a). 
The disease should be diagnosed when clinical symptoms are present along with diagnostic 
criteria listed in Table 2.4. 
Table 2.4 Diagnostic criteria of diabetes mellitus and intermediate hyperglycaemia 
Conditions 
WHO ADA  
Fasting 
glucose  
2 hours 
glucose * 
Fasting 
glucose  
2 hours 
glucose * 
mmol/L mmol/L mmol/L mmol/L 
Impaired fasting glycaemia 
(IFG) 
6.1-6.9 <7.8 5.6-6.9 - 
Impaired glucose tolerance 
(IGT) 
<7.0 ≥7.8 & <11.1 - 
≥7.8 & 
<11.1 
Diabetes ≥7.0 ≥11.1 ≥7.0 ≥11.1 
* Following a 75 g oral glucose challenge, WHO; World Health Organisation, and ADA; 
American Diabetic Association 
 Risk factors for type 2 diabetes 
The numbers of individuals with T2D is rapidly increasing worldwide. The risk factors for 
developing T2D are likely to be a combination of lifestyle and genetic factors (Ripsin et al., 
2009). Important lifestyle factors that contribute to the development of T2D include diets, lack 
of physical activity, a sedentary lifestyle, smoking and generous consumption of alcohol, stress, 
urbanisation and possibly others (Hu et al., 2001, Smyth and Heron, 2006).  
 Dietary factors 
Excess caloric intake is a major driving force of increasing obesity and T2D epidemics globally. 
This nutritional shift typically involves increased consumption of animal fat, a high fat diet 
(HFD) and more frequent intake of fast foods. Furthermore, consumption of sugar or sweetened 
beverages (SSB) in large amounts or eating large amounts of white rice is associated with an 
increased risk of developing T2D (Malik et al., 2010, Hu et al., 2012). A metanalysis showed 
that that 26% of individuals have the chance of developing T2D who were with SSB intake 
(most often 1-2 servings/day) (Hu, 2013). A high glycaemic diet can increase insulin demand 
and may lead to pancreatic β-cell exhaustion resulting in T2D (Hu and Willett, 2002). A HFD, 
particularly saturated fats and trans fatty acids, has been reported to increase the risk of diabetes 
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while polyunsaturated and monounsaturated fats decrease the risk (Riserus et al., 2009). The 
mechanism by which obesity induces insulin resistance is poorly understood. In contrast, 
dietary fibres, both soluble and insoluble, may improve T2D (Akinmokun et al., 1992). Whole-
grain intake (2 servings/day) has been observed to lower the risk (21%) of developing diabetes 
(de Munter et al., 2007). However, low vitamin D intake enhances the chance of developing 
T2D (Pittas et al., 2006, Knekt et al., 2008). The possible mechanism is that vitamin D 
deficiency may lead to β-cell dysfunction and contribute to insulin resistance and excessive 
inflammation.  
Obesity is one of the major risk factors for developing T2D (Walley et al., 2006). The WHO 
has recognised that the prevalence of obesity is increasing at an alarming rate, putting the 
populations of most countries at risk of developing many diseases including diabetes (WHO., 
2008). Of those diagnosed with T2D, 80% were overweight (Smyth and Heron, 2006). Excess 
body fat among patients of Chinese and Japanese descent contributes 30% of cases of T2D 
whereas the rate is 60-80% in those of European and African descent and 100% in Pima Indians 
and Pacific Islanders. The reasons for the rapid rise in global obesity include increased 
consumption of diets with a high glycaemic index, the changing structures and compositions of 
diets (Popkin and Nielsen, 2003) and physical inactivity (Bell et al., 2002). Childhood obesity 
rates between the 1960s and 2000s has also contributed to the sharp global rise of DM in 
children and adolescents (Barlow, 2007). Obesity ultimately makes the individual insulin 
resistant (Ding and Malik, 2008).  
 Smoking  
Cigarette smoking is an important independent risk factor for T2D. A meta-analysis reported 
that smokers had a 45% greater chance of developing T2D compared to non-smokers (Willi et 
al., 2007) and the risk is influenced by the duration of smoking and number of cigarettes 
smoked. The relationship between cigarette smoking and diabetes can also be illustrated by 
possible biological mechanisms including: (i) although smokers tend to be physically leaner 
they have increased risk of central adiposity or abdominal fat deposition (Barrett-Connor and 
Khaw, 1989, Shimokata et al., 1989) and (ii) smoking has anti-oestrogenic effects in women 
and decreases plasma testosterone level in men (Meikle et al., 1988). These factors may 
promote abdominal fat deposition and enhance the likelihood of insulin resistance. 
Furthermore, nicotine exposure during the prenatal or neonatal period can cause β-cell 
dysfunction and increase β-cell apoptosis (Bruin et al., 2008). 
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 Physical inactivity 
Physical activity reduces the risk of developing diabetes whereas sedentary behaviour increases 
the risk. An epidemiological study reported that individuals who spend 2 hours/day watching 
television had a 14% increased chance of developing diabetes (Hu et al., 2003). In contrast, the 
possibility of developing diabetes decreased by 12% if an individual spends 2 hours/day 
walking or standing working. The authors also documented that hurried walking may reduce 
the chances of diabetes by 34%. Another study reported that lack of exercise is believed to 
cause 7% cases of T2D (Lee et al., 2012).  
 Genetic factors 
Type 2 diabetes most likely represents a complex interaction among the genetics of the 
individual and environmental factors. Genome-wide association studies (GWAS) has identified 
common factors contributing to diabetes susceptibility (McCarthy, 2010). At least 40 different 
genetic loci have been identified that are associated with T2D (Herder and Roden, 2011). Most 
of these genes are associated with impairment of β-cell functions. Studies showed that 
monozygotic twins have a 90-100% chance of developing diabetes in his/her lifetime if one 
identical twin is affected by the disease. Conversely, the rate of developing T2D in non-identical 
offspring is 25-50% (Gardner and Shoback, 2011). Many diabetes-associated genes or 
poylmorphisms identified in Caucasian populations have also been identified in some Asian 
populations. For example, the risk allele in the TCF7L2 gene is common in European and South 
Asian populations (20-30%), but rare in East Asians (~2%) (Ng et al., 2001, Wu et al., 2008). 
The prevalence of T2D also varies markedly between ethnic groups living in the same 
geographical area (Knowler et al., 1993). African Americans, Native Americans, Pima Indians 
and Hispanic Americans have a 2 to 6 times higher chance of being affected by the disease 
compared with Caucasian Americans (Carter et al., 1996, Harris et al., 1998). The prevalence 
of T2D is also higher in South Asian people (e.g. > 50% in mass population in India), indicating 
that genetic factors are more important than environmental factors in developing T2D. 
 Medical conditions 
Many medications and other health problems can predispose people to diabetes (Feinglos, 
2008). Use of medications including glucocorticoids, beta blockers, thiazides, atypical 
antipsychotics (Izzedine et al., 2005) and statins may contribute to T2D. Health problems 
associated with developing diabetes include acromegaly, Cushing's syndrome, 
hyperthyroidism, thyrotoxicosis, chronic pancreatitis, pheochromocytoma, and certain cancers 
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such as glucagonomas (Feinglos, 2008). Testosterone deficiency can also influence the 
occurrence of T2D (Saad and Gooren, 2009, Sampson et al., 2011).  
 Other factors 
Individuals with blood glucose levels higher than normal but not high enough to be classified 
as diabetes are said to have impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). 
The term ‘prediabetes’ is used to describe this grey area between normal glucose levels and 
diabetes. In prediabetes, the pancreatic β-cell can no longer produce enough insulin to overcome 
insulin resistance, causing blood glucose levels to rise above the normal range. Individuals with 
pre-diabetes often have no signs or symptoms but have a higher risk of developing T2D and 
other complications (e.g. cardiovascular). Worldwide there are large numbers of people with 
prediabetes at risk of developing T2D at any point in their life time if proper preventive 
measures are not taken (Zhang et al., 2010).  
 Pathophysiology of type 2 diabetes  
Under normal physiological conditions, glucose homeostasis in the body is maintained 
correctly despite wide fluctuations in supply and demand (Figure 2.5). Plasma concentration 
remains normal through a tightly regulated and dynamic interaction between tissue sensitivity 
to insulin (especially in the liver) and insulin secretion (DeFronzo, 1988). In T2D, these 
mechanisms are disturbed (Figure 2.5). In this situation, the body’s insulin sensitive cells fail 
to uptake glucose, resulting in hyperglycaemia. Further, certain cells such as fat and muscle 
cells are also disrupted if insulin resistance/deficiency exists. In general, insulin suppresses 
hepatic glucose release to maintain normal plasma glucose levels (Figure 2.5) (Groop et al., 
1993). It was reported that 80-85% of the glucose is disposed in muscle and liver and 4-5% is 
metabolised by adipocytes by insulin dependent manner (Bergman, 2013). If insulin resistance 
or deficiency exists, pancreatic β-cell attempts to secrete more insulin to overcome the 
underlying defects of insulin resistance (DeFronzo et al., 1992). Hyperglycaemia and 
hyperinsulinimia manifest in the subjects of T2D if this compensatory mechanism fails. 
Furthermore, fat cells also fail to uptake circulating lipids to store them as triglycerides, causing 
hydrolysis of these triglycerides (Lipolysis) contributing more fatty acids in plasma. These fatty 
acid concentrations also reduce muscle glucose uptake, increase liver glucose production and 
aggravate hyperglycaemia and hyperinsulinemia (Boden, 1999) resulting in severe 
complications like hypertension (Reaven et al., 1996, Ginsberg, 2000) and other vascular 
abnormalities (Ginsberg, 2000).  
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T2D involves two primary pathogenic mechanisms: (i) a progressive decline in pancreatic islet 
cells function (β-cells) resulting in reduced insulin secretion and inadequate suppression of 
glucagon secretion (Muller et al., 1970, Weyer et al., 1999); and (ii) peripheral insulin resistance 
by skeletal muscle, liver and adipose tissue which decrease metabolic responses to insulin 
(DeFronzo, 1988, ADA., 2010). In fact, both insulin resistance and impairment of insulin 
secretion/β-cell defects are important components in the pathophysiology of T2D.  
 
Figure 2.5 Glucose homeostasis and its disruption in individuals with diabetes mellitus 
Figure illustrates the mechanism of glucose homeostasis and disruption in diabetes. Glucose 
homeostasis is mainly maintained by the insulin and glucagon. Insulin is secreted from 
Pancreatic β-cell and allows glucose to be taken up and used by insulin-dependent tissues (e.g. 
skeletal muscle, fat). This hormone also stimulates liver cells to convert excess glucose to 
glycogen (glycogenolysis) to maintain normoglycaemia. In contrast, glucagon is secreted from 
the alpha cells of Pancreas in response to hypoglycaemia. It increases the blood glucose level 
by breaking down the liver glycogen into glucose (Glycogenolysis). In case of insulin resistance 
in diabetes, the function of the insulin is disrupted resulting in hyperglycaemia. Hyperglycaemia 
further stimulate the Pancreatic β-cell to secrete more insulin. However, due to inadequate 
suppression of glycogen by insulin, the hyperglaycamic state of diabetic patients further 
aggravated by glycogenolysis. Figure modified from IDF. (2013).  
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  Cellular defects in type 2 diabetes 
2.2.5.1.1 Islets of Langerhans dysfunctions 
In T2D, the most noticeable alteration in the islets of Langerhans is the deposition of amyloid 
material in the insulin secretory granules. The amyloid mass is derived from the polymerisation 
products of β-cell regulatory proteins including the islet amyloid polypeptide (IAPP) or amylin 
(Westermark et al., 1986, Westermark et al., 1987). High concentrations of amylin may 
decrease glucose uptake and inhibit endogenous insulin secretion, suggesting that amylin may 
be directly involved in the pathogenesis of T2D (Hull et al., 2004). Furthermore, it was observed 
that even a small amyloid particle deposition in the insulin secretory granules shows the ultra-
structural signs of cell membrane destruction (Janson et al., 1999). Therefore, it is suggested 
that in T2D aggregation of amylin could regulate the progressive loss of pancreatic β-cell 
(Carrera Boada and Martinez-Moreno, 2013). However other studies failed to find a 
pathological role for amylin with administration of physiologic amounts of amylin showing no 
acute effect on insulin secretion or insulin actions in humans (Wilding et al., 1994). Hence the 
precise role of amylin deposits in the pancreas and their contribution to the pathophysiology of 
T2D remains unclear. 
2.2.5.1.2 Loss of β-cells mass and function  
Prospective studies have indicated that β-cell functions are impaired and lost progressively 
during the development of T2D (Gerich, 1998, Xiang et al., 2006). This functional impairment 
of β-cell is related to the loss of β-cell mass. Autopsy studies of patients with T2D revealed 
substantial amounts of β-cell mass loss; up to 65% compared with non-diabetic controls 
(Sakuraba et al., 2002). Studies also demonstrated that β-cell deficit and apoptosis increased 
with the progression of the disease (Butler et al., 2003, Marchetti et al., 2004). β-cell mass loss 
may be progressive unless there is concurrently increased β-cell formation. The frequency of 
pancreatic β-cell apoptosis was reported to increase 10 times in lean compared to 3 times in 
obese cases of T2D, suggesting that a lower β-cells mass in T2D patients is due to an increase 
rate of β-cell apoptosis (Butler et al., 2003). Recently, a meta-analysis found a strong 
relationship between diabetes and telomere length (Wang et al., 2016). This report suggested 
that islet β-cell undergo apoptosis because the telomere length gradually becomes shorter in 
diabetes, which in turn worsen the complications of diabetes.  
Three possible mechanisms have been proposed to explain the β-cell deficiency of T2D (Scheen 
and Lefebvre, 1996). Firstly, there may be some genetic β-cell defects , although this prediction 
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has not been confirmed yet in T2D (Polonsky, 1995). Secondly, insufficient β-cell development 
is related to in-utero malnutrition which may lead to a partial insulin secretory defect (thrifty 
phenotype hypothesis) (Hales and Ozanne, 2003). Thirdly, an unfavourable metabolic 
environment can alter insulin secretion due to glucotoxicity (Yki-Jarvinen, 1992) and 
lipotoxicity (Unger and Zhou, 2001). Moreover, ectopic deposition of triglycerides in the 
pancreatic islets can lead to dysfunction of β-cell via a nitric oxide-dependent mechanism which 
subsequently damages the β-cell by oxidation and induces apoptosis (Unger and Zhou, 2001). 
 Role of adiposity, its distribution and mediators in the development of type 2 
diabetes 
2.2.5.2.1 Adiposity 
Adiposity or obesity is one of the major risk factors in the development of T2D. It decreases 
the sensitivity of β-cell to glucose (Henry et al., 1985, Carey et al., 1996) by increasing 
peripheral resistance to insulin-mediated glucose uptake (Henry et al., 1985, DeFronzo and 
Ferrannini, 1991). The mechanism by which obesity induces insulin resistance is poorly 
understood. Genetic abnormality in the beta-3-adrenergic receptor is believed to be a possible 
cause of obesity induced insulin resistance. Further, the c-Jun amino-terminal kinase (JNK) 
pathway may be an important mediator of insulin resistance as JNK activity is increased in 
obesity. In animal models, the absence of JNK1 results in decreased adiposity and enhanced 
insulin sensitivity (Hirosumi et al., 2002). 
2.2.5.2.2 Body fat distribution 
Body fat distribution seems to be a critical aspect in the pathophysiology of T2D. The intra-
abdominal fat deposition is more strongly correlated with insulin resistance than subcutaneous 
fat (Montague and O'Rahilly, 2000). Several mechanisms have been identified to describe how 
obesity increases insulin resistance. Excess accumulation of fat in insulin sensitive organs, 
particularly in skeletal muscle and the pancreatic β-cells, can hamper insulin action and its 
secretion. Fat from the visceral depots has a significant role in insulin resistance because 
visceral fat cells are less sensitive to the suppression of lipolysis as well as having direct access 
to the portal circulation. Increased free fatty acids in the portal circulation may impair 
metabolism, blocking insulin signalling pathways and increasing gluconeogenesis from the 
liver (Carey et al., 1996, Lebovitz, 1999). 
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2.2.5.2.3 Adipose tissue mediators 
Adipose tissue is considered to be a storage depot of fat as an energy reserve. Indeed, the role 
of adipose tissue is diverse and, as an endocrine organ, it is capable of secreting a number of 
adipose tissue specific chemical mediators such as leptin, adiponectin and resistin. It can also 
secrete inflammatory cytokines which impair insulin secretion. There may be more than one 
mechanism by which obesity induces insulin resistance.  
Leptin is produced by adipocytes and its secretion is proportional to adipocyte mass. Generally, 
it has influence on appetite regulation via the central hypothalamic neuroendocrine pathways 
(Goldstein, 2002). Moreover, it has a more direct role in influencing obesity and insulin 
resistance. Human and animal model studies have shown that leptin deficiency increases 
obesity and insulin resistance. Studies in a leptin receptor knock out (LepR KO) mouse model 
indicated that leptin signalling is associated with improved glucose tolerance in LepR KO group 
compared to control animals when they were feed a standard diet. On the other hand, rapid 
weight gain followed by insulin resistance was observed in LepR KO mice fed a HFD and this 
was due to the functional impairment of β-cell of the pancreas (Morioka et al., 2007, Niswender 
and Magnuson, 2007). 
Adiponectin is an adipocyte-derived collagen like protein (Goldstein, 2002). It reduces the level 
of blood free fatty acids and improves lipid profiles, reduces inflammation following better 
glycaemic control in diabetic patients (Mantzoros et al., 2005). Interestingly, adiponectin has 
also been associated inversely with insulin sensitivity, which increases the risk of developing 
diabetes (Ferrannini, 1998, Li et al., 2009). The protein is downregulated in obesity (Arita et 
al., 1999) leading to increased insulin resistance followed by hyperinsulinemia for developing 
T2D (Kadowaki et al., 2006). However, adiponectin and adiponectin receptors also play an 
important role in the regulation of diabetes. Two studies have suggested that intake of dietary 
cereal fibres and food with a lower glycaemic index can improve adiponectin secretion in 
diabetic patients (Qi et al., 2005) and women (Qi et al., 2006). 
Resistin is another adipocyte-specific protein molecule associated with insulin resistance. 
Administration of resistin decreases insulin mediated glucose uptake by adipocytes (Steppan et 
al., 2001) and its expression can be reduced by treating patients with thiazolidinediones 
(glitazones) (Shuldiner et al., 2001). 
Studies have reported the role of increased inflammation and obesity in the pathogenesis of 
diabetes and its complication (Shoelson et al., 2006, Vandanmagsar et al., 2011). Increased 
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inflammation and diabetic complications are mainly associated with the increased production 
of reactive oxygen species (ROS) as a result of oxidative stress (Wright et al., 2006). These 
ROS production increase markers of inflammation reduced nitric oxide availability and 
chemical modification of lipoproteins leading to macrovascular (e.g. cardiovascular diseases, 
atherosclerosis) and microvascular (e.g. neuropathy, nephropathy, retinopathy) complications. 
For an example, in diabetes, advanced glycation end products bind with receptor for AGEs 
(RAGE) on the surface of endothelial cells triggering the production of ROS, in particular, 
super oxide anion, by NADPH. Then, these ROS activate nuclear factor kB (NF-kB), results in 
the transcriptional activation of genes relevant for inflammation leading to atherosclerosis 
(Wright et al., 2006, Chawla et al., 2016).  
However, elevated level of ROS in T2D increase the markers of inflammation, such as C-
reactive protein, plasminogen activator inhibitor-1, TNF-α, IL-6, peripheral blood leucocyte 
counts and cellular adhesion molecules (e.g. intracellular and vascular adhesion molecules) 
(Pradhan et al., 2001, de Rekeneire et al., 2006, Wright et al., 2006). Among the markers, 
elevated TNF-α derived is strongly associated with insulin resistance (Hotamisligil et al., 1993, 
Uysal et al., 1997) by blocking the insulin signalling pathway (Liu et al., 1998). This markers 
of inflammation further worsen the vascular complication in diabetes (Wright et al., 2006). 
 Immune defects in diabetes 
Immune defects in diabetic patients result in many complications (e.g micro and macrovascular 
complications) including increased susceptibility to infectious agents (also discussed in section 
2.3.5.1). These complications are the result of both defective innate and adaptive immune 
responses. In T1D, auto-reactive T cells drive the chronic inflammatory changes resulting in 
dysfunction of pancreatic β-cell (Atkinson and Eisenbarth, 2001). In T2D, insulin resistance is 
the primary cause which triggers the alteration of immunity particularly innate immune 
responses (Pedicino et al., 2013). It is suggested that the key factors for immune alteration in 
diabetes is due to poor control of hyperglycaemia attributed by insulin resistance or insulin 
deficiency. Systemic low-grade inflammation with higher level of pro-inflammatory proteins 
such as C-reactive protein, TNF-α and IL-6 in diabetic patients are not only associated with 
worsening of the insulin resistance (Kroder et al., 1996, Esposito et al., 2002, Freeman et al., 
2002, Meigs et al., 2004, Goldberg, 2009) but also enhance vascular damages (Hotamisligil et 
al., 1993, Uysal et al., 1997, Wright et al., 2006).  
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Macrophages appear to play the pivotal role in the innate immune dysfunction seen in T2D 
(Fujiwara and Kobayashi, 2005, Ma et al., 2008). These cells perform many important functions 
including phagocytosis, antigen processing and presentation and act as a bridge between the 
innate and adaptive immune systems (Fujiwara and Kobayashi, 2005, Ma et al., 2008). 
Abnormalities in macrophage phenotype, chemotaxis, phagocytosis and cytokine secretion 
have been documented in diabetes patients and animal models. Studies in diabetic patients have 
shown that phagocytic and chemotaxis functions of polymorphonuclear leucocytes were 
impaired (Mowat and Baum, 1971, Marhoffer et al., 1992, Delamaire et al., 1997). The 
adherence of these cells was also decreased (Bagdade et al., 1978, Bagdade and Walters, 1980, 
Andersen et al., 1988) with reduced neutrophil degranulation observed in diabetic patients 
(Stegenga et al., 2008). An animal model of diabetes has demonstrated a significantly reduced 
phagocytosis of latex beads by the resident peritoneal macrophages (RPM) with reduced 
number of F4/80+cells in the peritoneal exudate. These authors also observed macrophages 
skewed to M2 polarised macrophages with altered phenotype, reduced chemotaxis and 
adherence capability (Liu et al., 2012). Ma and colleagues (2008) also observed a significantly 
reduced phagocytic capability of F4/80+ splenic macrophages and peritoneal exudate 
macrophages (PEM) in streptozotocin (STZ)-induced diabetic mice. In diabetes-co-morbid 
infections (e.g. tuberculosis, melioidosis), reduced phagocytosis of the bacteria and their killing 
were also observed in peritoneal or peripheral blood mononuclear cells (PBMCs) (Saiki et al., 
1980, Hodgson et al., 2011, Tan et al., 2012). The precise mechanisms underlying this 
decreased phagocytosis (uptake and killing) by diabetic macrophages remain unclear. Ma and 
colleagues (2008) suggested the possibility of reduced macrophage numbers due to deficient 
differentiation of macrophages from bone marrow cells. Defective and lower yields of 
macrophages (and stem cells) from bone marrow cells have also been observed in diabetes 
(Nikolic et al., 2004, Fu et al., 2006, Kuki et al., 2006, Rota et al., 2006). Other reasons 
suggested for impaired phagocytosis in diabetes include reduced association (attachment) 
between bacteria and monocyte/macrophages, alteration of serum opsonins or complement 
proteins (C3b) and complement receptors (CR1 and CR3) (Schlesinger et al., 1990, Schlesinger, 
1998, Gomez et al., 2013). Recent studies indicated that compromised phagocytosis of mycolic 
acid coated beads in diabetic macrophages was due to the lower expression of the macrophage 
receptors with collagenous structure (MARCO), Toll-like receptor 2 (TLR2) and the coreceptor 
for bacterial LPS (lipopolysaccharide), CD14 (Bowdish et al., 2009, Martinez et al., 2016). 
Advanced glycation end products accumulation in diabetes has also been shown to alter the 
expression of macrophage surface receptors (Lachmandas et al., 2015, Martinez et al., 2016). 
Furthermore, a study has shown that addition of AGEs to the peritoneal macrophages in vitro 
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reduced the phagocytic capability of latex beads, which further confirmed the role of AGEs in 
phagocytosis (Liu et al., 1999). Another possibility of lower phagocytosis might be due to 
reduced level of glutathione (GSH). It is noted that in healthy individuals, production of ROS 
is balanced by an increase in antioxidant activity, primarily mediated by GSH. In diabetes, this 
balance is impaired with reduced/deficient levels of GSH. A study in a T2D animal model 
demonstrated that depletion of GSH level increases bacterial (e.g. Burkholderia pseudomallei) 
susceptibility. The authors also showed that bacterial internalisation and killing improved by 
the addition of GSH in PBMCs culture (Tan et al., 2012). Moreover, cytokine production by 
the diabetic macrophages may also influence the macrophage functions during phagocytosis. 
Reduced production of cytokines (TNF-α, IFN-γ, IL-6) from diabetic peritoneal macrophages 
were observed in diabetic mice (Ma et al., 2008, Sun et al., 2012) and comorbid infections with 
Burkholderia pseudomallei (Hodgson et al., 2011, Hodgson et al., 2013b). Impaired phagocytic 
activity of macrophages from diabetic mice leads to poor antigen presentation which in turns 
results in compromised T cell mediated immunity (Ma et al., 2008, Ahmad, 2011).  
Other than macrophages, diabetes has impact on the functions of the neutrophil and dendritic 
cells. Neutrophil is considered one of the earliest cells in phagocytosis. Increased production of 
inflammatory cytokines (TNF-α, IL-6, IL-8, IL-17,) and ROS by unstimulated diabetic 
neutrophils has been reported in diabetics which further worsen the insulin resistance (Collison 
et al., 2002, Hatanaka et al., 2006, Talukdar et al., 2012). The function of neutrophils in the host 
immune response to intracellular bacterial infections is still poorly understood. However, 
neutrophil responses to infection appear to be suppressed in diabetic hosts (Alba-Loureiro et 
al., 2006). Prior research demonstrated that impaired activity of glutathione reductase (required 
for the neutrophil-based ROS production and phagocytosis) contributed to neutrophil 
dysfunction in diabetic hosts (Yan et al., 2012). Furthermore, ROS production from the diabetic 
individual stimulates the release of neutrophil extracellular traps; another important bactericidal 
mechanism. Such defect in neutrophil in diabetics favour the bacteria to hijack neutrophil as a 
means of refuse and dissemination (Eruslanov et al., 2005). In diabetes-comorbid infection (e.g. 
melioidosis), defects of neutrophils in terms of impairment of phagocytosis, bacterial killing, 
neutrophil migration, cytokine production, apoptosis were reported (Chanchamroen et al., 2009, 
Kewcharoenwong et al., 2013). However, elevated levels of inflammatory cytokines after 
neutrophil stimulation has also been documented in diabetes (Hatanaka et al., 2006, Morris et 
al., 2012). It is suggested that excessive neutrophil activation in diabetic individual with 
intracellular bacterial infection attributed to severe pathology formation in organs (Hodgson et 
al., 2015).    
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Dendritic cells (DC) are considered an important link between host innate and adaptive immune 
responses. Increased expression of activation markers (TNF-α, IL-1β, IL-6, IL-12, IL-23, GM-
CSF) from unstimulated DC in diabetics has been documented (Musilli et al., 2011, Bertola et 
al., 2012, Surendar et al., 2012). In diabetic mice infected with Mtb, an initial delay in the 
recruitment of the immune cells to the lungs were observed in spite of effective trafficking of 
DC cells to the regional lymph nodes (Martens et al., 2007). It was suggested that DC and 
macrophages were deficient at the site of infection due to reduced level of chemoattractant 
factors such as MCP-1/CCL2. In addition, reduced phagocytosis with delayed kinetics of 
antigen presentation were demonstrated in STZ-induced diabetic mouse model (Williams et al., 
2011). Impaired phagocytosis and delayed recruitment of APC to the primary site of infection 
leads to poor control and impaired T cell activation.  
Adaptive immune responses are also altered in diabetes. These alterations are due either to 
defects in innate cells (described above) or other associated factors (e.g. obesity, diet and 
smoking) that intensify the conditions of the diabetic patients. Plouffe and colleagues (1978) 
documented that the cell mediated immunity of diabetes patients was delayed compared to non-
diabetic patients. Several studies also documented the role of T cell subset imbalance due to 
poor glycaemic control (Jagannathan-Bogdan et al., 2011, Zhang et al., 2011, Zeng et al., 2012) 
In diabetic patients with obesity, there is a shifting in T cell responses. Th1 and Th17 cells 
increased in comparison to Th2 and Treg cells in diabetes. Consequently, pro-inflammatory 
cytokines (IL-1β, TNF-α, IL-6) lead to chronic inflammation and worsen insulin resistance 
(Tiemessen et al., 2007, Olefsky and Glass, 2010, Ouchi et al., 2011). Experimental studies in 
mice demonstrated that higher levels of IFN-𝛾 affect glucose homeostasis and increase tissue 
inflammation in T2D (Winer et al., 2009, Zhang et al., 2011). In diabetes-comorbid infection 
(e.g. tuberculosis) T cells were also impaired (discussed in section 2.3.5.1). It is obvious that 
functional abnormalities of both innate and adaptive immune cells are believed to increase 
diabetic related complications and susceptibility to many bacterial infections. How innate and 
adaptive immune responses in diabetic patients react to an infectious agent need to be 
addressed.  
 Convergence of mycobacterial infection and diabetes: the dual impact 
 Current global burden of tuberculosis  
The current worldwide scenario of TB shows a continuing increase, causing the disease to be 
one of the leading global health problems resulting in millions of deaths each year. According 
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to the recent report of World Health Organisation, it is the ninth leading cause of deaths globally 
and the leading cause from a single infectious agent, ranking above HIV infection  (WHO., 
2017). The latest estimates revealed 10.4 million new TB cases occurred in 2016 and more than 
1.3 million deaths. The incidence of TB is equally high in men, women and children. In 2017, 
an estimated 6.7 million (range, 4-9.4 million) cases of TB among males were recorded, of 
which 6.2 million (range, 3.7-8.6 million) were adults and 550 000 (range, 340 000–760 000) 
were children. There were 3.7 million (range, 2.2-5.2 million) cases of TB in females, of which 
3.2 million (range, 1.9-4.5 million) were adults and 490 000 (range, 300 000–680 000) were 
children (WHO., 2017).  
 
 
 
 
 
 
 
 
Figure 2.6 Estimated global tuberculosis incidence in 2016 (WHO., 2017) 
According to the recent estimate by WHO, most of the TB cases have occurred in South-East 
Asia Region (45%), African Region (25%) and the Western Pacific Region (17%) (Figure 2.6). 
Smaller proportions of TB cases have occurred in Eastern Mediterranean Region (7%), 
European Region (3%) and the Americas (3%). The majority of all estimated cases globally 
were found in high burden countries (HBCs). Among them, 64% of the total global estimates 
were contributed by seven high burden countries; India, Indonesia, China, the Philippines, 
Pakistan, Nigeria, and South Africa. Moreover, in 2016, 85% of TB deaths occurred in African 
Region and the South-East Asia Region where India itself accounted for 26% of global TB 
deaths (WHO., 2017).  
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 Current global burden of diabetes 
The global burden of diabetes has been estimated regularly over the last two decades (McCarty 
and Zimmet, 1994, Amos et al., 1997, King et al., 1998, WHO., 2016b, IDF., 2017). Most 
recently, International Diabetes Federation (IDF) has estimated that approximately 425 million 
(range, 346.4-545.4 million) people were suffering from diabetes worldwide in 2017. The 
global prevalence is 8.8% (range, 7.2-11.3%) in the age group 20 to 79 years in the same year. 
Conversely, the predicted global estimate of diabetic population is 629 million (range, 477.0-
808.7 million) contributing to a global prevalence 9.9% in the age group 20 to 79 years by 2045 
(IDF., 2017). However, the global prevalence of IGT (impaired glucose tolerance) positive 
people (352.1 in 2017), those with high blood sugar in pregnancy (21.3 million live births 
affected in 2017) and additional undiagnosed people (212.4 million) will add significantly to 
the global occurrence of diabetes. It was also assumed that around 80% of patients will be living 
in low and middle income countries where developing economies are predominant (WHO., 
2016b, IDF., 2017). 
The burden of diabetes varies considerably from one geographical area to the other due to 
environmental and lifestyle risk factors (Olokoba et al., 2012). The regional burden and 
estimates of diabetes (20-79 age groups) in 2017 and 2045 in the IDF region is presented in 
Table 2.5. 
Table 2.5 Regional estimates of diabetes (20-79 age groups) in 2017 and 2045 
 2017 2045 
IDF region 
Prevalence 
(%) 
No. of people with 
diabetes 
(million) 
Prevalence 
(%) 
No. of people with 
diabetes 
(million) 
North America and 
Caribbean 
26.3 17.7 26.9 33.4 
Middle East and 
North Africa 
20.4 6.5 22.1 21.5 
Western Pacific 20.0 48.1 17.6 96.7 
Europe 19.4 28.5 19.8 43.9 
South and Central 
America 
19.0 7.9 19.3 20.4 
South East Asia 13.5 12.5 13.9 33.0 
Africa 5.2 1.6 5.4 4.6 
Worldwide 8.8 425 9.9 629 
(IDF., 2017) 
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In 2017, the highest prevalence of diabetes was recorded in the North America and Caribbean 
region (26.3%) where it is expected to rise to 26.9% by 2045. The lowest prevalence of diabetes 
was recorded in Africa at 5.4%, although the highest proportion of undiagnosed diabetes 
(69.2%; an estimated 10.7 million) people was also in that region indicating that a lack of 
diagnostic health care facilities may be the cause of the low numbers (IDF., 2017). 
In 2016 China recorded 114.4 million people with diabetes, ranking it first in terms of diabetes 
sufferers. This number is expected to rise to 119.8 million by 2045 (IDF., 2017). Similarly, in 
India, the number was 72.9 million and is predicted to grow dramatically to reach 134.3 million 
by the end of 2045. The other rapidly growing top eight countries with diabetic patients are 
United States of America (USA), Brazil, Mexico, Indonesia, Russian Federation, Egypt, 
Germany and Pakistan (IDF., 2017). Moreover, the incidence of diabetes also increases in 
indigenous populations with over 370 million people in 90 countries reported (>5% of the 
world’s population) (UNDESA, 2009). The Pacific Islanders have the highest rate of diabetes 
prevalence among the world’s indigenous communities. Ten percent of Taiwanese Ami and 
Atayals (Chen et al., 1997), 30% of Australian Aborigines (Minges et al., 2011) and 40% of 
North American Sioux (Lee et al., 1995), 2.3% of Pima Indians (Pavkov et al., 2007), 1% of 
Chilean Aymara (Santos et al., 2001) suffer from diabetes.  
 The association between diabetes and tuberculosis 
The association between DM and TB was documented by reports prior to 1960s (Root, 1934, 
Oscarsson, 1958) and is known to have existed for at least one thousand years (Kapur and 
Harries, 2013). In the early 20th century, it was assumed that people died either because of 
diabetes or TB (Root, 1934, Oscarsson, 1958). Later, following the invention of insulin for 
diabetes and antibiotics for TB treatment, the potential relationship between these two life 
threatening diseases was eclipsed. Interest revived due to the sluggish reduction of TB (2.2% 
reduction annually) through the TB control strategy (WHO, 2011) along with a worldwide rapid 
escalation of T2D incidence in TB populations (Corris et al., 2012).   
Diabetes is indeed positively correlated with TB infection, as documented by multiple studies 
(Kim et al., 1995, Restrepo, 2007, Jeon and Murray, 2008, Workneh et al., 2017). Surveys 
carried out before 1960 reported that diabetic patients had a two to four times higher risk of 
being infected with PTB than other individuals (Banyai, 1931, Root, 1934, Boucot et al., 1952, 
Oscarsson, 1958). More recently, the association between these two diseases is supported by a 
growing body of literature (Mugusi et al., 1990, Mori et al., 1992, Kim et al., 1995, Pablos-
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Mendez et al., 1997, Restrepo, 2007, Stevenson et al., 2007, Jeon and Murray, 2008, Kapur and 
Harries, 2013, Workneh et al., 2017) showing that diabetic patients are three to eight times more 
susceptible to TB compared to the general population (Jeon and Murray, 2008, Corris et al., 
2012). Studies using animal models have also demonstrated that poor glycaemic control 
increases TB susceptibility (Saiki et al., 1980, Yamashiro et al., 2005, Martens et al., 2007, 
Vallerskog et al., 2010, Podell et al., 2014, Cheekatla et al., 2016). However, the biological 
basis for the association between both diseases is not completely understood. A compromised 
immune response in diabetic patients with poor glycaemic control might facilitate either 
primary progression of TB or reactivation of LTBI resulting in higher morbidity and mortality 
(Martens et al., 2007, Restrepo et al., 2008a, Vallerskog et al., 2010) 
 Tuberculosis incidence in diabetic patients  
TB incidence in the diabetic population is increasing globally. A recent systematic review 
documented that the prevalence of diabetes among TB patients ranged from 1.9 to 45% with an 
overall median global prevalence of 16% (Figure 2.7). In contrast, the prevalence of TB patients 
with concomitant diabetes was 0.38 to 14%. The review also showed that the highest number 
of DM-TB co-morbid patients were found in Asia, North America and Oceania (Workneh et 
al., 2017).  
 
 
Figure 2.7 Regional prevalence of diabetes among tuberculosis patients (adapted from 
Workheh et al., 2017)  
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Studies have been conducted to determine the incidence of TB in diabetic patients in different 
countries. In India, diabetes combined with PTB was 14.8% in the mass population. The 
percentage of smear positive TB individuals with diabetes was 20.2% (8.3 to 41.9%) with a 
higher proportion from urban populations compared to rural (Stevenson et al., 2007). Several 
other reports have documented figures of 24.5% (Viswanathan et al., 2012), 29% (Balakrishnan 
et al., 2012) and 44% (Raghuraman et al., 2014) of diabetic patients with TB in the Indian 
population. TB incidence in diabetic patients in Texas and at the Mexican border was similar 
to India, at 36 to 39% (Restrepo et al., 2011). Faurholt-Jepsen and colleagues (2011)  conducted 
a study in Mwanza in Tanzania and reported that the rates of diabetes were 16.7% (CI: 14.2–
19.4) and 9.4% (CI: 6.6–13.0), in case (n=803) and control populations (n=350), respectively. 
Another study in Tanzania reported that 9.0% of patients with T2D and 2.7% of patients T1D 
had developed PTB (Mugusi et al., 1990). Olmos and colleagues (1989) conducted a cohort 
study considering 1529 diabetic individuals in Chile over 10 years (1959 to 1985) and 
concluded that the probability of developing TB in T2D was 24% compared to 48% in T1D 
patients. The authors also noticed that IGT (impaired glucose tolerance) was found in 37.6% 
(CI: 34.2–41.1%) of TB cases and 21.4% (CI: 17.2-26.1%) of control individuals, suggesting 
that insulin dependence was an important marker for increased TB susceptibility and its 
severity. Alisjahbana and others (2006) worked on prospective data from a cohort of TB 
patients in Indonesia where the prevalence of diabetes was confirmed at 14.8% compared to 
3.2% in the general population. A study conducted in Taiwan stated that diabetes accounted for 
TB incidence was 4.09% and 3.03% in male and female population, respectively (Kuo et al., 
2013). The authors also asserted that the relative risk of developing TB in diabetic populations 
was higher in younger people (from 30 to 70 years). Pablos-Mendez and co-workers (1997)  
also observed that 25% of Hispanic people aged between 25 and 54 years had a higher risk of 
being infected with TB attributed by diabetes. Saskatchewan Aboriginal people were also 
suffering from the epidemics of both T2D and TB. Higher TB incidence was noticed in diabetic 
women aged 20-59 years than non-diabetic women (Dyck et al., 2007). In Spain, 44% (69) 
patients were skin test positive among diabetes patients (n=163) indicating a higher burden of 
LTBI in diabetic patients. Unfortunately, there was no control group and no predictor of the 
disease was taken into account during this study (Mansilla Bermejo et al., 1995). 
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 Consequences of the associations 
 Diabetes increases tuberculosis susceptibility 
Diabetes has severe effects on human health. The major complications include increased 
occurrence of cardiovascular diseases, nephropathy, retinopathy, impaired wound healing, 
accelerated atherosclerosis etc. (Shah and Hux, 2003, Leutholtz and Ripoll, 2011). One of the 
major complications of poorly controlled diabetes is increased susceptibility to infections 
including TB (Martens et al., 2007, Jeon and Murray, 2008, Hodgson et al., 2015). The possible 
mechanisms for increased susceptibility to Mtb infections are thought to be directly related to 
hyperglycaemia with insulin resistance or deficiency, which affect both the innate and adaptive 
immune responses (Dooley and Chaisson, 2009, Tan et al., 2012, Gan, 2013).   
The most important effector cells of the innate immune response in TB defence are the tissue 
macrophages. These cells perform many important functions including phagocytosis, antigen 
processing and presentation to T cells (CD4+ and CD8+ T cells) to enable an effective immune 
response to be mounted against TB. Abnormalities in macrophage phenotype, number 
polarization, chemotaxis, phagocytosis and cytokine responses have been documented in 
diabetes patients and animal models discussed in section 2.2.6. Such changes to macrophage 
may increase the susceptibility to Mtb infections. Macrophage function was also inhibited in 
diabetic-TB patients with impairment in the production of ROS, phagocytic and chemotactic 
functions (Hill et al., 1983, Glass et al., 1987, Abrass, 1991, Chang and Shaio, 1995, Geerlings 
and Hoepelman, 1999, Restrepo et al., 2008a, Lecube et al., 2011, Tan et al., 2012). Saiki and 
colleagues (1980) reported that a STZ-induced diabetic mouse model challenged with Mtb 
showed higher susceptibility to infection due to functional impairment of macrophages. Recent 
studies demonstrated that compromised phagocytosis of mycolic acid coated beads in diabetic 
macrophages was due to the lower expression of the macrophage receptors with collagenous 
structure (MARCO), TLR2 and the coreceptor for bacterial LPS (lipopolysaccharide), CD14 
(Bowdish et al., 2009, Martinez et al., 2016). However, the success of host defence against TB 
largely depends on the activation of both CD4+ and CD8+ T cells (Kaufmann, 1991). These 
activated T cells release IFN-γ which is considered a principal mediator of protective immunity 
against TB (Wong and Pamer, 2003, Sud et al., 2006). In DM-TB patients, T cell mediated 
immunity is also adversely affected (Goonetilleke et al., 2003, Niazi and Kalra, 2012). Several 
studies documented that there were fewer T lymphocytes resulting in reduced production of 
IFN-γ, TNF-α, IL-1β and IL-6 observed in diabetic patients with TB compared to non-diabetic 
individuals (Tsukaguchi et al., 1997, Geerlings and Hoepelman, 1999). Furthermore, functional 
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impairment of T cells in a diabetic mouse model challenged with Mtb has also been documented 
(Saiki et al., 1980, Yamashiro et al., 2005, Martens et al., 2007, Vallerskog et al., 2010). Saiki 
and colleagues (1980) and Yamashiro and co-workers (200) reported T cell priming was 
delayed as macrophages failed to produce IL-12, resulting in higher bacterial burden in different 
organs. Afterwards, two other reports documented that increased TB susceptibility in diabetic 
mice was associated with reduced production of IL-12 and IFN-γ (Martens et al., 2007, 
Vallerskog et al., 2010). In fact, the functional abnormalities of both innate and adaptive cells 
(e.g. macrophage and T cell) in diabetic patients increase susceptibility to Mtb infections, as 
well as being responsible for other diabetic related complications.  
 Diabetes increases non-tuberculous mycobacterial infections 
Epidemiological studies indicate a rising incidence of pulmonary and skin and soft tissue 
infections by NTM infections (De Groote and Huitt, 2006, Jackson et al., 2007, Hoefsloot et 
al., 2013). However, there is lack of reports relating to DM-NTM infections. Although there is 
a growing body of evidence of NTM infections in immunocompromised individuals with HIV 
infection (Tortoli et al., 1995, Piersimoni et al., 1997, Gholizadeh et al., 1998, O'Brien et al., 
2014, Orme and Ordway, 2014, Xu et al., 2016), there are few studies reporting a link between 
diabetes and NTM infections (Uslan et al., 2006, de Mello et al., 2013, Bridson et al., 2016). A 
recent retrospective review of hospital data covering a 20 year period showed that NTM 
infections in diabetic patients were three times over-represented in comparison to the general 
population (Bridson et al., 2016). A study in Brazil showed that 9.8% of diabetes patients had 
associated pulmonary NTM infections, which was considered one of the leading co-morbid 
infections in those patients (Falkinham, 1996, de Mello et al., 2013, Orme and Ordway, 2014). 
Skin and soft tissue infections with NTM are often under-diagnosed; however, recent studies 
have shown the rates of infection are increasing. Bridson and colleagues (2016) observed 34.1% 
patients studied had skin and soft tissue infection due to M. fortuitum of which 11.4% were in 
T2D patients. Further, in the same study, 2.3% diabetic patients were infected with M. ulcerans 
(Bridson et al., 2016). Uslan and others (2006)  observed 27.6% patients surveyed had skin and 
soft tissue infections caused by M. ascessus or M. chelonae and 16.7% by M. fortuitum in the 
same group of patients. A study on an Australian population observed a high rate of patients 
with oedematous M. fortuitum lesions with co-morbid diabetes (O'Brien et al., 2014). There are 
no studies conducted to date to determine how diabetes increases NTM infections. Therefore, 
studies are required to investigate the reasons behind increased NTM infections in diabetic 
patients.  
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 Burden of mortality 
The burden of mortality due to diabetes and its complications is enormous and rising sharply. 
In 2017, approximately 4 million (range, 3.2-5.0 million) people aged 20 to 79 years died from 
diabetes complications, which is equivalent to one death every eight seconds (IDF., 2017). The 
disease accounted 46.1% deaths due to diabetes itself and 10.7% of global mortality overall for 
people in this age group. This is higher than the combined number of deaths from any infectious 
diseases; 1.1, 1.8 and 0.4 million deaths from HIV infection, TB and malaria, respectively 
(IDF., 2017). On the other hand, TB remains as one of the deadliest diseases in the world and 
kills nearly 2 million people every year (WHO, 2013a). Alarmingly, between 5-10%, and in 
some countries more than 50% of diabetic patients suffer from TB, contributing to even more 
deaths (Dooley and Chaisson, 2009, Workneh et al., 2017). Further, there are 2 billion LTBI 
globally, where 5-10% reactivate every year due to immune suppressive conditions (Vynnycky 
and Fine, 2000, Martens et al., 2007, Mack et al., 2009, Dye et al., 2011). Therefore, the global 
death scenario arising from the association between these two life threatening diseases has 
revived over the last few years. Although there are no statistics on mortality due to this 
comorbid situation, several studies have shown that diabetes patients infected with PTB have 
6-7% (Oursler et al., 2002, Dooley and Chaisson, 2009), 12.2% (Wang et al., 2009) and 16% 
(Lindoso et al., 2008) higher chances of death compared to non-diabetic patients. Indeed, the 
actual prediction of the number of deaths due to diabetes patients infected with TB is 
challenging because more than one-third of countries globally do not have any data on particular 
diseases and their mortality rates (Roglic and Unwin, 2010). 
 Economic burden 
In addition to burden of mortality due to diabetes and its complications, the disease exerts a 
serious economic burden on individuals, families and societies. According to IDF, people with 
diabetes spent USD 232 billion in 2007 which reached to USD 727 billion in 2017 for the age 
group 20-79 years. This cost was USD 850 billion in 2017 when it was calculated for the 
expanded age group; 18-99 years (IDF., 2017). Region-wise health expenditure in 2017 clearly 
makes the difference in healthcare spending on diabetes. The North America and Caribbean 
region spent the highest among the seven IDF regions with an estimated USD 363 billion, which 
corresponded to 52% of the total amount spent in 2017. The second highest expenditure on 
diabetes was the European region (USD 181 billion) followed by Western Pacific region (USD 
179 billion), which corresponded to 23% and 17%, respectively of the total global spending. 
The other regions (South and Central America, Middle East and North Africa, South-East Asia 
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and African regions) spent significantly less, responsible for only 9% of the total global 
spending on the diseases. However, the total healthcare expenditure on diabetes is predicted to 
reach USD 776 billion by 2045 for the age group 20-79 years (IDF., 2017).  
TB has devastating economic effects on all ages, but the greatest effects are observed during 
the most productive years of life (15 to 44 years of age). The social effects of TB particularly 
on families are significant as it decreases the earning capability of an individual. In addition, 
failure to treat the infected person leads to a greater risk of infection for other family or 
community members. The disease reduces the productivity of the afflicted person by an average 
of 30% (WHO., 2013a). The annual estimated toll of TB infection was USD 1 billion, 2 million 
deaths and an average loss of 15 years’ income per person, adding another 11 billion USD 
(WHO., 2013b).  
Several studies have reported that diabetes leads to the treatment failure of TB (Morsy et al., 
2003) and increases the chances of death of afflicted people (Mboussa et al., 2003, Lindoso et 
al., 2008, Dooley and Chaisson, 2009, Wang et al., 2009). Therefore, the impact would be huge 
in TB and DM co-morbid infections although no specific statistics on economic burden are 
available.  
 Animal models and their suitability in the investigation of type 2 diabetes-co-morbid 
infections  
There are currently several rodent/murine models in use for diabetes studies, based on either 
naturally occurring mutations, inbred strains, tissue-specific knockout or transgenic mice. 
These have been used for studying the pathophysiology of diabetes itself and host-pathogen 
interactions which occur during co-morbid infection with diabetes. Genetically modified 
murine models of T2D such as Leptdb/db and Leptob/ob mice were developed from a spontaneous 
autosomal recessive mutation in the leptin gene (Zhang et al., 1994, Srinivasan and Ramarao, 
2007). Such genetic models fail to incorporate the significant nutritional and polygenic 
determinants involved in the aetiopathology of the disease in humans. Further, the leptin 
signalling-deficiency can interfere with the host immune system, as leptin has many 
physiological and immunological roles, which limits the application of these models for 
research on T2D and associated diseases (Hodgson et al., 2011). The Kuo Kuondo (KK) mouse 
model of T2D develops insulin resistance at the age of 16-20 weeks. The problem with this 
model is that mice die very soon due to the lethal yellow gene (Ay) (Srinivasan and Ramarao, 
2007). The Nagoya-Shibata-Yasuda (NSY) mouse model develops diabetes at a very slow rate 
and insulin resistance appears after 24 weeks of induction. This mouse model does not show 
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the islet pathology observed in human T2D patients (Ueda et al., 2000). The Zucker diabetic 
fatty rat (ZDF) and Goto-Katazaki rat model of T2D are also based on genetic defects (Chen et 
al., 1996, Movassat et al., 1997). The chemically induced mouse model using streptozotocin 
(STZ)/STZ+Nicotinamide (NA), destroys the pancreatic β-cell to shorten the length of time 
required for the development of T1D (Gilbert et al., 2011, King and Bowe, 2016). The 
limitations of those models are that the micro and macrovascular complications associated with 
clinical T2D require a considerable time to become established and these cannot be achieved in 
a short-term treatment regime. Moreover, chemically induced models have limited utility due 
to the toxicity of STZ on the renal and hepatic tissue (Deeds et al., 2011).  
The diet-induced diabetic (DID) murine model is considered more akin to the aetiopathology 
of T2D of human patients (Hodgson et al., 2013a). However, there are considerable 
discrepancies in the metabolic features reported in the studies using DID models, which are 
confounded by the differences in dietary composition, fat content, age of the mice, duration of 
diet intervention, along with gender and inbred strain variability (King and Bowe, 2016). The 
DID mouse model was first introduced by Surwit and colleagues (1988)  in C57BL/6 mice. The 
authors used an extremely HFD (60% of energy) to induce T2D, which markedly exceeds the 
typical dietary intake of the human population within any developed nation (34 % of energy) 
(Ludwig et al., 1999). Subsequently, others worked on the development of a more appropriate 
dietary model by changing the dietary compositions, however, they failed to fully characterise 
the model (Srinivasan et al., 2005, Adeyi et al., 2012). Over the past decade, it has become 
evident that intake of refined carbohydrates is one of the important contributing factors for the 
development of metabolic dysfunction. An energy-dense diet (EDD) characterised by the 
higher consumption of processed and red meat, high-fatty foods, sugary drinks and desserts, 
are positively correlated with the incidence of cardiovascular disease, cancer and T2D (Malik 
and Hu, 2015; Riccardi et al., 2008; Rizkalla, 2014). Hodgson and colleagues (2013a) 
investigated the impact of an EDD (23% fat, 19% protein and 50.5% dextrose) on the 
development of hyperglycaemia and glucose intolerance in male C57BL/6 mice after 10 weeks 
of the dietary intervention. The authors found a rapid progression of severe hyperglycaemia and 
glucose intolerance in mice after 10 weeks of dietary intervention. Although the authors used 
the model for Melioidosis-T2D co-morbid infection studies based on preliminary findings, they 
didn’t fully characterise the model for the chronic clinical signs of T2D and its associated 
complications. The preliminary findings by Hodgson and co-workers (2013a) suggested that 
prolonged consumption of an EDD might be useful in developing chronic signs of T2D and its 
associated complications. Therefore, a fully characterised DID model would be a more 
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appropriate model of T2D over other genetically or chemically induced models for co-morbid 
infections studies (e.g. TB, NTM infections, melioidosis, malaria etc.)  
 Conclusion  
The global burden of mycobacterial infections particularly tuberculosis is enormous. The most 
alarming aspect is that the association between these and other life-threatening diseases such as 
T2D, resulting in increasing mortality. The growing literature has provided the proof that T2D 
is an independent risk factor that increases TB and NTM susceptibility. However, the 
underlying immune mechanisms have not yet been determined. Studies in animal models have 
described some aspects of the immune mechanisms occurring in T1D conditions, but rather 
fewer in T2D. Future research should be directed to clarifying the exact nature of the association 
between TB and T2D to answers questions such as whether functional impairment of immune 
cells such as macrophages and T cells in T2D patients leads to increased susceptibility to Mtb 
infections. Furthermore, treatment failure in TB patients with diabetes is becoming another 
major global health concern. Research should also be directed to justify the use of Metformin 
as a companion drug to current anti-TB drugs in the treatment of TB-DM comorbid infections. 
Finally, therapeutic and protective measures should be designed through future research by 
addressing these burgeoning areas of research, otherwise, the global death toll will continue 
rising.  
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3 CHAPTER 3  
GENERAL MATERIALS AND METHODS 
 
 Experimental animals 
 Animal ethics and biosafety approvals 
All animal experiments were conducted according to the National Health and Medical Research 
Council (NHMRC) guidelines. Institutional ethics approval (#A2016) for the studies was 
granted by the James Cook University (JCU) Animal Ethics Review Committee. All 
experimental mice were housed in the Small Animal Breeding Unit (SABU) of JCU (DB86-
002) for the induction of diabetes. Mice were moved to a physical containment 2 (PC2) 
laboratory (DB87-110) for M. fortuitum infection studies and a PC3 laboratory (DB87-120) for 
M. bovis (BCG) and M. tuberculosis (H37Rv) infection studies. Biosafety approval was granted 
for all experiments using all three species of mycobacteria (Table 3.1). All experiments and 
animal manipulations were performed in Class II biological safety cabinets.  
 
Table 3.1 Biosafety approval for type 2 diabetes-mycobacterial infections co-morbidity 
study 
Organism Risk Assessment number Biosafety Approval number 
M. fortuitum 4339, 4218 JCUIBC-160601-007 
M. bovis (BCG) 4892 JCUIBC-160601-011 
M. tuberculosis (H37Rv) 4654 MI14-08 
 
  Mice and husbandry  
Male C57BL/6 mice were used for the induction of diabetes based on previous findings 
(Hodgson et al., 2013a). Compared to female mice, male mice demonstrated increased 
susceptibility to obesity and insulin resistance in response to a high-fat diet  (Stubbins et al., 
2012). For this reason, male mice were used in the current study. Six-week old mice were 
obtained from two different sources: a) Australian Resource Centre (ARC), Perth, Western 
Australia (referred to as ARC bred mice) and b) Small Animal Breeding Unit (SABU) at the of 
College of Public Health, Medical and Veterinary Sciences, James Cook University (referred 
to as JCU bred mice). All experimental mice were housed in SABU of JCU. Mice at 4 weeks 
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of age were ear marked (for the identification, Figure 3.1) and housed in standard animal cases 
(5 mice/cage) in a temperature and light controlled room (18-220C, 12 hours light/dark cycle 
and relative humidity 70-75%). Saw dust was used as bedding materials. When the mice were 
moved to the particular laboratories for infection studies were housed in Tecniplast Green Line 
IVC (individually ventilated cages) in PC2 and Tecniplast N biocontainment ISOcages in PC3. 
To get rid of excess dust from the bedding materials, special bedding (Bed-o’Cobs® 1/8′′, The 
Anderson, Ohio, USA) was used in PC3. Animal cages, bedding, water bottles were changed 
at every seven days interval. Mice were regularly checked for feed and water.  
 Diets and feeding regime 
After two weeks being housed (acclimatisation period), mice were randomly separated into two 
dietary groups. The control group (Standard Rodent Diet; SRD or non-diabetic group) was 
provided with 4.5 g (per mouse/day) of SRD (Goldmix Stockfeeds, South Lismore, New South 
Wales, Australia, Rat and Mouse Nuts: 4.8% fat, 20% protein, 62.8% complex carbohydrates 
and 12.4% fibre). Experimental groups (Energy-dense diet; EDD or diabetic group) received 
an ad libitum amount of EDD (Specialty Feeds, Glen Forrest, Western Australia, SF03-030: 
23% fat, 19% protein, 50.5% refined carbohydrate as dextrose and 7.5% fibre). To control the 
possible differences in consumption rates due to the palatability of the diets, the control groups 
were supplied an isometric quantity of feed based on the daily consumption calculated based 
on previous week (4.5 g/mouse/day or 13.86 kcal/mouse/day). Previous literature states an 
approximately 3.5 to 3.75 g/mouse/day (equivalent to 13.65 to 14.62 kcal/mouse/day) is the 
average feed intake for a mouse to reach the maturity (National Research Council 
Subcommittee on Laboratory Animal Nutrition., 1995). Therefore, the control mice were not 
given more feed per day beyond the daily requirement. Mice were kept on dietary intervention 
for a period of 30 weeks.  
Moreover, the average daily feed consumption of the mice was measured by subtracting the 
amount of feed remaining after 24 hours from the initial amount of feed supplied. At least two 
feed intakes were recorded for each of the cage in a week and then overall average daily feed 
intake per mouse was calculated. This procedure was repeated at the same time of each week 
until the end of the diet intervention period. The weekly body weight gain was monitored 
throughout the period. 
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Figure 3.1 Ear marking of mouse for longitudinal tracking 
 Assessment of metabolic parameters 
 Measurement of fasting blood glucose 
Feed from cages was removed 6 hours prior to measure the fasting blood glucose (FBG) 
concentration as per the previous literature (Ayala et al., 2010, Hodgson et al., 2013a). Each 
mouse was placed in a restraining box with tail exposed. The tip of the tail (<1 mm) was cut 
using a sterile scalpel blade (Livingstone sterile surgical blades #SBLDCL24). A gentle 
pressure was applied to get a small drop of blood (~5 µL) which was then placed on the blood 
glucose test strips of the Accu-Chek® Performa blood glucose meter (Roche, Castle Hill, NSW, 
Australia).  
 Glucose tolerance test 
Glucose tolerance test (GTT) was performed after the dietary intervention. As per the 
measurement of FBG concentration (section 3.2.1), it was done on 6 hourly morning fasted (6 
am to 12 pm) mice according to the published methods (Ayala et al., 2010, Hodgson et al., 
2013a). In short, the glucose solution (2 g/kg lean body weight) was first calculated (70% and 
90% of the gross body weight of mice on EDD and SRD, respectively). The baseline FBG level 
(as ‘0’ minutes) was first measured before injecting the glucose solution. Then, a volume of 
100 µL containing the desired amount of glucose was injected intraperitoneally to individual 
mouse (Appendix 1). The blood glucose level was measured at 15, 30, 60 and 120 minutes post 
injection from the lateral tail vein. After performing GTT, an appropriate amount of feed was 
provided and water supply was checked. 
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Hyperglycaemic threshold was considered as a marker of type 2 diabetes (T2D) if the EDD fed 
mice demonstrated a raised FBG level with an evidence of glucose intolerance and area under 
the curve (calculated based on GTT) at levels higher than the upper 99% confidence interval 
for the mean of age-matched control group fed on a SRD (Hodgson et al., 2013a, Morris et al., 
2016). Mice failed to meet the above criteria were not considered for the subsequent studies.  
 Mycobacterium spp culture 
 Mycobacterial isolates 
Mycobacterium fortuitum was kindly provided by Dr Jacqueline Picard, College of Public 
Health, Medical and Veterinary Sciences, Centre for Biosecurity in Tropical Infectious 
Diseases, JCU. Mycobacterium bovis (BCG) was provided by Dr Nick West, School of 
Chemistry and Molecular Biosciences, The University of Queensland, Australia. 
Mycobacterium tuberculosis (H37Rv) ATCC (American Type Culture Collection) strain was 
imported (permit number # 0000281462) from BEI resources of United States of America 
(USA) under licensed by Professor Natkunam Ketheesan with prior approval from the 
Department of Agriculture and Water Resources, Australian Government. 
 Preparation of mycobacterial stocks 
Mycobacterium fortuitum was grown on 7H11 agar plates (cat. no. M0428, Sigma; Appendix 
1) for 10-15 days at 370C with 5% CO2 (Figure 3.2 A). Several single colonies were selected 
and cultured in 100 mL of 7H9 broth (cat. no. M0178, Sigma; Appendix 1) supplemented with 
OADC (Oleic Acid–Dextrose-Catalase) medium (cat. no. 212240, BD Biosciences, Australia). 
The broth was cultured at 370C with mild agitation (100 rotation per minute; rpm) for 72-96 
hours to bring the bacteria to the logarithmic phase (Optical Density; OD600nm 0.6 to 0.9). The 
bacteria were pelleted (4000 xg for 10 minutes) and washed twice with phosphate buffer saline 
(PBS; pH 7.2, Appendix 1). The cell pellet was finally resuspended in 50 mL (half of the 
originally cultured volume) of storage medium (Appendix 1) and aliquoted into 1 mL screw 
capped vials for preservation at -800C. To determine the concentration (CFU/mL) of this frozen 
stock, serial 10-fold dilutions were prepared and plated on 7H11 agar plates (10 µL of 
triplicates/dilution). The colonies were counted after one week of incubation at 370C with 5% 
CO2. The purity of the culture was checked by plating on 7H11 culture plates (with no added 
antibiotic or antifungal agents) and blood agar. Gram and Ziehl-Neelsen (ZN) staining (Figure 
3.2 B) was also done to confirm the acid-fastness of the bacteria. 
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Figure 3.2 Colony morphology and acid-fast staining of the mycobacterial species 
Colony morphology (left panel) on 7H11 agar plates and acid-fastness (right panel) of 
mycobacteria after Ziehl-Neelsen staining. A) & B) Mycobacterium fortuitum, C) & D) M. 
bovis (BCG) and E) & F) Mycobacterium tuberculosis (H37Rv). Scale bar of the images: B, D 
& F, 20 µm. 
Mycobacterium bovis (BCG) was first grown on the 7H11 agar plates (Figure 3.2 C). A pure 
single colony was then inoculated into a 50 mL tube having 10 mL of 7H9 broth supplemented 
with OADC medium. After 1-2 weeks of culture at 370C with 120 rpm. The culture was then 
transferred into a 100 mL of 7H9 broth and further incubated at 370C with mild agitation (100 
rpm) to bring the culture to the logarithmic phase (OD600nm 0.6 to 0.9). Processing of the 
bacterial culture, enumeration (after 2-3 weeks of plating) and purity checking were done 
following the same procedure described for M. fortuitum. Acid-fastness of the bacteria was 
confirmed by using ZN staining (Figure 3.2 D).  
Mycobacterium tuberculosis (H37Rv) stock received from BEI resources was cultured on 7H11 
agar slant and preserved on cryobeads (Microbank®, PL.170/R, USA). The working stock was 
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prepared by removing one bead into a 50 mL tube containing 10 mL of 7H9 broth. Further 
culturing, processing, enumeration and purity checking were done following the same 
procedure described for M. bovis (BCG) and M. fortuitum (Figure 3.2 E & F). Previously 
published protocols were followed for the culturing of the all the mycobacterial species (Larsen 
et al., 2007, Singh and Reyrat, 2009). 
 Amikacin susceptibility testing of Mycobacterium fortuitum 
To make sure the Amikacin susceptibility of the used M. fortuitum strain, a minimum inhibitory 
concentration (MIC) value was determined by the broth microdilution method (Yang et al., 
2003). Briefly, a twofold serial dilution was prepared using amikacin (cat no. A2324-5G, 
Sigma) in a 96 well plate. The highest and lowest concentration of the antibiotic in the well was 
8 µg and 0.25 µg, respectively. After adding the bacteria at a concentration of 1-104 to 5x105 
CFU/well, the plate was incubated at 370C with 5% CO2 for 7 days. The MIC value was 
interpreted according to the approved guidelines (National Committee for Clinical Laboratory 
Standards., 2002). The recommended range for amikacin susceptibility for M. fortuitum was 1-
16 µg/mL. We observed the value of our studied M. fortuitum strain was 0.5 µg/mL. However, 
amikacin susceptibility for M. bovis (BCG) and M. tuberculosis (H37Rv) was not done as we 
already know they are susceptibility to Amikacin.  
 Histopathological analysis of tissue samples 
Tissue samples collected for histopathological examinations were fixed in 10% neutral buffered 
formalin (NFB) (Appendix 1) for a minimum of 24-48 hours. The preserved tissue samples 
were processed by a 6 hours cycle using a Shandon Citadel 2000 Tissue Processor (Shandon 
Southern Products Ltd, United Kingdom). After paraffin embedding, 5 µm sections (at least 
two sections from each mouse tissue) were cut and stained with the Haematoxylin and Eosin 
(H&E, Appendix 1), Jones Periodic Acid Schiff’s (PAS; Appendix 1) and Ziehl-Neelsen (ZN) 
stain (Appendix 1) using standard protocols. Cryosections of formalin fixed liver were prepared 
in optimum cutting temperature (OCT) medium (Tissue Tek, Olympus, Notting Hill, VIC, 
Australia). Cryosections (5 µm thickness) were then stained with Herxheimer’s solution and 
counterstained with Mayer’s Haematoxylin (Appendix 1). Overall, modified Herxheimer’s 
staining of the cryosections of the liver was considered for the quantification of lipid deposition. 
Haematoxylin and Eosin staining of visceral adipose tissue and pancreas were done to quantify 
the size of adipocyte and percent islet area over the total pancreatic area, respectively. The PAS 
staining was performed to quantify the mesangial matrix thickening and thickening of the 
Bowman’s capsule in kidneys. However, H&E staining of the mycobacteria infected liver and 
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lungs were also done to quantify the inflammatory lesions in those organs. The ZN staining was 
used to quantify the mycobacterial load in the inflammatory foci/granuloma of the liver.  
 Assessment of lipid deposition in liver 
All stained liver sections were visualised and analysed using a light microscope (BX43 
Olympus), connected to CellSens® Image Analysis software. Histological analyses of captured 
digital images of each tissue were conducted on representative sections. For the determination 
of the extent of neutral lipid deposition in liver sections, a minimum of 10 images of each liver 
section of each mouse was taken at the 20x objective (200x magnification). A control slide with 
desired (red colour as lipid accumulation in the liver, Figure 3.3 A & B) and other lesions were 
prepared using a threshold-based phase segmentation technique, where lipid, nuclei and other 
structures were defined as red, deep blue and light blue and yellow, respectively (Figure 3.3 B). 
The software calculates the intensity of each colour compared to those already defined. The 
control image was used as a standard image for the calculation of the percentage of each colour 
intensity in each representative image. Data were expressed as the percentage of red colour (i.e. 
lipid) on each representative image (Morris et al., 2016). The lipid deposition was determined 
on liver sections of mice following diet intervention because it has shown that ectopic lipid 
deposition in liver associated with hepatic insulin resistance in patients with diabetes (Bays et 
al., 2004, Cusi, 2010). 
 Assessment of adipocyte size 
The mean adipocyte size within visceral adipose tissue (VAT) section from each mouse was 
assessed by measuring the area of a minimum of 50 adjacent adipocytes per section. At least 5 
images (200x magnification) from each VAT section of each mouse were evaluated (Figure 3.3 
C & D). Selection bias was minimised by taking 5 continuous images starting from a random 
point for each section. Microscope fields with incomplete adipocytes or artefacts were not 
imaged (Morris et al., 2016). The adipocyte size was determined in mice following diet 
intervention as adiposity and abnormal adipocyte morphology is associated with insulin 
resistance and complication of diabetes (Black et al., 1998, Herberg, 1998).  
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Figure 3.3 Measuring the lipid deposition and size of the adipocyte 
The lipid deposition in the liver was quantified based on the phase segmentation technique 
using the CellSens® Image Analysis software. All the images were taken using a 20x objective. 
A control image was selected having both desired and other lesions. Then, all the colours on 
that chosen control image were defined in the software; red as lipid (desired lesion), deep blue 
as nuclei of the cells and light blue and yellow as cytoplasm and intracellular/empty spaces (B). 
All the images were then analysed based the control image (B) where, the software provides 
the percentages of each colour intensity of those already defined. Moreover, the size of each 
individual adipocyte was determined by taking the photographs at 20x objective (C) and 
followed by measuring the size of adjacent each individual adipocyte using a polygonal tracing 
tool of the CellSens® software (D). Scale bar of the images: A-D, 100 µm.  
 
 Assessment of pancreatic islet hyperplasia 
The total pancreatic area was determined from representative H&E stained sections (40x 
magnification) from individual mouse (Figure 3.4 A). The area of each islet of Langerhan's 
measured at 20x objective (200x magnification) (Figure 3.4 B). Data were expressed as the 
percentage of pancreatic islet area over the total pancreatic area of each mouse (Morris et al., 
2016). The pancreatic area over the total pancreatic area was measured because compensatory 
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hyperplasia represents insulin resistance, which is a characteristic feature of type 2 diabetes 
(T2D) (Del Prato, 2009, Kahn et al., 2014). 
 
 
 
Figure 3.4 Measuring the pancreatic islet hyperplasia 
For the quantification of pancreatic islet hyperplasia, the total area of the pancreas was 
measured using the polygonal tracing tools of the Cellsens® software on images taken at 4x 
objective (A). Then, the size of each pancreatic islet was measured on the images taken at 20x 
objective using the same tools (B). Scale bar of the images: A; 500 µm and B; 100 µm. 
 
 Assessment of kidney for mesangial thickening and glomerular hypertrophy 
Kidney sections were evaluated by the threshold-based phase segmentation technique 
(described in section 3.5.1) to compare the percentage of the PAS-positive staining within the 
glomerular capillary tufts, relative to the glomerular area (red colour, Figure 3.5 B). All the 
photographs of the glomeruli were taken at 20x objective (200x magnification). A control image 
was prepared and definied based on the colour where red, blue and less pink area represents the 
deposition of collagen and glycoprotein in the capillary tufts, nuclei of the cells and other 
structure; respectively on the kidney sections (Figure 3.5 A). The perimeter of each glomerulus 
was outlined using a polygonal tracing tool of the CellSens® software. The colours of the 
selected glomerular area were then analysed by the area fraction ROI (region of interest) tool 
of the software (Figure 3.5 B). All the remaining images were quantified for ROI (colour 
intensity within the glomerulus only) based on the control image. A minimum of 30 glomeruli 
per kidney was considered. Glomeruli free of artefacts were selected for measuring. Selection 
bias was minimised by starting from equivalent points in the outer cortex moving clockwise 
and selecting the first acceptable glomerulus (Morris et al., 2016). The kidney damages as a 
measure of microvascular complications in diabetes lead to renal failure (McKenna and 
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Thompson, 1997). Therefore, kidney damages were measured in terms of mesangial matrix 
thickening, thickening of the Bowman’s capsule and glomerular hypertrophy to ensure that 
prolong EDD fed mice showed the features of microvascular complications.  
.  
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.5 Assessment of size of glomerulus and Periodic Acid Schiff’s (PAS)-positive 
stained area in kidney 
For the quantification of the PAS-positive stained area within the glomerular capillary tufts, 
photographs of the glomeruli were taken at 20x objective. A control image was selected 
comprising both desired (red colour representing the collagen and glycoprotein deposition) and 
other lesions (other colour such blue for incluei of the cells). Then, all the colours on that chosen 
image were defined in the software; red as PAS-postive stain, blue as nuclei and rest of the 
colours (light pink and white) as other structures/empty spaces on the kidney section (A). The 
colours of the only selected glomerular area were analysed by the area fraction ROI (region of 
interest) tool of the CellSens® software (B). Scale bar of the images: A-B; 100 µm. 
 
 Assessment of organ inflammation 
The percentage of the inflamed area over the liver section was quantified on the representative 
images. A minimum of 10 representative images from each liver section was taken at 20x or 
10x objective. The polygonal tracing tool of the CellSens® software was used to measure the 
total area of the representative tissue and the inflamed area (i.e. size of each inflammatory 
focus/granuloma) (Figure 3.6 A & B). A minimum number of 50 inflammatory cells (as 
determined by nuclear staining) was considered to be an area of inflammation on the liver. 
Previous studies in animal models have demonstrated a diffuse inflammation at the earliest 
timepoint of infection, whereas the granulomatous response becomes more conspicuous at later 
timepoints post-infection (pi). This is one of the reasons for choosing 50 inflammatory cells; in 
the current study, aggregates of cells started to appear from 14 days pi. However, during image 
capturing, selection bias was minimised by taking 10 continuous images starting from a point 
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of each liver section. Data were expressed as the percentage of the inflamed area over the total 
liver area measured on each liver section. The inflammatory foci/granuloma on liver sections 
were represented as average number of inflammatory foci on each image taken at 200x 
magnification (Flynn et al., 1998, Chambers et al., 2006, Silva et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Quantification of the inflamed area in liver and lungs 
The percentage of the inflamed area over the total area of liver and lungs were quantified on 
the representative images using the CellSens® software. For the quantification of the inflamed 
area on the liver section, photographs (starting from a point and then the photo of 10 continuous 
fields) were taken at 20x or 10x objective followed by the measuring the total area (A) and the 
inflamed area (B) by a  tracing tool of the software. For lungs lesions, the total area of the lungs 
(area of entire lobes) was measured on the images taken at 4x objective (C) using the same tool 
of the software. Then, the total inflamed area was computed on images (for the same lungs 
lobes) taken at 10x objective using the same tracing tool (D). Scale bar of the images: A-B; 100 
µm, C; 500 µm and D; 200 µm.  
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The inflamed area over the total area of the lungs was evaluated on representative images of 
lung sections. The total area of a representative section (left lobe of lungs from each mouse) 
was measured by images captured using the 4x objective (Figure 3.6 C). The inflamed area was 
calculated on the same lung section taking by capturing images using 10x objective (Figure 3.6 
D). A minimum number of 50 inflammatory cells in an area on a lung section was considered 
an inflamed area. Data were expressed as the percentage of the inflamed area over the total lung 
area measured on each mouse section (Schneider et al., 2010, Kupz et al., 2016).   
 Ziehl-Neelsen staining of liver sections for localisation of mycobacteria  
A representative liver section from each mouse was deparaffinised. Sections were first stained 
with Carbol fuschin (Appendix 1) for 5 minutes with mild heat. Decolorisation of the section 
was done using acetone alcohol (Appendix 1) and followed by staining with 0.5% Methylene 
blue for 5-10 seconds. Stained sections were dehydrated with a series of graded alcohol 
solutions before mounting with mounting media (Reynolds et al., 2009). 
Stained representative liver sections were imaged using the 100x objective to facilitate the 
counting of bacteria within inflammatory foci/granulomas. A total of 10 first positive 
inflammatory foci/granuloma (presence of at least one bacterium) from each liver section were 
counted for the acid-fast bacilli. Selection bias was minimised by starting from a random point 
of the liver section and moving back and forth motion until counting the desired number of the 
positive inflammatory foci/granulomas. Bacilli within the individual cells or dispersed over the 
liver parenchyma were not counted. Data were expressed as percentage of acid-fast bacilli in 
each inflammatory focus/granuloma over the total bacilli counted in 10 inflammatory 
foci/granulomas on each of the liver section (Chambers et al., 2006).   
 Flow cytometry 
In this investigation, BD FACSCalibur™ flow cytometer (BD Biosciences) was used to 
determine phagocytosis based on beads labelled with fluorescent dye. Cytokine data during 
performing bead based multiplex BD cytometric bead array (BD Biosciences) were also 
acquired by the same flow cytometer. This cytometer comprises one blue laser (488 nm) and a 
red laser (~635 nm). The blue laser excites FITC (Fluorescein isothiocyanate), PE 
(Phycoerythrin) and PerCP (peridinin chlorophyll protein) fluorescent dyes, whereas the red 
laser excites APC (Allophycocyanin) dye. All data were acquired by BD CellQuest™ software 
(BD Biosciences).  
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 Cytokine analysis in cell culture and organ homogenates’ supernatants 
Inflammatory cytokines concentrations in cell culture and organ homogenates’ supernatants 
were determined using the BD Cytometric Bead Array Mouse Inflammation Kit® (cat. no. 
552364, TNF-α, MCP-1, IL-6, IFN-γ, IL-10 and IL-12p70), Mouse Th1/Th2/Th17 Cytokine 
Kit® (cat. no. 60485, IL-2, IL-4, IL-17A) and Mouse IL-1β Flex Set (cat. no. 560232). 
Manufacturer’s instructions were followed to assess the cytokine level. The limit of detection 
of each cytokine was presented in Table 3.2. The principles of BD Cytometric Bead Array 
involve capturing of a soluble analyte or set of analytes with beads of known size and 
fluorescence, making it possible to detect analytes using flow cytometry. When the capture 
beads and detector reagent are incubated with an unknown sample containing recognised 
analytes, sandwich complexes (capture bead + analyte + detection reagent) are formed. These 
complexes can be measured using flow cytometry to identify particles with fluorescence 
characteristics of both the bead and the detector. Then the flow cytometry data are analysed by 
the BD FCAP Array TM software (version 3). The software generates a standard curve based on 
the known fluorescent intensity of cytokine standard. The fluorescent intensity for each of the 
sample is compared with the standard curve to generate the concentration of the cytokines. In 
this investigation, cytokine data were acquired by the BD FACSCalibur™ flow cytometer using 
BD CellQuest® software and analysed by BD FCAP Array TM software (version 3.0).  
Table 3.2 Limit of detection of cytokines  
Name of cytokines Limit of detection 
(pg/mL) 
TNF (tumor necrosis factor)-α 7.3 
MCP (monocyte chemoattractant factor)-1 52.7 
IL (interleukin)-6 5.0 
IFN (interferon)-γ 2.5 
IL-10 17.5 
IL-12p70 10.7 
IL-2 0.1 
IL-4 0.03 
IL-17A 0.8 
IL-1β 1.9 
 
However, at the last step of the staining, we treated the samples with 3.33% paraformaldehyde 
(PFA; cat. no. 00-8222-49, Thermofisher Scientific, Australia) for 30 minutes for the killing of 
all the viable mycobacteria. The mentioned time required for killing of the mycobacteria were 
determined by performing a separate experiment where mycobacterial cultures (M. bovis, BCG 
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and M. tuberculosis, H37Rv) were treated with the 3.33% PFA for 0, 30, 40 and 50 minutes. 
No growth was observed after 30 minutes of PFA treatment (Appendix 1).  
 Animal and animal-derived waste disposal 
Mice were monitored daily and moribund/dead animals (if any) were removed from the cages 
and disposed according to the institutional biosafety guidelines. The mycobacteria 
infected/uninfected sacrificed mice at the endpoint of the experiment were also disposed 
following the guidelines. For M. tuberculosis (H37Rv) infected wastes were removed from the 
PC3 lab after an appropriate autoclave cycle and records were maintained strictly.  
 Statistical analysis 
Statistical analysis was performed using the SPSS version 24.0 and GraphPad Prism 7.03 
software. Data were checked for normality using the Shapiro-Wilk’s test. Data passed the test 
of normality if p≥0.05. The normally distributed data were compared between the groups using 
the unpaired t-test with Welch’s correction. The normally distributed data of multiple groups 
were compared using the ordinary one-way ANOVA with Holm-Sidak's multiple comparisons 
test. In contrast, the non-normally distributed data were compared between the groups using the 
non-parametric Mann-Whitney U test. The Kruskal-Wallis test with Dunn's multiple 
comparisons was performed for non-normally distributed data of multiple groups. However, 
the two-way ANOVA with Sidak’s multiple comparisons test was performed for the data 
having the repetitive measures (e.g. glucose tolerance test, kinetics of feed and energy intake, 
body mass). The Kaplan Meier survival curves with log-rank (Mantel-Cox) tests were used to 
compare diabetic and control mouse survival after mycobacterial infections. All data were 
presented as mean±SEM (Standard Error of the Mean). The level of significance was indicated 
as *p≤0.05, **p≤0.01, ***p≤0.001 and ****p≤0.0001. 
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4 CHAPTER 4  
CHARACTERISATION OF A DIET-INDUCED MURINE MODEL OF TYPE 2 
DIABETES 
 
 Introduction 
Diabetes mellitus (DM), in particular, type 2 diabetes (T2D) is a multifactorial metabolic 
disorder. The key factor that contributes to the development of T2D involves the dynamic 
interplay between lifestyle factors and genetic predisposition. Obesity is considered one of the 
key factors for the escalation of global T2D over the last half century (Gerich, 1998, Lewis, 
2013, Scheen and Van Gaal, 2014). The consumption of high glycaemia index diet associated 
with the persistent hyperglycaemia results in the deposition of advanced glycation end products 
and oxidative stress, chronic inflammation and many immune defects, microvascular (e.g. 
retinopathy, nephropathy and neuropathy) and macrovascular complications (e.g. 
atherosclerosis, cardiovascular diseases) (Shah and Hux, 2003, Leutholtz and Ripoll, 2011). 
Another important complication of T2D includes the increased susceptibility to infections, 
results in a higher morbidity and mortality of those patients (Bridson et al., 2014, Hodgson et 
al., 2015). Despite the global health priority of T2D, the pathophysiological mechanisms 
underlying it are still incomplete. Moreover, the escalating association between T2D with other 
diseases (e.g. HIV infection, tuberculosis, melioidosis) warranted an appropriate animal model 
to further understand the mechanisms of host-pathogen interaction and evaluation of potential 
therapeutic drugs for their treatment.   
In addition to clinical studies in human diabetic patients, previous studies using animal models 
have contributed to our understanding of some aspect of insulin resistance, obesity and diabetes 
(Surwit et al., 1988, Tomita et al., 1992, Zhang et al., 1994, Black et al., 1998, Suzuki et al., 
1999, Sharma et al., 2003, Kawasaki et al., 2005, Cefalu, 2006, Kanetsuna et al., 2007, Brosius 
et al., 2009, Hodgson et al., 2013a). There are currently several rodent/murine models in use 
either on naturally occurring mutations, genetically engineered, inbred strains, tissue-specific 
knockout and transgenic mice. Such genetic models fail to reflect the significant nutritional and 
polygenic determinants involved in the aetiopathology of the disease in humans (Hodgson et 
al., 2011). Chemically induced mouse models using streptozotocin (STZ), which destroys the 
pancreatic β-cell to shorten the length of time required for the development of diabetic 
symptoms (Gilbert et al., 2011, King and Bowe, 2016). The limitations of those models are that 
the micro and macrovascular complications associated with clinical T2D require a considerable 
time to become established and these cannot be achieved in a short-term treatment regime. 
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Moreover, chemically induced models have limited utility due to the toxicity of STZ on the 
renal and hepatic tissue (Deeds et al., 2011).  
In contrast, the diet-induced diabetic (DID) murine model is considered more akin to the 
aetiopathology of T2D of human patients. The DID mouse model was first introduced by Surwit 
and colleagues (1988)  in C57BL/6 mice. The authors used an extremely high-fat diet (60% of 
energy) to induce diabetes, which markedly exceeds the typical dietary intake of the population 
within any developed nation (34 % of energy) (Ludwig et al., 1999). Subsequently, others 
worked on the development of a more appropriate DID model by changing the dietary 
compositions (Srinivasan et al., 2005, Adeyi et al., 2012), but they didn’t characterise the model 
based on the biochemical parameters and vascular complications that occur in human T2D 
patients. Furthermore, there are considerable discrepancies in the metabolic features reported 
in the studies using DID models, which are confounded by the differences in dietary 
composition, fat content, age of the mice, duration of diet intervention, along with gender and 
inbred strain variability (King and Bowe, 2016). 
Considering the global dietary pattern, we have used an energy-dense diet (EDD) (23% fat, 
19% protein and 50.5% dextrose) in the development of hyperglycaemia and glucose 
intolerance in C57BL/6 mice after 10 weeks of dietary intervention (Hodgson et al., 2013a). A 
rapid progression of hyperglycaemia and glucose intolerance were observed in mice on EDD 
compared to the controls on standard rodent diet (SRD). The preliminary findings by the 
Hodgson and co-workers (2013a) suggest that prolonged consumption of EDD can lead to the 
development of chronic features of T2D and its associated vascular complications. Previous 
studies on DID mouse models (Surwit et al., 1988, Srinivasan et al., 2005) including our study 
using EDD (Hodgson et al., 2013a), were only characterised the model for insulin resistance 
based on fasting blood glucose concentration and glucose tolerance test. The caveats of these 
studies were the model was not characterised for many biochemical parameters (e.g. HbA1c, 
lipid profile) and associated pathologies in organs (e.g. pancreas, liver, adipose tissue, kidneys) 
observed in human T2D patients (Bays et al., 2004, ADA., 2009a, ADA., 2009b, Quan et al., 
2013). Research in human diabetic patients has shown that insulin resistance not only develops 
due to the destruction of pancreatic β-cell but also due to ectopic fat deposition in the body (e.g. 
hepatic steatosis) (Bays et al., 2004, Cusi, 2010). Furthermore, one of the foremost 
complications of poorly controlled glycaemia is chronic renal failure (McKenna and 
Thompson, 1997). The progression to renal failure is commonly screened for by tests for 
microalbumin, creatinine and albumin creatinine ratio (ACR) and associated pathological 
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lesions in the kidneys (mesangial expansion and sclerosis) (Mauer et al., 1981, Brito et al., 
1998, Katz et al., 2002). Based on the preliminary findings of Hodgson and colleagues (2013a), 
the current study used the same EDD for a period of 30 weeks to further characterise the model 
based on different metabolic and biochemical parameters along with histological findings in 
pancreas, liver, adipose tissue and kidneys. Similar to our previous study (Hodgson et al., 
2013a), male C57BL/6 mice was considered for this study as females are shown to be more 
protective to adipocyte inflammation and insulin resistance due to higher levels of oestrogen 
(Stubbins et al., 2012). In this current investigation, mice were sourced from the Small Animal 
Breeding Unit of James Cook University (named as JCU bred mice) and commercially available 
mice from Animal Resource centre, Perth, Western Australia (named as ARC bred mice) having 
the same parent stocks. The use of the same mouse strain from two separate sources will also 
facilitate our understanding of any phenotypic and environmental differences.  
Therefore, the specific Aims of the research described in this Chapter are:  
1. To determine the effect of prolonged consumption of EDD on body weight, glucose 
parameters, glucose tolerance and HbA1c level 
2. To assess the effects of EDD on the renal function through the analysis of urine 
(microalbuminuria, creatininuria, albumin creatinine ratio and glycosuria)  
3. To investigate the effect of EDD on hepatic, renal, visceral adipose tissue and 
pancreatic islet pathology by histopathological examination  
 Materials and Methods 
4.2.1 Animal ethics and biosafety approvals 
The animal ethics and relevant biosafety approvals are described in Chapter 3 (section 3.1.1). 
 Experimental animals and study design 
Male C57BL/6 mice were used for this study. Mice originated from two sources; the Small 
Animal Breeding Unit of James Cook University (referred in this Chapter as JCU bred mice) 
and the Animal Resource Centre, Perth, Western Australia (referred in this Chapter as ARC 
bred mice). Mice at 4 weeks of age were randomly housed in cages (5 mice/cage) within a 
temperature and light controlled environment. Ear marking was done to allow longitudinal 
analysis of individual mouse across the study period. After 2 weeks of being housed with a 
regular diet, mice were randomly divided into two dietary groups. One group of mice received 
an ad libitum access to an EDD (Energy-dense diet, JCU bred mice, n=34, ARC bred mice, 
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n=39) and the control group received SRD (Standard rodent diet, JCU bred mice, n=35, ARC 
bred mice, n=40) based on the daily requirement (4.5 g/mouse/day). The experimental groups 
of mice were kept on the EDD for a total period of 30 weeks. The details of animal care and 
nutritional provisions are described in Chapter 3 (section 3.1.2 and 3.1.3). 
 Sample collection following diet intervention 
 Blood sample 
The whole blood was collected from both JCU and ARC bred mice after 25 and 30 weeks of 
diet intervention. It was collected from retro-orbital sinus from the 6 hourly fasted mice 
according to the published standard procedure (Donovan and Brown, 2005). The mouse was 
manually restrained, neck gently scuffed with ears pulled back to expose the eyes. The sterile 
capillary tube (Livingstone Microhaematocrit capillary tubes with sodium-heparin 80 IU/mL 
#CAPTUBH) was then inserted at the medial canthus of the orbit to an appropriate depth 
(indicated by a red line on each tube). The capillary tube very gently rotated until blood flows 
through the tube. Immediately after collection of 200-300 µL of blood per mouse, the capillary 
tube was removed and the excess blood was wiped by a swab moistened with PBS (phosphate 
buffer saline, pH 7.2). Mice were observed to ensure bleeding had stopped and feed and water 
provided. The whole blood was preserved at -800C until analysis.  
 Urine sample 
Urine samples (≥80 µL/mouse) was collected from both JCU and ARC bred mice after 30 
weeks of diet intervention. For the collection of urine, mice were individually housed in 
reusable food storage containers until spontaneous urination occurred (spot collection). If mice 
did not provide a sample within 20 minutes, a gentle palpation of the lower abdominal area or 
minor handling was done to induce urination. All urine samples were collected into 
appropriately labelled sterile microcentrifuge tubes and preserved at -800C until analysis.  
 Tissue sample 
The JCU bred mice were sacrificed after 30 weeks of diet intervention to collect visceral adipose 
tissue, liver, pancreas and kidney for histological examinations. The collected tissue samples 
were kept in 10% neutral buffered formalin (NBF) for a minimum period of 24 hours before 
they are processed for histological examinations. No tissue samples were collected from ARC 
bred mice after the diet intervention as another researcher of the same research group used them 
for her study (Bridson, 2015). 
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  Assessment of metabolic and biochemical parameters following diet intervention 
 Feed intake and body weight 
The average daily feed intake and weekly body weight of the JCU bred mice (both EDD and 
SRD groups) was measured for the duration of the diet intervention (Chapter 3, section 3.1.3). 
The kinetics of the daily feed and weekly body weight gain of ARC bred mice were not 
considered for this study as these parameters were determined previously by another researcher 
of the same research group (Bridson, 2015).  
 Fasting blood glucose and glucose tolerance test  
The fasting blood glucose (FBG) concentration and glucose tolerance test (GTT) of both JCU 
and ARC bred mice were determined after 25 and 30 weeks of diet intervention. The detailed 
procedure is described in Chapter 3 (section 3.2.1 and 3.2.2).  
 Biochemical analysis of the blood and urine samples 
Biochemical analyses of the whole blood and urine samples were performed using the AU480 
Chemistry Analyser (Beckman Coulter, Mt Waverly, VIC, Australia) according to the 
manufacturer’s instructions. Measurement of specific parameters using the AU480 Chemistry 
Analyser requires loading of the appropriate reagents and calibrators. For the measurement of 
glycosylated haemoglobin (HbA1c) from whole blood and microalbumin, creatinine and 
glucose from urine samples, all appropriate reagents (Appendix 1) were loaded into the specific 
location of the analyser. Then, the blood samples were thawed and thoroughly mixed. The 
whole blood was first lysed by mixing with the haemoglobin denaturant (cat. no. OSR004) in a 
1:41 dilution (25 µL blood and 1000 µL haemoglobin denaturant) followed by 5 minutes 
incubation at room temperature. Five hundred µL of the lysed blood was taken into to Beckman 
Coulter sample cups (0.5 mL; cat. no. 651412). Afterwards, sample racks were loaded into the 
rack supply unit of the analyser. For the measurement of urine parameters, urine samples were 
defrosted thoroughly and briefly centrifuged (350 xg, 5 minutes at room temperature). Eighty 
µL of the urine sample was taken into each Beckman Coulter sample cup followed by loading 
of the samples racks to the analyser. The data for whole blood (total haemoglobin; Hb and total 
glycosylated haemoglobin; HbA1c) and urine (microalbumin, creatinine and glucose) was 
retrieved form the analyser after end of the run. The percentage of HbA1c was then calculated 
based on the total Hb and total HbA1c. However, the percent of urine albumin creatinine ratio 
(ACR) was calculated based on microalbumin and creatinine value.  
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 Histopathological examination of tissue samples 
The formalin fixed tissue samples were processed for histological examination. To assess the 
neutral lipid accumulation, the liver samples were cryosectioned (5 µm thickness) in OCT 
(optimum cutting temperature) medium and stained with the modified Herxheimer’s solution 
and counter stained with the Mayer’s Haematoxylin (Appendix 1). The adipose tissue, pancreas 
and kidney samples were embedded in paraffin and sectioned at 5 µm thickness. The adipose 
tissue and pancreas were stained with Haematoxylin and Eosin (H&E) for morphological 
evaluation and quantification of the tissue specific lesions. The kidney sections were stained 
with periodic acid-Schiff (PAS) stain for the quantification of lesions in the glomeruli (Chapter 
3, section 3.5 and Appendix 1).  
Stained sections were visualised on a computer connected to a light microscope (BX43 
Olympus). Quantitative analysis of tissue sections was performed on the representative digital 
images (200x magnification) using the CellSens® Image Analysis software (Olympus). For the 
determination of the extent of lipid deposition in the liver section from each mouse, a threshold-
based phase segmentation technique was used. A minimum of 10 images of each liver section 
of each mouse was considered for the evaluation (Chapter 3, section 3.5.1). The mean adipocyte 
size within visceral adipose tissue (VAT) section from each mouse was assessed by measuring 
the area of a minimum of 50 adjacent adipocytes per image. At least 5 images from each VAT 
section of each mouse were evaluated (Chapter 3, section 3.5.2). The total pancreatic area of 
each mouse was measured on H&E stained sections. The total number of pancreatic islet of 
each section was counted and each islet area were measured. Data were expressed as the 
percentage of pancreatic islet area over the total pancreatic area of each mouse (Chapter 3, 
section 3.5.3). Kidney sections were evaluated by the threshold-based phase segmentation 
technique to compare the percentage of the PAS-positive staining within the glomerular 
capillary tufts, relative to the glomerular area. The perimeter of each glomerulus was outlined 
using a polygonal tracing tool of the CellSens® software. (Chapter 3, section 3.5.4).   
 Statistical analysis 
Statistical analysis was performed using the GraphPad Prism 7.03 software. All glycaemic, 
biochemical parameters (e.g. FBG level, HbA1c, albumin, creatinine, urine glucose) and 
histological findings (e.g. lipid deposition in liver, adipocyte size) were checked for normality 
using the Shapiro-Wilk’s test. Data passed the test of normality if p≥0.05. The normally 
distributed data (e.g. 30th week feed and energy intake) were compared between the groups 
(SRD vs EDD) using unpaired t-test with Welch’s correction. The normally distributed data of 
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multiple groups (e.g. 30th week body weight of SRD vs EDD of JCU and ARC bred mice) were 
compared using the ordinary one-way ANOVA with Holm-Sidak's multiple comparisons test. 
In contrast, the non-normally distributed data (e.g. lipid deposition in liver) were compared 
between the groups using the non-parametric Mann-Whitney U test. The Kruskal-Wallis test 
with Dunn's multiple comparisons test was performed for non-normally distributed data of 
multiple groups (e.g. 25th week HbA1c data of SRD vs EDD of JCU and ARC bred mice). 
However, the two-way ANOVA with Sidak’s multiple comparisons test was performed for the 
data having the repetitive measures (e.g. glucose tolerance test, kinetics of feed and energy 
intake, body mass). All the data were presented as mean±SEM. The level of significance was 
indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and ****p≤0.0001. 
 Results  
 Metabolic parameters following diet intervention 
 Energy-dense diet changes body mass kinetics  
Prior to the diet intervention, the commencing body weights of both dietary groups of the JCU 
bred (EDD, 15.49±0.29 vs SRD, 15.03±0.43, g, p= >0.9999) and ARC bred mice (EDD, 
19.21±0.22 SRD vs 19.78±0.20, g, p= >0.9999) were equivalent. Although the daily feed intake 
was lower in EDD fed mice, the daily energy intake was significantly higher (1.36 fold) (Figure 
4.1 A). Higher energy intake of the EDD fed mice corresponded with a significant increase of 
body mass in both JCU bred and ARC bred mice (Figure 4.1 B, C, & D). The daily feed and 
energy intake (Appendix 2) and body weight gain of JCU bred mice showed that body mass 
gain was significantly higher in EDD group from the first week to the 30th week of diet 
intervention (Figure 4.1 B). The highest body weight gain was recorded at the 30th week of diet 
intervention in both JCU bred mice and ARC bred mice (Figure 4.1). After 30 weeks, an overall 
increase of body mass was 208.11% (EDD) and 79.86% (SRD) in JCU bred mice and 142.79% 
(EDD) and 41.05% (SRD) in ARC bred mice.  
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Figure 4.1 Changes in mouse body mass in response to energy-dense diet  
Male C57BL/6 JCU (EDD, n=34 vs SRD, n=35) and ARC bred mice (EDD, n=39 vs SRD, 
n=40) were fed either an energy-dense diet (EDD) or a standard rodent diet (SRD) for a period 
of 30 weeks. Daily feed and energy intake and body mass of JCU bred mice were monitored 
throughout the study period. Feed intake was significantly higher in mice on SRD, whereas 
energy intake was significantly higher in mice on EDD (A). Changes in the body mass kinetics 
were also comparable between the two groups following the diet intervention (B). Body mass 
was significantly higher in mice on EDD of both JCU and ARC bred mice at 25th and 30th week 
of diet intervention (C & D). Data presented as mean±SEM (Appendix 2). The significant 
differences were determined using the unpaired t-test with Welch’s correction (A), two-way 
ANOVA with Sidak’s multiple comparisons tests (B), Kruskal-Wallis test with Dunn's multiple 
comparisons test (C) and the ordinary one-way ANOVA with Holm-Sidak's multiple 
comparisons test (D). The level of significance was indicated as **p≤0.01, ***p≤0.001, 
****p≤0.0001 and ns=non-significant. 
 
 Energy-dense diet increased fasting blood glucose and glucose intolerance  
Glucose tolerance test (GTT) demonstrated that the blood glucose level was significantly higher 
in mice fed on EDD compared to controls at both 25th and 30th week of diet intervention (Figure 
4.2 A, B, D & E). Immediately after the intraperitoneal glucose challenge, the blood glucose 
concentration rose significantly in EDD group compared to SRD group. At 30th week of diet 
intervention, the 2 hours post-glucose challenge blood glucose level of JCU bred (EDD, 
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10.10±0.24 vs SRD, 8.71±0.22, mmol/L) and ARC bred mice (EDD, 11.73±0.42 vs SRD, 
8.46±0.22, mmol/L) was comparable to the baseline blood glucose level (0 minutes) of JCU 
bred (EDD, 8.8±0.25 vs SRD, 8.5±0.25, mmol/L) and ARC bred mice (EDD, 9.34±0.23, SRD, 
8.68±0.23 mmol/L) indicating the higher glucose intolerance in EDD fed mice compared to 
controls. Overall, compared to the control group on SRD, the baseline fasting blood glucose 
(FBG) of mice on EDD was higher at both 25th and 30th week of diet intervention and the mice 
were less efficient in clearing the circulatory blood glucose even after 2 hours post-glucose 
challenge (Figure 4.2 A, B, D & E). Moreover, the FBG concentration was also assessed from 
the retro-orbital sites before the collection of whole blood for the determination of HbA1c. 
Similar to the baseline FBG level (0 minutes) determined from tail vein (Figure 4.2 A, B, D & 
E), an elevated blood glucose level was recorded in EDD fed mice compared to SRD group at 
both 25th and 30th week of diet intervention. At week 30, the FBG level (retro-orbital bleeding) 
was significantly higher in EDD fed mice compared to the control groups in both JCU bred 
(EDD, 11.07±0.43 vs SRD, 8.61±0.27, mmol/L, p=0.0405) and ARC bred mice (EDD, 
11.85±0.33 vs SRD, 9.33±0.29, mmol/L, p= <0.0001). At the 25th week, a similar trend was 
observed in both JCU bred (EDD, 10.47±0.35 vs SRD, 9.12±0.27, mmol/L, p=0.0002) and ARC 
bred mice (EDD, 11.32±0.35 vs SRD, 8.92±0.24, mmol/L, p= <0.0001).  
 
The area under the curve (AUC) based on GTT (AUC-GTT) was significantly higher in EDD 
group compared to SRD group at both 25th and 30th week (Figure 4.2 C & F). At 30th week, the 
AUC-GTT was 1.21 and 1.29 times higher in EDD group compared to controls of JCU and 
ARC bred mice, respectively (Figure 4.2 F). This finding indicates the higher glucose 
intolerance by the mice on EDD compared to control group. A similar trend of AUC-GTT was 
observed in the EDD group compared to SRD group of JCU and ARC bred mice at 25th week 
(Figure 4.2 C). 
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Figure 4.2 Glucose tolerance in mice following diet intervention 
The blood glucose level was measured at 0 (baseline), 15, 30, 60 and 120 minutes of post-
intraperitoneal glucose challenge after 6 hours fasting of mice. Significantly impaired glucose 
tolerance was observed in mice (JCU and ARC bred) fed on EDD compared to control mice on 
SRD after both 25th and 30th week of diet intervention (A, B, D & E). A significantly higher 
AUC was also observed in mice fed EDD compared to SRD group indicating an impaired 
glucose intolerance or insulin resistance (C & F). Data presented as mean±SEM; n=34-35 (JCU 
bred) and 39-40 (ARC bred) mice/group (Appendix 2). The Significant differences were 
determined using the two-way ANOVA with Sidak’s multiple comparisons tests (A, B, D & E) 
and the ordinary one-way ANOVA with Holm-Sidak's multiple comparisons test (C & F). The 
level of significance was indicated as * p≤0.05, **p≤0.01. ***p≤0.001. ****p≤0.0001 and 
ns=non-significant. 
 
 Energy-dense diet changes glycosylated haemoglobin  
Glycosylated haemoglobin (HbA1c) was measured from retro-orbital blood after 6 hours of 
fasting. At 25 and 30 weeks, an elevated level of HbA1c was recorded in mice fed on EDD 
compared to the control mice fed on SRD (Figure 4.3 A & B). At 30 weeks on diet, the HbA1c 
level of JCU bred mice was 2.70±0.05 vs 2.34±0.08, % (EDD vs SRD, p=0.0115) and ARC 
bred mice 2.85±0.06 vs 2.51±0.08, % (EDD vs SRD, p=0.0012) (Figure 4.3 B). A higher level 
of glycosylated haemoglobin was also measured in EDD fed mice at 25th week at both JCU 
(p=0.0589) and ARC bred mice (Figure 4.3 A).  
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Figure 4.3 Glycosylated haemoglobin (HbA1c) level of mice following diet intervention 
The percentage of the HbA1c level was comparable between the dietary groups at both 25th (A) 
and 30th (B) week of diet intervention. The HbA1c level was higher in mice on EDD compared 
to controls on SRD. Data presented as mean±SEM; n=31-35 (JCU bred) and 38-40 (ARC bred) 
mice/group (Appendix 2). The significant differences were determined using the Kruskal-
Wallis test with Dunn's multiple comparisons test. The level of significance was indicated as 
*p≤0.05, **p≤0.01 and ns=non-significant. 
 
 Energy-dense diet changes renal function  
Microalbumin, creatinine and glucose in urine were investigated after 30 weeks of diet 
intervention. The primary evidence of renal impairment in response to EDD was assessed by 
microalbuminuria, which was significantly higher in EDD fed mice compared to controls of 
both JCU and ARC bred mice (Figure 4.4 A). The urine creatinine value also differed 
significantly between the dietary groups in both JCU and ARC bred mice (Figure 4.4 B). 
Compared to the control mice on SRD, the lower urinary creatinine value in EDD fed mice 
indicated that they may be less efficient in clearing the high circulating creatinine due to 
impairment of renal function (Morris et al., 2016). Furthermore, the urine albumin creatinine 
ratio (ACR) was significantly higher in mice fed on EDD of JCU and ARC bred mice (Figure 
4.4 C) suggesting some kidney damage. However, the EDD groups demonstrated the symptoms 
of glycosuria as measured by an elevated urine glucose concentration (Figure 4.4 D). Although 
a slightly higher level of glycosuria was recorded in EDD fed mice of JCU mice at 30th week, 
the differences were not statistically significant. A larger volume of urine was collected from 
the EDD fed mice at both 25th and 30th week, which was an indication of polyuria. This evidence 
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was not further confirmed as the current study did not measure the water intake and urine output 
during the diet intervention period.   
 
  
    
 
 
  
 
 
  
  
 
 
 
 
 
 
 
 
 
Figure 4.4 Renal profile of mice after 30 weeks of the diet intervention 
Microalbumin, creatinine and the albumin creatinine ratio (ACR) were comparable between the 
dietary groups of both JCU and ARC bred mice. A significantly higher concentration of 
microalbumin in urine was recorded in EDD fed mice compared to SRD fed mice (A). Whereas 
the creatinine concentration was significantly lower in the urine of EDD fed mice in comparison 
to controls (B). The ACR was significantly higher in mice fed on EDD compared to the control 
mice (C). However, there was no significant difference was observed in the urine glucose 
concentration of EDD and SRD fed JCU and ARC bred mice (D). Data presented as 
mean±SEM; n=31-33 (JCU bred) and 38 (ARC bred) mice/group. The significant differences 
were determined using the Kruskal-Wallis test with Dunn's multiple comparisons test. The level 
of significance was indicated as ***p≤0.001, ****p≤0.0001 and ns= non-significant. 
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 Histopathological changes in response to energy-dense diet 
 Energy-dense diet results in lipid deposition in liver  
The lipid deposition in the liver was comparable in mice fed on EDD and SRD for 30 weeks. 
The Modified Herxheimer’s staining (red colour indicates lipid deposition) of liver sections 
demonstrated marked lipid deposition in the liver of EDD fed mice compared to control mice 
on SRD (Figure 4.5 A & B). Quantification of the Herxheimer’s stained area on the liver 
sections also demonstrated a marked hepatic steatosis in EDD fed mice compared to control 
mice (Figure 4.5 C).  
 
Figure 4.5 Lipid deposition in liver of mice after 30 weeks of the diet intervention  
Representative cryosections of liver of JCU bred mice were stained by the Modified 
Herxheimer’s stain and quantified using CellSens® Image Analysis software. The 
photomicrographs of a representative liver section of mice on SRD (A) and EDD (B) showed 
the deposition of lipid (red colour) in the liver parenchyma. A significantly higher percentage 
of Herxheimer’s stained area over the total liver area measured in EDD fed mice compared to 
controls (C). Scale bar of the photomicrographs: 100 µm. Data presented as mean±SEM; n=16-
21 mice/group (Appendix 2). The significant differences were determined using the Mann-
Whitney U test. The level of significance was indicated as ****p≤0.0001. Images from other 
animals are given in Appendix 2, Figure A2.1-A2.2. 
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 Energy-dense diet results in ectopic fat deposition and abnormal adipocyte 
morphology  
After 30 weeks, a marked fat deposition (gross morphology) was evident as visceral (dotted 
circle in Figure 4.6) and subcutaneous adiposity (dotted lines in Figure 4.6) in EDD group 
compared to control group on SRD. Haematoxylin and Eosin staining of the visceral adipose 
tissue sections demonstrated the abnormal adipocyte morphology of the EDD group compared 
to SRD group (Figure 4.6 C & D). Measurement of the size of each of adipocyte showed that 
the mean size of each adipocyte was 3.99 times higher in EDD fed mice compared to control 
mice on SRD (Figure 4.6 B).  
 
Figure 4.6 Ectopic lipid deposition and abnormal adipocyte morphology in mice after 30 
weeks of diet intervention 
The photographs demonstrated the gross ectopic subcutaneous (dotted line) and visceral fat 
deposition (dotted circle) (A) in JCU bred mice after 30 weeks of the diet intervention (A). 
Quantification of the H&E stained visceral adipose tissue (VAT) sections demonstrated 
significantly increased size of adipocyte (adipocyte hypertrophy) of mice fed on EDD compared 
to control mice on SRD (B). The photomicrographs of a representative VAT section of mice on 
SRD (C) and EDD (D) showed the comparative size of the adipocyte. Scale bar of the 
photomicrographs: C-D; 100 µm. Data presented as mean±SEM; n=15-17 mice/group 
(Appendix 2). The significant differences were determined using the unpaired t-test with 
Welch’s correction. The level of significance was indicated as ****p≤0.0001. Images from 
other animals are given in Appendix 2, Figure A2.3-A2.4. 
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 Energy-dense diet results in pancreatic islet hyperplasia  
Hyperplasia of pancreatic islet, an indication of insulin resistance, was measured after 30 weeks 
in JCU bred mice (Figure 4.7 A & B. The total pancreatic islet area over the total pancreatic 
area were 2.35 times higher in EDD fed mice compared to controls on SRD (Figure 4.7 C).  
 
Figure 4.7 Hyperplasia of pancreatic islet in mice after 30 weeks of diet intervention 
The H&E stained photomicrographs of representative pancreatic sections of JCU bred mice 
demonstrated the variable size and islet density on the pancreatic section of a mouse on EDD 
(A). Compensatory pancreatic islet hyperplasia was evident in the pancreas of mice on EDD 
(B). Quantification of the percent (%) islet area over the total pancreatic area demonstrated a 
significantly higher islet area in mice on EDD compared to control mice on SRD (C). Scale bar 
of the photomicrographs: A; 500 µm and B; 100 µm. Data presented as mean±SEM; n=21-27 
mice/group (Appendix 2). The significant differences were determined using the unpaired t-test 
with Welch’s correction. The level of significance was indicated as ****p≤0.0001. Images from 
other animals are given in Appendix 2, Figure A2.7-A2.8. 
 
 Energy-dense diet results in renal pathology  
Renal pathology was assessed by semi-quantitative analysis of the PAS-positive stained area of 
the glomeruli of kidney section of mice after 30 weeks. Compared to control mice on SRD, 
EDD fed mice demonstrated a higher glomerular damage as thickening of basement membrane 
of the Bowman’s capsule (Figure 4.8 B, arrow), expansion and thickening of the mesangial 
matrix (Figure 4.8 B, asterisk) and hypertrophy of glomeruli (Figure 4.8 B & D). The 
percentage of the PAS-positive stain within the glomerular area was significantly higher in 
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EDD fed mice compared to controls (Figure 4.8 C). Furthermore, the EDD fed mice 
demonstrated a 1.60 times higher area of each glomerulus (glomerular hypertrophy) compared 
to SRD fed mice (Figure 4.8 D). Histopathological findings together with the urine ACR and 
glycosuria suggested that mice fed on EDD over the period of 30 weeks developed renal 
impairment and pathologies. These findings are characteristic features of nephropathy 
associated with clinical T2D in human patients. 
 
Figure 4.8 Nephropathy in mice after 30 weeks of diet intervention 
Representative kidney sections were taken after 30 weeks of diet intervention and stained with 
the Periodic Acid-Schiff’s (PAS) stain. Pronounced nephropathy was observed in mice fed on 
EDD, which includes the thickening of the Bowman’s capsule (B, indicated by arrows) and 
mesangial matrix thickening (B, asterisk) compared to the control mice on SRD (A). The PAS-
positive staining of the kidney sections demonstrated significant mesangial thickening within 
the glomeruli of kidneys of mice fed on EDD compared to mice on SRD (C). Glomerular size 
(glomerular hypertrophy) was also significantly higher in mice on EDD compared to SRD (D). 
Data presented as mean±SEM; n=11-15 mice/group (Appendix 2). The significant differences 
were determined using the unpaired t-test with Welch’s correction. The level of significance 
was indicated as ***p≤0.001 and ****p≤0.0001. Images from other animals are given in 
Appendix 2, Figure A2.5-A2.6. 
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 Energy-dense diet consumption drives progression to type 2 diabetes 
The diagnostic criteria for clinical type 2 diabetes (T2D) in human comprises a fasting blood 
glucose (FBG) level >7 mmol/L (>126 mg/dL), a 2 hours blood glucose level after a 75 g of 
oral glucose tolerance test (OGTT) showing >11.1 mmol/L (>200 mg/dL) and HbA1c > 6.5% 
(>48 mmol/L) (WHO., 2006, ADA., 2009b, ADA., 2010, Vijan, 2010, d'Emden et al., 2012). 
Mice in the present study EDD fed mice were considered as having T2D if they demonstrated 
a raised FBG level and HbA1c with evidence of glucose intolerance at levels higher the upper 
99% confidence interval for the mean of age-matched control group fed on a SRD. The JCU 
bred and ARC bred mice fed on EDD for a period of 25 and 30 weeks demonstrated the clinical 
features of T2D (Table 4.1, Appendix 2). After 30 weeks of EDD commencement, 76.47 % of 
JCU and 76.31 % of ARC bred mice had higher FBG level and this was supported by the data 
form GTT at the same timepoint. Furthermore, FBG levels (after 2 hours of glucose challenge) 
demonstrated a higher percentage of mice (76.47, JCU vs 97.43, %, ARC bred mice) had 
developed insulin resistance at 25th week compared to 30th week (67.64, JCU vs 84.21, %, ARC 
bred mice). There was a rising trend of the HbA1c level from 25th week to 30th week in both 
JCU and ARC bred mice. After 30 weeks, 73.33% of JCU bred and 76.31% of ARC bred mice 
demonstrated an elevated level of HbA1c (Table 4.1).  
Table 4.1 Percentage of mice demonstrating metabolic features of type 2 diabetes 
following consumption of the energy-dense diet 
 
*6 hours fasting, **6 hours fasting and 2 hours after glucose challenge, FBG; fasting blood 
glucose, HbA1c; glycosylated haemoglobin, GTT; glucose tolerance test, AUC; area under the 
curve 
 
Histological evidence after 30 week of diet intervention in JCU bred mice also demonstrated 
that EDD feeding can induce features indicative of diabetic nephropathy and pancreatic 
Parameters 
Length of time on EDD 
25th week 30th week 
JCU bred 
mice 
ARC bred 
mice 
JCU bred 
mice 
ARC bred 
mice 
 
*FBG 
 
67.64% 
(23/34) 
78.94% 
(30/38) 
76.47% 
(26/34) 
76.31% 
(29/38) 
*HbA1c 
64.70% 
(22/34) 
68.42% 
(26/38) 
73.33% 
(22/30) 
76.31% 
(29/38) 
*GTT (AUC) 
64.70% 
(22/34) 
94.43% 
(37/39) 
76.47% 
(26/34) 
78.94% 
(30/38) 
**FBG+glucose 
challenge 
 
76.47% 
(26/34) 
97.43% 
(38/39) 
67.64% 
(23/34) 
84.21% 
(32/38) 
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pathology. Overall, diabetic nephropathy was evident in more than 80% of mice based on 
elevated urine ACR (83.87%; 26 of 31 mice), glomerular hypertrophy (93.33%; 14 of 15 mice) 
combined with mesangial thickening (73.33%; 11 of 15 mice). Pancreatic hyperplasia was also 
evident in 85.71% (18 of 21 mice) of the EDD fed mice. 
Our findings on metabolic and pathological changes in organs demonstrated that feeding of 
JCU or ARC bred mice with EDD for a prolong period (either 25 or 30 weeks) can induce overt 
clinical features of T2D.  
 Discussion 
The objectives of the research described in this Chapter were to evaluate whether prolonged 
consumption of EDD can induce the development of key metabolic, biochemical and 
pathophysiological features of clinical T2D in male C57BL/6 mice. The key aims (1-3) of the 
current study were to evaluate the differences in the body weight, systemic glucose 
concentration and glucose tolerance, glycosylated haemoglobin (HbA1c) concentration, renal 
and pancreatic pathology in mice during diet intervention. The parameters were measured at 
two terminal timepoints at the 25th and 30th week of diet intervention and data analysed to 
determine whether the mice demonstrated the overt clinical features of T2D similar to human 
patients. We have demonstrated that prolonged EDD feeding induces overt clinical features of 
T2D in mice. 
Obesity is one of the major risk factors for developing T2D (Walley et al., 2006, Eckel et al., 
2011). In humans, 80% of the diagnosed cases of diabetes are in overweight individuals (Smyth 
and Heron, 2006). Obesity-induced diabetes has also been observed in animal models of 
diabetes (Surwit et al., 1988, Tomita et al., 1992, Lee et al., 1994, Black et al., 1998, Loskutoff 
et al., 2000, Finegood et al., 2001, Leiter and Reifsnyder, 2004, Kawasaki et al., 2005, Shafrir 
et al., 2006, Hodgson et al., 2013a). Researchers linked obesity to insulin resistance, abnormal 
glucose metabolism (glucotoxicity), lipotoxicity and pancreatic dysfunction (Baetens et al., 
1978, Kawasaki et al., 2005, Shafrir et al., 2006, Hodgson et al., 2013a). Therefore, in the 
current study, mice were weighed on a weekly basis throughout the diet intervention period to 
monitor the weight gain. The body mass gain was significantly higher in EDD fed mice and an 
increasing trend of body mass gain was observed in the same group from 1 to 30 weeks of the 
diet intervention period (Figure 4.1 B, C & D). A similar type of trend was observed by Bridson 
(2015) using the same diet. Control mice fed SRD gained weight very slowly in first few weeks 
and remained almost steady during the entire diet intervention period (Figure 4.1 B). This 
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finding was in agreement with other studies (Kawasaki et al., 2005, Bridson, 2015, Envigo 
research laboratory., 2015, Jackson laboratory., 2015). The overall body mass increase in EDD 
fed mice was comparable with C57BL/6 (Black et al., 1998) and db/db mice (Kawasaki et al., 
2005). In contrast to our results, Han and co-workers (2015) fed mice a high-fat diet (HFD) for 
a period of 8 weeks and did not see these significant differences in early weight grain.  Mice in 
that study were treated with Cathepsin k inhibitor which prevents body weight gain and insulin 
resistance. The higher body mass of EDD fed mice of the current study was due to the prolonged 
diet intervention period. Excessive subcutaneous and visceral fat deposition (Figure 4.6 A) also 
correlated with higher body mass. Although this study didn’t quantify the gross ectopic fat 
deposition, a study done by Hodgson and colleagues (2013a) found significantly higher 
amounts of subcutaneous (2.17 fold) and visceral fat deposition (8.88 fold) in EDD fed mice 
compared to controls after 10 weeks of the diet intervention. Histopathological analysis of 
visceral adipose tissue demonstrated adipocyte hypertrophy in mice fed an EDD (Figure 4.6 B, 
C & D). This finding was supported by previous studies, where a high-fat high-glycaemic (HF-
HG) index diet was used (Black et al., 1998, Herberg, 1998, Bridson, 2015). The correlation 
among increased adipose tissue, insulin resistance and hyperglycaemia has been noted in 
clinical settings. Obesity induced T2D has been shown to have an effect on insulin resistance 
and glucose intolerance leading to micro- and macro-vascular complications (Arner, 2003, 
Cefalu, 2006).  
 
Diabetes mellitus includes a variety of metabolic abnormalities. Abnormalities in glucose 
metabolism are one of the most specific diagnostic criteria of hyperglycaemia often measured 
as fasting blood glucose (FBG) level and impaired glucose tolerance (post-oral glucose load) 
(REC, 1997, Sacks et al., 2002, ADA., 2010, Vijan, 2010). Similar to human patients with T2D, 
animals should also demonstrate the signs of hyperglycaemia to be called diabetic. Other animal 
model studies classified the animals as diabetic based on the systemic glucose concentration 
often determined by the POC test using a glucose meter (Hodgson et al., 2013a, Bridson, 2015, 
Morris et al., 2016). In addition, impaired glucose tolerance, insulin resistance based on glucose 
tolerance test (GTT)-Area Under the Curve (AUC) and circulatory insulin level are also criteria 
for advance classification of diabetes in some animal models (Surwit et al., 1988, Cefalu, 2006, 
Zhang et al., 2008, Ayala et al., 2010). In this study, mice fed an EDD demonstrated a 
significantly elevated FBG concentration (Figure 4.2). This is similar to previous studies using 
mouse models where a higher FBG level was observed in the diabetic group (Surwit et al., 
1988, Tomita et al., 1992, Suzuki et al., 1999, Leiter and Reifsnyder, 2004, Kawasaki et al., 
2005, Hodgson et al., 2013a, Bridson, 2015). Blood glucose concentrations of mice fed an SRD 
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were also consistent with those reported in prior studies (Surwit et al., 1988, Hodgson et al., 
2013a, Bridson, 2015). An impaired blood glucose and the increased GTT-AUC of mice on 
EDD demonstrated insulin resistance (Figure 4.2 C & F). Hodgson and co-workers (2013a) 
observed insulin resistance using the same diet for a period of 10 weeks. The current study 
didn’t quantify the plasma insulin level or pancreatic insulin content to further confirm the 
insulin resistance in EDD fed mice compared to controls.  
 
In addition to FBG level and impaired glucose tolerance, the measurment of the advanced 
glycation end products particularly HbA1c is another important diagnostic feature of T2D 
(ADA., 2009b, ADA., 2010). In humans, the HbA1c is a form of haemoglobin that is measured 
to detect the 3 months average plasma glucose concentration. Therefore, it is considered a 
precise measure for diagnosing and monitoring the chronic hyperglycaemic status of the patient 
as it is well correlated with diabetic associated complications (ADA., 2009b). In the clinical 
setting, a HbA1c level greater than or equal to 6.5% is considered indicative of T2D (ADA., 
2009a, ADA., 2009b, ADA., 2010). In the current study, JCU bred and ARC bred mice fed on 
EDD had an elevated HbA1c level at both the 25th and 30th week (Figure 4.3 A & B). 
Furthermore, the level of HbA1c was higher at the 25th week compared to the 30th week. The 
HbA1c level at any timepoint is contributed by all circulating Red Blood Cells (RBCs) from 
the oldest to the youngest, which might be one of the reasons for variation of HbA1c in the 
mentioned timepoints (National Glycohemoglobin Standardization Program., 2010). Analyses 
of blood samples in two different batches in the AU480 analyser might also be a reason of 
slightly variable results in the timepoints mentioned. If the current study had determined the 
plasma glucose concentration, an appropriate interpretation could be drawn about the variation 
of HbA1c level in two different timepoints. However, there are no standard criteria for defining 
diabetes in a mouse model based on the HbA1c concentration in blood. The range for HbA1c 
in mice was between 3-4.5% determined by the previous studies (Morris et al., 2016). The 
AGEs including HbA1c are formed when haemoglobin of RBCs is exposed to systemic glucose. 
In diabetes, insulin resistance or decreased systemic insulin levels causes more AGEs products 
to be formed against an increased concentration of systemic plasma glucose (Vistoli et al., 
2013). Differences in HbA1c concentration in humans and mice are due to the exposure time 
of haemoglobin to plasma glucose because human RBCs have three times longer lifespan 
compared to RBCs of mice (120 vs 40 days). A study on HbA1c and plasma glucose levels in 
a diabetic mouse model also suggested that HbA1c concentration is related to the reduced 
lifespan of RBCs and reduced HbA1c half-life in mice (14 days in mice vs 35 days in humans) 
(Dan et al., 1997). The current study determined the HbA1c level to be 1-4% in EDD fed mice 
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at 25 and 30 weeks. This finding was consistent with Bridson (2015), who used the same dietary 
composition for the induction of diabetes in mice and this observation was also comparable 
with the findings of Dan and co-workers (1997).  
Glycosuria is often used as a tool for the screening of diabetes. The hyperglycaemic condition 
of diabetic patients results in the classical signs of diabetes such as polyuria (frequent urination), 
polydipsia (increased thirst) and polyphagia (increased hunger) (WHO., 2006, Cooke and 
Plotnick, 2008, ADA., 2010). In the present investigation, mice fed an EDD demonstrated a 
slightly elevated (JCU bred mice) or similar urine glucose concentration (ARC bred mice) 
compared to controls (Figure 4.4 D). Polyuria and a larger volume of urine might be the 
determining factors of such glucose urine concentration in EDD fed mice of this experiment. 
Polyuria in mice fed on EDD was evident, which is supported by the prior studies on animal 
models (Suzuki et al., 1999, Nagata et al., 2006). In the current study polyuria was not 
specifically quantified (i.e. by regular monitoring of water intake of output). However, we did 
observe increased urine volume. 
Hepatic insulin resistance is associated with the accumulation of triglycerides (TAG) and free 
fatty acid (FA) metabolites (fatty acyl-CoA, diacylglycerol, ceramide and glycosphingolipid 
(Nagale, 2009). In the current study, mice became diabetic in response to the EDD with the 
demonstration of lipid deposition in different sites of the body including the liver. Histology of 
liver tissues demonstrated extensive lipid accumulation in EDD fed mice (Figure 4.5), which 
has been associated with hepatic insulin resistance. Hepatic steatosis in diabetic animal models 
has also been reported previously (Leiter and Reifsnyder, 2004, Harishankar et al., 2011). The 
current study did not measure the TAG levels to correlate to hepatic lipid deposition and insulin 
resistance. Bridson (2015) demonstrated an elevated level of TAG in EDD fed mice at 10, 20, 
30 weeks of diet intervention, which supports excess lipid accumulation in different organs of 
the body. Other researchers have reported previously that excess lipids and their FA metabolites 
are directed to diabesity leading to impairment of insulin signalling and insulin resistance (Bays 
et al., 2004, Cusi, 2010). 
Diabetic nephropathy (DN) is one of the foremost microvascular complications in diabetic 
patients. This complication may ultimately lead to renal failure (Gross et al., 2005, Fowler, 
2008, Dabla, 2010). The renal impairment or damage is diagnosed by measuring albuminuria 
as microalbuminuria, macroalbuminuria and the urine albumin creatinine ratio (ACR) (Gross 
et al., 2005). In the current study, microalbuminuria and ACR and renal histology were assessed 
to determine if the EDD fed mice show the signs of DN and produce associated pathological 
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lesions in kidneys. Microalbuminuria (spot collection) and a higher urine ACR were found in 
EDD fed mice (Figure 4.4 A & C), which indicated kidney damage. A higher trend for 
microalbuminuria and the ACR was also observed previously in diabetic animal models (Leiter 
and Reifsnyder, 2004, Zheng et al., 2004, Zhao et al., 2006, Kanetsuna et al., 2007, Mohan et 
al., 2008). Microalbumin and ACR of control mice were higher in comparison to prior study 
(Jackson laboratory., 2015). This particular laboratory reared the mice for a period of 10 weeks, 
whereas in the current study, mice were on diet for a period of 30 weeks. The degree of variation 
in the results may have been due to genetic background of the mouse strain and environmental 
factors including diet, duration of diet intervention, housing, dark and light cycle, handling etc., 
which might explain reasons for overall variations of the above mentioned parameters of the 
current study (Brosius et al., 2009).  
Diabetic albuminuria in humans is associated with the development of characteristic 
histopathological changes such as glomerulosclerosis. Glomerulosclerosis in diabetic patients 
is characterised by increased glomerular basement membrane width, diffuse mesangial 
sclerosis, hyalinosis, microaneurysm, hyaline arteriosclerosis (Mauer et al., 1981), interstitial 
changes (Brito et al., 1998) and extreme mesangial expansion (Katz et al., 2002). In the current 
study, histopathological changes of the kidney samples were assessed to observe if mice on 
prolonged dietary interventions demonstrated the lesions of glomerulosclerosis similar to 
human patients. Results showed that mice fed on the EDD demonstrated thickening of the 
basement membrane of Bowmans’s capsule, mesangial matrix thickening and hypertrophy of 
glomeruli compared to control mice on the SRD (Figure 4.8). These findings were consistent 
with other studies using diabetic animal models (Koya et al., 2000, Cohen et al., 2001, 
Reifsnyder and Leiter, 2002, Leiter and Reifsnyder, 2004, Danda et al., 2005, Mohan et al., 
2008). These observations suggested that prolonged EDD intervention is able to induce some 
aspects of DN which are similar to human patients. The current study did not assess the plasma 
creatinine level and other histopathological changes in kidney associated with DN.  
 At the onset of T2D, the ability of insulin to stimulate glucose uptake is impaired. 
Subsequently, pancreatic β-cell become over activated to produce more insulin resulting in an 
elevated insulin level in the circulation. Compensatory hyperplasia of the pancreatic islet occurs 
because of a compensatory increase in circulatory insulin levels (Del Prato, 2009, Kahn et al., 
2014). One of the Aims (3) of the current study was to determine the total pancreatic islet area 
over the total pancreatic area to understand the over activity of the pancreatic β-cell and insulin 
resistance. Metabolic parameters such as FBG, impaired glucose tolerance and AUC-GTT 
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already demonstrated that mice on the EDD for a prolonged period became insulin resistant. 
Further confirmation of the hyperactivity of pancreatic islet cells and insulin resistance of EDD 
fed mice was determined by observing pancreatic pathology. Histological examination of the 
pancreas revealed an increase in the size of pancreatic islet (pancreatic hyperplasia) in EDD fed 
mice compared to aged-matched control littermates on SRD (Figure 4.7). The increased area of 
the pancreatic islet was an indication of insulin resistance, which is one of the characteristic 
features of T2D in humans (Quan et al., 2013). Previous studies in animal models observed a 
similar type of compensatory hyperplasia of pancreatic islet in diabetic mice (Lavine et al., 
1977, Suzuki et al., 1999, Bock et al., 2003, Leiter and Reifsnyder, 2004, Kawasaki et al., 2005, 
Nagata et al., 2006, Kanetsuna et al., 2007). Pancreatic insulin content, HOMA-IR 
(Homeostasis Model Assessment-Insulin Resistance) is also an important marker to further 
confirm the insulin resistance. The current study did not determine the pancreatic insulin 
content and HOMA-IR. In the same laboratory, Morris and colleagues (2016) demonstrated an 
elevated total pancreatic insulin and HOMA-IR in EDD fed ARC bred mice compared to 
control mice on SRD.  
In this investigation, both the JCU and ARC bred mice demonstrated the clinical features of 
T2D at 25 and 30 weeks of diet intervention. Based on the metabolic features (FBG, AUC-
GTT, HbA1c and the FBG after 2 hours of glucose challenge), 25 weeks of diet intervention 
was sufficient for the development of diabetic related features in most of the ARC and JCU 
bred mice. However after 30 weeks of diet intervention, the maximum number of mice become 
diabetic based on the same metabolic parameters. Histopathological evidences also 
demonstrated that the JCU bred mice mimicked several aspects of diabetic related 
complications including diabetic nephropathy and pancreatic pathology. Overall, at the 30th 
week of diet intervention, more ARC bred mice (overall 78.94%) showed clinical features of 
T2D compared to JCU bred mice (overall 73.45 %). Bridson (2015) also found a higher 
proportion of ARC bred mice (82% based on FBG) showed the features of diabetes in response 
to the same diet. In the current study, histopathology of ARC mice was not done which was a 
limitation of the study. In an earlier study, histological evidence of ARC bred mice in response 
to the EDD feeding also supported the diabetic related complications observed in JCU bred 
mice (Morris et al., 2016). 
In this study, we didn’t observe any statistically significant differences in the metabolic 
parameters (body weight, AUC, HbA1c, microalbumin, creatinine and ACR) between the SRD 
(control vs control) and EDD fed groups (EDD vs EDD) of JCU and ARC bred mice. A slight 
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variation (high or low) in the diabetic parameters in EDD and SRD fed JCU and ARC bred 
mice might be due to use of separate sources of the mice, genetic background and breeding 
environment (Bernard et al., 2013). It is important to note that under the same experimental 
setting, there was variation in feed consumption, body weight gain and metabolic changes in 
mice fed an EDD. A smaller portion of mice failed to develop hyperglycaemia or an elevated 
level of HbA1c even after the 30 weeks of diet intervention. This is also the case in the human 
diabetic population. Not all obese individuals with poor dietary habits develop diabetes or not 
all the diabetic patients lead an unhealthy lifestyle (Prando et al., 1998). Although obesity and 
lifestyle factors are important predictors of the development of diabetes, there are many other 
risk factors that contribute to the progression of this disease (Fletcher et al., 2002). 
The work described in this Chapter has demonstrated that EDD feeding to C57BL/6 mice 
induces overt features of T2D. The polygenic DID murine model described in the present study 
proposes some advantages over the conventional murine models of T2D such as i) use of a diet 
containing the moderate level of fat with high glycaemic index reflects the global dietary 
pattern, ii) unlike other models which use short-term diet intervention, the present study 
described prolonged diet intervention for progression of pre-diabetes to overt/chronic T2D 
diabetes and its associated complications similar to human T2D patients. Therefore, this model 
can be used for future studies of diabetes alone or host-pathogen interaction in diabetes. 
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5 CHAPTER 5 
EFFECT OF TYPE 2 DIABETES ON MACROPHAGE FUNCTIONS DURING 
MYCOBACTERIAL INFECTIONS 
 
 Introduction 
In mycobacterial infections, some of the first cells to encounter the organism are macrophages, 
in particular, alveolar macrophages (Tascon et al., 2000, Gonzalez-Juarrero et al., 2001, Dheda 
et al., 2010). The primary function of the alveolar macrophage is phagocytosis (uptake and 
killing) of the bacilli (Henderson et al., 1997, Thurnher et al., 1997). If the mycobacteria are 
not killed during this initial encounter, bacteria survive and proliferate within macrophages 
(Iona et al., 2012, Helguera-Repetto et al., 2014). Mycolic acid on the cell wall of mycobacteria 
is a key factor influencing   phagocytosis and bacterial killing. Trehalose 6,6′ dimycolate (TDM) 
is considered the most abundant and toxic mycolic acid which elicits major immunological 
events (Karakousis et al., 2004). It is crucial for the survival of the bacteria within the 
macrophages. It prevents phagosome-lysosome fusion, inhibits acidification of the 
phagolysosome, decreases macrophage expression for pattern recognition receptors (PRR) and 
costimulatory molecules leading to impaired antigen presentation followed by T cell mediated 
immune responses (Indrigo et al., 2002, Indrigo et al., 2003, Kan-Sutton et al., 2009). Bowdish 
and colleagues (2009)  demonstrated that the phagocytosis of TDM coated latex beads by 
macrophages (resident peritoneal and bone marrow-derive) was reduced due to impaired 
recognition of it by the PRR (e.g. Toll like receptors 2; TLR2) including scavenging receptors 
(e.g. macrophage receptors with collagenous structure; MARCO). In the literature, the impact 
of diabetes on the phagocytosis of mycobacteria by macrophages has not been extensively 
investigated. Previous studies on the impact of diabetes in phagocytosis were evaluated mostly 
in peripheral blood mononuclear cells (PBMC) infected with various organisms and beads 
(Geisler et al., 1982, Marhoffer et al., 1992, Delamaire et al., 1997, Geerlings and Hoepelman, 
1999, Lecube et al., 2011, Kumar Nathella and Babu, 2017). The role of alveolar macrophages 
in the primary defence of M. tuberculosis infection, has been poorly investigated in TB-T2D 
co-morbid infection. 
During phagocytosis, macrophages elaborate pro-inflammatory (e.g. TNF-α, MCP-1, IL-1β, 
IL-12, IFN-γ, IL-6) and anti-inflammatory cytokines (e.g. IL-10, IL-4) (Cooper, 2009, Cooper 
et al., 2011).These cytokines are key factors that determines the fate of infections. Studies have 
shown that mice lacking TNF-α promptly succumb to infection with increased bacterial loads 
in spleen, liver and lungs compared to control mice (Flynn et al., 1995, Benoit et al., 2008). 
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TNF-α is essential for the activation of macrophages and neutrophils (Orme and Cooper, 1999, 
Tsenova et al., 1999, Gan et al., 2005) and subsequent lung granuloma formation (Kindler et 
al., 1989, Flynn et al., 1995, Senaldi et al., 1996). The production of IL-1β is also required for 
macrophage activation and it enhances the secretion of TNF-α, IL-6, IFN-γ for an effective 
granuloma formation (Toossi et al., 1990, Juffermans et al., 2000). IL-12 is required for T helper 
1 cell differentiation (e.g. CD4+ T cells for IFN-γ production) (Sieling et al., 1994, Cooper et 
al., 1995, Trinchieri, 1995, O'Neill and Greene, 1998). Secretion of IFN-γ from CD4+, CD8+ 
T cells and Natural Killer (NK) cells not only activates macrophages but also increases MHC 
(Major Histocompatibility Complex) class II molecule expression on antigen presenting cells. 
A deficiency of IL-12 and IFN-γ is known to increase susceptibility to TB, further 
demonstrating the importance of these cytokines (Altare et al., 1998a, de Jong et al., 1998, 
Ottenhoff et al., 2002). In contrast, anti-inflammatory cytokines such as IL-10 and TGF-β 
secreted by macrophages are responsible for the downregulation of IFN-γ, TNF-α and IL-12, 
causing adverse TB-related pathology in the host (Redford et al., 2011). It is the intricate 
interplay of these cytokines that orchestrates effective innate and adaptive immunity in response 
to TB. Although the production of cytokines by macrophages is well documented in TB 
research, there is limited informaton on the impact of diabetes on cytokine production by 
macrophages in mycobacterial infections. Previous research has determined cytokine 
production using in vitro PBMC, but not in alveolar macrophages (Geerlings and Hoepelman, 
1999, Lachmandas et al., 2015). Further, in vivo studies examined the cytokine production in 
diabetic patients with or without TB but yielded contradictory results. Some reports have shown 
an elevated production of pro-inflammatory cytokines in diabetes-TB patients whereas other 
reported the opposite (Restrepo et al., 2008a, Stalenhoef et al., 2008, Tan et al., 2012, Kumar 
et al., 2013, Kumar et al., 2014).  
Therefore, we investigated the phagocytic function and cytokine production by two different 
types of macrophages (resident peritoneal and alveolar) from diabetic and control mice. We 
used both inert mycolic acid coated latex particles and in vitro mycobacterial infections to 
explore the impact of T2D on macrophage function in mycobacterial infections, in particular, 
M. tuberculosis infection.  
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The specific Aims of the research described in this Chapter are:  
1. To determine the uptake capability of alveolar and resident peritoneal macrophages 
from diabetic and control mice following co-culture with mycolic acid coated beads  
2. To investigate the uptake and killing capability of alveolar and resident peritoneal 
macrophages from diabetic and control mice following infection with of M. 
fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) 
3. To assess pro-inflammatory (TNF-α, MCP-1, IL-1β, IL-12, IFN-γ, IL-6) and anti-
inflammatory cytokine (IL-10) production by alveolar and resident peritoneal 
macrophages from diabetic and control mice following co-culture with M. fortuitum, 
M. bovis (BCG) and M. tuberculosis (H37Rv) 
 Materials and Methods 
 Experimental animals  
The mice used for the characterisation of diet-induced murine model of T2D described in 
Chapter 4 were used for the study presented in this Chapter. In addition, other T2D and control 
mice sets were also used for this study.  
 Assessment of mycolic acid coated bead phagocytosis 
 Preparation of mycolic acid coated beads  
Fluoresbrite® 2 µm Yellow Green Microspheres (411 nm excitation and 485 nm emission, 
Polysciences, Inc, USA) were coated with two commercially available cell wall extracts of 
Mycobacterium tuberculosis (bovine strain): (i) mycolic acid (cat. no. M4537, Sigma) and (ii) 
Trehalose 6, 6′ dimycolate, cat. no. T3034, Sigma). Initially, mycolic acid stocks were prepared 
by dissolving the powder in chloroform: methanol solution (Appendix 1). The amount of 
mycolic acid required to deposit as a monolayer was calculated as described by Retzinger and 
colleagues (1981). Lipid coated beads were prepared according to the protocol described by 
Indrigo and co-workers (2003) with some modifications. Briefly, Fluoresbrite® beads were 
washed three times with carbonate-bicarbonate buffer (cat. no. C3041, Sigma; Appendix 1) by 
centrifugation at 3000 xg for 15 minutes at 150C. Beads to be coated with either mycolic acids 
were further washed once in 30% ethanol followed by 1% ethanol (Appendix 1). The required 
volume of mycolic acids (20 µg/1x108 beads) was then added to the beads suspension in 
carbonate bicarbonate buffer. The beads and mycolic acid mixtures were alternatively vortexed 
and sonicated (50% of the maximum frequency) at 550C for 5 minutes and incubated for 12 
hours at 370C with constant gentle mixing (120 rpm in an orbital shaker). Following coating, 
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beads were washed twice with PBS. Mycolic acid coated beads were further washed once in 
0.1% F68 buffer (cat. no. P566, Sigma; Appendix 1) followed by RPMI 1640 (Invitrogen, 
Mulgrave, Australia) before resuspending in RPMI. Lipid coated beads were stored at 40C and 
further sonicated for 2 minutes before adding to cell suspensions for phagocytosis assays. The 
control beads were prepared exactly the same way where carbonate bicarbonate buffer was 
added instead of mycolic acids. However, we have also used fresh beads to assess the 
phagocytosis. They were not treated with anything as described for mycolic acid coated beads 
and control beads. Finally, the mycolic acid coated beads were assessed using the BD 
FACSCalibur™ flow cytometer to evaluate the light scattering properties as an indicator of the 
successful coating. The higher forward scatter (indicates the relative size) of the lipid coated 
beads in comparison to uncoated beads confirmed the successful coating with mycolic acids 
(Figure 5.1). The exact amount of mycolic acid coated onto the beads surface was not 
determined.  
 
  
 
 
 
 
 
 
 
 
Figure 5.1 Scattering of mycolic acid coated beads and control beads 
Figure illustrated the higher forward scattering of the mycolic acid coated beads (blue) 
compared to the uncoated control beads (light red).  
 
 Isolation of thioglycollate-elicited and resident peritoneal cells 
Thioglycollate-elicited peritoneal and resident peritoneal cells were collected according to the 
protocol described by Hodgson and co-workers (2011) and Williams and colleagues (2011). 
Briefly, mouse peritoneal exudate cells (PEC) were elicited for 3 days by injecting mice 
intraperitoneally with 2 mL of 3% Brewer’s thioglycollate medium (Appendix 1). After carbon 
dioxide (CO2) asphyxiation, the elicited PEC were collected aseptically from the peritoneal 
cavity of mice by injecting 10 mL of the cold harvest medium with heparin (5 IU/mL, Appendix 
Forward scatter 
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1) followed by aspirating the fluids. Non-elicited resident peritoneal exudate cells (RPEC) were 
collected from other mice using the same harvesting method as described for PEC. The PEC 
and RPEC from each mouse within an experimental group were pooled separately and treated 
with Red Blood Cells (RBC) lysis buffer (cat no. 004300, eBioscience, Australia; Appendix 1). 
Then the treated cells were washed twice with RPMI 1640 at 500 xg for 10 minutes at 150C. 
Cells were counted using the trypan blue (0.4%) exclusion technique (Appendix 1). Finally, 
cells were resuspended to a concentration of 1x106 or 1x105 cells/mL in single strength culture 
medium (SSCM, Appendix 1) for plating into 48 well cell culture plates. However, the average 
cell (PEC) yield from the thioglycollate-elicited diabetic and non-diabetic mice was 1x107 
cells/mouse. Whereas the non-elicited RPEC yield from the non-elicited diabetic and control 
mice was 5x106 cells/mouse.  
 Isolation of leucocytes from broncho-alveolar lavage fluid 
Broncho-alveolar lavage fluid (BALF) from mouse lungs was collected according to the 
protocol described by Collins and co-workers (2014) with some modifications. In short, a 
ventral midline incision was made to open the abdominal and thoracic region after CO2 
euthanasia. The vena cava was cut to allow for drainage of the blood from the upper trunk of 
the body. The ribs and the lower portion of the sternum were removed to make room for the 
lung inflation during BALF collection. The trachea was exposed carefully after removing skin, 
glands and muscles and raised using blunt forceps. A 21-gauge blunted butterfly needle (Surflo® 
winged infusion set, cat. no. SV 21B2K, TERUMO, Japan) or an 18-gauge blunt needle was 
inserted into the proximal end of the trachea (Figure 5.2). To secure the needle into the trachea, 
it was tied with a sterile surgical suture (Supramid white, cat. F1184040, Spain). Care was taken 
not to puncture the trachea. One to two mL of broncho-alveolar buffer (Appendix 1) was gently 
injected into the lungs and slowly extracted. Subsequently, another 2 mL of same buffer was 
injected slowly and sucked with back and forth motion (4-5 times) and the procedure was 
repeated twice. The collected fluid was kept in a 50 mL polypropylene tube with 5 mL of RPMI 
1640 on the ice. The collected BALF from both diabetic and control mice was centrifuged at 
500 xg for 10 minutes at 150C. Five hundred µL of RBC lysis buffer was added to the cell pellet 
for 2 minutes and then diluted it with RPMI 1640. Finally, the cells were filtered with a sterile 
63 µm nylon mesh and washed. The cell pellet was resuspended at a concentration of 1x105 
cells/mL with SSCM for plating into 48 well cell culture plates. However, the average alveolar 
leucocytes (AL) yield from each diabetic and non-diabetic mouse was 1x105 cells.  
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Figure 5.2 Collection of broncho-alveolar lavage fluid from a mouse  
 Culture of peritoneal cells and alveolar leucocytes 
The resuspended peritoneal (PEC), resident peritoneal (RPEC) and alveolar leucocytes (AL) 
were seeded into 48 well cell culture plates (3-7 replicates per sample). The PEC and RPEC 
were plated at 1x105 cells/well (5x105 cells/well in some experiments), whilst AL were seeded 
at 1x105 cells/well in 500 µL of SSCM (Appendix 1). Plates were incubated for one hour at 
370C with 5% CO2 to allow cell adherence. Fluoresbrite® Yellow Green Microspheres (2 µm), 
trehalose 6,6′ dimycolate coated beads (TDMCB) and whole mycolic acid coated beads 
(MACB), control beads (CB) including fresh beads (FB; without washing) were added to 
appropriate wells at two different ratios 1:1 and 1:10 (cell:bead). After 4 hours incubation, cell 
supernatants were collected for cytokine analysis and stored at -800C. Adherent cells were 
scraped from the base of wells and all cells were transferred into flow cytometry tubes for 
macrophage surface staining. Replicate wells were stained individually. 
 Staining of macrophage surface markers and flow cytometry  
Following 4 hours incubation of peritoneal (PEC) and resident peritoneal exudate cells (RPEC) 
with mycolic acid coated beads, they were surface stained for macrophage surface markers 
F4/80 and CD11b (Table 5.1). The harvested PEC and RPEC were washed (2000 rpm for 5 
minutes) with standard azide buffer (SAB; Appendix 1) to obtain the cell pellets. The antibody 
master mix (Fc blocker, CD11b and F4/80 antibodies; Table 5.1) was added to cell pellets and 
incubated for 20 minutes at 40C followed by washing once with SAB. The cell pellets were 
stained with PE Streptavidin for 10 minutes followed by washing once with SAB. Then, the 
cell pellets were resuspended in 300 µL of PBS. Similarly, the harvested alveolar leucocytes 
(AL) were surface stained for CD11c and PE Streptavidin according to the methods described 
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above. A cell viability dye (7-Amino-Actinomycin D, cat no. 559925, BD PharmingenTM) was 
added to the cell suspensions (PEC, RPEC and AL) for 10 minutes before acquring the samples 
by BD FACSCalibur™ flow cytometer. This particular dye will only stain the dead cells with 
the compromised cell membrane. The flow cytometry data were acquired and analysed using 
BD CellQuest® Pro software. The gating strategies for acquiring the samples were described in 
Figure 5.3 and 5.4. However, the F4/80 and CD11b positive cells from PEC and RPEC were 
considered as peritoneal macrophages (PEM) and resident peritoneal macrophages (RPM), 
respectively. The CD11c+ cells from AL were considered as alveolar macrophages (AM).  
 
Table 5.1 Antibodies used for surface staining of the macrophages 
Antibodies  
Catalogue 
number 
Dose/test Supplier 
Anti-mouse CD16/32 Purified, clone: 
6F12, isotype: Rat IgG2a, λ 
14-0161 
0.25 µg 
BD PharmingenTM 
 
Purified Rat Anti-Mouse F4/80 biotin, 
clone: 6F12, isotype: Rat IgG2a, κ, 
552958 
Alexa Fluor® 647 Rat Ani-Mouse CD11b, 
clone: M1/70, isotype: Rat IgG2b, κ, 
557686 
Biotin Hamster Anti-Mouse CD11c, clone: 
HL3, isotype: Hamster IgG1, λ, 
55380 
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Figure 5.3 Flow cytometry gating strategy for assessing phagocytosis of beads by 
peritoneal macrophages  
The peritoneal (elicited, PEC) and resident peritoneal exudate cells (non-elicited, RPEC) were 
surface stained for macrophage surface marker F4/80 and CD11b. Phagocytosis of Fluoresbrite 
beads (FITC) was assessed in both F4/80 and CD11b positive macrophages from PEC and 
RPEC. Region 1 (R1) indicated either PEC and RPEC (A). A total of 30 thousand events were 
acquired in R1. Region 2 (R2) indicated live and dead cells (located outside of R2 based on cell 
viability dye; 7-Amino-Actinomycin; D) (B). Region 4 (R4) indicated the live peritoneal 
(elicited) or resident (non-elicited) peritoneal exudate macrophages (PEM/RPM; CD11b and 
F4/80 double positive cells) (C). Counting of the internalised and cell-associated FITC 
conjugated Fluoresbrite beads; ‘M1’ (marker 1) indicated PEM or RPM with beads and ‘M2’ 
showed the macrophages without beads (D). 
 
 106 
 
Figure 5.4 Flow cytometry gating strategy for assessing phagocytosis of beads by alveolar 
macrophages  
The alveolar leucocytes (AL) were stained with macrophage surface marker CD11c. 
Phagocytosis of Fluoresbrite beads (FITC) was assessed in CD11c positive macrophages from 
AL. Region 1 (R1) indicated AL (A). A total of 30 thousand events were acquired in R1. Region 
2 (R2) indicated live cells, whereas dead cells were located outside of R2 (based on cell viability 
dye; 7-Amino-Actinomycin; D) (B). Region 4 (R4) indicated the live alveolar macrophages 
(AM; CD11c positive cells) (C). Counting of internalised and cell-associated FITC conjugated 
Fluoresbrite beads; ‘M1’ (marker 1) indicated AM with beads and ‘M2’ showed the 
macrophages without beads (D).  
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 Assessment of mycobacterial uptake and killing 
 Mycobacterial isolates 
The details of bacterial isolates are described in Chapter 3 (section 3.3.1) 
 Preparation of mycobacterial inoculum for in vitro uptake and killing assays 
The details of mycobacterial culture are described in Chapter 3 (section 3.3.2). Preparation of 
M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) inocula for in vitro uptake and 
killing assays were done from the frozen aliquots. The required number of frozen aliquots were 
thawed, vortexed and passed through a 27-gauge needle a total of 10-15 times. The bacterial 
suspensions were further sonicated for 10 seconds before adding to the cell culture. The 
bacterial suspension was further plated on 7H11 agar plates to confirm the number of bacteria 
in the inocula.  
 Isolation of CD11b+ cells from resident peritoneal exudate cells 
CD11b+ cells were separated from the resident peritoneal exudate cells (non-elicited, RPEC) 
using Anti-CD11b Magnetic Particles-DM (cat. no. 558013, BD Biosciences, Australia) 
according to the manufacturer’s instructions. In short, The RPEC were collected (section 
5.2.2.2) and filtered through a sterile 63 µm nylon mesh to remove clumps of cells and/or debris. 
Mouse FcR blocking reagent (purified rat Anti-Mouse CD16/CD32, cat. no. 553141, BD 
Biosciences; Australia, 0.25 µg for 1x106 cells) was added and incubated at 40C for 15 minutes. 
Cells were washed with at least an equal volume of 1x BD IMag™ buffer (cat. no. 55236, BD 
Biosciences, Australia; Appendix 1) and the supernatant was carefully aspirated. The CD11b 
magnetic particles (50 μL of particles/1x107 cells) were added and the cell/bead suspension was 
incubated at 40C for 30 minutes. The volume was brought to 2 mL with the 1x BD IMag™ 
buffer and immediately placed into the BD IMagnet™ for 8 minutes. With the tube on the BD 
IMagnet™, the supernatant was aspirated (negative fraction) using a glass pasteur pipette. To 
wash the cells again, tubes were removed from the magnet and an equal amount of 1x BD 
IMag™ buffer was added and kept in the magnet for another 8 minutes (second wash). To 
increase the purity of the CD11b positive fraction, the washing step was repeated. After the 
final wash, the cell pellet (positive fraction) was diluted in a smaller volume (3-5 mL) for 
counting by trypan blue exclusion technique using a haemocytometer. The cells were 
resuspended in the desired volume of SSCM to give a concentration of 1x105 cells/well in 1 
mL. The purity of the positively selected CD11b+ cells (referred to from now as resident 
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peritoneal macrophages; RPM) was assessed by flow cytometry after staining with CD11b 
surface marker (BD FACSCalibur™) and found to be above 85% (Figure 5.5 A & B). 
 Isolation of CD11c+ cells from the broncho-alveolar lavage fluid 
CD11c+ cells were positively selected from the broncho-alveolar lavage fluid using the 
EasySep™ Mouse CD11c positive selection kit (cat. no. 18758, STEMCELL™ technologies) 
according to the manufacturer’s instructions. In brief, following collection (section 5.2.2.3) the 
BALF was filtered through a sterile 63 µm nylon mesh to remove clumps of cells and/or debris. 
Mouse FcR blocking antibody (10 µL/1x108 cells) and CD11c PE labelling reagent was added 
to the cell pellet and incubated at room temperature for 15 minutes. The EasySep™ PE 
Selection Cocktail (100 µL/mL cells) was added and incubated for another 15 minutes. Finally, 
the magnetic nanoparticles were added to the pellet and incubated for further 10 minutes. The 
cell pellet was resuspended in 2.5 mL with 1x BD IMag™ buffer (Appendix 1) and kept in 
EasySep® magnet (cat. no.18000, STEMCELL™ technologies). After 15 minutes of 
incubation, the supernatant was poured off by inverting the magnet. The tube was removed 
from the magnet and resuspended in an equal volume of IMag™ buffer and placed in the 
magnet for 10 minutes (second wash). To increase the purity of the CD11c positive cells, the 
washing step was repeated. After the final wash, the cell pellet (positive fraction) was diluted 
in a smaller volume (2-3 mL) and counted by trypan blue exclusion technique using a 
haemocytometer. The cells were then resuspended in the desired volume of SSCM give a 
concentration of 1x105 cells/well in 1 mL. Moreover, the purity of the CD11c+ cells (referred 
to from now as alveolar macrophages; AM) were assessed by flow cytometry (BD 
FACSCalibur™) and found to be around 95% (Figure 5.5 C & D).  
 
 
 
 
 
 
 
 
 
 
 
 
 109 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Purity checking of CD11b+ and CD11c+ cells  
CD11b+ cells were isolated from resident peritoneal exudate cells (RPEC). Figure illustrates 
the forward and side scatter of RPEC (A). An overlay histogram showed unstained (unpurified 
RPEC, light red) and CD11b+ cells population (purified; light green) (B). CD11c+ cells were 
isolated from alveolar leucocytes (AL) from broncho-alveolar lavage fluid. Figure indicates the 
forward and side scatter of AL (C). An overlay histogram demonstrated unstained (unpurified 
AL, light red) and CD11c+ cells population (green).  
 Bacteria internalisation and killing assay  
The magnetically separated cell suspensions (CD11b+ cells as RPM and CD11c+ cells as AM) 
were resuspended in SSCM at a concentration of 1x105 cells/well in 1 mL and added to 48 well 
cell culture plates. Three-five replicates were used for each organism. After 4 hours incubation, 
internalisation was assessed and killing of the internalised bacteria was measured after 24 hours 
(48 hours in some experiments) according to previously described protocols (Parti et al., 2005, 
Williams et al., 2008, Hodgson et al., 2011). Briefly, M. fortuitum, M. bovis (BCG) and M. 
tuberculosis (H37Rv) were added to the cells seeded into 48 well plates at MOI 1:10 (cell: 
bacteria). After 4 hours of co-culture, supernatants were collected for cytokine assays. The wells 
were washed and treated with Amikacin (200 µg/mL) for a further 2 hours to kill any 
extracellular bacteria. To determine bacterial uptake, cell culture pellets were washed (3000 
rpm for 5 minutes) with PBS and cells were lysed with 0.1% Triton X-100TM (Sigma) for 10 
minutes. The cell lysates were further washed with PBS and plated on 7H11 agar plates to 
determine the viable bacteria (CFU). Duplicate plates were used to determine bacterial killing 
after 24/48 hours. For these experiments, plates were washed after Amikacin treatment. After 
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adding the fresh cell culture media, the cells were further incubated at 370C for 24/48 hours. 
Following collection of supernatants, the cells were washed, lysed with Triton X-100TM. 
Finally, the washed cell lysates were plated on 7H11 agar plates to determine the viable 
bacteria. In some experiments, 4 hours uptake by non-elicited resident peritoneal cells (REPC, 
without CD11b+ cells separation) were assessed to determine the internalised and cell 
associated bacteria. The above described procedures were followed except treating the plates 
with Amikacin. The killing capability of the RPEC was also assessed after 24 hours as described 
above. Bacterial uptake and survival were calculated based on the following formula.  
 
 
4 hours uptake =
(𝑁𝑜. 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙𝑖𝑠𝑒𝑑 𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎 𝑎𝑓𝑡𝑒𝑟 4 ℎ𝑜𝑢𝑟𝑠)
(𝑁𝑜. 𝑜𝑓 𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎 𝑔𝑖𝑣𝑒𝑛 𝑖𝑛𝑡𝑖𝑎𝑙𝑙𝑦)
𝑋100 
24 or 48 hours survival =
(𝑁𝑜. 𝑜𝑓 𝑠𝑢𝑟𝑣𝑖𝑣𝑒𝑑 𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎 𝑎𝑓𝑡𝑒𝑟 24/48 ℎ𝑜𝑢𝑟𝑠)
(𝑁𝑜. 𝑜𝑓 𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙𝑖𝑠𝑒𝑑 𝑎𝑓𝑡𝑒𝑟 4 ℎ𝑜𝑢𝑟𝑠)
𝑋100 
 Assessment of cytokines 
Culture supernatants following 4, 24 and 48 hours of macrophages: bacterial co-culture were 
used to determined cytokine production using the BD Cytometric Bead Array Mouse 
Inflammation Kit® (cat. no. 552364) and Mouse IL-1β Flex Set® (cat. no. 560232, BD 
Bioscience, Australia). Manufacturer’s instructions were followed to measure the cytokine 
secretion (TNF-α, MCP-1, IL-6, IL-12, IFN-γ, IL-10, IL-1β). Samples were acquired using the 
BD FACSCalibur™ flow cytometer with BD CellQuest Pro® software. The acquired data were 
analysed by BD FCAP Array TM software (version 3.0) (Chapter 3, section 3.8). Cytokine levels 
that were below the limit of detection (Chapter 3, Table 3.2) are shown as zero (‘0’).   
 Statistical analysis 
Statistical analysis was performed using the GraphPad Prism 7.03 and SPSS version 24 
software. All the data were checked for normal distribution using the Shapiro-Wilk’s test. Data 
passed the test of normality if the p≥0.05. Normally distributed data (e.g. mycobacterial uptake 
and killing) were compared between the groups using the unpaired t-test with Welch’s 
correction. The non-normally distributed data were compared between the groups using the 
Mann-Whitney U test. An ordinary one-way ANOVA with Holm Sidak’s multiple comparisons 
test was performed to compare within the groups if the data sets were normally distributed (e.g. 
cytokine production by stimulated and unstimulated AM from diabetic and control mice). When 
all 3 sets of data out of 4 were normally distributed, in those circumstances, one-way ANOVA 
with Holm Sidak’s multiple comparisons test was done assuming all the data sets were normally 
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distributed. The non-normally distributed data were compared within the groups using the 
Kruskal-Wallis test with Dunn's multiple comparisons test. All the data were expressed as 
mean±SEM. The level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and 
****p≤0.0001. 
 Results 
 Features of the diabetic mice following diet intervention  
The effects of energy-dense diet (EDD) intervention on mice were optimised and described in 
detail in Chapter 4. The same mice and some additional mouse sets were used for the current 
study. All mice used were on their respective EDD and control diets for 30 weeks. The 
metabolic profiles and histological findings in organs were highlighted in Chapter 4 and 
summarised here in Table 5.2. Mice in the current study were considered T2D if they 
demonstrated a raised FBG level and AUC-GTT with evidence of glucose intolerance at levels 
higher than the upper 99% confidence interval for the mean of the age-matched control group 
(Appendix 2). As the mice fed on EDD showed the metabolic and histologic characteristic of 
T2D (Chapter 4), hereafter they will be termed ‘diabetic mice’. 
Table 5.2 Metabolic profiles and histological features of mice used in the study described 
in this Chapter  
Parameters 
Control 
(mean±SEM) 
Diabetic 
(mean±SEM) 
p-value  
Body mass (g) 27.86 ±0.29 46.31±0.69 **** <0.0001 
Blood glucose (mmol/L) 8.61±0.27 11.07±0.43 **** <0.0001 
Insulin resistance (GTT-AUC) 1374±29.56 1657±42.81 **** <0.0001 
Glycosylated haemoglobin (% 
HbA1c) 
2.40±0.44 2.61±0.38 *0.0115 
Renal profile 
Microalbumin (mg/L) 4.08±1.60 10.39±0.65 *** 0.0005 
Creatinine (mmol/L) 4.51±0.21 3.15±0.17 *** 0.0003 
ACR (mg/mmol) 0.91±0.14 3.34±0.69 **** <0.0001 
Urine glucose (mmol/L) 1.38±0.06 1.57±0.15 ns >0.9999 
Histological features 
Herxheimer’s stained area (%) 0.19±0.91 28.26±2.20 **** <0.0001 
Adipocyte size (µm2) 496.5±55.54 1980±130.0 **** <0.0001 
Pancreatic islet area/total pancreatic 
area (%) 
0.62±0.06 1.46±0.14 **** <0.0001 
Glomerular area (µm2) in kidneys 1425±79.52 2275±89.27 **** <0.0001 
PAS positive stain within glomeruli 
(%) in kidneys 
17.14±1.48 25.23±1.34 *** 0.0005 
GTT; glucose tolerance test, AUC; area under the curve, ACR; albumin creatinine ratio, PAS; periodic 
acid schiff; * level of significance and ns=non-significant 
 Phagocytosis of mycolic acid coated beads by the macrophages  
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The phagocytic capability of peritoneal exudate macrophages (PEM) from elicited peritoneal 
exudate cells (PEC; section 5.2.2.2), resident peritoneal macrophages (RPM) from non-elicited 
resident peritoneal cells (RPEC, section 5.2.2.2) and alveolar macrophages (AM) from alveolar 
leucocytes (AL; section 5.2.2.3) was assessed following 4 hours of co-culture with polystyrene 
beads (fresh beads; FB), whole mycolic acid coated beads (MACB), trehalose 6, 6′-dimycolate 
coated beads (TDMCB) and control beads (CB) (Figure 5.6).  
 
 
 
 
 
 
 
 
Figure 5.6 Mycolic acid coated bead phagocytosis by peritoneal, resident peritoneal and 
alveolar macrophages  
Phagocytosis of beads by peritoneal (PEM, elicited) and resident peritoneal macrophages 
(RPM, non-elicited) and alveolar macrophages (AM, non-elicited) was assessed after 4 hours 
of co-culture with beads at ratios of 1:1 and 1:10. At MOI 1:10,  the PEM and RPM from 
diabetic mice were less efficient in uptake of polystyrene beads as fresh beads (FB), mycolic 
acid coated beads (MACB) and control beads (CB) compared to controls (A & B). The trehalose 
6, 6′-dimycolate coated beads (TDMCB), MACB and CB phagocytosis were also significantly 
lower in AM (C) and RPM (D) from the same group of diabetic mice compared to controls. 
Data presented as mean±SEM; n=3-5 replicates/group. The significant differences for non-
normally distributed data were determined using the Mann-Whitney U test (A & B, CB of PEM 
and RPM) and the independent samples t-test for normally distributed data (A, B, C & D) 
(Appendix 3). The level of significance was indicated as *p≤0.05, **p≤0.01, ****p≤0.0001 
and ns=non-significant. 
 
Initially, the uptake of FB, MACB and CB by PEM and RPM at ratios of 1:1 and 1:10 (cell: 
bead) was assessed. Results showed that there was no consistent trend for bead phagocytosis 
by PEM from diabetic and control mice at MOI 1:1 (Figure 5.6 A). At MOI 1:10, the PEM and 
RPM from diabetic mice were less efficient in taking up the beads in comparison to controls 
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(Figure 5.6 A & B). The uptake of beads by the elicited PEM was higher than the non-elicited 
RPM from both groups of mice (Figure 5.6 A & B).  
Furthermore, phagocytosis of TDMCB at MOI 1:10 by the AM and RPM collected from the 
same group of diabetic and control mice were also assessed. The internalisation of TDMCB 
and MACB was significantly lower in both AM (Figure 5.6 C) and RPM (Figure 5.6 D) from 
diabetic mice compared to control mice. Overall, AM had a higher capability of phagocytosis 
than RPM collected from diabetic and control mice (Figure 5.6 C & D).  
In addition, the percentage of F4/80 and CD11b+ cells in PEC and RPEC and CD11c+ cells in 
AL were also evaluated during the assessment of phagocytosis using flow cytometry (as 
described in Figure 5.3 and 5.4) presented in Table 5.3. The PEC from diabetic mice contained 
lower number of F4/80+ and CD11b+ cells (PEM and RPM) compared to the controls. A 
similar trend was observed in RPEC from diabetic mice compared to controls. The AL from 
diabetic mice contained less number of CD11c+ cells (AM) compared to the controls. Although 
the viability of the PEC and RPEC after 4 hours of co-culture was found to be significantly 
higher in diabetic mice compared to controls, there were no significant differences in the 
viability of the AL at the same timepoint of co-culture.  
Table 5.3 Percentage of macrophages in peritoneal exudates and broncho-alveolar lavage 
fluid 
 Cell types 
Control 
Mean (%)±SEM) 
Diabetic 
Mean (%)±SEM) 
p-value 
 F4/80 and CD11b+ cells (PEM/RPM)  
PEC (elicited) 66.65±1.55 44.72±1.25 **** 0.0000 
RPEC  58.30±2.26 46.02±1.84 *** 0.0002 
 CD11c+ cells (AM)  
AL (BALF) 58.06±1.29 33.47±1.44 **** 0.0000 
 Viability  
PEC (elicited) 89.28±0.68 95.63±0.0.73 **** 0.0000 
RPEC 87.02±0.96 94.75±0.44 **** 0.0000 
AL (BALF) 67.33±2.90 65.47±2.00%, ns  0.6046 
n=13-19 replicates/group, PEC; peritoneal exudate cells, RPEC; resident peritoneal exudate 
cells, AL; alveolar leucocytes, BALF; broncho-alveolar lavage fluid, PEM; peritoneal exudate 
macrophages, RPM; resident peritoneal macrophages, AM; alveolar macrophages, * level of 
significance and ns=non-significant 
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 Cytokine production by alveolar and resident peritoneal cells co-cultured with 
mycolic acid coated beads 
Inflammatory cytokines were measured from the supernatant samples collected following co-
culture with mycolic acid coated beads. After 4 hours of co-culture with the beads at a ratio of 
1:10 (section 5.2.2.4), TNF-α and IL-6 were detected in both stimulated (AL/RPEC: beads) and 
unstimulated cells [AL/RPEC (cells)]. TNF-α (Figure 5.7 A) and IL-6 (Figure 5.7 E) were 
significantly lower in all diabetic AL compared to control AL. Importantly, mycolic acid coated 
bead (TDMCB and MACB) stimulation further impaired both TNF- and IL-6 secretion in 
diabetic AL. TNF- and IL-6 secretion by control AL in response to TDMCB and MACB was 
similar to unstimulated and CB treatments. TNF-α (Figure 5.7 B) and IL-6 (Figure 5.7 F) were 
also significantly lower in diabetic RPEC compared to control RPEC although there was no 
significant difference compared to unstimulated diabetic or control RPEC. The production of 
MCP-1, IL-12, IFN-γ and IL-10 were not detected in either bead stimulated or unstimulated AL 
and RPEC of diabetic or control mice (Figure 5.7 C, D, G, H, I, J, K & L).  
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Figure 5.7 Cytokine production by alveolar leucocytes and resident peritoneal exudate 
cells co-cultured with mycolic acid coated beads 
Alveolar leucocytes (AL) and resident peritoneal exudate cells (RPEC, non-elicited) were co-
cultured with mycolic acid coated beads as control beads (CB), trehalose 6,6′-dimycolate 
(TDMCB) and whole mycolic acid coated beads (MACB) at a ratio of 1:10. Cytokine 
production was measured after 4 hours of co-culture. The production of TNF-α (A & B) and 
IL-6 (E & F) was detected in AL and RPEC. Although there was a significant difference in the 
production of TNF-α and IL-6 in AL and RPEC from diabetic mice compared to controls, they 
were not significant compared to their unstimulated control cells (not shown in the graphs). The 
production of MCP-1 (C & D), IL-12 (G & H), IFN-γ (I & J) and IL-10 (K & L) was not 
detected in either AL and RPEC from diabetic and control mice during co-culture. Data 
presented as mean±SEM; n=3-5 replicates/group. The significant differences were determined 
using the ordinary one-way ANOVA with Holm-Sidak’s multiple comparisons test (Appendix 
3). The level of significance was indicated as **p≤0.01, ***p≤0.001, ****p≤0.0001 and 
ns=non-significant. 
 
 Phagocytosis and bactericidal capacity of macrophages  
 Internalisation and killing of M. fortuitum by resident peritoneal cells 
Counts of M. fortuitum were determined after 4 hours of MOI 1:1 and 1:10 co-culture with 
resident peritoneal exudate cells (RPEC, non-elicited, without CD11b+ cells isolation). The 
internalised and cell-associated bacteria were lower in RPEC from diabetic mice compared to 
the control mice, although the difference was not statistically significant (Figure 5.8 A). At 
MOI 1:10, the bacteria taken up/cell-associated was 1.35 times lower in RPEC from diabetic 
compared to control mice. The killing of internalised bacteria (extracellular bacteria were killed 
by treating with amikacin) by RPEC from diabetic mice was 1.50 times lower than RPEC from 
control mice (Figure 5.8 B).  
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Figure 5.8 Internalisation and cell-associated M. fortuitum and killing by resident 
peritoneal exudate cells  
Internalised and cell-associated bacterial number were quantified after 4 hours of co-culture of 
the resident peritoneal exudate cells (RPEC) with M. fortuitum at MOI 1:1 and 1:10 (cell: 
bacteria). After 4 hours of co-culture, the number of internalised and cell-associated bacteria 
were reduced in RPEC from diabetic mice compared to controls. The killing of internalised M. 
fortuitum by RPEC from diabetic mice was also lower after 24 hours of co-culture compared to 
the controls (B). The experiment was repeated thrice and result of a representative experiment 
was presented here. Data presented as mean±SEM; n=3 replicates/group. The significant 
differences were determined using the unpaired t-test with Welch’s correction (Appendix 3). 
The level of significance was indicated as ns=non-significant (p≥0.05).  
 
 Internalisation and killing of M. fortuitum by alveolar and resident peritoneal 
macrophages  
The uptake and killing capabilities of CD11c+ alveolar macrophages (AM) and CD11b+ 
resident peritoneal macrophages (RPM) were assessed by co-culture with M. fortuitum (Mft) at 
MOI 1:10 (cell: bacteria). The internalisation of Mft by AM from diabetic mice was 1.66 times 
lower compared to control mice after 4 hours of co-culture (Figure 5.9 A). The killing of Mft in 
AM from diabetic mice after 24 hours of co-culture was 1.46 times lower compared to controls 
(Figure 5.9 B). A similar trend for uptake and killing was observed for RPM (Figure 5.9 C & 
D). Overall, the uptake and killing capability of AM was greater than RPM for both diabetic 
and control mice (Figure 5.9). 
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Figure 5.9 Internalisation and killing of M. fortuitum by alveolar and resident peritoneal 
macrophages  
Following 4 hours of uptake and 24 hours of killing capability of the alveolar macrophages 
(AM, CD11c+ cells) resident peritoneal macrophages (RPM, CD11b+ cells) were assessed by 
co-culture with M. fortuitum (Mft) at MOI 1:10 (cell: bacteria). M. fortuitum uptake after 4 
hours (A) and killing of the internalised bacteria after 24 hours (B) was reduced significantly 
in AM from diabetic mice compared to controls. There was a reduction in Mft uptake by RPM 
from diabetic mice co-cultured with the bacterium at 4 hours (C) and a significant reduction in 
the killing of the bacterium after 24 hours of co-culture (D). The experiment was repeated thrice 
and result of a representative experiment was presented here. Data presented as mean±SEM; 
n=3 replicates/group. The significant differences were determined using the unpaired t-test with 
Welch’s correction (Appendix 3). The level of significance was indicated as *p≤0.05, **p≤0.01 
and ns=non-significant. 
 
5.4.3.2.1 Cytokine production by alveolar and resident peritoneal macrophages 
following co-culture with M. fortuitum 
Alveolar macrophages (AM) from diabetic mice produced significantly lower amounts of TNF-
α after 4 hours and 24 hours of co-culture with Mft compared to control mice (Figure 5.10 A & 
B). There was no difference between the groups in MCP-1 production by AM following 4 hours 
of co-culture although it was significantly reduced in AM from diabetic mice compared to 
controls after 24 hours of co-culture (Figure 5.10 C & D). A similar trend of IL-6 production 
was observed in AM from diabetic mice after 4 hours and 24 hours of incubation with Mft 
(Figure 5.10 E & F). Interleukin-12, IFN-γ and IL-10 were not detected in AM from either 
diabetic or control mice following either 4 or 24 hours of co-culture (5.10 G, H, I, J, K & L). 
IL-1β assays were not done in this experiment. 
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Figure 5.10 Cytokine production by alveolar macrophages co-cultured with M. fortuitum 
Alveolar macrophages (AM, CD11c+ cells) were co-cultured with M. fortuitum (Mft) at MOI 
1:10 (cell: bacteria). Cytokine production was measured after 4 and 24 hours of co-culture with 
Mft. There was a significant reduction in the production of TNF-α by AM from diabetic mice 
compared to controls after 4 (A) and 24 hours (B) of co-culture with the bacteria. The 
production of MCP-1 by AM from diabetic and control mice was negligible after 4 hours of co-
culture (C) although it was significantly reduced in AM from diabetic mice compared to 
controls after 24 hours (D). The production of IL-6 by AM from diabetic mice was significantly 
decreased in both 4 (E) and 24 hours (F) of co-culture. Little or no cytokine production was 
detected for IL-12 (G & H), IFN-γ (I & J) and IL-10 (K & L) by AM from both diabetic and 
control mice after 4 and 24 hours of co-culture. Data presented as mean±SEM; n=2-6 
replicates/group. The significant differences were determined using the ordinary one-way 
ANOVA with Holm-Sidak’s multiple comparisons test (A-L except D) and the unpaired t-test 
with Welch’s correction (D) (Appendix 3). The level of significance was indicated as **p≤0.01, 
***p≤0.001, ****p≤0.0001 and ns=non-significant. 
 
 
The production of TNF-α was significantly reduced in resident peritoneal macrophages (RPM) 
from diabetic mice after 4 hours and 24 hours of co-culture compared to controls (Figure 5.11 
A & B). There were no differences in the levels of MCP-1 secretion by RPM at 4 hours of co-
culture although a significantly reduced production was found in RPM from diabetic mice 
compared to control after 24 hours of co-culture (Figure 5.11 C & D). The production of IL-6 
was lower in RPM from diabetic mice compared to control mice at both timepoints of co-culture 
(Figure 5.11 E & F). Furthermore, the overall IL-6 production was higher by the RPM compared 
to AM (Figure 5.10 and 5.11 E & F). The secretion of IL-10 was higher in RPM from control 
mice compared to the diabetic mice after 4 hours of co-culture although its level was not 
sustained at the later timepoint of infection (Figure 5.11 K & L). The production of IL-12 and 
IFN-γ by RPM was minimal at both 4 and 24 hours of co-culture with the bacteria (Figure 5.11 
G, H, I & J). IL-1β assays were not done in this experiment. 
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Figure 5.11 Cytokine production by resident peritoneal macrophages co-cultured with M. 
fortuitum 
Resident peritoneal macrophages (RPM, CD11b+ cells) were co-cultured with M. fortuitum 
(Mft) at MOI 1:10 (cell: bacteria). Cytokine production was measured after 4 and 24 hours of 
co-culture with Mft. After 4 hours of co-culture, there was a significant reduction in the 
production of TNF-α by RPM from diabetic mice compared to controls after 4 (A) and 24 hours 
(B) of co-culture with the bacteria. The production of MCP-1 by RPM from both diabetic and 
control mice was negligible after 4 hours (C) although it was significantly reduced in RPM 
from diabetic mice compared to controls after 24 hours (D). The production of IL-6 by RPM 
from diabetic mice was significantly decreased compared to controls in both 4 (E) and 24 hours 
(F) of co-culture. The production of IL-10 by RPM from control mice was higher at 4 hours of 
co-culture (K) although its level was not sustained at the later timepoint (L). A minimum or no 
cytokine production was detected for IL-12 (G & H) and IFN-γ (I & J) by RPM from both 
diabetic and control mice after 4 and 24 hours of co-culture. Data presented as mean±SEM. The 
significant differences were determined using the ordinary one-way ANOVA with Holm-
Sidak’s multiple comparisons test (B, D-F and J), Kruskal-Wallis test with Dunn’s multiple 
comparison tests (C) and the unpaired t-test (A & K) and Mann-Whitney U test (I & L) 
(Appendix 3). The level of significance was indicated as *p≤0.05, ***p≤0.001, ****p≤0.0001 
and ns=non-significant. 
 
  Internalisation and killing of M. bovis (BCG) by alveolar and resident peritoneal 
macrophages  
The internalisation of M. bovis (BCG) by alveolar macrophage (AM) from diabetic mice was 
1.35 times lower compared to control mice after 4 hours of co-culture (Figure 5.12 A). The 
killing of same bacterium by AM from diabetic mice after 24 hours of co-culture was 1.04 times 
lower compared to controls (Figure 5.12 B). Similarly, the bacterial uptake by resident 
peritoneal macrophages (RPM) from diabetic mice was 1.51 times lower compared to control 
(Figure 5.12 C). Although the killing capability of the RPM increased over time, the killing 
efficiency after 24 and 48 hours of co-culture remained 1.04 and 1.02 times lower, respectively 
in RPM from diabetic mice compared to controls (Figure 5.12 D & E). Overall, the 
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internalisation and killing capability of AM was found to be comparatively higher than RPM 
from diabetic and control mice (Figure 5.12). 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 Internalisation and killing of M. bovis (BCG) by alveolar and resident 
peritoneal macrophages 
Uptake after 4 hours and killing capability after 24/48 hours of alveolar macrophages (AM, 
CD11c+ cells) and resident peritoneal macrophages (RPM, CD11b+ cells) were assessed by 
co-culture with M. bovis (BCG) at MOI 1:10 (cell: bacteria). There was a significant reduction 
observed in the uptake (A) and killing of internalised (B) M. bovis (BCG) by the AM from the 
diabetic mice compared to the controls. A similar trend was observed in 4 hours uptake (C) and 
24 (D) and 48 hours of killing (E) by the RPM from diabetic mice compared to controls. The 
experiment was repeated twice and result of a representative experiment was presented here. 
Data presented as mean±SEM; n=3-5 replicates/group. The significant differences were 
determined using the unpaired t-test with Welch’s correction (Appendix 3). The level of 
significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. 
 
5.4.3.3.1 Cytokine production by alveolar and resident peritoneal macrophages 
following co-culture with M. bovis (BCG) 
TNF-α production by alveolar macrophages (AM) increased between 4 and 24 hours of co-
culture with M. bovis (BCG). Compared to the controls, AM from diabetic mice produced less 
TNF-α at both 4 and 24 hours timepoints (Figure 5.13 A & B). An opposite trend was observed 
in IL-6 production, where AM from diabetic mice released more IL-6 in response to M. bovis 
(BCG) at 4 and 24 hours (Figure 5.13 E & F). The production of IL-10 by AM from diabetic 
mice was higher after 4 and 24 hours of co-culture, although an elevated level of IL-10 was 
observed from the uninfected cells (Figure 5.13 M & N). The MCP-1, IL-1β, IL-12 and IFN-γ 
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production was undetectable in AM from both diabetic and control mice at both timepoints 
(Figure 5.13 C, D, G, H, I, J, K & L).  
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Figure 5.13 Cytokine production by alveolar macrophages co-cultured with M. bovis 
(BCG) 
Alveolar macrophages (AM, CD11c+ cells) were co-cultured with M. bovis (BCG) at MOI 1:10 
(cell: bacteria). Cytokine production was measured after 4 and 24 hours of co-culture with the 
bacterium. There was a significant reduction in the production of TNF-α by AM from diabetic 
mice compared to controls after 4 (A) and 24 hours (B) of co-culture. IL-6 production was 
increased by AM from diabetic mice compared to controls at both 4 (E) and 24 hours (F). 
Compared to control, IL-10 production by the AM from diabetic mice was higher at both 4 (M) 
and 24 hours (N) of co-culture. There was little or no MCP-1 (C & D), IL-1β (G & H), IL-12 
(I & J) and IFN-γ (K & L) production by AM from both diabetic and control mice after 4 and 
24 hours of co-culture. Data presented as mean±SEM; n=2-4 replicates/group. The significant 
differences were determined using the ordinary one-way ANOVA with Holm-Sidak's multiple 
comparisons test (A-B, E-F & M-N) and Mann-Whitney U test (H-J). (Appendix 3). The level 
of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-
significant. 
 
 
TNF-α production by resident peritoneal macrophages (RPM) from diabetic and control mice 
was detected following 4, 24 and 48 hours of co-culture with M. bovis (BCG) (Figure, 5.14 A 
& B and Table 5.4). There was an increasing trend in TNF-α production in RPM from control 
mice over time. The production of TNF-α was significantly lower in RPM from diabetic mice 
at 4 and 48 hours (Figure 5.14 A and Table 5.4) although its level was similar in RPM from 
both groups of mice at 24 hours (Figure 5.14 B). MCP-1 production by RPM from diabetic 
mice was significantly lower than controls at 24 and 48 hours (Figure 5.14 D and Table 5.2) 
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and was not detectable at 4 hours (Figure 5.14 C). Compared to controls, RPM from diabetic 
mice produced significantly reduced levels of IL-6 at all timepoints (Figure 5.14 E & F and 
Table 5.4). There was a reduced amount of IL-1β observed at 24 and 48 hours (Figure 5.14 H 
and Table 5.4) although its secretion was undetectable at 4 hours (Figure 5.14 G). A higher 
level of IL-10 was observed in the RPM from controls than diabetic mice at all the timepoints 
of co-culture (Figure 5.14 M & N and Table 5.4). The production of IL-12 and IFN-γ by the 
RPM from both diabetic and control mice was undetectable at all the timepoints (Figure 5.14 I, 
J, K & L and Table 5.4).  
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Figure 5.14 Cytokine production by resident peritoneal macrophages co-cultured with M. 
bovis (BCG) 
Resident peritoneal macrophages (RPM, CD11b+ cells) were co-cultured with M. bovis (BCG)  
at MOI 1:10 (cell: bacteria). Cytokine production was measured after 4, 24 and 48 hours of co-
culture with the bacterium. A significant reduction of TNF-α by RPM from diabetic mice 
compared to controls was observed after 4 hours of co-culture (A) although there was no 
difference of it after 24 hours (B). Although MCP-1 secretion by the RPM from both diabetic 
and control mice was undetectable after 4 hours (C), it was significantly reduced by RPM from 
diabetic mice after 24 hours (D). The production of IL-6 (E & F) and IL-10 (M & N) was higher 
by RPM from diabetic mice compared to controls. IL-1β production was lower by RPM from 
diabetic mice compared to controls after 24 hours (H) although its secretion by RPM from both 
diabetic and control mice was undetectable at the initial timepoint of co-culture (G). There were 
no or minimum production IL-12 (I & J) and IFN-γ (K & L) was observed in the RPM of both 
diabetic and control mice at both timepoints of infection. Data presented as mean±SEM; n=3-
4 replicates/group. The significant differences were determined by the ordinary one-way 
ANOVA with Holm-Sidak's multiple comparisons test (A-B, E-F, J & M-N), unpaired t-test 
with Welch’s correction (D & H) and Mann-Whitney U test (I) (Appendix 3). The level of 
significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-
significant. 
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Table 5.4 Cytokine production by resident peritoneal macrophages after 48 hours of co-
culture with M. bovis (BCG) 
 48 hours cytokines (pg/mL) 
 RPM (uninfected) RPM: M. bovis (BCG) 
Cytokine Control Diabetic p-value Control Diabetic p-value 
TNF-α 2.85±1.12 1.29±1.00 0.9750 415.00±53.27 78.48±10.28 <0.0001 
MCP-1 0.00±0.00 0.00±0.00 - 238.44±40.20 30.54±12.32 0.0105 
IL-6 0.00±0.00 0.00±0.00 - 439.08±70.62 81.80±21.72 0.0112 
IL-1β 0.00±0.00 0.00±0.00 - 6.04±1.15 0.28±0.28 0.0128 
IL-12 0.02±0.01 0.24±0.24 0.5233 0.00±0.00 0.00±0.00 - 
IFN-γ 0.12±0.12 0.57±0.47 0.4016 0.00±0.00 0.00±0.00 - 
IL-10 8.34±0.67 11.07±0.59 0.0373 56.82±4.51 18.89±1.32 <0.0001 
Data presented as mean±SEM; n=3-4 replicates/group, RPM; resident peritoneal macrophages 
 Internalisation and killing of M. tuberculosis (H37Rv) by alveolar and resident 
peritoneal macrophages  
The internalisation of M. tuberculosis (Mtb H37Rv) by alveolar macrophages (AM) from 
diabetic mice was 1.45 times lower compared to control mice after 4 hours of co-culture (Figure 
5.15 A). The killing of Mtb by AM from diabetic mice after 24 hours of co-culture was 1.07 
times lower compared to controls (Figure 5.15 B). A similar trend for uptake and killing was 
observed in resident peritoneal macrophages (RPM) (Figure 5.15 C & D). Overall, the uptake 
and killing capability of AM was higher than RPM from diabetic and control mice during co-
culture with the Mtb. 
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Figure 5.15 Internalisation and killing of M. tuberculosis (H37Rv) by alveolar and resident 
peritoneal macrophages 
The uptake and killing capability of the alveolar macrophages (AM, CD11c+ cells) and resident 
peritoneal macrophages (RPM, CD11b+ cells) were assessed by co-culture with M. tuberculosis 
(Mtb H37Rv) at MOI 1:10 (cell: bacteria). There was a significant reduction in the uptake (A) 
and killing of internalised Mtb (B) by AM from diabetic mice compared to controls. A similar 
trend was observed in uptake (C) and killing (D) by the RPM from diabetic mice compared to 
controls. The experiment was repeated twice and result of a representative experiment was 
presented here. Data presented as mean±SEM; n=2-5 replicates/group. The significant 
differences were determined using the unpaired t-test with Welch’s correction (Appendix 3). 
The level of significance was indicated as *p≤0.05 and ns=non-significant. 
 
5.4.3.4.1 Cytokine production by alveolar and resident peritoneal macrophages 
following co-culture with M. tuberculosis (H37Rv) 
Following co-culture with M. tuberculosis (Mtb), the secretion of TNF-α by AM was observed 
after 4 and 24 hours co-culture. There was a significantly lower level of TNF-α production by 
the AM from the diabetic mice compared to controls at both 4 and 24 hours timepoints (Figure 
5.16 A & B). A similar trend was observed in the production of IL-6 by AM from diabetic mice 
compared to control at 4 and 24 hours (Figure 5.16 E & F). The secretion of MCP-1 and IL-1β 
was significantly lower from AM of diabetic mice compared to control mice after 24 hours 
(Figure 5.16 D & H), although the levels were negligible at 4 hours (Figure 5.16 C & G). 
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Moreover, there was no IL-12, IFN-γ and IL-10 production by AM from either diabetic or 
control mice (Figure 5.16 I, J, K, L, M & N).  
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Figure 5.16 Cytokine production in alveolar macrophages co-cultured with M. 
tuberculosis (H37Rv) 
Alveolar macrophages (AM, CD11c+ cells) were co-cultured with M. tuberculosis (Mtb 
H37Rv) at MOI 1:10. Cytokine production was measured after 4 and 24 hours of co-culture 
with Mtb. There was a significant reduction in the production of TNF-α (A & B) and IL-6 (E 
& F) by AM from diabetic mice compared to controls after 4 and 24 hours co-culture. A 
significantly reduced amount MCP-1 (D) was detected in AM from diabetic mice compared to 
controls after 24 hours, although they were negligible at 4 hours (C). A similar trend was found 
in the production of IL-1β production by the AM from diabetic mice compared to controls at 4 
and 24 hours (G & H). There was no production of IL-12 (I & J), IFN-γ (K & L) and IL-10 (M 
& N) by the AM from both diabetic and control mice at 4 and 24 hours. Data presented as 
mean±SEM; n=1-4 replicates. The significant differences were determined using the ordinary 
one-way ANOVA with Holm-Sidak's multiple comparisons test (A-B & E-F) and unpaired t-
test with Welch’s correction (D & H) (Appendix 3). The level of significance was indicated as 
*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-significant. 
 
 
A significantly reduced level of TNF-α was found in RPM supernatants from diabetic mice 
compared to controls at 4 and 24 hours timepoints (Figure 5.17 A & B). A similar trend was 
observed in the production of IL-6 by RPM from diabetic mice compared to controls at both 4 
and 24 hours (Figure 5.17 E & F). MCP-1 and IL-1β production by RPM from diabetic mice 
was lower than controls at 24 hours (Figure 5.17 D & H) and these cytokines were undetectable 
at 4 hours timepoint (Figure 5.17 C & G). There was no detectable IL-12, IFN-γ and IL-10 
produced by RPM from either diabetic or control mice during Mtb co-culture (Figure 5.17 I, J, 
K, L, M & N).  
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Figure 5.17 Cytokine production by resident peritoneal macrophages co-cultured with M. 
tuberculosis (H37Rv) 
Resident peritoneal macrophages (RPM, CD11b+ cells) were co-cultured with M. tuberculosis 
(Mtb H37Rv) at MOI 1:10 (cell: bacteria). Cytokine production was measured after 4 and 24 
hours of co-culture. There was a significant reduction in the production of TNF-α (A & B) and 
IL-6 (E & F) by RPM from diabetic mice compared to controls after 4 and 24 hours co-culture. 
A significantly reduced amount MCP-1 (D) was detected in RPM from diabetic mice compared 
to controls after 24 hours although it was negligible at 4 hours timepoint(C). A similar trend 
was found in the production of IL-1β production by the RPM from diabetic mice compared to 
controls at 4 and 24 hours (G & H). IL-12 (I & J), IFN-γ (K & L) and IL-10 production (M & 
N) by the RPM from both diabetic and control mice at 4 and 24 hours were below the limits of 
detection of the assay. Data presented as mean±SEM; n=1-4 replicates/group. The significant 
differences were determined using the ordinary one-way ANOVA with Holm-Sidak's multiple 
comparisons test (B & D-F) and the unpaired t-test with Welch’s correction (A) and Mann-
Whitney U test (H & M) (Appendix 3). The level of significance was indicated as *p≤0.05, 
**p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-significant. 
 
 Discussion 
In host-mycobacterial interactions, macrophages play the pivotal role in phagocytosis of the 
bacilli, secretion of chemical mediators, antigen presentation and subsequent activation of 
adaptive immune responses (Cooper, 2009). Previous studies have suggested that increased TB 
susceptibility in diabetic patients may be due to compromised macrophage function (Saiki et 
al., 1980, Martinez et al., 2016). We investigated the phagocytic capability, killing and cytokine 
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production in mouse alveolar macrophages (AM) and resident peritoneal macrophages (RPM) 
using mycolic acid coated beads, a non-tuberculous mycobacterium (NTM, M. fortuitum) and 
two species of M. tuberculosis complex (M. bovis, BCG and M. tuberculosis, H37Rv strain). 
We have shown that phagocytic function is impaired and cytokine production is dysregulated 
in macrophages from diabetic animals. 
This study showed that the uptake of mycolic acid coated beads was reduced in AM and RPM 
of diabetic mice compared to controls (Figure 5.6). In previous studies using a streptozotocin 
(STZ)-induced diabetes model, polystyrene bead uptake was reduced in F4/80+ peritoneal 
macrophages (Saiki et al., 1980, Ma et al., 2008). This observation supported the findings of 
our study, where RPM from diabetic mice was less capable of internalising either mycolic acid 
coated beads or bacteria compared to controls. Ma and colleagues (2008) highlighted the 
alteration of macrophage phenotype and reduced numbers of F4/80+ cells in the peritoneal 
exudate as a reason for decreased uptake of beads in STZ-induced diabetic mice. We also 
observed a significantly lower number of F4/80+ and CD11b+ cells in both thioglycollate-
elicited peritoneal (PEC) and resident peritoneal exudate cells (RPEC) of diabetic mice 
compared to controls (Table 5.3). Similar to the data presented here, impaired uptake of TDM 
coated latex beads was previously observed in AM from STZ-induced hyperglycaemic mice 
(Martinez et al., 2016). A significantly reduced uptake and killing of M. fortuitum (Figure 5.9), 
M. bovis (BCG) (Figure 5.12) and M. tuberculosis (H37Rv) (Figure 5.15) was observed in both 
AM and RPM from diabetic mice compared to controls. Martinez and colleagues (2016) 
demonstrated a lower uptake of M. tuberculosis (H37Rv/mCherry strain) in AM of 
hyperglycaemic mice which was in line with the findings of this study. Similar deficits in the 
phagocytic uptake function of macrophages have been reported in diabetic patient samples 
using other intracellular and extracellular bacteria including Salmonella enterica serovar 
Typhimurium, Escherichia coli, Burkholderia pseudomallei, Streptococcus pneumoniae and 
Staphylococcus aureus (Bagdade et al., 1972, Chanchamroen et al., 2009, Williams et al., 2011, 
Mathews et al., 2012). 
The precise mechanisms underlying this decreased uptake and killing of mycobacteria by 
diabetic macrophages remain unclear. Ma and colleagues (2008) suggested the possibility of 
reduced macrophage numbers due to deficient differentiation of macrophage from bone marrow 
cells as one of the reasons of lower phagocytosis in diabetic mice. Defective and lower yields 
of macrophages (and stem cells) from bone marrow cells have also been observed in diabetes 
(Nikolic et al., 2004, Fu et al., 2006, Kuki et al., 2006, Rota et al., 2006). We have also observed 
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the lower number of F4/80+cells (considered as macrophages) from the broncho-alveolar 
lavage and resident peritoneal exudate cells from diabetic mice.  Other reasons suggested for 
impaired phagocytosis in diabetes include reduced association (attachment) between bacteria 
and monocyte/macrophages, alteration of serum opsonins or complement proteins (C3b) and 
complement receptors (CR1 and CR3) (Schlesinger et al., 1990, Schlesinger, 1998, Gomez et 
al., 2013). Recent studies indicated that compromised phagocytosis of mycolic acid coated 
beads in diabetic macrophages was due to the lower expression of the macrophage receptors 
with collagenous structure (MARCO), Toll-like receptor 2 (TLR2) and the co-receptor for 
bacterial LPS (lipopolysaccharide), CD14 (Bowdish et al., 2009, Martinez et al., 2016). 
Advanced glycation end products accumulation in diabetes has also been shown to alter the 
expression of macrophage surface receptors (Lachmandas et al., 2015, Martinez et al., 2016). 
Impaired phagocytic activity of macrophages from diabetic mice leads to poor antigen 
presentation which in turns results in compromised T cell mediated immunity (Ma et al., 2008, 
Ahmad, 2011).  
Significantly reduced killing (or higher survival) of M. fortuitum (Figure 5.9 B & D), M. bovis 
(BCG) (Figure 5.12 B & D) and M. tuberculosis (H37Rv) (Figure 5.15 B & D) was observed 
in both AM and RPM from diabetic mice compared to controls in the current study. The reason 
for decreased killing or higher surviving numbers of bacteria in macrophages from diabetic 
mice may be due to the restricted secretion of antimycobacterial compounds (e.g. reactive 
oxygen species; ROS, inducible nitric oxide synthase; iNOS), delayed acidification of the 
phagosome and phagosome-lysosome fusion and inappropriate cytokine expression (Appelberg 
et al., 1994b, Da Silva et al., 2002, Jordao et al., 2008, Cooper, 2009, Cebula et al., 2012). 
Vallerskog and colleagues (2010) found decreased production of iNOS in the lungs of diabetic 
mice and suggested that this may explain the inability of diabetic macrophages to efficiently 
kill Mtb. The precise antimicrobial compounds deficient in diabetic macrophages in our model 
system were not undertaken as part of the current study. Future research is required to 
investigate this knowledge gap and identify the key defects and mediators in diabetic mice.  
M. fortuitum survived better in both macrophages from diabetic and control mice as opposed to 
the survival of M. bovis (BCG) and M. tuberculosis (H37Rv). The increased survival of NTM 
including M. fortuitum has been described previously (Crowle et al., 1986, Da Silva et al., 2002, 
Parti et al., 2005, González-Pérez et al., 2013). Following infection, mycobacteria (pathogenic 
or non-pathogenic) are internalised into the macrophages. Although the non-pathogenic 
mycobacteria are invariably killed, the surviving bacteria can quickly multiply within the cells 
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(Da Silva et al., 2002, Jordao et al., 2008). Higher survival of M. fortuitum compared to M. 
bovis (BCG) and M. tuberculosis (H37Rv) within macrophages may be due to differences in 
the cell wall structure, composition of the phagosome, time required for phagosome-lysosome 
fusion, secretion of antimycobacterial compounds and the replication time of the bacteria (Orme 
and Collins, 1983, Appelberg et al., 1994b, Da Silva et al., 2002, Ahmed and Hasnain, 2011, 
Cebula et al., 2012, Honda et al., 2015). It has been reported that the inability of less or non-
pathogenic bacteria (M. smegmatis, M. fortuitum) to cause disease despite their higher number 
in macrophages was due to their rapid induction of host cell apoptosis. The rapid induction of 
apoptosis of infected macrophages is followed by the rapid killing of internalised mycobacteria 
(Molloy et al., 1994, Keane et al., 2002, Bohsali et al., 2010). Whereas survival of the 
pathogenic bacteria in macrophages (M. tuberculosis) was due to their inhibition or evasion of 
the host cell apoptotic mechanisms (Keane et al., 2000). A higher survival of M. fortuitum, M. 
bovis (BCG) and M. tuberculosis (H37Rv) in macrophages in diabetic mice in our studies 
suggests a detailed investigation of the mechanisms of survival of bacteria inside the 
macrophages in diabetes by further research. The understanding of the mechanisms may help 
in designing therapeutic agents to increase killing of the bacteria in the early stages of infection 
thereby increasing antigen presentation to T cell.  
Macrophage-mycobacterial interactions result in the secretion of various cytokines and 
chemokines which ultimately determine the fate of infection (Benoit et al., 2008). Classically 
activated macrophages (M1 macrophages) are pro-inflammatory and have a central role in host 
defence against infection. Upon activation of M1 macrophages exhibit antimicrobial pro-
inflammatory properties via the production of many pro-inflammatory cytokines including 
TNF-α, IL- 1β, IL-12, IL-15, IL-23 and IFN-γ (Doherty et al., 1996, Wang et al., 1999, Verreck 
et al., 2004, Verreck et al., 2006). In contrast, the alternatively activated macrophage (M2) lacks 
significant antimicrobial activity and fails to produce inflammatory cytokines. M2 subsets have 
poor antigen presenting capability and suppress cellular immunity by producing anti-
inflammatory cytokines (IL-10, IL-4, TGF-β) (VanHeyningen et al., 1997, Guyot-Revol et al., 
2006, Verreck et al., 2006). Pro-inflammatory cytokines are essential for effective immune 
responses against mycobacterial infections, although dysregulated and/or excessive pro-
inflammatory cytokines can also be detrimental in infection (Garlanda et al., 2007). 
In the current study, we determined the cytokine production from supernatant samples collected 
following co-culture with mycolic acid coated beads, M. fortuitum, M. bovis (BCG) and M. 
tuberculosis (H37Rv). After 4 hours of co-culture with mycolic acid coated beads, TNF-α and 
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IL-6 were found in the supernatants of RPEC and AL (Figure 5.7 A, B, E & F). No other 
cytokines (MCP-1, IL-12, IL-6, IL-10, IFN-γ) were detected following bead co-culture. The 
production of both TNF-α and IL-6 by RPEC and AL of both diabetic and control mice wasn’t 
significantly different when compared to unstimulated cells. Bowdish and colleagues (2009) 
stimulated bone marrow-derived macrophages (BMMφ) and RPM with TDM coated beads for 
24 hours and found detectable amounts of TNF-α. The amount of cytokine produced depends 
on the size of the beads and the localisation of the beads (outside or inside macrophages). 
Previous studies have shown that BMMφ produce less pro-inflammatory cytokines in response 
to TDM coated beads on the cell surface that are too large to be phagocytosed. In contrast, RPM 
can produce higher amounts of TNF-α in response to smaller beads capable of being 
phagocytosed (Geisel et al., 2005, Bowdish et al., 2009). In our study, we used RPEC and AL. 
These cell populations do not contain purified macrophages which could be one of the reasons 
for lower cytokine production during co-culture with beads observed. The shortest stimulation 
time was another reason for lower secretion of cytokines by these cells. This study also didn’t 
determine the size of the mycolic acid coated beads which also had some role in the production 
of cytokines.  
TNF-α production was decreased in AM and RPM from diabetic mice compared to controls 
following co-culture with M. fortuitum (Figure 5.10 A & B and 5.11 A & B), M. bovis (BCG) 
(Figure 5.13 A & B, 5.14 A & B and Table 5.4) and M. tuberculosis (H37Rv) (Figure 5.16 A 
& B and 5.17 A & B). Previous studies have shown that mice lacking the ability to secrete TNF-
α had increased susceptibility to mycobacterial infections (Flynn et al., 1995, Benoit et al., 
2008). This cytokine is crucial for enhancing the capability of macrophages to secrete different 
antimycobacterial compounds for uptake and killing of the bacteria (Yu et al., 1999, Keane et 
al., 2000, Scanga et al., 2001). It is also crucial for the formation of the granuloma and its 
continued maintenance by controlling the growth of bacteria (Kindler et al., 1989, Flynn et al., 
1995, Senaldi et al., 1996, Olleros et al., 2005, Saunders et al., 2005). Consistent with our 
findings, lower levels of TNF-α were observed in macrophages of type 1 and 2 diabetic animal 
models (Sugawara et al., 2004, Sugawara and Mizuno, 2008). Decreased production of TNF-α 
in macrophages from diabetic animals corresponded to the lower uptake and killing of the 
bacteria observed in the current study (Figure 5.9 A & B, 5.12 A & B and 5.15 A & B). In 
comparison to AM, the overall TNF-α secretion was lower in RPM resulting in lower bacterial 
uptake and higher survival. Sun and colleagues (2012) reported lower secretion of TNF-α from 
F4/80+ peritoneal exudate macrophages in STZ-induced mice which was similar to the findings 
of this study. Furthermore, increased IL-10 production by RPM is related to the downregulation 
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of the TNF-α production (Fulton et al., 1998). We also observed higher production of IL-10 in 
RPM compared to AM from both diabetic and control mice. This might be one of the reasons 
for an overall lower TNF-α production by RPM contributing to the comparatively lower uptake 
and killing of the bacteria.  
M. fortuitum infected macrophages showed an overall higher production of TNF-α from both 
diabetic and control mice compared to M. tuberculosis (H37Rv) and M. bovis (BCG) infected 
cells. Falcone and colleagues (1994) reported a higher production of TNF-α in murine 
peritoneal macrophages cultured with live avirulent M. tuberculosis H37Ra and M. smegmatis 
compared to live virulent M. tuberculosis H37Rv. Another study using human macrophages 
with non-pathogenic (M. smegmatis, M. phlei) and other selected pathogenic mycobacteria (M. 
tuberculosis, M. avium, M. kansasii, M. xenipi) found differences in TNF-α production with 
non-pathogenic mycobacteria stimulating higher amounts of TNF-α production compared to 
pathogenic mycobacteria (Beltan et al., 2000). This observation was also true for the current 
study where the less pathogenic M. fortuitum, avirulent M. bovis (BCG) and pathogenic 
mycobacteria (M. tuberculosis, H37Rv) were used. Although it was not clear how TNF-α is 
triggered in pathogenic and non-pathogenic bacteria, possible reasons might be related to their 
differences in lipoarabinomannan (LAM) structure on the cell wall (Chatterjee et al., 1992b, 
Singh and Goyal, 2013). Chatterjee and colleagues (1992b) reported that LAM from avirulent 
M. tuberculosis was 100-fold more potent at inducing TNF-α than LAM from the virulent 
Erdman strain. Non-pathogenic mycobacteria possess extensive arabinose side-chains on LAM 
which is a potential inducer of cytokines. In contrast, pathogenic mycobacteria possess a short 
mannan chain which extensively masks the arabinose side chain (Chatterjee et al., 1991, 
Chatterjee et al., 1992b). Another possible mechanism for greater TNF-α production induced 
by non-pathogenic bacteria compared to pathogenic bacteria is the relative differences in 
phagolysosome fusion. Phagolysosome fusion is a pre-requisite to enhance the production of 
cytokines. Phosphatidylinositol 3-phosphate (PI3P) is a membrane trafficking regulatory lipid 
which is important for the phagosomal acquisition of lysosomal contents (Vergne et al., 2005b). 
Pathogenic mycobacteria (e.g. M. tuberculosis H37Rv) and M. bovis (BCG) secrete an acid 
phosphatase known as SapM which is required to hydrolyse PI3P, resulting in inhibition of 
phagos lysosomal fusion. Non-pathogenic mycobacteria (e.g. M. fortuitum) do not produce 
SapM, thus no inhibition of phagosome with lysosomes resulting in more cytokine production 
(Saleh and Belisle, 2000). The inherent toxicity of pathogenic mycobacteria on macrophages 
may be another reason for lower production of cytokines. The non-pathogenic or attenuated 
pathogenic bacteria (e.g. heat-killed M. tuberculosis H37Rv) is non-toxic and can induce a 
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significant amount of TNF-α compared to its live counterparts (Falcone et al., 1994). The 
current study found a lower production of TNF-α from M. bovis (BCG) and M. tuberculosis 
(H37Rv) infected macrophages compared to the M. fortuitum infected macrophages. This may 
be due to a higher cytotoxic effect on macrophages by the M. bovis (BCG) and M. tuberculosis 
(H37Rv) compared to M. fortuitum. This was not investigated in the current study. 
MCP-1 (also known as CCL2) is crucial for the influx of the different immune cells (monocytes, 
dendritic cells, natural killer cells and activated T cells) to provide protection at sites of infection 
(Kipnis et al., 2003). Kipnis and colleagues (2003) observed that fewer macrophages entered 
the lungs of CCL2 knockout mice compared to wild type littermates in experimental Mtb 
infections. This allowed for increased lung bacterial load followed by a failure recruitment of 
antigen-specific effector T lymphocyte into the lung. Expression of this cytokine was well 
documented in both animal models (Rhoades et al., 1995, Peters et al., 2001) and patients with 
M. tuberculosis infection (Lin et al., 1998, Lee et al., 2003). In the current investigation, we 
observed a significantly lower production of MCP-1 in AM (Figure 5.10 D and 5.16 D) and 
RPM (Figure 5.11 D, 5.14 D, 5.17 D and Table 5.4) from diabetic mice compared to controls 
after 24/48 hours of co-culture with the mycobacteria. The diminished production of this 
cytokine could result in a defect in immune cells recruitment into the lungs during Mtb 
infections (Rhoades et al., 1995, Lin et al., 1998, Peters et al., 2001, Lee et al., 2003). Vallerskog 
and colleagues (2010) observed a reduced level of chemoattractant factors including MCP-1 
(CCL2) as a cause of delayed recruitment of myeloid cells followed by delayed antigen 
presentation in STZ-induced diabetic mice infected with Mtb. 
IL-6 has both pro- and anti-inflammatory roles in Mtb infection (VanHeyningen et al., 1997). 
There are conflicting reports in the literature as to the role of IL-6 in Mtb infection (Ladel et al., 
1997a, Sodenkamp et al., 2012). IL-6 knockout mice were highly susceptible to Mtb infection 
and this cytokine also contributed to vaccine induced protective immunity in mice (Saunders et 
al., 2000, Leal et al., 2001). In the current study, higher levels of IL-6 were found in 
mycobacteria infected AM and RPM from diabetic mice compared to controls although overall 
concentrations were higher in RPM compared to AM (Figure 5.10 E & F, 5.11 E & F, 5.14 E 
& F, 5.16 E & F, 5.17 E & F and Table 5.4). Furthermore, an overall higher production of IL-
6 was observed in RPM in M. fortuitum infection compared to M. bovis (BCG) and M. 
tuberculosis (H37Rv) at the later timepoint of infection. Singh and Goyal (2013) observed a 
higher IL-6 secretion in murine peritoneal macrophages using a heat killed, avirulent M. 
tuberculosis compared to live, virulent M. tuberculosis. The authors also found higher IL-6 
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secretion in the same macrophages using a non-pathogenic M. smegmatis compared to M. 
tuberculosis H37Ra/v. These findings were consistent with our observations. Beltan and 
colleagues (2000) also observed higher production of IL-6 by human macrophages co-cultured 
with various non-pathogenic mycobacteria (M. smegmatis, M. phlei) compared to pathogenic 
bacteria (M. tuberculosis, M. avium). The precise mechanism underlying the role of IL-6 
production in response to pathogenic and non-pathogenic mycobacterial infection is not clear. 
Elevated production of IL-6 from less/non-pathogenic (e.g. M. fortuitum) mycobacteria 
compared to highly pathogenic bacteria (e.g. M. tuberculosis) might be due to the extensive 
LAM structure on the cell wall and less inhibition and fusion of the phagosome with late 
endosomes (Singh and Goyal, 2013). The reduced production of IL-6 in macrophages from 
diabetic animals of this study indicated higher bacterial survival. Martinez and colleagues 
(2013) also observed higher M. tuberculosis growth in macrophages of IL-6 knockout mice. 
Despite the lower IL-6 production in AM, a higher TNF-α production might compensate the 
situation to reduce bacterial growth compared to RPM as observed in this study.  
IL-1β secretion was significantly lower in the AM and RPM of diabetic mice compared to 
controls following co-culture with M. tuberculosis (H37Rv) (Figure 5.16 H and 5.17 H). 
Although there was no IL-1β production by AM infected with M. bovis (BCG), a reduction of 
this cytokine was noticed in RPM from diabetic mice compared to controls (Figure 5.13 H, 5.14 
H and Table 5.4). Previous studies have shown that IL-1β is required to stimulate macrophages 
to produce TNF-α and IL-6 (Toossi et al., 1990, Dinarello, 2005). This observation was 
consistent with our findings which suggests that IL-1β positively correlated with the secretion 
of TNF-α and IL-6. Reduced production of IL-1β section by macrophages from diabetic mice 
also related to the higher survival of the bacteria as it has a role in the activation of macrophages 
to increase secretion of antimycobacterial compounds to kill the bacteria (Dinarello, 2005). 
Other studies have demonstrated that IL-1 receptor or IL-1β gene knockout mice showed higher 
susceptibility to M. tuberculosis infection resulting in a higher bacterial burden in organs, 
defective granuloma formation and less production of IFN-γ leading to the death of the mice 
(Juffermans et al., 2000, Bourigault et al., 2013).  
This study showed significantly higher production of IL-10 by RPM from control mice at the 
earliest timepoint of M. fortuitum infection although this wasn’t observed at later timepoint 
(Figure 5.11 K & L). A similar trend was observed at all timepoints of infection during co-
culture with M. bovis (BCG) (Figure 5.14 M & N and Table 5.4). There was no detectable IL-
10 production by AM and RPM following co-culture with M. tuberculosis (H37Rv) (Figure 
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5.16 M & N and 5.17 M & N). The production IL-10 has the roles in limiting the immune 
responses during mycobacterial infections (Bermudez and Champsi, 1993, Murray and Young, 
1999, Jacobs et al., 2000, Roque et al., 2007). Enhanced protection from M. bovis (BCG) 
mortality and reduced immune-mediated pathology was observed in IL-10 knockout mice 
(Murray and Young, 1999). Furthermore, addition of an IL-10 antagonist as an adjuvant during 
vaccination improved infection outcomes (Silva et al., 2001, Roberts et al., 2005, Stober et al., 
2005). Increased production of IL-10 is associated with the down-regulation of pro-
inflammatory cytokines (e.g. TNF-α) leading to lower uptake and killing of the organism (Gong 
et al., 1996, Fulton et al., 1998, Hirsch et al., 1999a). Although we detected a higher amount of 
IL-10 in macrophages of control mice, the survival of the organism inside the macrophages was 
low. The anti-inflammatory environment and the higher killing of the phagocytosed bacteria by 
the macrophages from control mice may be compensated by the higher secretion of other pro-
inflammatory cytokines (TNF-α, MCP-1, IL-6, IL-1β) as observed in this investigation. Despite 
secretion of a lower amount of IL-10 in macrophages of diabetic mice, they are unable to secrete 
sufficient amounts of other pro-inflammatory cytokines leading to the higher survival of 
mycobacteria within macrophages. Higher secretion of IL-10 by RPM might also contribute to 
this lower production of pro-inflammatory cytokines.  
In the current investigation, we observed a reduced uptake and killing of the mycobacteria by 
the AM and RPM from diabetic mice compared to non-diabetic controls. Bacterial uptake and 
killing were impaired in diabetic macrophages and this was associated with the reduced or 
impaired production of various cytokines. Findings of this in vitro study enhance our 
understanding of how macrophage functions are impaired in TB-T2D co-morbid infections. It 
is also important to understand how antimycobacterial immunity is impaired in diabetic 
individuals infected with TB. Therefore, in the subsequent three Chapters (Chapter 6, 7 and 8) 
antimycobacterial immunity will be studied in vivo in diabetic mice infected with M. fortuitum, 
M. bovis (BCG) and M. tuberculosis (H37Rv).  
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6 CHAPTER 6  
EFFECT OF TYPE 2 DIABETES ON SURVIVAL AND ORGAN 
MYCOBACTERIAL KINETICS IN MICE 
 
 Introduction 
Patients with co-morbid TB-DM (Diabetes Mellitus), have increased severity of infections and 
mortality (Oursler et al., 2002, Lindoso et al., 2008, Dooley et al., 2009, Wang et al., 2009). 
Studies have demonstrated a higher bacterial burden on sputum culture, reinfection and relapse 
during the time of treatment and a longer time required for bacterial clearance from sputum in 
TB-DM patients than in non-diabetic TB patients (Restrepo et al., 2008b, Dooley et al., 2009, 
Wang et al., 2009, Jimenez-Corona et al., 2013). There are controversies as to the impact of 
diabetes on the development of extrapulmonary TB, with some studies reporting a similar or 
even reduced relative risk of extrapulmonary TB progression in diabetic compared to non-
diabetic patients (Long et al., 1997, Leung et al., 2008, Young et al., 2012). However, in parallel 
to the growing incidence of TB in diabetic patients, there is growing evidence of an increased 
incidence of non-tuberculous mycobacterial (NTM) infections in patients with AIDS (acquired 
immunodeficiency syndrome) and diabetes (Tortoli et al., 1995, Piersimoni et al., 1997, 
Gholizadeh et al., 1998, Uslan et al., 2006, Orme and Ordway, 2014, Bridson et al., 2016, Xu 
et al., 2016). Although the host-TB/NTM infections are well documented in the literature, there 
is lack of information on how T2D influences the outcomes of these infections.  
Understanding the impact of T2D on mycobacterial dissemination and clearance in TB/NTM 
patients is crucial. Currently, the mouse model most often used to study the pathogenesis of 
TB-DM co-morbid infections is one in which animals are treated with high-doses of cytotoxic 
Streptozotocin (STZ)/ STZ+Nicotinamide (NA) to induce type 1 diabetes (T1D) (Saiki et al., 
1980, Yamashiro et al., 2005, Martens et al., 2007, Vallerskog et al., 2010, Podell et al., 2014, 
Cheekatla et al., 2016). Some researchers have used Goto Kakizaki (GK) T1D and T2D rat 
models in TB-DM co-morbid infections (Sugawara et al., 2004, Sugawara and Mizuno, 2008). 
In the GK T1D rat model, animals are not obese and total insulin resistance develops due to 
severe insulitis which most closely models the features of T1D (Sugawara et al., 2004). The 
GK T2D rat model is also a non-obese and is less commonly used due to its limitations. The 
development of hyperglycaemia in this model is associated with increased secretion of 
corticosterone which differs significantly from the mechanism of hyperglycaemia development 
in T2D (Beddow and Samuel, 2012). Although the above-mentioned animal models have 
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provided important information as to how hyperglycaemia affects chronic TB disease, they did 
not model the effects of diet on the development and outcome of acute TB-DM co-morbid 
infections. To our knowledge, this is the first study examining mycobacterial susceptibility 
using tuberculous and non-tuberculous mycobacterial species in diet-induced murine model of 
T2D.  
In this Chapter, we hypothesise that chronic persistent hyperglycaemia in a diet-induced murine 
model of T2D leads to higher bacterial burden in organs leading to decreased survival from 
mycobacterial infections. As mycobacterial susceptibility increases in poorly controlled 
diabetic patients (Restrepo et al., 2008a), the animals used is the current study were  maintained 
on the energy-dense-diet (EDD; Chapter 4) for extended periods and monitored for energy 
intake, body weight loss and blood glucose level during acute mycobacterial infections. We 
investigated the survival and kinetics of bacillary burden in our T2D model following 
mycobacterial infections. We used non-tuberculous mycobacteria (M. fortuitum) and 
tuberculous (M. bovis; BCG and M. tuberculosis; H37Rv) mycobacteria throughout this study 
to investigate whether T2D influences the outcomes of diverse mycobacterial infection types.  
The specific Aims of this research described in this Chapter are: 
1. To investigate the survival of T2D mice following infection with a high-dose of M. 
fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) 
2. To determine the effect of T2D on kinetics of organ bacterial load following infection 
with a low-dose of M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) 
  Materials and Methods 
 Animal ethics and institutional approvals 
The details of animal ethics and institutional approvals are described in Chapter 3 (section 
3.1.1). 
 Experimental animals and induction of diabetes  
Six-week old male C57BL/6 mice were used for the induction of diabetes. Mice were received 
from SABU, James Cook University at 4 weeks of age and randomly housed in cages (5 
mice/cage) within a temperature and light controlled environment. Ear marking was done for 
longitudinal characterisation of individual mouse. Three sets of mice (Table 6.1) were kept on 
diets for a period of 30 weeks. The diabetic groups were provided with an ad libitum access to 
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an energy-dense diet (EDD), whereas the non-diabetic control groups were fed a standard 
rodent diet (SRD). The body weight gain, glucose tolerance test and area under the curve as the 
measures of insulin resistance were determined after the end of the diet intervention period. 
Animal care and nutritional provisions, marking of individual mouse and methods for 
determining the metabolic parameters are described in Chapter 3 (section 3.1.3).  
Table 6.1 Mice used for the induction of diabetes for infection studies  
Infection studies Mouse set 
Diet (30 weeks) 
EDD (n) SRD (n) 
M. fortuitum 1 33 33 
M. bovis (BCG) 2 33 31 
M. tuberculosis (H37Rv) 3 40 39 
EDD; energy-dense diet, SRD; standard rodent diet, n; number of mice 
  Mycobacterial infections 
 Preparation of mycobacterial culture for infection  
For the preparation of bacterial inocula for injection, frozen aliquots of the bacterial culture 
were thawed and washed twice with PBS at 4000 xg for 10 minutes. Bacterial pellets were then 
vortexed for several minutes. The bacterial clumps were further broken down by passing the 
suspension 10-15 times through 27-gauge needles followed by sonication for 10 seconds (50% 
maximum frequency). The diluted bacterial inoculum was plated on 7H11 agar plates to 
confirm the bacterial CFU/mL (Chapter 3, section 3.3.1 and 3.3.2).  
For the infection studies using M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv), 
diabetic and control mice were injected intravenously via the lateral tail vein with an either a 
high-dose or a low-dose of bacteria in a final volume of 200 µL of PBS (Table 6.2). 
Table 6.2 Infective doses for mycobacterial infections  
Organism 
Dose  
(CFU/mouse) 
Mice number 
Reference 
Diabetic Control 
M. fortuitum 
High 3x108 14 13 
Parti et al. (2005) 
Low 1x107 30 33 
M. bovis (BCG) 
High 2x 106 9 12 
Orme and Roberts (2001) 
Pedras-Vasconcelos et al. 
(2002) 
Low 1x106 32 34 
M. tuberculosis (H37Rv) 
High 2x 107 12 10 
Low 4x106 40 39 
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 Monitoring and culling of infected mice  
Following infections and throughout the infection period mice were monitored for survival and 
metabolic parameters (daily feed and energy intake, body weight loss and blood glucose level). 
Mice infected with a low-dose of bacteria were sacrificed at 1, 14 and 30/35 days post-infection 
(dpi) to determine the bacterial loads, histopathological changes (Chapter 7) and cytokine 
production (Chapter 8). Some low-dose M. fortuitum infected mice were monitored for their 
survival for 60 dpi although no metabolic parameters were recorded after 4 weeks. 
Mice infected with a high-dose of mycobacteria were observed primarily for their survival at 
60 dpi and metabolic parameters were monitored for 7 weeks. Some high-dose M. fortuitum 
infected mice were sacrificed at 14 dpi to investigate the kinetics of infection.  
 Preparation of organ homogenates 
Three to five mice from each group were euthanised by CO2 asphyxiation at 1, 14, 35 days post 
infection (dpi) (30 dpi for M. tuberculosis infection) for the collection of spleen, liver and lungs. 
All samples were processed according to previously published protocols (Da Silva et al., 2002, 
Parti et al., 2005, Yamashiro et al., 2005, Vallerskog et al., 2010, Ordway and Orme, 2011). 
Briefly, spleen (half total organ weight), liver (1 g), lungs (left lung) were homogenised 
separately in a stomacher bag containing 1 mL of PBS with 0.05% Tween 80. The homogenates 
were centrifuged (3000 xg for 5 minutes) and supernatants were collected and stored at -800C 
for cytokine assays (Chapter 7). The cell pellets were then lysed with 300 µL of 0.1% Triton 
X-100® for 10 minutes followed by sample dilution with 700 µL of PBS. Serial 10 or 5-fold 
dilutions were prepared from lysates and plated on 7H11 agar plates. Colonies were counted 
after 5-7 days (M. fortuitum infection) and from 16 days after (M. bovis; BCG and M. 
tuberculosis; H37Rv) infection of incubation at 370C with 5% CO2. Organs from 2 moribund 
diabetic and 3 non-diabetic mice infected with high-dose M. fortuitum were also culled and 
samples were processed as described above.  
 Statistical analysis 
Statistical analysis was performed using the SPSS version 24.0 and GraphPad Prism 7.03 
software. All the data were checked for normality using the Shapiro-Wilk’s test. Data passed 
the test of normality if p≥0.05. The normally distributed data were compared between diabetic 
and control groups using the independent samples t-test. The non-normally distributed data 
were compared between the groups using the non-parametric Mann-Whitney U test. Normally 
distributed data of multiple groups were compared using the ordinary one-way ANOVA with 
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Holm-Sidak's multiple comparisons test. The Kruskal-Wallis test with Dunn's multiple 
comparisons test was performed for non-normally distributed data of multiple groups. The two-
way ANOVA with Sidak’s multiple comparisons test was performed for repeated measures 
data (e.g. kinetics of feed and energy intake, body weight loss, changes in blood glucose level). 
The Kaplan Meier survival curves with log-rank (Mantel-Cox) tests were used to compare 
diabetic and control mouse survival post-infection. All data were expressed as mean±SEM. The 
level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and ****p≤0.0001. 
 Results 
 Assessment of metabolic parameters following diet intervention 
Prior to the diet intervention, the starting body weight of mice on the energy-dense diet (EDD) 
and standard rodent diet (SRD) was similar in all the mouse sets (Figure 6.1 A, D & G). After 
30 weeks of diet intervention, the body weight gain was significantly higher in mice on EDD 
compared to controls (Figure 6.1 A, D & G). For mouse set 1, the overall increase in the body 
weight was 58.21% in SRD group and 143.06% in EDD group. A similar trend of body weight 
gain was also observed in mouse set 2 (SRD, 8.97 vs EDD, 83.51, %) and mouse set 3 (SRD, 
35.77 vs EDD, 137.73, %). The glucose tolerance test (GTT) demonstrated that mice on EDD 
were more glucose intolerant compared to control mice on SRD (Figure 6.1 B, E & H). In 
mouse set 1, the baseline fasting blood glucose (FBG) level (before the glucose challenge 
indicated as 0 minutes) was 6.66±0.13 and 9.11±0.20 mmol/L in mice on SRD and EDD, 
respectively. Compared to controls, diabetic mice were less efficient in clearing the glucose 
from the circulation even 2 hours after an intraperitoneal glucose challenge (SRD, 5.99±0.12 
vs EDD, 10.00±0.24, mmol/L, p≤0.0001) (Figure 6.1 B). In mouse set 2 and 3, the baseline 
FBG concentration and 2 hours post-glucose challenge blood glucose level was also higher in 
mice on EDD compared to control mice on SRD (Figure 6.1 E & H). The area under the curve 
(AUC) based on GTT (AUC-GTT) was also significantly higher in EDD fed mice compared to 
controls (Figure 6.1 C, F & I), which also indicated a higher glucose intolerance by diabetic 
mice due to higher insulin resistance.  
In the current study, EDD fed mice were considered T2D if they demonstrated an elevated FBG 
level and AUC-GTT with evidence of glucose intolerance higher than the upper 99% 
confidence interval for the mean of the age-matched control group (described in Chapter 4). 
Based on FBG level and AUC-GTT, a total of 96.97 to 100% mice on EDD became diabetic in 
mouse set 1 (Appendix 4) and mouse set 2 (Appendix 5). In mouse set 3, 100% of mice became 
 147 
diabetic based on FBG and AUC-GTT after the diet intervention (Appendix 6). Those mice 
which failed to meet at least one of the above criteria mentioned were excluded from the 
infection study.  
As the mice fed on EDD showed the characteristic features of T2D, hereafter they will be 
termed ‘diabetic mice’.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Metabolic profile of three sets of mice used in this study  
C57BL/6 mice were kept on the energy-dense diet (EDD) and standard rodent diet (SRD) for a 
period of 30 weeks. After diet intervention, weight gain (A, D & G), glucose tolerance test 
(GTT) after 6 hours of morning fasting (B, E & H) and Area Under the Curve (AUC) based on 
GTT (C, F & I) were significantly higher in mice on EDD compared to control mice on SRD. 
The mice set 1 (A, B & C), 2 (D, E & F) and 3 (G, H & I) were used for M. fortuitum, M. bovis 
(BCG) and M. tuberculosis (H37Rv) infection study, respectively. Data presented as 
mean±SEM (Appendix 4; M. fortuitum, 5; M. bovis BCG and 6; M. tuberculosis H37Rv). 
Significant differences were determined using the Kruskal-Wallis test with Dunn’s multiple 
comparisons test (A, D & G), the two-way ANOVA with Sidak’s multiple comparisons test (B, 
E & H), Mann-Whitney U test (C, F) and the independent sample t-test (I). The level of 
significance was indicated as **p≤0.01, ***p≤0.001 and ****p≤0.0001. 
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 Assessment of metabolic parameters following mycobacterial infections 
 Metabolic parameters following M. fortuitum infection 
Following infection with M. fortuitum at a dose of 1x107 CFU/mouse (low-dose), the daily feed 
(Appendix 4, Figure A4.1) and energy intake of diabetic mice was reduced during the first 2 
weeks of infection, compared to the later weeks post-infection (pi) (Figure 6.2 A). In contrast, 
the feed (Appendix 4, Figure A4.1) and energy intake (Figure 6.2 A) of control mice fluctuated 
throughout the infection period. Four weeks pi, the overall energy intake/mouse/day was 
reduced in control mice by 3.76% compared to pre-infection (baseline; 0 week) intake. 
However, in diabetic mice, daily energy intake increased by 10.83% pi which might be due to 
feed waste. It was observed that when HFD feed was supplied for 7-days, pellets softened and 
dropped down to the bottom of the cages.  Infected diabetic mice showed a gradual loss in body 
weight over the infection period, whereas fluctuations in weight of the control group were 
observed (Figure 6.2 B). Overall diabetic mice lost 13.58% body weight, whereas control mice 
gain 8.94% in the same period pi. Prior to infection, the blood glucose level of diabetic mice 
was significantly higher than the control group (control, 6.65±0.13 vs diabetic, 9.23±0.20, 
mmol/L, p≤0.001). Following infection and for the first 3 weeks pi, we observed an initial 
decrease in blood glucose level in diabetic mice. In the control mice, a fall in blood glucose 
level was not seen after the second week pi. During the final week of the infection study (day 
35), the blood glucose level of both groups was elevated (control, 7.70±0.36 vs diabetic, 
11.07±0.54, mmol/L) and significantly higher than their pre-infection blood glucose levels. 
When the mice were infected with high-dose (3x108 CFU/mouse) bacteria, diabetic mice were 
observed to be considerably more inactive and lethargic compared to control mice. The daily 
feed (Appendix 4, Figure A4.10) and energy intake, weekly body weight and blood glucose 
level were reduced significantly in both diabetic and control mice (Figure 6.2 D, E & F) 
following high-dose infection. The overall daily energy intake/mouse/day was reduced by 
28.43% in control and 66.01% in diabetic mice, which also corresponded to their body weight 
loss. At 2 weeks pi, control and diabetic mice had lost 10% and 33.33% of their body weight 
respectively. In contrast to the low-dose infection, the blood glucose level of both control and 
diabetic mice dropped sharply following infection and failed to return to pre-infection levels 
(Figure 6.2 C vs Figure 6.2 F). 
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Figure 6.2 Metabolic parameters of mice following M. fortuitum infection 
Diabetic and control mice were infected with a dose of 1x107 CFU/mouse intravenously (A-C). 
Following infection, the daily energy intake (A), weekly body weight (B) and blood glucose 
level (C) were monitored for a period of 35 days. Whereas some mice were infected at a high-
dose of 3x108 CFU/mouse (D-F). The daily energy intake (D), weekly body weight (E) and 
blood glucose level (F) were also monitored for a period of 2 weeks (until the death of the 
mice). In both low and high-dose infection groups, the overall reduction of energy intake, body 
weight and blood glucose level were observed in both diabetic and control mice. Data presented 
as mean±SEM; n=30-33 (low-dose) and 13-14 (high-dose) mice/group. The significant 
differences were determined using the two-way ANOVA with Sidak’s multiple comparisons 
test (Appendix 4). The level of significance was indicated as *p≤0.05, ***p≤0.001, 
****p≤0.0001 and ns=non-significant. 
 
 Metabolic parameters following M. bovis (BCG) infection 
In mice infected with 1x106 CFU M. bovis (BCG), the daily feed (Appendix 5, Figure A5.1) 
and energy intake (Figure 6.3 A) fell progressively in the first 2 weeks of infection in both 
diabetic and control mice followed by a gradual rise until the last week of the infection study. 
After 4 weeks, the energy intake/mouse/day was reduced by 14.70% for diabetic mice 
compared to pre-infection. In the control group, the overall reduction of energy 
intake/mouse/day was 31.33%. Weight loss was gradual in diabetic mice (22.05% weight loss 
compared to pre-infection), whereas control mice maintained their weight over the study period 
(Figure 6.3 B). The pre-infection (indicated as ‘0 week’) blood glucose level of the diabetic 
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mice was significantly higher than the control group (control, 7.35±0.20 vs diabetic, 8.54±0.29, 
mmol/L, p=0.0012). Following infection, blood glucose levels decreased from the second to 4th 
week pi (Figure 6.3 C). At the end of the infection study, the blood glucose levels in both groups 
were elevated compared to pre-infection levels, although these increases were not statistically 
significant (control, 8.39±0.22 vs diabetic, 9.01±0.53, mmol/L, p=0.2632). 
 
 
 
 
 
 
 
 
 
Figure 6.3 Metabolic parameters of mice following M. bovis (BCG) infection 
Diabetic and control mice were infected with a low-dose of (1x106 CFU/mouse) M. bovis 
(BCG) to observe the kinetics of infection (A-C). Following infection, the daily energy intake 
(A), weekly body weight loss (B) and blood glucose level (C) were monitored for a period of 
35 days. Whereas mice infected with a high-dose (2x106 CFU/mouse) of the same bacteria were 
monitored for the daily energy intake (D), weekly body weight loss (E) and blood glucose level 
(F) for 7 weeks during determining the survial. In both groups, the overall reduction of energy 
intake, body weight and blood glucose level was higher in the diabetic group compared to 
controls. Data presented as mean±SEM; n=32-34 (low-dose) and 09-12 (high-dose) 
mice/group. The significant differences were determined using the two-way ANOVA with 
Sidak’s multiple comparisons test (Appendix 5). The level of significance was indicated as 
*p≤0.05, **p≤0.01, ***p≤0.001 and ****p≤0.0001 and ns=non-significant. 
 
Both diabetic and control mice infected with high-dose M. bovis BCG (2x106 CFU/mouse), 
showed an erratic trend of daily feed (Appendix 5, Figure A5.10) and energy intake (Figure 6.3 
D) throughout the infection period. Compared to their pre-infection energy intake/day/mouse, 
a 12.01% and 0.5% reduction of energy intake/mouse/day was observed in diabetic mice and 
controls, respectively. A sharp decrease in body weight was observed in diabetic mice at weeks 
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1-3 pi and then body weight stabilised until the end of the infection period (Figure 6.3 E). In 
control mice, the body weight was generally stable throughout the infection study (Figure 6.3 
E). After the end of 7th week of infection, we observed a 29.44% and 4.66% body weight 
reduction in diabetic and control mice, respectively. Furthermore, the blood glucose level in 
both diabetic and control mice fell in the first 2 weeks of infection but after this time glucose 
levels gradually increased to pre-infection levels (Figure 6.3 F).  
 Metabolic parameters following M. tuberculosis (H37Rv) infection 
The daily feed (Appendix 6, Figure A6.1) and energy intake (Figure 6.4 A) of diabetic mice 
infected with low-dose (4x106 CFU) M. tuberculosis (H37Rv), reduced dramatically in the first 
2 weeks followed by a gradual increase at later weeks of the infection period. In control mice, 
the feed (Appendix 6, Figure A6.1) and the energy intake was lower in the first 2 weeks pi and 
then slowly increased until the last week (Figure 6.4 A). At 4 weeks pi, the energy 
intake/mouse/day of diabetic mice decreased by 26.06% compared to pre-infection intake. In 
the control group, the opposite trend was observed i.e. energy intake/mouse/day increased by 
19.39% compared to pre-infection intake (Figure 6.4 A). A gradual decrease in the body weight 
of diabetic mice was observed during the entire period of infection. In contrast, the body weight 
of the control mice was maintained (Figure 6.4 B). At 4 weeks pi, diabetic mice lost an average 
of 15.39% of their body weight which contrasted with the minor (1.56%) body weight reduction 
measured from control mice. Pre-infection blood glucose level in diabetics was significantly 
higher than the control group (control, 5.68±0.30 vs diabetic, 9.78±0.30, mmol/L, p=0.0000). 
In diabetic mice, the pi blood glucose level dropped until the second week of infection followed 
by a gradual rise until the last week of infection (Figure 6.4 C). The pi blood glucose level of 
the control group was higher than the pre-infection level throughout the infection (Figure 6.4 
C) with some control animals even showing higher blood glucose than diabetic animals during 
the last 2 weeks of infection, although this was not statistically significant. 
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Figure 6.4 Metabolic parameters of mice following M. tuberculosis (H37Rv) infection 
Diabetic and control mice were infected with a low-dose of (4x106 CFU/mouse) M. tuberculosis 
(H37Rv) to observe the kinetics of infection (A-C). Following infection, the daily energy intake 
(A), weekly body weight loss (B) and blood glucose level (C) were monitored for a period of 
30 days. Whereas mice infected with a high-dose (2x107CFU/mouse) of the same bacteria were 
monitored them for the daily energy intake (D), weekly body weight loss (E) and blood glucose 
level (F) for 7 weeks during determining the survial. In both low- and high-dose groups, the 
overall reduction of energy intake, body weight and blood glucose level was higher in the 
diabetic group compared to control group. Data presented as mean±SEM; n=39-40 (low-dose) 
and 10-12 (high-dose) mice/group. The significant differences were determined using the two-
way ANOVA with Sidak’s multiple comparisons test (Appendix 6). The level of significance 
was indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and ****p≤0.0001 and ns=non-significant. 
 
Diabetic and control mice infected with high-dose (2x107 CFU) M. tuberculosis (H37Rv) both 
showed inactivity, lethargy, decreased responsiveness to external stimuli and rough hair coats, 
although the signs were more apparent in diabetic mice. Moribund animals were found 
emaciated and their movement was diminished with a sign of dyspnoea. A dramatic fall in feed 
(Appendix 6, Figure A6.10) and energy intake (Figure 6.4 D) was recorded for diabetic mice 
until the second week of infection, whereas slight reduction of energy intake (Figure 6.4 D) was 
observed in control mice. After the second week pi, feed and energy intake increased gradually 
in both control and diabetic mice although some fluctuation was noticed during the last 3 weeks 
of the study period (Figure 6.4 D). Compared to the pre-infection values, a 35.92% reduction 
of energy intake/mouse/day was observed in diabetic mice, whereas a 13.89% increase was 
measured for control mice. A significant reduction in body weight loss was observed in diabetic 
mice during the first 3 weeks pi followed by a gradual loss until the end of the infection period 
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(Figure 6.4 E). In control mice, a slow reduction in the body weight was observed during the 
first few weeks of infection although it remained static in the subsequent weeks (Figure 6.4 E). 
An overall 52.56% and 10.65% body weight reduction was measured in diabetic and control 
mice respectively after 7 weeks of infection. Furthermore, the blood glucose level dropped 
sharply in the first 3 weeks of infection in both diabetic and control mice followed by a slightly 
rising trend which continued until the end of infection (Figure 6.4 F).  
 Survival of mice following mycobacterial infections 
In M. fortuitum infection with a dose of 1x107 CFU/mouse (low-dose), there was no mortality 
observed after 60 days post-infection (dpi) (Appendix 4, Figure A4.2). When the mice were 
infected with a high-dose (3x108 CFU/mouse) of the same bacteria, a higher mortality was 
found in diabetic mice compared to controls (Figure 6.5, A). After 14 dpi, 41.67% of the control 
and 20% of diabetic mice were survived although the difference was not statistically significant 
(p=0.0601).  
 
 
 
 
 
 
 
 
 
Figure 6.5 Survival of mice following mycobacterial infections 
Mice were infected with a high-dose of M. fortuitum (3x108 CFU/mouse), M. bovis BCG (2x106 
CFU/mouse) and M. tuberculosis (H37Rv, 2x107 CFU/mouse) to observe the survival of mice. 
Following infection, a lower survival (higher mortality) was observed in diabetic mice 
compared to control mice (A, B & C). The Kaplan Meier survival curves with Log-rank 
(Mantel-Cox) tests were used to compare susceptibility between the groups. A total of 14 
diabetic, 13 control mice were infected for M. fortuitum, 9 diabetic and 12 controls for M. bovis 
(BCG) and 12 diabetic and 10 controls for M. tuberculosis (H37Rv) study. The level of 
significance was indicated as *p≤0.05 and ns=non-significant.  
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In M. bovis (BCG, 1x106 CFU/mouse) and M. tuberculosis (H37Rv, 4x106 CFU/mouse) 
infection with a low-dose, there was no mortality observed in both diabetic and control mice 
after 35/30 dpi (data not shown). When the mice were infected with a high-dose M. bovis (BCG, 
2x106 CFU/mouse), a total of 70% of the diabetic mice were survived, whereas 92.31% control 
mice survived after 60 dpi (Figure 6.5 B). Similarly, a significantly lower survival of diabetic 
mice compared to controls infected with a high-dose of M. tuberculosis (H37Rv, 2x107 
CFU/mouse) was observed (control, 66.66 vs diabetic, 22.22, %, p=0.0246) (Figure 6.5 C). 
Overall, the survival of diabetic mice was lower compared to controls infected with a high-dose 
of mycobacteria. 
 Kinetics of organ bacterial load following mycobacterial infections 
 Organ bacterial load in M. fortuitum infected mice 
Diabetic mice infected with M. fortuitum (1x107 CFU/mouse), were less efficient in controlling 
organ bacterial loads compared to control mice (Figure 6.6). Overall, a high M. fortuitum load 
was observed in the organs of diabetic mice at 14 and 35 days post-infection (dpi) compared to 
controls. The M. fortuitum burden in the spleen of diabetic mice was 1.33 times higher at 1 dpi 
compared to controls albeit it was not statistically significant (Figure 6.6 A). A declining trend 
of M. fortuitum organ load was observed at the later timepoints of infection. The M. fortuitum 
burden in the spleen of diabetic versus control mice was significantly different at 35 dpi (Figure 
6.6 A) with diabetic mice showing 1.79 times higher load than control mice. There was no 
difference in the M. fortuitum burden in the liver at 1 dpi. However, the liver load in diabetic 
mice was 2 times higher at 14 dpi and 2.43 times higher at 35 dpi compared to controls (Figure 
6.6 B). There was no significant difference in M. fortuitum load in the lungs at 1 dpi (Figure 
6.6 C). However as observed for liver, the lung counts for diabetic mice were 4.26 times higher 
at 14 dpi and 3.69 times higher at 35 dpi compared to controls. An increasing trend of M. 
fortuitum burden was observed in kidneys following infection (Figure 6.6 D). Compared to 
controls, the kidney M. fortuitum counts at 14 and 35 dpi in diabetic mice were 2.93 and 5.42 
times  higher, respectively.  
Diabetic mice infected with high-dose (3x108 CFU/mouse) M. fortuitum, had higher counts at 
14 dpi than controls in all organs examined (Figure 6.6 D). Organ M. fortuitum burden was 6.51 
times higher in the spleen of diabetic mice compared to controls. In liver, the bacterial burden 
was 16.94 times higher in diabetic mice in comparison to control mice. Compared to controls, 
diabetic mice demonstrated a 14.79 and 3.78 times higher bacterial burden in lungs and kidneys, 
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respectively, although these were not statistically significant as only small group sizes were 
used for these high-dose experiments. 
 
 
Figure 6.6 Organ bacterial load following M. fortuitum infection 
Mice were infected with a dose of 1x107 CFU/mouse were sacrificed at 1, 14 and 35 days post-
infection (dpi). M. fortuitum load was higher in spleen (A), liver (B), lungs (C) and kidneys (D) 
of diabetic mice compared to controls at 14 and 35 dpi. Moreover, some moribund diabetic and 
control mice infected with a high-dose of M. fortuitum (3x108 CFU/mouse) were also sacrificed 
at 14 dpi to observe the organ bacterial load. In this group, bacterial load was also recorded 
higher in spleen, liver, lungs and kidneys of the diabetic mice compared to controls (D). Data 
were mean Log10 CFU±SEM; n=3-5 (low-dose) and 2-3 (high-dose) mice/group. The 
significance differences were determined using the independent sample t-test except a few non-
normally distributed data set (14 days organ load in liver and lungs), which were analysed using 
the Mann-Whitney U test (Appendix 4). The level of significance was indicated as *p≤0.05, 
**p≤0.01 and ns=non-significant. 
 
 Organ bacterial load in M. bovis (BCG) infected mice 
Mice infected with M. bovis (BCG) were culled at 1, 14 and 35 days post-infection (dpi) to 
determine the organ M. bovis (BCG) load in spleen, liver and lungs. Following infection, a 
gradual rise in the M. bovis (BCG) counts was observed in the spleen, liver and lungs of both 
diabetic and control mice followed by a decline at later timepoints (Figure 6.7 A, B & C). The 
M. bovis (BCG) counts in the spleen at 1 dpi were 1.23 higher in diabetic mice compared to 
controls (Figure 6.7 A). Similarly, at 14 dpi spleen counts were 2.55 times higher in diabetic 
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mice compared to controls. A decreasing trend in M. bovis (BCG) load was observed in the 
spleen at 35 dpi in both groups although it was 1.81 times higher in diabetic mice. In liver, the 
M. bovis (BCG) burden was 2.44 times higher in diabetic mice at 1 dpi although it did not reach 
significance (Figure 6.7 B). Compared to controls, diabetic mice had 3.40 and 6.10 times higher 
M. bovis (BCG) counts in the liver at 14 and 35 dpi, respectively. In the lungs, the highest M. 
bovis (BCG) counts was found at 14 dpi which was 2.23 times higher in diabetic mice compared 
to controls (Figure 6.7 C). At 35 dpi, the lung M. bovis (BCG) burden remained high in diabetic 
mice (2.88 times higher) compared to controls. Overall, a higher M. bovis (BCG) load was 
observed in organs of diabetic mice at 14 and 35 dpi compared to controls. These findings 
indicated that diabetic mice were less efficient in clearing M. bovis (BCG) from all organs 
compared to controls.  
 Organ bacterial load in M. tuberculosis (H37Rv) infected mice 
The counts of M. tuberculosis (H37Rv) in the spleen, liver and lungs of diabetic and control 
mice were determined at 1, 14 and 30 days post-infection (dpi). The trends for M. tuberculosis 
(H37Rv) burden in all organs were similar to those for M. bovis (BCG) (Figure 6.7). At 1 dpi, 
the spleen M. tuberculosis (H37Rv) counts were similar in control and diabetic mice (Figure 
6.7 D). Compared to controls, diabetic mice had 5.80 and 4.95 times higher spleen M. 
tuberculosis (H37Rv) burden at 14 and 30 dpi, respectively. A similar trend was observed in 
the liver organ bacterial load, where diabetic mice had 1.79 and 2.62 times higher M. 
tuberculosis (H37Rv) burden at 14 and 30 dpi, respectively (Figure 6.7 E). In lungs, the M. 
tuberculosis (H37Rv) load was 1.26 times higher in control mice at 1 dpi although this was not 
statistically significant. A continuous rise in the counts of M. tuberculosis (H37Rv) in the lungs 
of both diabetic and control mice was seen at later timepoints of infection (Figure 6.7 F). At 14 
and 30 dpi, the lung M. tuberculosis (H37Rv) load was 3.5 and 1.96 times higher in diabetic 
mice compared to controls, respectively. 
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Figure 6.7 Organ bacterial load following M. bovis (BCG) and M. tuberculosis (H37Rv) 
infections 
Mice were infected with M. bovis (BCG, 1x106 CFU/mouse) and M. tuberculosis (H37Rv, 
4x106 CFU/mouse) were sacrificed 1, 14 and 35/30 days post-infection (dpi). The M. bovis load 
was higher in spleen (A), liver (B), lungs (C) of diabetic mice compared to control at 14 and 35 
dpi. A similar trend of M. tuberculosis (H37Rv) load was observed in spleen (D) liver (E) and 
lungs (F) at the same timepoint of infection. Data presented as mean Log10 CFU±SEM; n=4-5 
mice/group. The significance differences were compared between groups using the independent 
sample t-test except for few non-normally distributed data sets. The non-normally distributed 
data were compared between groups using the Mann-Whitney U test (M. bovis, Appendix 5 and 
M. tuberculosis, Appendix 6). The level of significance was indicated as *p≤0.05, **p≤0.01, 
***p≤0.001 and ns=non-significant.  
 
 Discussion 
Susceptibility to TB can be increased by type 2 diabetes mellitus with diabetic patients having 
an overall threefold increased risk of developing active TB (Jeon and Murray, 2008). There is 
also increasing evidence that the risk of non-tuberculous mycobacterial infections is elevated 
in patients with diabetes (Bridson et al., 2016). In this study, we investigated whether diabetic 
mice showed increased susceptibility to both TB complex and NTM infection compared to 
control non-diabetic mice. We demonstrated that indeed diabetic mice are more susceptible to 
these infections with severely impaired glucose regulation during infection, increased bacterial 
loads in the lungs and other organs and increased mortality. 
Both low- and high-dose intravenous infections of M. fortuitum, M. bovis (BCG and M. 
tuberculosis (H37Rv) were used in this study. Low-dose infections were used to examine the 
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course of infection at 1, 14 and 30/35 days timepoints, whereas high-doses were used to 
determine mouse survival post-infection (pi). In the current Chapter, the metabolic parameters, 
mouse survival and organ mycobacterial loads following infections are described. Organ 
pathology and inflammatory cytokines are described in the following Chapters. 
Following infection with all mycobacteria species examined, energy intake, body weight and 
blood glucose levels were monitored during the course of infection. Control mice infected with 
low-dose M. fortuitum and M. bovis (BCG) showed a minimal reduction in overall energy intake 
pi with a slight increase in body weight (Figure 6.2, 6.3 A & B). Control mice were provided 
with a controlled amount of feed (4.5 g/day/mouse) during the pre-infection period, whereas 
feed was given ad libitum during the pi period. The feed and energy intake were calculated on 
a weekly basis to reduce the frequency of animal handling during the time of infection. The 
explanation for the slightly higher body weight in control mice despite the small reduction of 
dietary energy intake may be due to the sudden exposure to ad libitum feed supply. 
Furthermore, mice infected with either low or high-dose of M. tuberculosis (H37Rv) infection, 
the overall energy intake by the control mice was higher although an overall body weight 
reduction was observed (Figure 6.4 A, B, D & E). The lower body weight gain (1.56%) of 
control mice against their calculated higher energy intake (19.39%) in low-dose of M. 
tuberculosis (H37Rv) infection suggested a feed waste. These findings were further supported 
by the observation in low-dose of M. bovis (BCG) infection, where the body weight of control 
mice was almost constant although 31.33% energy intake reduction was determined (Figure 6.3 
A & B). However, control mice infected with the high-dose of mycobacteria lose more body 
weight which was contributed by both less energy intake and effect of the infections as mice 
were found lethargic during infection.  
In diabetic mice, an overall reduction of energy intake was recorded following both high or 
low-doses M. tuberculosis (BCG) and M. bovis (BCG) infection. The decrease in body weight 
pi reflected this diminished feed intake (Figure 6.3 and 6.4 A, B, D & E). Diabetic mice infected 
with low-dose M. fortuitum, increased their feed and energy intake during the pi period (Figure 
6.2 A). Mice on the EDD were provided with ad libitum feed during the pre-infection period 
and the amount consumed was determined weekly. The reason for the apparent higher feed 
intake may be due to feed wastage.  
A reduction in body weight in M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) 
infected mice was more noticeable in diabetic mice compared to control mice (Figure 6.2, 6.3 
and 6.4 B & E). As expected weight reduction was higher in high-dose than low-dose infections. 
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The greatest reduction in body weight was in M. tuberculosis (H37Rv) infected animals. This 
may be related to organism virulence or differences in infectious doses. The overall reduction 
in body weight in diabetic mice is likely due to the impact of infection on the desire for feed 
consumption. Anorexia is a typical feature of infection-induced sickness behavior. During the 
infection period diabetic mice displayed more severe lethargy and sickness compared to 
controls (Parti et al., 2005). 
Systemic blood glucose levels in diabetic animals decreased pi with low- and high-dose M. 
fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) (Figure 6.2, 6.3 and 6.4 C & F). This 
drop-in blood glucose level corresponded to the overall reduced energy intake and body weight 
reduction. The blood glucose also fell in control mice infected with high-dose M. fortuitum, M. 
bovis (BCG) and M. tuberculosis (H37Rv) infection although in low-dose infected control 
animals the level actually increased above the pre-infection level (0 week). The sudden upward 
shift in glucose in the control group may be explained by the introduction of the ad libitum 
rather than controlled feed supply. For both control and diabetic mice infected with high-dose 
M. fortuitum, M. bovis (BCG) or M. tuberculosis (H37Rv) infection, the blood glucose level 
fell in the first few weeks pi and this corresponded with lower energy intake, body weight loss 
and increased mortality during this period. At the later timepoints of the infection period blood 
glucose levels in both diabetic and control mice were restored to, or surpassed, pre-infection 
levels, suggesting that mice had started to recover from the infections. Martens and colleagues 
(2007) found no significant difference in blood glucose level between control mice and 
streptozotocin (STZ)-induced diabetic mice following an aerosolised infection with M. 
tuberculosis (Erdman). This finding contradicted the findings of the current study however 
differences in dose, route of infection and the diabetes model used may explain these 
differences.  
There was no difference in the 60 days survival of diabetic versus control mice infected with 
low-dose M. fortuitum (Appendix 4, Figure A4.2). Parti and colleagues (2005) found minimal 
mortality of BALB/c mice infected intravenously with 5x107 M. fortuitum/mouse. In our study, 
we used a M. fortuitum dose 5 times lower than the dose used by Parti and co-workers (2005). 
Increased mortality was observed at 14 dpi following high-dose M. fortuitum infection (Figure 
6.5 A). Parti and co-workers (2005) observed 40-50% mortality after 60 dpi when the mice 
were infected with 5x108 CFU/mouse. This observation was consistent with the findings of the 
current study, in which 58.53% mortality was recorded for control mice infected with 3x108 
CFU/mouse.  
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No mortality was recorded in either diabetic or control mice infected with low-dose M. bovis 
(BCG, 1x106 CFU) or M. tuberculosis (H37Rv, 4x106 CFU) over 30/35 dpi (data not shown). 
Other study reports similar findings for 100 days survival following M. bovis (BCG; 107 CFU) 
or M. tuberculosis (H37Rv; 105 CFU) intravenous infections in non-diabetic mice (Olleros et 
al., 2005), which supported the findings of this study. In contrast, Maeurer and colleagues 
(2000) showed some BALB/c mice infected intravenously with 3x106 M. tuberculosis 
succumbed to infection by 30 dpi with the majority of animals dead by 60 dpi. This finding 
supported the observations of high-doses M. bovis and M. tuberculosis infection, in which we 
observed a higher mortality of both diabetic and control mice by 60 dpi (Figure 6.5 B & C).  
Several previous studies have investigated the survival of diabetic animals during M. 
tuberculosis infections (Saiki et al., 1980, Podell et al., 2014, Cheekatla et al., 2016), although 
to our knowledge, no studies have investigated mortality during M. fortuitum and M. bovis 
(BCG) infections. An overall higher mortality was observed in diabetic mice infected with M. 
fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) (Figure 6.5 A, B & C). A recent study 
demonstrated that 100% of STZ+ NA-induced diabetic C57BL/6 mice infected with M. 
tuberculosis via the aerosol route, died after 10 months pi, whilst only 6.6% of the control mice 
died by this same timepoint (Cheekatla et al., 2016). Saiki and colleagues (1980) observed that 
60 days mortality of M. tuberculosis infected STZ-induced ICR diabetic mice was higher 
compared to controls (>90 vs 30%). In the guinea pig model of TB-diabetes comorbidity, the 
survival time of M. tuberculosis infected STZ-induced diabetic guinea pigs was decreased 
compared to controls (Podell et al., 2014). These authors reported that 60% diabetic guinea pigs 
died by 45 dpi (aerosolised M. tuberculosis) compared to 50% death of control animals over 
145 days. The early death of diabetic guinea pigs compared to diabetic mouse is likely to be 
due to differences in host-mycobacterial susceptibility, routes of infection, disease progression 
and immune responses (Gupta and Katoch, 2005, Ordway and Orme, 2011). Hodgson and 
colleagues (2013b) observed higher mortality in DID mice following infection with the 
intracellular Gram-negative Burkholderia pseudomallei. Overall, these previous studies support 
the findings of the current study with higher mortality in diabetic mice compared to controls. 
Studies on TB-T2D co-morbidity in humans showed that diabetics infected with TB have a 6.5-
7% (Oursler et al., 2002, Dooley and Chaisson, 2009), 12.2% (Wang et al., 2009) or 16% 
(Lindoso et al., 2008) higher chance of death compared to non-diabetic individuals.  
We also investigated the bacterial burden in different organs of diabetic and control mice 
following infection with M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv). Following 
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intravenous infection with all species, we observed a disseminated infection in both diabetic 
and control mice characterised by an initial increase in bacterial load in lungs, spleen and liver 
followed by a progressive reduction (Figure 6.6 and 6.7). The kinetics of M. fortuitum infection 
in our study was consistent with the trends described in previous reports (Parti et al., 2005, Silva 
et al., 2010). The M. fortuitum kinetics described in the current study were different from those 
reported by Orme and Collins (1983) for other NTM such as M. kansaii and M. avium, where 
a peak in bacterial burden was observed at 40 dpi. This difference may be due to the differences 
of surface lipid components of the cell wall and subsequent host recognition and responses by 
different NTM (Maeda et al., 2003, Honda et al., 2015). The kinetics of M. bovis (BCG) and 
M. tuberculosis (H37Rv) infection in the current study showed similar trends to those described 
previously (North and Izzo, 1993, North, 1995, Lagranderie et al., 1996, Beamer and Turner, 
2005, Singhal et al., 2011). A higher bacterial burden in organs was observed in M. tuberculosis 
(H37Rv) infected mice compared to M. bovis (BCG) infected mice (Figure 6.7). The organ 
bacterial burden decreased slowly from 14 dpi to 30 dpi in M. tuberculosis (H37Rv) infected 
mice compared to M. bovis (BCG) infected mice. In the current investigation, a 4 times higher 
infective dose was used in M. tuberculosis (H37Rv) infected mice compared to M. bovis (BCG) 
infected mice. A higher organ bacterial load in M. tuberculosis (H37Rv) infected mice 
compared to M. bovis (BCG) infected mice might be due to the dose difference. However, the 
growth and survival of the bacteria in organs also depends on the nature and virulence of the 
organism, as well as organism specific immune responses (North and Izzo, 1993, Fulton et al., 
2000, Sherman et al., 2004). Prior research demonstrated that mice infected with M. 
tuberculosis intravenously develop a chronic, progressive infection (North and Jung, 2004, 
Orme, 2005, Basaraba, 2008) with the presence of non-replicating bacilli (Munoz-Elias et al., 
2005) and that bacterial numbers do not change appreciably over a long period of time (Rhoades 
et al., 1997, Ordway and Orme, 2011). Mice can control M. bovis (BCG) load more efficiently 
than virulent M. tuberculosis (H37Rv) with M. tuberculosis more able to evade host bactericidal 
immune responses (North and Izzo, 1993, Fulton et al., 2000).  
One of the Aims (2) of this study was to compare the organ mycobacterial load in diabetic and 
control mice. We observed a significantly higher bacterial burden in the spleen, liver and lungs 
of diabetic mice compared to controls infected with M. fortuitum. M. bovis (BCG) and M. 
tuberculosis (H37Rv) at 14 and 30/35 dpi (Figure 6.6 and 6.7). Yamashiro and colleagues 
(2005) first observed a higher bacterial burden in the spleen, liver and lungs of STZ-induced 
diabetic mice compared to controls infected intravenously with M. tuberculosis (H37Rv) at 14 
and 35 dpi. A similar pattern of bacterial burden in spleen, liver and lungs was observed in 
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STZ-induced diabetic mice compared to controls when the mice were infected via the aerosol 
route with M. tuberculosis (H37Rv) (Cheekatla et al., 2016). A higher M. tuberculosis burden 
in lungs was observed in STZ-induced diabetic mice infected aerogenically by the prior 
research (Martens et al., 2007, Vallerskog et al., 2010). Sugawara and colleagues (2004) 
observed a higher bacterial burden in lungs and spleen of spontaneously induced GK/Jcl 
diabetic rats compared to controls infected aerobically with M. tuberculosis (kurono strain) at 
1, 3, 7 and 12 weeks of infection. A higher M. tuberculosis (kurono strain) burden was reported 
in the lungs and spleen of rats with T1D at 7 weeks of infection (Sugawara and Mizuno, 2008). 
In an STZ-induced pig model of TB-DM co-morbidity, a significantly higher bacterial burden 
was found in spleen, liver, lungs and lymph nodes of diabetic guinea pig compared to controls 
aerobically-infected with low-dose M. tuberculosis (H37Rv) at 30 dpi (Podell et al., 2014). 
Podell and colleagues (2014) also observed a higher organ bacterial load in mice with impaired 
glucose tolerance at 60 and 90 dpi compared to controls. Higher organ loads were demonstrated 
in DID mice infected with Burkholderia pseudomallei (Hodgson et al., 2011, Hodgson et al., 
2013b). All these observations are consistent with our findings and suggest that diabetic 
individuals are less efficient in controlling and clearing infections and hence more susceptible 
to mycobacterial infection compared to non-diabetic patients. Impaired phagocytosis and 
dysregulated secretion of key cytokines may explain this phenomenon (as described in Chapter 
5).  
In this study, we observed lower survival (higher mortality) of diabetic mice compared to 
controls in high-dose infections with M. fortuitum, M. bovis (BCG) and M. tuberculosis 
(H37Rv). When mice were infected with low-dose mycobacteria to determine the kinetics of 
infection, we observed higher organ bacterial loads in spleen, liver and lungs of diabetic mice 
compared to controls. The precise defects responsible for this increased susceptibility to 
mycobacterial infection remain unclear. In Chapter 7 we will describe the gross and histological 
changes that occur in organs during these mycobacterial infections and explore differences that 
may underlie this increased susceptibility. 
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7 CHAPTER 7  
EFFECT OF TYPE 2 DIABETES ON TISSUE INFLAMMATION DURING 
MYCOBACTERIAL INFECTIONS 
 
  Introduction 
Inflammation is essential to the control of microorganisms, but excessive or dysregulated 
inflammatory responses can disrupt the function of tissues. Mycobacterial infections, 
particularly M. tuberculosis infection, are accompanied by intense local (primarily in the lungs) 
and chronic responses which are critical to the disease pathogenesis (Toossi, 2000). Following 
infection with mycobacteria, the primary encounter is mediated by phagocytosis of bacilli by 
macrophages (Dheda et al., 2010). During this process, macrophages trigger inflammation via 
the secretion of various cytokine and chemokines for attracting more inflammatory cells to the 
sites of infection (Dheda et al., 2010, Cooper et al., 2011). These inflammatory mediators 
activate the adaptive immune responses and determine the fate of infection. With the intricate 
interplay between the host innate and adaptive immune cells, granulomas are formed (Saunders 
and Britton, 2007, Korbel et al., 2008) which are considered the hallmark of TB infections 
(Silva Miranda et al., 2012). Immune cells within the granuloma prevent further bacterial 
dissemination as well as reactivation of bacilli (Saunders and Cooper, 2000, Ehlers, 2009).  
Existing data suggest a role for inflammation in the pathogenesis of T2D which is now 
considered to be a chronic inflammatory disease characterised by an exaggerated and 
dysregulated inflammatory response. Components of the immune system are altered in obesity 
and T2D with the most significant changes occurring in adipose tissue, liver, pancreatic islet, 
the vasculature and in circulating leucocytes. Metabolic disturbances including impaired insulin 
secretion and sensitivity and resulting loss of glucose homeostasis are increasingly being 
attributed to the inflammatory process. Oxidative stress, lipid deposition in muscle, liver and 
pancreas, amyloid deposition in pancreas, lipotoxicity and glucotoxicity may induce an 
inflammatory response or are exacerbated by or associated with inflammation. Immune 
dysregulation in T2D is believed to play a significant role in the increased susceptibility of T2D 
individuals to infections (Hodgson et al., 2015).  
Type 2 diabetes is considered one of the most significant co-morbidities associated with 
increased TB susceptibility (Jeon and Murray, 2008, Martinez and Kornfeld, 2014). Effective 
protective immunity against TB appears to be lost in individuals with T2D as a consequence of 
their dysregulated inflammatory and immune response networks (Sasindran and Torrelles, 
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2011). Hence individuals with T2D may mount inappropriate immune responses against the 
invading organism that cannot control the bacterium or its dissemination and at the same time 
tissues may become damaged and dysfunctional.  
In the previous Chapters (5 and 6) of this thesis, it has been demonstrated that diabetic 
macrophage function is impaired, cytokines are dysregulated and diabetic hosts have increased 
susceptibility to mycobacterial infections compared to non-diabetic controls. What happens in 
tissues infected with mycobacteria is the subject of this Chapter.  
Other studies have identified higher inflammatory lesions in the lungs of streptozotocin 
(STZ)/STZ+NA (Nicotinamide) induced type 1 diabetic (T1D) mice compared to controls 
following aerosol infection with M. tuberculosis (Martens et al., 2007, Vallerskog et al., 2010, 
Cheekatla et al., 2016). Similarly, Sugawara and Mizuno (2008) and Sugawara and colleagues 
(2004) observed larger lung granulomas in T1D and T2D Goto Kakizaki (GK) rats following 
M. tuberculosis infection. Only lung pathology was examined in these studies, although 
extrapulmonary TB is also an important clinical manifestation in patients with TB (Knechel, 
2009). In a guinea pig model of diabetes induced by high-fat high-carbohydrate (HFHC)+STZ, 
lung and spleen inflammatory lesions were quantified at 30, 60 and 90 days post-infection (dpi) 
(Podell et al., 2014) although there was minimal detailed data regarding the size and numbers 
of granulomas in these tissues. The authors did not include any earlier timepoints. Many of the 
key immunological events that influence infection outcome and disease progression occur 
within 3-4 weeks of infections (Ordway and Orme, 2011), however, analysis of tissue 
inflammation at early timepoints post-infection is currently lacking.  
Previous research has shown that in immunocompetent individuals with TB infection, 
granulomas are small, compact and characterised by the presence of a signfiicant number of 
IFN-γ producing CD4T cells. In contrast to immunodeficient individuals, the TB granuloma is 
larger in size, rich in activated macrophages and with few surrounding lymphocytes. These 
granulomas are unable to effectively control and confine the infection (Ulrichs et al., 2005). 
One of the key reasons for tissue injury and clinical manifestations of pulmonary TB is the large 
caseating granuloma and fibrotic scarring which is also driven by granulomatous inflammation 
(Sasindran and Torrelles, 2011). There are controversies as to the impact of diabetes in the 
development of extrapulmonary TB. The relative risk of extrapulmonary TB progression is 
similar or less to that of non-diabetic patients (Long et al., 1997, Leung et al., 2008, Knechel, 
2009, Young et al., 2012). Clearly, there are many gaps in our knowledge of the precise 
relationships between diabetes and control of the tuberculosis organism within tissues. 
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We hypothesised that the reason for increased mortality and higher bacterial burden in organs 
of diabetic mice (Chapter 6) was due to dysregulated inflammation followed by 
defective/delayed granuloma formation. Therefore, in this Chapter, we studied the gross and 
histopathological lesions in lungs (pulmonary) and liver (extra-pulmonary) in diet-induced T2D 
mice during infections with M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv). 
Previous reports have indicated that in M. fortuitum infection, kidneys are one of the preferred 
niches above other organs (Saito and Tasaka, 1969, Parti et al., 2005). Therefore, kidneys were 
also included in the current study. The findings of this study will increase our understanding of 
the reasons for increased mycobacterial susceptibility in T2D patients with concomitant 
mycobacterial infections.  
The specific Aims of this research described in this Chapter are: 
1. To investigate the gross pathological changes in spleen, liver, lungs and kidney of T2D 
mice following infection with low- and high-dose M. fortuitum  
2. To evaluate the histopathological changes in liver, lungs and kidneys of T2D mice 
following infection with low- and high-dose M. fortuitum  
3. To assess the gross pathological changes in spleen, liver and lungs of T2D mice 
following infection with low-dose M. bovis (BCG) and M. tuberculosis (H37Rv) 
4. To measure the histopathological changes in liver and lungs of T2D mice following 
infection with low-dose M. bovis (BCG) and M. tuberculosis (H37Rv) 
 Materials and Methods 
 Animal Ethics and institutional approvals 
The details of animal ethics and institutional approvals are described in Chapter 3 (section 
3.1.1). 
 Experimental animals and induction of diabetes  
The details of experimental animals and induction of diabetes are described in Chapter 3 
(section 3.1.3) and Chapter 6 (section 6.2.2).  
 Preparation of mycobacterial culture for infection 
The details of the preparation of mycobacterial culture for infection are described in Chapter 3 
(section 3.3.2) and Chapter 6 (section 6.2.3.1).  
 166 
 Monitoring and culling of infected mice  
The details of monitoring and culling of infected mice are described in Chapter 6 (section 6.2.4).  
 Gross and histopathological examinations  
Following infection with M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv), mice 
were monitored once daily until the end of the study. Infected mice were sacrificed at 1, 14 and 
30 (for M. tuberculosis infection) or 35 days post-infection (dpi). The whole organs, namely 
spleen, liver, lungs and kidney (M. fortuitum only) were weighed, observed and photographed 
for the presence of gross lesions. For histopathological examination, liver (after removing 1 g 
for bacterial count), left lobe of lungs and both kidneys were collected in 10% neutral buffered 
formalin (NBF). Tissue sections; liver and lungs and kindneys (only for M. fortuitum infection 
study) were prepared from formalin fixed tissue for Haematoxylin and Eosin (H&E) staining 
(Chapter 3, section 3.5).  
The relative percentage of the inflamed area on the liver sections were quantified according to 
previously described methods (Flynn et al., 1998, Chambers et al., 2006, Silva et al., 2010). 
Briefly, the number of inflammatory foci/granulomas was counted on 10 continuous 
microscopic fields (200x magnification) per slide. The relative percent of inflamed area with 
liver sections was calculated by measuring the total area of the inflammatory foci/granulomas 
over the total area of 10 microscopic fields (Chapter 3, section 3.5.5). The inflamed area within 
the lungs was evaluated on representative lung sections according to previously published 
methods (Schneider et al., 2010, Kupz et al., 2016). In short, the total area of a representative 
section was measured on images captured using 4x objectives (40x magnification). The 
inflamed area was calculated on the same lung sections by capturing images using 10x 
objectives (100x magnification). Inflammatory lesions in the kidney sections were not 
quantified. The CellSens® Image Analysis software (Olympus) was used for digital 
photography and quantitative analysis of the tissue sections (Chapter 3, section 3.5.5).  
 Tissue Ziehl-Neelsen staining for localisation of bacteria 
Ziehl-Neelsen (ZN; acid-fast) staining of liver sections was performed at 14 and 30/35 days 
post-infection (dpi). Counting of acid-fast bacilli was done using previously published 
protocols (Chambers et al., 2006, Reynolds et al., 2009). In short, a representative liver section 
from each mouse was stained and visualised at 1000x magnification for counting the acid-fast 
bacilli within each of the inflammatory focus/granuloma. Individual ZN positive magenta 
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bacilli were counted in a total of first 10 positive inflammatory foci/ granulomas (presence of 
at least one bacterium) from each mouse section (Chapter 3, section 3.6).  
 Statistical analysis 
The details of the statistical analysis are described in Chapter 6 (section 6.3).  
 Results 
 Organ pathology following mycobacterial infections 
 Gross pathological findings in organs of M. fortuitum infected mice 
Thirty-five days after low-dose (1x107) M. fortuitum infection, diabetic mice were found 
inactive and lethargic compared to the control mice. Gross morphology at 35 days post-
infection (dpi) showed obvious splenomegaly and hepatomegaly in both controls (Figure 7.1 
A, B & C) and diabetic mice. (Figure 7.1 F, G & H). Spleen weight was 2.57 and 3.11 times 
higher than the initial weight at 1 dpi for diabetic and control mice, respectively (Figure 7.2 A). 
Liver weight increased gradually in diabetic and control mice at 14 and 35 dpi compared to the 
initial weight measured at 1 dpi (Figure 7.2 B). Lungs appeared larger in diabetic mice (Figure 
7.1 I) although lungs weight remained similar for both groups throughout the infection period 
(Figure 7.2 C). Kidneys from diabetic mice were noticeably paler and appeared distended 
compared to those from control mice (Figure 7.1 E & J). Kidney weight at 35 dpi was 
significantly higher than weight at 14 dpi (1.13 and 1.09 times higher for diabetic and control 
mice, respectively) (Figure 7.2 D).  
When mice were infected with high-dose (3x108) M. fortuitum, diabetic mice were observed to 
be more inactive and lethargic compared to control mice. Spleen, liver, lungs and kidneys were 
harvested from moribund mice at 14 dpi and weighed and observed for gross lesions. 
Splenomegaly was a common finding in both groups (Figure 7.3 B & G). Livers of both diabetic 
and control mice were enlarged and abscess-like lesions were found across the surface of liver 
lobes of both groups, although the numbers of lesions were higher in diabetic mice (Figure 7.3 
C & H). Congested, haemorrhagic foci and distended lungs were observed in both groups of 
mice (Figure 7.3 D & I). Kidneys of diabetic mice were found more distended and were 
extremely pale compared to controls (Figure 7.3 E & J). Moreover, in some diabetic mice, pus-
like semi-solid masses were revealed upon incision of the kidneys.  
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Figure 7.1 Gross pathological findings following low-dose M. fortuitum infection  
Mice infected with low-dose (1x107) M. fortuitum were sacrificed at 1, 14, 35 days post-
infection (dpi). Splenomegaly and hepatomegaly were evident in both control and diabetic mice 
at 14 (not shown in this figure) and 35 dpi. Images showed the dissection of a control mouse 
(A) at 35 dpi demonstrating splenomegaly (B), hepatomegaly (C), lungs (D) and distended 
kidney (E). Similar types of gross lesions were also observed in diabetic mice at 35 dpi (F, G, 
H, I & J).  
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Figure 7.2 Weight of organs following low-dose M. fortuitum infection  
Mice infected with low-dose (1x107) M. fortuitum were culled at 1, 14, 35 days post-infection 
(dpi). Spleen, liver, lungs and kidney (left) from both diabetic and control were weighed at all 
timepoints of infection. Splenomegaly (A) and hepatomegaly (B) were observed in both 
diabetic and control mice at 14 and 35 dpi. Lungs weight remained steady for both groups 
throughout the infection period (C). Moreover, an increasing trend of kidney weight was 
observed in both diabetic mice compared to controls (D). Data presented as mean±SEM; n=6-
10 mice/group. Significant differences between the groups were determined using the 
independent sample t-test except for few non-normally distributed data sets. The non-normally 
distributed data were analysed using the Mann-Whitney U test (Appendix 4). The level of 
significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001,****p≤0.0001 and ns=non-
significant. 
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Figure 7.3 Gross pathological findings following high-dose M. fortuitum infection 
Mice infected with high-dose (3x108) M. fortuitum were sacrificed at 14 days post-infection 
(dpi). Dissection of a control mouse was showing internal organs (A) along with marked 
splenomegaly (B), hepatomegaly (arrow indicates necrotic foci) (C), hemorrhagic and 
distended lungs (arrow indicates hemorrhagic foci) (D) and an enlarged kidney in control mice 
(E). Similar types of lesions were also observed in diabetic mice at the same timepoint of 
infection (F, G, H, I & J).  
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 Gross pathological findings in organs of M. bovis (BCG) infected mice 
Mice infected with 1x106 M. bovis (BCG) were sacrificed at 1, 14 and 35 days post-infection 
(dpi) and organs (spleen, liver and lungs) were weighed and visually observed for lesions. 
Splenomegaly and hepatomegaly was observed in both diabetic and control mice, however, 
there were no obvious lesions on the surface of the spleen and liver (Figure 7.4 A). The lungs 
of mice in both groups were found slightly congested and distended at 14 and 35 dpi (Figure 
7.4 A).  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 Gross pathological findings following M. bovis (BCG) infection  
Mice infected with 1x106 M. bovis (BCG) were culled at 1, 14, 35 days post-infection (dpi). 
Splenomegaly and hepatomegaly were evident in both control and diabetic mice at 14 (not 
shown in this figure) and 35 dpi (A). Weighing of the spleen and liver demonstrated a marked 
splenomegaly (B) and hepatomegaly (C) in diabetic and control mice at 14 and 35 dpi compared 
to controls. The lungs weight slightly increased in both diabetic and control mice at the later 
timepoint of infection compared to 1 and 14 dpi (D). Data presented as mean±SEM; n=4-10 
mice/group. The significant differences between the groups were determined using the 
independent sample t-test except for non-normally distributed data sets. The non-normally 
distributed data were analysed using the Mann-Whitney U test (Appendix 5). The level of 
significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-
significant. 
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Spleen and liver weights confirmed splenomegaly and hepatomegaly in both control and 
diabetic mice. (Figure 7.4 B & C). The highest weight increase of the spleen was recorded at 
14 dpi with spleen from diabetic and control mice weighing 2.53 and 1.67 times more than their 
initial weights at 1 dpi (Figure 7.4 B). The liver weight increased gradually in both diabetic and 
control mice over the infection period (Figure 7.4 C). At 35 dpi, the weight of the liver increased 
1.31 and 1.53 times in diabetic and control mice, respectively compared to the initial weight at 
1 dpi (Figure 7.4 C). Lungs weight had increased by 35 dpi compared to 1 dpi although this did 
not reach significance (Figure 7.4 D).  
 Gross pathological findings in organs of M. tuberculosis (H37Rv) infected mice 
Similar to M. fortuitum and M. bovis (BCG) infections, mice infected with 4x106 M. 
tuberculosis (H37Rv) were monitored once daily. Mice were culled and organs samples were 
collected at 1, 14 and 30 days post-infection (dpi). Splenomegaly, hepatomegaly and distention 
and congestion of the lungs were common observations at necropsy of both diabetic and control 
mice (Figure 7.5). An abscess-like lesion was found on the surface of livers of all diabetic mice 
(Figure 7.5 D). Spleen and liver weight confirmed splenomegaly and hepatomegaly in both 
control and diabetic mice. (Figure 7.5 E & F). The highest weight increase of the spleen was 
found at 14 dpi, where spleen weight was 2.65 and 5 times higher than the initial weight at 1 
dpi for diabetic and control mice, respectively. Liver weight increased gradually in diabetic 
mice although a decreasing trend was noticed for control mice after 14 dpi (Figure 7.4 F). At 
35 dpi, the weight of the liver increased 1.42 and 1.35 times in diabetic and control mice, 
respectively compared to the initial weight at 1 dpi. The weight of diabetic and control mice 
lungs remained steady throughout the infection period. Although an increase in lungs weight 
was observed in diabetic mice at 14 dpi, this did not reach significance (Figure 7.5 G).  
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Figure 7.5 Gross pathological findings following M. tuberculosis (H37Rv) infection  
Mice infected with 4x106 M. tuberculosis (H37Rv) were sacrificed at 1, 14, 30 days post-
infection (dpi). Splenomegaly and hepatomegaly were evident in both control and diabetic mice 
at 14 (A, B, C & D) and 35 dpi (not shown in this figure). In livers of all diabetic mice, abscess-
like (yellow arrows) whitish spots were seen (D). Lungs of both control and diabetic mice were 
found slightly distended at later timepoints (B & D). Spleen and liver weights demonstrated a 
marked splenomegaly (E) and hepatomegaly (F) in both diabetic and control mice at 14 and 35 
dpi. The lungs weight was remained steady throughout the infection period although a 
fluctuation was observed at 14 dpi in diabetic mice (G). Data presented as mean±SEM; n=5 
mice/group. The significant differences between the groups were determined using the 
independent sample t-test except for non-normally distributed data sets. The non-normally 
distributed data were determined using the Mann-Whitney U test (Appendix 6). The level of 
significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and ns=non-significant. 
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 Inflammatory lesions in liver following mycobacterial infections 
7.4.1.4.1 Inflammation in liver of M. fortuitum infected mice 
Following infection with low-dose M. fortuitum (Mft), histopathological examination revealed 
inflammatory cells and foci in the liver of both diabetic and control mice (Figure 7.7). At 1 day 
post-infection (dpi), a diffuse accumulation of inflammatory cells was observed in both diabetic 
and control groups (Figure 7.7 A & B). At 14 dpi, the number of inflammatory foci/granulomas 
was 2.21 times higher in diabetic mice than control mice (Figure 7.6 A and 7.7 C, D). The 
percent inflamed area in the liver was 2.78 times higher in diabetic mice compared to controls 
(Figure 7.6 B). At 35 dpi, a similar trend was observed for inflammatory foci/granuloma and 
percent inflamed area in the liver of diabetic mice compared to controls (Figure 7.6 A, B and 
Figure 7.7 E & F). The mean area of individual liver inflammatory focus at 14 and 35 dpi was 
higher in diabetic mice compared to controls (Figure 7.6 C and Figure 7.7 C, D, E & F).  
At high-dose of infection, severe inflammatory responses were observed in the liver of both 
diabetic and control mice at 14 dpi (Figure 7.8 E & F). The number of inflammatory 
foci/granulomas was 2.10 times higher in the liver of diabetic mice compared to controls 
(Figure 7.8 A). The percent area of inflammation in the liver was 1.92 times higher in diabetic 
mice compared to controls (Figure 7.8 B). Furthermore, slightly smaller inflammatory 
foci/granulomas were found in the liver of diabetic mice compared to control although it was 
not statistically significant (Figure 7.8 C).  
7.4.1.4.2 M. fortuitum in the inflammatory foci/granulomas 
Ziehl-Neelsen staining of 35 dpi liver sections of infected mice demonstrated a higher number 
of bacilli per inflammatory focus/granuloma for diabetic mice compared to controls (Figure 7.6 
D and Figure 7.7 G & H). Similar findings were noted in liver of diabetic and control mice 14 
dpi with high-dose of Mft infection (Figure 7.8 D, G & H).  
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Figure 7.6 Inflammatory lesions in liver following low-dose M. fortuitum infection 
H&E stained liver sections infected with low-dose M. fortuitum were used to assess the 
inflammatory lesions at 1, 14 and 35 days post-infection (dpi). Quantification of liver lesions 
demonstrated a significantly higher number of inflammatory foci (A) and percent inflamed area 
(B) in the liver of diabetic mice compared to control at both timepoints. The relative size of 
each inflammatory focus was higher in diabetic mice compared to controls (C). Ziehl-Neelsen 
staining demonstrated a higher number of acid-fast bacilli in each of inflammatory 
focus/granuloma of diabetic mice compared to controls (D). Data presented as mean±SEM, n=5 
mice/group. The significant differences between the groups were determined using the 
independent sample t-test (A, B & C) and Mann-Whitney U test (D) (Appendix 4). The level 
of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant.  
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Figure 7.7 Inflammatory lesions and acid-fast bacill in the inflammatory foci of liver 
following low-dose M. fortuitum infection 
H&E stained liver sections was used to assess the inflammation following infection with low-
dose (1x107) M. fortuitum. A diffuse infiltration of inflammatory cells was observed in the liver 
of both diabetic and control mice at 1 day post-infection (dpi) (A & B; arrow indicates 
inflammatory cells). Compared to controls, a higher number of inflammatory foci/granuloma 
formation (arrow and insert image) in the liver of diabetic mice was evident in both 14 (C & D) 
and 35 dpi (E & F). Ziehl-Neelsen staining demonstrated a higher bacillary burden in each 
inflammatory focus/granuloma in liver of diabetic mice compared to controls (G & H). Images 
are representative of n=5 mice/group. Magnification of photomicrographs: A-F; 200x (scale bar 
100 µm), insert images at 1000x (scale bar 20 µm). Images from other animals are in Appendix 
4, Figure A4.3-A4.6.  
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Figure 7.8 Inflammatory lesions and acid-fast bacill in the inflammatory foci of liver 
following high-dose M. fortuitum infection  
H&E stained liver sections infected with high-dose M. fortuitum were used to assess the 
inflammatory lesions at 14 days post-infection (dpi). Quantification of liver lesions 
demonstrated a significantly higher number of inflammatory foci/granulomas (A) and percent 
inflamed area in the liver of diabetic mice compared to controls (B). The relative size of each 
inflammatory focus/granuloma was slightly lower in diabetic mice compared to controls (C). 
Ziehl-Neelsen (ZN) staining showed the presence of higher number of acid-fast bacilli in each 
inflammatory focus/granuloma of liver of diabetic mice compared to controls (D). However, 
the photomicrographs demonstrated the inflammatory aggregates (arrow) on liver section of 
both control (E) and diabetic mice (F) at 14 dpi. ZN stained liver sections demonstrated the 
presence of acid-fast bacilli (magenta) in an inflammatory focus/granuloma in liver of control 
(G) and diabetic mice (H) at the same timepoint of infection. Magnification of 
photomicrographs: E-F; 200x (scale bar 100 µm) and G-H; 1000x (scale bar 20 µm). Data 
presented as mean±SEM; n=2-3 mice/group. The significant differences between the groups 
were determined using the independent sample t-test (A, B, C & D) (Appendix 4). The level of 
significance was indicated as ns=non-significant. Images from other animals are in Appendix 
4, Figure A4.11-A4.12.  
 178 
7.4.1.4.3 Inflammation in liver of M. bovis (BCG) infected mice 
Similar to M. fortuitum infection, histopathological examination revealed marked inflammation 
in the liver of M. bovis infected diabetic and control mice (Figure 7.9 D, E, F & G). At 1 day 
post-infection (dpi), a diffuse infiltration of inflammatory cells was observed in both diabetic 
and control groups (Appendix 5, Figure A5.2). The number of inflammatory foci/granulomas 
and inflamed area increased at later timepoints of infection (Figure 7.9 A & B). At 14 and 35 
dpi, the number of inflammatory foci/granulomas in the liver was higher in diabetic mice 
compared to controls (Figure 7.9 A, D, E, F & G). The percent area of inflammation in the liver 
was 1.83 and 1.32 times higher in diabetic compared to controls at both 14 and 35 dpi, 
respectively (Figure 7.9 B, D, E, F & G). Moreover, the mean area of each inflammatory 
focus/granuloma at 14 and 35 dpi were greater in the liver of diabetic mice compared to controls 
(Figure 7.9 C).  
7.4.1.4.4  M. bovis (BCG) in the inflammatory foci/granulomas 
The Ziehl-Neelsen staining of the liver sections demonstrated the presence of higher number of 
bacilli in each of the inflammatory focus/granuloma of diabetic mice at both 14 and 35 days 
post-infection (dpi) compared to controls (Figure 7.10 A, B & C). This was not however 
statistically significant. Inflammatory cells in the foci/granulomas in liver of diabetic mice 
appeared to be more diffuse and less compact than those of control mice (Figure 7.10 B & C; 
dotted line indicates the area of a granuloma/inflammatory focus). In diabetic mice, bacilli were 
not only localised within the inflammatory foci/granuloma but were also found dispersed 
throughout the liver parenchyma and within cells (Figure 7.10 D). This localisation was quite 
different to what was observed for control mice, in which the majority of bacteria appeared to 
be contained within inflammatory foci (Figure 7.10 B). In diabetic liver, a higher number of 
bacilli was observed per infected cell compared to control liver, although bacilli/cell were not 
directly quantified (Figure 7.10 E).  
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Figure 7.9 Inflammatory lesions in liver following M. bovis (BCG) infection  
H&E stained liver sections infected with low-dose M. bovis (BCG) were used to assess the 
inflammatory lesions at 1, 14 and 35 days post-infection (dpi). Quantification of liver lesions 
at 14 and 35 dpi demonstrated a higher number of inflammatory foci/granulomas (A) and 
percent inflamed area (B) in the liver of diabetic mice compared to controls. The relative size 
of each inflammatory focus/granuloma was higher in diabetic mice compared to controls (C). 
Photomicrographs of the liver sections demonstrated inflammatory foci/granulomas at 14 (D & 
E) and 35 dpi (F & G) in diabetic and control mice. Magnification of photomicrographs: D-G; 
200x (scale bar 100 µm). Data presented as mean±SEM; n=5 mice/group. The significant 
differences between the groups were determined using the independent sample t-test (A, B, & 
C) (Appendix 5). The level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-
significant. Images of other animals are given in Appendix 5, Figure A5.2-A5.4. 
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Figure 7.10 Acid-fast bacilli in inflammatory foci of M. bovis (BCG) infected mice 
The Ziehl-Neelsen staining of liver sections infected with M. bovis (BCG) was performed at 1, 
14 and 35 days post-infection (dpi). Quantification of the acid-fast bacilli demonstrated a higher 
number of M. bovis (BCG) in each inflammatory focus/granuloma in liver section of diabetic 
mice compared to controls (A). The photomicrographs demonstrated a relatively well-organised 
inflammatory or granuloma (demarcated by a dotted line) in the liver section of control mice 
with a lower number of bacilli (B). Whereas inflammatory cells in the granuloma/inflammatory 
foci of diabetic mice were loosely associated with a higher number of bacilli (C). In liver section 
of diabetic mice, bacilli were found more scattered across the liver parenchyma (outside of the 
granuloma/inflammatory foci) (D) and a higher number of the bacilli were also found in each 
infected cell (E). Magnification of photomicrographs: B-E; 1000x (scale bar 200 µm). Data 
presented as mean±SEM; n=4-5 mice/group. The significant differences between the groups 
were determined using the Mann-Whitney U test (A) (Appendix 5). The level of significance 
was indicated as ns=non-significant. Images from other animals are in Appendix 5, Figure 
A5.5-A5.6. 
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7.4.1.4.5 Inflammation in liver of M. tuberculosis (H37Rv) infected mice 
In M. tuberculosis (H37Rv) infection, a strong inflammatory response was observed in the liver. 
At 1 day post infection (dpi), accumulation of inflammatory cells was evident throughout the 
liver sections of both diabetic and control mice (Appendix 6, Figure A6.2). This was similar to 
M. fortuitum and M. bovis (BCG) infection. At 14 dpi, there was no significant difference in 
the number of inflammatory foci/granulomas formation in the liver of diabetic mice compared 
to controls (Figure 7.11 A, D & E). The inflamed area was 1.38 times higher in the liver of 
diabetic mice compared to the control mice at the same timepoint (Figure 7.11 B, D & E). At 
30 dpi, the number of inflammatory foci/granulomas in liver was higher in diabetic mice 
compared to controls although this was not statistically significant (Figure 7.11 A, F & G). 
Diabetic mice had 1.32 times higher inflamed area in the liver of diabetic mice compared to 
controls at 30 dpi (Figure 7.11 B, F & G). The area of each inflammatory focus/granuloma was 
greater in diabetic mice at both 14 and 30 dpi (Figure 7.11 C).  
7.4.1.4.6 M. tuberculosis (H37Rv) in the inflammatory foci/granuloma 
Similar to M. fortuitum and M. bovis (BCG) infection, a higher number of bacilli per 
inflammatory focus/granuloma of the liver of diabetic mice were observed at both 14 and 30 
dpi compared to controls (Figure 7.12 A, B & C). Similar to M. bovis (BCG) infection, the 
inflammatory cells involved in the formation of foci of inflammation/granuloma were more 
loosely associated in diabetic mice compared to control mice at both timepoints of infection 
(Figure 7.12 B & C). The bacilli were also seen dispersed in the liver parenchyma of diabetic 
mice compared to control (Figure 7.12 D). A higher number of bacilli were observed per 
infected cell compared to control, although bacilli/cell were not directly quantified (Figure 7.12 
E).  
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Figure 7.11 Inflammatory lesions in liver following M. tuberculosis (H37Rv) infection  
H&E stained liver sections infected with low-dose M. tuberculosis (H37Rv) were used to assess 
the inflammatory lesions at 1, 14 and 30 days post-infection (dpi). Quantification of liver lesions 
at 14 and 30 dpi demonstrated that there was no significant different in number of inflammatory 
foci/granulomas in liver of diabetic mice compared to controls (A). The percent inflamed area 
in the liver was higher in diabetic mice compared to controls at the same timepoints of infection 
(B). The relative size of each inflammatory focus/granuloma on liver section was found higher 
in diabetic mice comparted to controls at both timepoints of infection (C). The 
photomicrographs of liver sections demonstrated inflammatory area at 14 (D & E) and 35 dpi 
(F & G) in diabetic and control mice. Magnification of the photomicrographs: D-G; 200x (scale 
bar 100 µm). Data presented as mean±SEM; n=5 mice/group. The significant differences 
between the groups were determined using the independent sample t-test (A & B), Mann-
Whitney U test (C) (Appendix 6). The level of significance was indicated as *p≤0.05 and 
ns=non-significant. Images from other animals are in Appendix 6, Figure A6.2-A6.4. 
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Figure 7.12 Acid-fast bacilli in the granuloma of M. tuberculosis (H37Rv) infected mice 
The Ziehl-Neelsen staining of liver sections infected with M. tuberculosis (H37Rv) was 
performed at 1, 14 and 30 days post-infection (dpi). Quantification of acid-fast bacilli 
demonstrated a higher number of M. tuberculosis (Mtb) in each inflammatory focus/granuloma 
from diabetic mice compared to control mice at both 14 and 30 dpi. Photomicrographs 
demonstrated a relatively well-organised granuloma/inflammatory foci in the liver section of 
control mice with a lower number of bacilli (magenta) (B). Whereas inflammatory cells in 
inflammatory foci/granulomas of the diabetic mice were more loosely associated with a higher 
number of bacilli (C). In liver section of diabetic mice, bacilli were also found more disperse 
(outside of inflammatory focus/granuloma) (D). A higher number of bacilli was found in each 
infected cell of diabetic mice comparted to controls (E). Magnification of the 
photomicrographs: B-E; 200x (scale bar 100 µm). Data presented as mean±SEM; n=4-5 
mice/group. The significant differences between the groups were determined using the Mann-
Whitney U test (14 dpi) and the independent sample t-test (30 dpi) (Appendix 6). The level of 
significance was indicated as *p≤0.05, and ns=non-significant. Images from other animals are 
in Appendix 6, Figure A6.5-A6.6. 
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 Inflammatory lesions in lungs following mycobacterial infections 
7.4.1.5.1 Inflammation in lungs of M. fortuitum infected mice 
Lung sections from diabetic and control mice infected with low-dose (1x107) M. fortuitum 
showed a marked inflammatory response (Figure 7.13 A, C, D, E & F). At 1 day post-infection 
(dpi), a diffuse accumulation of inflammatory cells was observed in both diabetic and control 
groups (Appendix 4, Figure A4.7). At 14 dpi, the inflamed area in the lungs was 1.38 times 
more in diabetic mice compared to controls although this difference was not significant (Figure 
7.13, A, C & D). At 35 dpi, diabetic mice had a significantly 1.21 times higher inflamed lung 
area compared to control mice (Figure 7.13 A, E & F).  
When the mice were infected with high-dose (3x108) M. fortuitum, extensive inflammation was 
observed in the lungs of both diabetic and control mice (Figure 7.13 B, G & H). Compared to 
control mice, diabetic mice had a 1.29 times higher inflamed area across the lung sections at 14 
dpi (Figure 7.13 B).   
7.4.1.5.2 Inflammation in lungs of M. bovis (BCG) infected mice 
Examination of H&E stained lung sections from M. bovis infected mice revealed similar 
findings as those of M. fortuitum infection, with inflammation in both diabetic and control lungs 
(Figure 7.14). A diffuse accumulation of inflammatory cells was observed in both diabetic and 
control groups at 1 day post-infection (dpi) (Figure 7.14 B & C). At 14 dpi, diabetic mice had 
1.65 times higher inflamed area across the lung sections compared to controls (Figure 7.14 A, 
D & E). A similar trend was observed at 35 dpi where diabetic mice had a 1.12 times more 
inflamed area in lungs compared to controls (Figure 7.14 A, F & G).  
7.4.1.5.3  Inflammation in lungs of M. tuberculosis (H37Rv) infected mice 
A strong inflammatory response was also evident in M. tuberculosis (H37Rv) infected mice 
(Figure 7.15). At 1 day post-infection (dpi), a diffuse inflammatory infiltrate was observed in 
the lungs of diabetic and control mice (Figure 7.15 B & C). Compared to controls, diabetic mice 
demonstrated a 1.43 times higher inflamed area across the lungs at 14 dpi (Figure 7.15 A, D & 
E). A similar trend was observed at 30 dpi (Figure 7.15 A, F & G).  
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Figure 7.13 Inflammatory lesions in lungs following M. fortuitum infection  
H&E stained lung sections of diabetic and control mice infected with low-dose (1x107) M. 
fortuitum were assessed for inflammation at 1, 14 and 35 days post-infection (dpi). Some 
moribund animals infected with high-dose (3x108) M. fortuitum were considered to quantify 
the lung lesions at 14 dpi. Quantification of the lungs lesions demonstrated a significantly 
higher inflamed area in lungs of diabetic mice compared to controls infected with low-dose of 
bacteria at both 14 and 35 dpi (A). Mice infected with a high-dose of bacteria showed a similar 
trend of inflammation in lungs at 14 dpi (B). Photomicrographs were representing the inflamed 
area in lungs at 14 (C & D) and 35 dpi (E & F) of mice infected with a low-dose of M. fortuitum 
and 14 dpi (G & H) of high-dose group. Magnification of photomicrographs: C-H; 40x (scale 
bar 500 µm). Data presented as mean±SEM; n=5 (low-dose) and 2-3 (high-dose) mice/group. 
The significant differences between the groups were determined using the independent sample 
t-test (Appendix 4). The level of significance was indicated as **p≤0.01 and ns=non-
significant. Images from other animals are in given in Appendix 4, Figure A4.7-A4.9 and 
A4.13. 
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Figure 7.14 Inflammatory lesions in lungs following M. bovis (BCG) infection  
H&E stained lung sections of diabetic and control mice infected with low-dose M. bovis (BCG) 
were assessed for inflammation at 1, 14 and 35 days post-infection (dpi). Quantification of the 
lesions demonstrated a significantly higher inflamed area in lungs of diabetic mice compared 
to controls at both 14 and 35 dpi (A). The photomicrographs represented the inflamed area in 
lungs of diabetic and control mice at 1 (B & C) 14 (D & E) and 35 dpi (F & G). Magnification 
of the photomicrographs: B-C; 100x (scale bar 200 µm) and D-G; 40x (scale bar 500 µm). Data 
presented as mean±SEM; n=5 mice/group. The significant differences between the groups were 
determined using the independent sample t-test (Appendix 5). The level of significance was 
indicated as *p≤0.05. Images from other animals are in Appendix 5, Figure A5.7-A5.9. 
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Figure 7.15 Inflammatory lesions in lungs following M. tuberculosis (H37Rv) infection  
H&E stained lung sections of diabetic and control mice infected with low-dose M. tuberculosis 
(H37Rv) were assessed for inflammation at 1, 14 and 30 days post-infection (dpi). 
Quantification of the lesions demonstrated a significantly higher inflamed area in lungs of 
diabetic mice compared to controls (A). The photomicrographs represented the inflamed area 
in lungs of diabetic and control mice at 1 (B & C) 14 (D & E) and 30 dpi (F & G). Magnification 
of the photomicrographs: B-C; 100x (scale bar 200 µm) and D-G; 40x (scale bar 500 µm). Data 
presented as mean±SEM; n=5 mice/group. The significant differences between the groups were 
determined using the independent sample t-test (Appendix 6). The level of significance was 
indicated as *p≤0.05 and **p≤0.01. Images from other animals are in Appendix 6, Figure A6.7-
A6.9. 
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 Inflammation in kidneys of M. fortuitum infected mice 
Histopathological examination of kidney sections of mice infected with low-dose of M. 
fortuitum demonstrated a gradual increase in inflammatory cells in both the cortex and 
medullary regions of kidneys of both diabetic and control mice (Figure 7.16 A, B, C, D, E & 
F). Inflammation was increased at 35 dpi compared to 14 dpi. The numbers of inflammatory 
cells appeared higher in the kidneys of diabetic mice compared to the controls, although 
inflammatory lesions were not quantified directly. Granuloma-like structures were 
predominantly observed in the kidneys of diabetic mice at 35 dpi (Figure 7.16 E & F).  
In mice infected with high-dose M. fortuitum inflammatory infiltrates were found in the cortex 
and medullary regions of kidneys of both diabetic and control mice at 14 dpi. (Figure 7.16 G & 
H). Granuloma like structures and hypertrophy of the glomeruli were mainly observed in 
diabetic mice compared to controls, albeit lesions were not quantified. 
As kidneys are known to be one of the initial organs affected following M. fortuitum infection, 
they were collected for analysis for this species only. Kidney samples of mice infected with M. 
bovis (BCG) and M. tuberculosis (H37Rv) were not considered as they are not under the area 
interest of this investigation. 
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Figure 7.16 Inflammatory lesions in kidneys following M. fortuitum infection  
H&E stained kidney sections were used to assess kidney inflammation. Mice infected with low-
dose (1x107) M. fortuitum showed inflammatory infiltrates in kidneys. More inflammation 
(arrow indicated inflammatory infiltrates) was observed in kidneys of diabetic mice at 1 (A & 
B), 14 (C & D) and 35 days post-infection (dpi) (E & F) compared to controls, although lesions 
were not quantified. Diabetic mice infected with high-dose (3x108) M. fortuitum had marked 
kidney inflammation including large granuloma-like structures (G & H). Magnification of 
photomicrographs: A-H; 200x (scale bar 100 µm). 
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 Discussion 
In Chapter 6 we investigated the susceptibility of diabetic mice to mycobacterial infections. 
Following M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) infections, we observed 
alterations in metabolic parameters, higher mortality and increased bacterial burden in the 
spleen, liver and lungs of diabetic mice compared to non-diabetic mice. Bacterial infection of 
tissues leads to inflammatory responses with the aim of effective control of bacterial replication. 
In mycobacterial infections, the granuloma plays an important role in killing and containment 
of the organism. In this Chapter, we examined the gross changes to organs and tissue 
inflammation in diabetic and control mice infected with M. fortuitum, M. bovis (BCG) and M. 
tuberculosis (H37Rv). Furthermore, the bacillary burden in each granuloma/inflammatory foci 
was quantified during infection. This study showed that inflammation was exaggerated and the 
structure of the mycobacterial granuloma altered in diabetic hosts.  
Following infection with M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) 
infections, splenomegaly and hepatomegaly were common observations in both diabetic and 
control mice (Figure 7.1-7.5). Diabetic mice infected with M. fortuitum (high-dose) and M. 
tuberculosis (H37Rv) showed abscess-like lesions and significant distention and congestion of 
the lungs (Figure 7.3 and 7.5). Histological examination demonstrated inflammation in liver 
(Figure 7.6-7.9 and 7.11) and lungs (Figure 7.13, 7.14 and 7.15) of both diabetic and control 
mice. In liver, diffuse inflammatory infiltrates were evident following M. fortuitum, M. bovis 
(BCG) and M. tuberculosis (H37Rv) infections. The inflammatory aggregates increased in mice 
during the infection period. Ziehl-Neelsen staining of liver sections also demonstrated the 
presence of higher numbers of bacilli per inflammatory focus/granuloma in diabetic mice 
compared to controls (Figure 7.6-7.8, 7.10 and 7.12). Previous studies in animal models have 
described poorly structured inflammatory aggregates early in mycobacterial infection. Whereas 
the granulomatous response becomes more conspicuous later in the course of infection (Ueda 
et al., 1972, Parti et al., 2005, Silva et al., 2010, Singhal et al., 2011). Silva and colleagues 
(2010) showed that the number of granulomas and their relative size increased at 14, 28 and 60 
dpi during M. fortuitum and M. avium intracellulare infection in BALB/c mice. A higher 
number of inflammatory foci containing a higher number of M. bovis per aggregate were found 
at 27 and 117 dpi compared to 2 and 14 dpi (Chambers et al., 2006). These observations were 
in line with the findings of the current study in which we observed a higher number of 
inflammatory foci with a higher number of acid-fast bacilli at later timepoints.  
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Similar to the inflammatory lesions in the liver, diffuse inflammation was seen in lungs early 
in infection with increasing number of lesions observed at later in infection (Figure 7.13-7.15). 
Rhoades and co-workers (1997) demonstrated a gradual progression of pulmonary lesions in 
mice infected with M. tuberculosis. Another study using M. bovis infected mice demonstrated 
increased numbers of inflammatory lesions at 27 dpi compared to 1 dpi (Chambers et al., 2006). 
These findings are consistent with the current study in which the inflammatory or 
granulomatous response in lungs was more evident in later timepoints. Previous investigators 
have characterised and enumerated specific cell types during the establishment of the 
mycobacterial granuloma in order to more fully understand the respective roles of immune cells 
in protective immunity and immunopathogenesis (Rhoades et al., 1997, Parti et al., 2005, 
Chambers et al., 2006, Costa et al., 2010). A detailed characterisation of lung-infiltrating cells 
was beyond the scope of the current study, however, future studies examining the cell 
phenotypes and numbers and detailed kinetics of lung inflammation in diabetic versus non-
diabetic mice may elucidate the cellular defects influencing the antimycobacterial immunity in 
diabetic animals.  
Previous reports documented that the kidney is a preferred niche for M. fortuitum growth (Saito 
and Tasaka, 1969, Parti et al., 2005). We examined the kidneys of M. fortuitum infected diabetic 
and control mice, determined the bacterial load in kidneys (Chapter 6) and examined H&E 
stained sections for inflammatory changes. We observed pale and distended kidneys in the 
diabetic mice infected with low-dose M. fortuitum (Figure 7.1 E & J). In animals receiving 
high-dose M. fortuitum, similar lesions were observed but in addition pus-filled kidneys were 
revealed upon incision (Figure 7.3 E & J). These findings were consistent with the previous 
reports (Saito and Tasaka, 1969, Parti et al., 2005). Histological staining revealed apparently 
higher inflammatory infiltrates in kidneys of diabetic mice compared to control (Figure 7.16 A, 
B, C, D E & F). Granuloma like inflammatory aggregates was also seen in the kidney sections 
of diabetic mice infected with a high-dose of M. fortuitum (Figure 7.16 H). Parti and his 
colleagues (2005) observed white spots on the external surface of the kidneys and renal 
enlargement in BALB/c mice infected with M. fortuitum. The authors also reported clustering 
of inflammatory aggregates in the interstitial tissue and abscess formation in the renal 
parenchyma of the kidneys at 15 dpi. A granuloma-like structure with densely packed 
lymphocytes surrounded by the fibrous tissue was also described by the same authors at 30 dpi. 
It is worth mentioning that during characterisation of the T2D mouse model (Chapter 4), we 
found features of nephropathy (section 4.4.2.4.). Precisely how pre-existing renal impairment 
compromised immunity to M. fortuitum is unclear. However, our initial findings showing renal 
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functional impairment in our T2D model will be a useful baseline for future studies on the 
influence of T2D on non-mycobacterial and tuberculous kidney infections.  
The primary Aims of the current study (Aim 2 to 4) were the quantification of inflammatory 
lesions in liver and lungs of diabetic and control mice infected with M. fortuitum, M. bovis 
(BCG) and M. tuberculosis (H37Rv). Increased areas of inflammation were observed in the 
liver of diabetic mice compared to controls following infection with M. fortuitum (Figure 7.6 B 
and 7.8 B), M. bovis (BCG) (Figure 7.9 B) and M. tuberculosis (H37Rv) (Figure 7.11 B). The 
number (Figure 7.6 A, 7.8 A, 7.9 A and 7.11 A) and size (Figure 7.6 C, 7.9 C and 7.11 C) of 
inflammatory foci/granulomas were also increased in diabetic mice. Furthermore, we observed 
higher number of acid-fast bacilli per inflammatory focus/granuloma in diabetic mice (Figure 
7.6 D, 7.8 D, 7.10 A and 7.12 A). The cells involved in the formation of inflammatory 
foci/granuloma in diabetics were loosely associated, resulting in diffuse cellular aggregates of 
increased size. This contrasted with the more compact lesions observed in liver sections from 
control mice (Figure 7.7 G & H, 7.10 B & C and 7.12 B & C). In diabetic mice, bacilli were 
also found scattered throughout the liver parenchyma and we observed higher number of bacilli 
per cell (Figure 7.10 D, E and 7.12 D, E). Only a few previous studies using T1D and T2D rat 
models have reported large granulomas in the liver and other organs in M. tuberculosis infection 
(Sugawara et al., 2004, Sugawara and Mizuno, 2008). The findings of our study are consistent 
with these previous studies. However, a higher number of bacilli in the inflammatory 
foci/granulomas in liver of diabetic mice indicated higher bacillary burden (Chapter 6). These 
findings further suggested that diabetic mice were less efficient in arresting and controlling the 
bacilli, resulting in a defective or delayed granuloma formation. Another important 
extrapolation of these findings may be that due to the loose, unorganised nature of the diabetic 
granuloma, granuloma breakdown may readily occur in diabetics with latent TB infection, 
resulting in more frequent reactivation events.  
In lungs, we observed increased numbers of inflammatory lesions in diabetic mice compared to 
controls infected with M. fortuitum (Figure 7.13), M. bovis (BCG) (Figure 7.14) and M. 
tuberculosis (H37Rv) (Figure 7.15). Several studies quantified the inflammatory lesions in 
lungs of STZ/STZ+NA- induced diabetic animal models following infection with M. 
tuberculosis. Martens and colleagues (2007) observed a gradual rise of inflammatory lesions in 
the lungs of STZ-induced diabetic mice suffered from an acute (4 weeks) to chronic (8 and 16 
weeks) M. tuberculosis (Erdman) infection. This research group also demonstrated a higher 
inflamed area in chronic infection in comparison to acute infection. In this study, mice were 
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infected intravenously which resulted in a rapid dissemination of the mycobacteria in lungs 
which might be a probable reason for higher inflammatory lesions development at 4-5 weeks 
of infection (acute). In a guinea pig model of TB-DM co-morbidity, a significantly higher 
inflamed area was detected in the of lungs of diabetic mice compared to controls at 30 dpi with 
a low-dose of M. tuberculosis infection (Podell et al., 2014). A higher lung inflammatory score 
was observed in STZ+NA-induced diabetic mice compared to controls at 6 months pi with M. 
tuberculosis (Cheekatla et al., 2016). Findings of this study were in agreement with the previous 
studies described above. Higher inflammation in lungs of diabetic mice indicates higher 
bacterial burden (Chapter 6) due to failure to control and confined the bacilli in the 
inflammatory foci/granuloma. Studies in human TB patients have shown that 
immunocompetent patients develop small, compact lung granulomas containing a large number 
of IFN-γ producing CD4 T cells, whereas immunocompromised patients, tend to have larger 
granulomas that are rich in macrophages but containing few lymphocytes (Ulrichs et al., 2005, 
Sasindran and Torrelles, 2011). In human tuberculosis, one of the reasons for tissue damage is 
the presence of large caseating granulomas with areas of central necrosis and fibrotic scarring 
driven by chronic granulomatous inflammatory responses (Sasindran and Torrelles, 2011). 
Whereas murine model of tuberculosis, granulomas are formed by loose non-necrotic cellular 
aggregates, lymphocytes, but lacking the encapsulation seen in human tuberculosis granulomas 
(Gupta and Katoch, 2005). Although replicating the human tuberculosis granuloma in a mouse 
model is challenging, the study of cellular involvement in this T2D model by future research 
will further extend our understanding in immunopathology in this co-morbid infection.  
Overall, increased liver and lung inflammation in diabetic mice compared to controls suggested 
impaired control of M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) infection and 
furthermore indicated aberrant inflammation may indeed be responsible for increased infection 
susceptibility and mortality was seen in diabetic mice. This increased inflammation is likely to 
drive by the higher bacillary load (Chapter 6) which was further confirmed by the presence of 
increased numbers of acid-fast bacilli in each inflammatory focus/granuloma. In this study, we 
found inflammatory cells involved in the formation of granuloma were more loosely associated 
along and bacteria were scattered throughout the liver parenchyma in diabetic mice. These 
findings indicated that diabetic mice were less efficient in arresting and controlling the bacilli 
resulting in a defective or delayed formation of granuloma. Exaggerated inflammatory 
responses as seen here in diabetic mice may also impair mycobacterial phagocytosis, leading to 
impaired and dysregulated cytokine production as shown in our in vitro study (Chapter 5). Pro- 
and anti-inflammatory cytokine networks play key roles in protective immunity in 
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mycobacterial infections (Cooper, 2009, Cooper et al., 2011). Examining whether cytokine 
production is dysregulated in infected diabetic animals may advance our understanding of the 
reasons for increased bacterial burden and inflammatory responses and abnormal granuloma 
formation in diabetics in mycobacterial infections. Hence, in Chapter 8, we will determine and 
discuss the role of different pro- and anti-inflammatory cytokines in our T2D model following 
mycobacterial infections.  
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8 CHAPTER 8  
EFFECT OF TYPE 2 DIABETES ON CYTOKINE PRODUCTION IN 
MYCOBACTERIAL INFECTIONS 
 
 Introduction 
Cytokines orchestrate the immune response in host-mycobacterial infections. Diverse cells 
involved in mediating the innate and adaptive immune response following mycobacterial 
infections secrete various pro-inflammatory (e.g. TNF-α, MCP-1, IL-1β, IL-18, IL-12, IL-17, 
IFN-γ, IL-6, IL-2) and anti-inflammatory cytokines (e.g. IL-10, IL-4, TGF-β) (Cooper, 2009, 
Cooper et al., 2011). The cytokine networks and combinations involved in mycobacterial 
immunity are complex, however certain cytokines have been identified in both human studies 
and animal models as key mediators of anti-TB immunity. Previous research has highlighted 
the essential role of TNF- in mycobacterial immunity, maintaining latency and preventing 
reactivation. Mice lacking TNF-α are more prone to lethal mycobacterial infections with very 
high bacterial loads in multiple organs (Flynn et al., 1995, Benoit et al., 2008). TNF-α is also 
essential for the activation of endothelial cells, macrophages and neutrophils (Orme and 
Cooper, 1999, Tsenova et al., 1999, Gan et al., 2005) followed by granuloma formation and its 
maintenance (Kindler et al., 1989, Flynn et al., 1995, Senaldi et al., 1996). Interleukin-1β (IL-
1β) and IL-18 enhance macrophage secretion of TNF-α, IL-6, IFN-γ leading to granuloma 
formation (Toossi et al., 1990, Juffermans et al., 2000). IL-12 and IL-18 are required for Th1 
cells differentiation and IFN-γ secretion required to restrict mycobacterial growth within 
macrophages (Sieling et al., 1994, Cooper et al., 1995, Trinchieri, 1995, O'Neill and Greene, 
1998). Human studies have documented that defects in components of IL-12 and IFN-γ 
pathways increase susceptibility to mycobacteria (Altare et al., 1998a, de Jong et al., 1998, 
Ottenhoff et al., 2002). IL-2 is associated with the activation and expansion of T cell (Johnson 
et al., 2003). This cytokine has been shown to reduce bacterial replication by the activation of 
macrophages through IFN-γ mediated pathways or by the development of cytotoxic T cells 
(Toossi et al., 1986, Jeevan and Asherson, 1988). Patients with TB often have deficient IL-2 
induced cell proliferation (Toossi et al., 1986). IL-10 is made by many hematopoietic cells and 
plays a major role in modulating macrophage and dendritic cells function, required for the 
phagocytosis and killing of bacteria and the initiation of adaptive immune responses to 
mycobacteria. Similarly, high levels of IL-4 made by Th2 cells, innate lymphoid cells (ILCs) 
and other cells may be responsible for the downregulation of IFN-γ, TNF-α and IL-12 
expression and suppressing essential Th1 cell protective immune functions (Redford et al., 
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2011). These inhibitory cytokines however also play essential roles in limiting host-mediated 
tissue damage induced by the pro-inflammatory cytokines. Hence it is the intricate interplay of 
multiple cytokines that orchestrates appropriate innate and adaptive immune responses for 
effective control of mycobacteria. 
The few studies that investigated cellular immune response in diabetic TB patients showed that 
cellular immunity was impaired (Goonetilleke et al., 2003, Niazi and Kalra, 2012). Fewer T 
lymphocytes with reduced production of IFN-γ, TNF-α, IL-1β and IL-6 were also seen in 
individuals with concomitant diabetes and TB compared to non-diabetics (Tsukaguchi et al., 
1997, Geerlings and Hoepelman, 1999). Conflicting reports however have suggested that there 
is either no difference (Zhang et al., 2012), decreased (Stalenhoef et al., 2008) or increased 
(Legesse et al., 2013) production of Th1 cell specific IFN-γ by diabetics compared to non-
diabetic TB patients. Kumar and colleagues (2013) reported that there was heightened 
production of type 1 (IFN-γ, IL-2, TNF-α), type 2 (IL-5) type 17 (IL-17A), other pro-
inflammatory cytokines (IL-1β, IL-6, IL-18) and decreased production of IL-10 in TB patients 
with diabetes. Whereas there was a diminished production of systemic and antigen specific type 
1 (IFN-γ, IL-2, TNF-α), type 17 (IL-17F) and other pro-inflammatory cytokines (IL-1β, IL-18) 
in diabetics and pre-diabetic individuals with latent TB infection (Kumar et al., 2014). 
In animal models of TB-diabetes comorbidity, the pattern of pro- and anti-inflammatory 
cytokine production is unclear. Martens and colleagues (2007) observed higher expression of 
pro-inflammatory cytokines (IFN-γ, IL-12, TNF-α) in the lungs of aerosol infected STZ-
induced diabetic mice at 8 and 16 weeks post-infection (pi) although IFN-γ expression was 
lower in their chronic diabetic mouse model during the first 3 weeks of infection. Decreased 
expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-2, IL-12) was seen at 3-4 weeks 
pi infection in the lungs of Goto Kakizaki (GK) rats infected with M. tuberculosis although the 
opposite trend was found at 12 weeks pi. (Sugawara et al., 2004). Cheekalta and colleagues 
(2016) found a significantly higher production of TNF-α, IL-6, IFN-γ, IL-1β, MCP-1 and IL-
10 in the lungs of STZ+NA-induced diabetic mice infected with M. tuberculosis at 6 months pi 
although lower production of IL-6, TNF-α, IFN-γ was found at 4 weeks pi. The aforementioned 
studies determined cytokine production mostly in lungs but not other organs and didn’t examine 
cytokines produced in early infection. Only one study measured cytokine production at 14 and 
35 dpi in spleen, liver and lungs after iv infection of STZ-induced diabetic mice with M. 
tuberculosis (Yamashiro et al., 2005).The authors observed reduced expression of IFN-γ and 
IL-12 and increased expression IL-4 at these timepoints. 
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Both human and animal studies have indicated a dysregulated cytokine production in TB-
diabetes co-morbid infections. Data presented in Chapter 6 of this thesis showed increased 
mortality and increased bacterial burden in spleen, liver and lungs of diabetic mice compared 
to controls. Furthermore, increased inflammation was found in the liver and lungs of diabetic 
mice compared to controls (Chapter 7).  
The study described in Chapter 8 was designed to investigate the relationships between 
mortality, bacterial burden and inflammation and organ pro-inflammatory and anti-
inflammatory cytokine production. This data will enhance our understanding of which, if any, 
cytokines are dysregulated in diabetics infected with mycobacteria.  
The specific Aims of this research described in this Chapter are: 
1. To measure cytokines in spleen, liver and lungs of diabetic mice following infection 
with low- and high-dose M. fortuitum  
2. To measure cytokines in spleen, liver and lungs of diabetic mice following infection 
with M. bovis (BCG) and M. tuberculosis (H37Rv) 
 Materials and Methods 
 Animal ethics and institutional approvals 
The details of animal ethics and all institutional approvals are described in Chapter 3 (section 
3.1.1).  
 Experimental animals and induction of diabetes  
The details of experimental animals and induction of diabetes are described in Chapter 3 
(section 3.1.3) and Chapter 6 (section 6.2.2).  
 Preparation of mycobacterial culture for infection 
The details of the preparation of mycobacterial culture for infection are described in Chapter 3 
(section 3.3.2) and Chapter 6 (section 6.2.3.1).  
 Organ collection  
The details of organ collection from the mycobacteria infected mice are described in Chapter 6 
(section 6.2.4 and 6.2.5).  
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 Cytokine assays 
Supernatants from spleen, liver and lungs homogenates’ were prepared at 1, 14, 35 days post-
infection (dpi) (low-dose) and 14 dpi (high-dose) with M. fortuitum. Cytokine concentrations 
in tissue supernatants were determined using the BD Cytometric Bead Array Mouse 
Inflammation Kit® (TNF-α, MCP-1, IL-6, IFN-γ, IL-12p70, IL-10; cat. no. 552364, BD 
Biosciences, Australia). For M. bovis (BCG) and M. tuberculosis (H37Rv) infections, organs 
were collected at 1, 14 and 35 dpi (30 dpi for M. tuberculosis) and cytokine concentrations 
determined as above and using the Mouse Th1/Th2/Th17 Cytokine Kit® (IL-2, IL-4, IL-17A; 
cat. no. 60485) and Mouse IL-1β Flex Set® (IL-1β; cat. no. 560232). Manufacturer’s 
instructions were followed. Samples were acquired using the BD FACS CaliburTM flow 
cytometer and analysed using BD FCAP ArrayTM software (version 3) (Chapter 3, section 3.8). 
Cytokine levels that were below the limit of detection (Chapter 3, Table 3.2) are shown as zero 
(‘0’).   
 Statistical analysis 
The details of the statistical analysis are described in Chapter 6 (section 6.3).  
 Results 
 Cytokine production following M. fortuitum infection  
 Cytokine production in spleen  
At 1 day post-infection (dpi) with low-dose M. fortuitum, the only significant difference in 
spleen cytokine concentration between diabetic and control mice was in IL-6, albeit its 
concentration was extremely low (Table 8.1). TNF-α, IL-10 etc., were decreased in diabetic 
spleen however the differences were not statistically significant. No significant differences 
were observed for any splenic cytokines in day 14 or day 35 samples (Table 8.1). MCP-1 peaked 
at day 14, IL-10 and TNF-α concentrations were similar at all timepoints, whereas the 
production of IFN-γ increased gradually in the spleen of both control and diabetic mice. No IL-
12 was detected during infection period (Table 8.1). 
In mice infected with high-dose M. fortuitum, decreased concentrations of TNF-α, MCP-1, IL-
6, IFN-γ and IL-10 were found in the spleen of diabetic mice compared to controls at 14 dpi 
although these differences were not significant (Table 8.1). There was no production of IL-12 
in the spleen of both control and diabetic mice during high-dose of M. fortuitum infection (Table 
8.1).  
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 Table 8.1 Cytokine production in spleen following M. fortuitum infection 
Spleen 
Days post-infection 
1 14 35 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p- 
value 
Mean±SEM 
(pg/mL) 
p- 
value 
Mean±SEM 
(pg/mL) 
p- 
value 
Low-dose (1x107) 
TNF-α 
Control 30.77±3.41 
0.0976 
13.16±3.59 
0.4104 
36.13±15.33 
0.4958 
Diabetic 17.05±2.08 22.35±9.74 23.63±8.48 
MCP-1 
Control 39.94±5.08 
0.9295 
58.71±5.63 
0.8471 
60.52±15.83 
0.7859 
Diabetic 38.38±13.74 63.96±22.72 55.52±8.13 
IL-6 
Control 1.63±0.03 
0.0495 
0.99±0.59 
0.8023 
1.38±0.74 
0.2898 
Diabetic 0.76±0.44 1.32±1.01 0.64±0.64 
IL-12 
Control 0.68±0.15 
0.1382 
0.31±0.31 
1.000 
0.23±0.23 
1.000 
Diabetic 0.00 0.33±0.33 0.47±0.47 
IFN-γ 
Control 6.63±0.48 
0.1269 
11.14±3.72 
0.3336 
15.77±5.14 
0.4958 
Diabetic 2.85±1.04 6.74±1.44 9.84±4.94 
IL-10 
Control 38.18±4.92 
0.1037 
14.24±1.66 
0.0790 
10.67±2.91 
0.8820 
Diabetic 16.41±5.68 9.19±1.75 11.32±3.07 
High-dose (3x108) 
TNF-α 
Control 
 
121.02±5.55 
0.1233 
 
Diabetic 51.20±16.92 
MCP-1 
Control 113.80±11.19 
0.3011 
Diabetic 88.10±19.73 
IL-6 
Control 17.68±9.32 
0.4614 
Diabetic 7.31±3.41 
IL-12 
Control 0.00±0.00 - 
Diabetic 0.00±0.00 - 
IFN-γ 
Control 44.12±8.22 
0.0752 
Diabetic 14.84±3.52 
IL-10 
Control 13.79±2.74 
0.4171 
Diabetic 10.38±1.13 
Data presented as mean±SEM; n=4-5 mice/group (low-dose) and 2-3 mice/group (high-dose)  
 
 Cytokine production in liver  
Following infection with low-dose M. fortuitum, TNF-α concentrations in diabetic liver 
appeared 3 times higher than control liver at 1 dpi, although this difference was not statistically 
significant (Table 8.2). However, at 14 and 35 dpi, TNF-α levels were lower in diabetic mice 
compared to controls (Table 8.2). A similar trend for MCP-1 levels were observed with higher 
initial levels in diabetic followed by decreased liver concentrations over time (Table 8.2). Liver 
IL-6 was relatively unchanged over time. IL-12 production was higher in the liver of diabetic 
mice compared to control mice at 1 dpi (Table 8.2) but lower at 14 and 35 dpi. IFN-γ production 
was similar in diabetic and control liver early in infection but was decreased compared to 
control liver at both 14 and 35 dpi (Table 8.2). The levels of IL-10 in the liver of diabetic mice 
were higher at 1 dpi although an opposite trend of was observed at 14 dpi (Table 8.2). At 35 
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dpi, a 1.03 times higher production of IL-10 was found in the liver of diabetic mice although 
this difference was not significant.  
Liver from diabetic mice infected with high-dose of M. fortuitum showed decreased TNF-α and 
IL-6 production compared to controls at 14 dpi although they did not reach significance (Table 
8.2). Increased MCP-1 and IL-10 production were found in liver of diabetic mice compared to 
controls at 14 dpi (Table 8.2). IFN-γ level was decreased in liver from diabetic mice compared 
to controls (Table 8.2). The level of IL-12 was undetectable in liver of both diabetic and control 
mice (Table 8.2). 
Table 8.2 Cytokine production in liver following M. fortuitum infection  
Data presented as mean±SEM; n=4-5 mice/group (low-dose) and 2-3 mice/group (high-dose)  
 
 
 
Liver 
Days post-infection 
1 14 35 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p- 
value 
Mean±SEM 
(pg/mL) 
p- 
value 
Mean±SEM 
(pg/mL) 
p- 
value 
Low-dose (1x107) 
TNF-α 
Control 63.39±19.74 
0.1742 
137.93±32.32 
0.0388 
177.19±26.09 
0.1616 
Diabetic 191.96±75.35 56.89±11.23 129.90±14.31 
MCP-1 
Control 152.97±26.26 
0.0986 
431.28±86.27 
0.2652 
347.19±16.87 
0.0002 
Diabetic 245.58±34.28 311.92±49.85 182.18±17.89 
IL-6 
Control 13.04±4.34 
0.3998 
11.66±5.02 
0.5136 
20.25±7.44 
0.8065 
Diabetic 20.08±6.09 8.05±1.63 14.81±4.28 
IL-12 
Control 24.32±6.17 
0.1866 
25.50±9.74 
0.2248 
62.90±0.75 
0.0425 
Diabetic 52.10±10.79 10.33±5.55 39.19±7.03 
IFN-γ 
Control 11.72±3.59 
0.7888 
57.39±18.67 
0.0928 
61.18±13.65 
0.1604 
Diabetic 13.18±3.60 19.84±2.18 33.72±10.26 
IL-10 
Control 94.71±11.90 
0.5708 
73.87±4.24 
0.0300 
89.17±26.35 
0.9121 
Diabetic 110.20±22.11 55.32±5.01 92.23±5.32 
High-dose (3x108) 
TNF-α 
Control 
 
330.08±42.43 
0.4295 
 
Diabetic 225.11±136.04 
MCP-1 
Control 433.29±192.66 
0.6579 
Diabetic 574.35±194.76 
IL-6 
Control 40.24±20.88 
0.5472 
Diabetic 21.41±9.35 
IL-12 
Control 0.00±0.00 
0.2722 
Diabetic 0.64±0.64 
IFN-γ 
Control 104.57±12.39 
0.0559 
Diabetic 34.50±22.30 
IL-10 
Control 27.76±1.86 
0.1108 
Diabetic 42.51±8.22 
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 Cytokine production in lungs  
The only notable difference between diabetic and control lungs cytokines following infection 
with low-dose M. fortuitum was decreased TNF-α in diabetic lungs at 1 dpi and decreased IL-
6 at 35 dpi. Lungs from diabetic mice infected with high-dose M. fortuitum had lower levels of 
TNF-α and IL-6 compared to control mice at 14 dpi. IFN-γ concentration was markedly reduced 
in lungs of diabetic mice compared to controls during the infection. No IL-12 was detected in 
any sample at any timepoint. 
Table 8.3 Cytokine production in lungs following M. fortuitum infection  
Data presented as mean±SEM; n=4-5 mice/group (low-dose) and 2-3 mice/group (high-dose)  
 
 
 
 
Lungs 
Days post-infection 
1 14 35 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p- 
value 
Mean±SEM 
(pg/mL) 
p- 
value 
Mean±SEM 
(pg/mL) 
p- 
value 
Low-dose (1x107) 
TNF-α 
Control 15.09±4.49 
0.2890 
1.06±0.81 
0.2896 
15.04±2.99 
0.3083 
Diabetic 7.62±0.46 0.76±0.76 10.41±3.02 
MCP-1 
Control 75.09±2.62 
0.8969 
62.14±9.95 
0.7315 
67.60±11.81 
0.7665 
Diabetic 72.60±15.22 66.96±9.22 71.94±7.75 
IL-6 
Control 3.83±3.35 
0.6818 
1.32±1.12 
0.8139 
8.46±2.27 
0.0432 
Diabetic 6.40±4.94 1.82±1.34 2.42±1.09 
IL-12 
Control 0.00 
0.2207 
0.14 
0.3739 
0.00 
0.3473 
Diabetic 0.04±0.04 0.00 0.46±0.46 
IFN-γ 
Control 5.17±2.03 
0.9681 
11.36±8.65 
0.3470 
7.86±2.31 
0.4395 
Diabetic 5.05±1.47 2.13±0.87 5.89±0.74 
IL-10 
Control 40.44±5.42 
0.4807 
31.08±9.20 
0.9163 
45.69±10.30 
0.4776 
Diabetic 34.76±1.44 30.29±7.69 35.73±8.51 
High-dose (3x108) 
TNF-α 
Control 
 
374.81±155.59 
0.2895 
 
Diabetic 126.57±77.57 
MCP-1 
Control 502.20±75.84 
0.7739 
Diabetic 412.17±263.55 
IL-6 
Control 58.15±36.28 
0.4972 
Diabetic 20.72±17.34 
IL-12 
Control 0.00±0.00 
- 
Diabetic 0.00±0.00 
IFN-γ 
Control 94.60±0.00 
0.0042 
Diabetic 8.95±5.59 
IL-10 
Control 24.06±4.51 
0.6524 
Diabetic 20.74±4.34 
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 Cytokine production following M. bovis (BCG) infection 
 Cytokine production in spleen  
IL-1β concentration in the spleen of diabetic mice was higher than control spleen at all 
timepoints of infection (Figure 8.1 A) with the peak level detected at 14 days post-infection 
(dpi). TNF-α concentration in diabetic spleen was lower at 1 dpi and 35 dpi compared to 
controls (Figure 8.1 B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Cytokine production in spleen following M. bovis (BCG) infection  
Mice infected with M. bovis (BCG) were assessed for cytokine production in spleen. Figure 
illustrates the kinetics of IL-1β (A), TNF-α (B), MCP-1 (C), IL-6 (D), IFN-γ (E), IL-12 (F), IL-
2 (G), IL-4 (H) and IL-10 (I) production in control and diabetic mice at 1, 14 and 35 days post-
infection (dpi). Overall, a higher production of IL-1β (A), TNF-α (B), MCP-1 (C), IL-6 (D) was 
observed in diabetic mice compared to controls. Whereas the production of IFN-γ (E), IL-2 (G) 
and IL-10 (I) was lower in diabetic mice compared to controls. The production of IL-12 (F) and 
IL-4 (H) was minimum or negligible in both of the groups throughout infection period. Data 
presented as mean±SEM; n=4-5 mice/group. The significant differences between the groups 
were determined using the independent sample t-test for the normally distributed data. The non-
normally distributed data were analysed using the Mann-Whitney U test (Appendix 5). The 
level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. 
 
MCP-1 levels were higher in diabetic spleen at all timepoints (Figure 8.1 C). IL-6 was higher 
in diabetic spleen at 14 dpi although it was lower at both 1 dpi and 35 dpi compared to controls 
(Figure 8.1 D). IFN-γ concentration was lower in spleen of diabetic mice compared to controls 
Diabetic Control 
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at 14 dpi and 35 dpi (Figure 8.1 E). IL-12 levels were negligible in both diabetic and control 
mice throughout the infection period (Figure 8.1 F). The production of IL-2 was lower in 
diabetic mice at 1, 14 and 35 dpi (Figure 8.1 G). A reduced level of interleukin-10 was observed 
in diabetic mice compared to controls at all the timepoints of infection although they did not 
reach a significant level (Figure 8.1 I). IL-4 (Figure 8.1 H) and IL-17A (Appendix 5, Table 
A5.12) were below the limits of detection in all samples. 
 Cytokine production in liver  
IL-1β level was significantly higher in the liver of diabetic mice compared to controls at 1 day 
post-infection (dpi) (Figure 8.2 A). At 14 dpi and 35 dpi, the level of TNF-α in diabetic liver 
was approximately half the concentration measured in control liver (Figure 8.2 B). MCP-1 
secretion peaked at 14 dpi however no significant differences were seen between diabetic and 
control mice (Figure 8.2 C). The concentration of IL-6 was significantly reduced in liver from 
diabetics at 35 dpi (Figure 8.2 D). IFN-γ production was significantly lower in diabetic mice at 
14 and 35 dpi compared to controls (Figure 8.2 E). IL-12 secretion was higher at 1 and 14 dpi 
although this was not statistically significant, however, at 35 dpi IL-12 level in diabetic liver 
was lower than controls (Figure 8.2 F). IL-2 was slightly higher in the liver of diabetic mice 
compared to controls at 14 dpi and 35 dpi but these did not reach significance (Figure 8.2 G). 
The production of IL-4 was 3.44 and 6.53 times higher in diabetic mice compared to controls 
at 1 and 14 dpi, respectively (Figure 8.2 H). At 35 dpi, no IL-4 was detected in liver of diabetic 
or control mice (Figure 8.2 H). IL-10 level was higher in diabetic liver compared to controls at 
1 and 14 dpi but reduced at 35 dpi (Figure 8.2 I). IL-17A was not detected (Appendix 5, Table 
A5.13).  
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Figure 8.2 Cytokine production in liver following M. bovis (BCG) infection  
Mice infected with M. bovis (BCG) were assessed for cytokine production in liver. Figure 
illustrates the kinetics of IL-1β (A), TNF-α (B), MCP-1 (C), IL-6 (D), IFN-γ (E), IL-12 (F), IL-
2 (G), IL-4 (H) and IL-10 (I) production in control and diabetic mice at 1, 14 and 35 days post-
infection (dpi). Overall, the production of IL-1β (A), TNF-α (B) and IFN-γ (E) was lower in 
diabetic liver compared to controls. The production of MCP-1 (C), IL-2 (G), IL-4 (H) was 
higher in liver of diabetic mice compared to controls. A higher production of IL-12 was 
observed in diabetic mice at 1 and 14 dpi although the level did not sustain to 35 dpi. The 
production of IL-10 (I) was higher in diabetic mice compared to controls at 1 and 14 dpi 
although its level was higher in control mice at the end timepoint of infection. Data presented 
as mean±SEM; n=4-5 mice/group. The significant differences between the groups were 
determined using the independent sample t-test for the normally distributed data. The non-
normally distributed data were analysed using the Mann-Whitney U test (Appendix 5). The 
level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and ns=non-significant. 
 
 Cytokine production in lungs  
Early after infection with M. bovis (BCG), higher concentration of IL-1β was found in the lungs 
of diabetic mice compared to controls (Figure 8.3 A). No differences were observed at 14 days 
post-infection (dpi) or 35 dpi (Figure 8.3 A). At 14 dpi and 35 dpi, TNF- level in the lungs of 
diabetic mice was lower than controls (Figure 8.5 B).  
Diabetic Control 
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Figure 8.3 Cytokine production in lungs following M. bovis (BCG) infection  
Mice infected with M. bovis (BCG) were assessed for cytokine production in lungs. Figure 
illustrates the kinetics of IL-1β (A), TNF-α (B), MCP-1 (C), IL-6 (D), IFN-γ (E), IL-12 (F), IL-
2 (G), IL-4 (H) and IL-10 (I) production in control and diabetic mice at 1, 14 and 35 days post-
infection (dpi). A lower production of IL-1β (A), IL-6 (D), IL-12 (F), IL-2 (G) was observed in 
the diabetic mice compared to controls at 35 dpi. The production of MCP-1 was found higher 
in diabetic mice compared to controls at all timepoints of infection. A significantly lower 
production of TNF-α (B) was observed in diabetic mice at 14 dpi compared to controls which 
maintained the same trend at the end timepoint of infection. The production of IFN-γ (E) was 
significantly lower in diabetic mice at both 14 and 35 dpi although its secretion was minimum 
1 dpi. IL-4 production was negligible throughout the infection in both control and diabetic mice 
(H). Although IL-10 production was higher in lungs of diabetic mice compared to controls at 1 
dpi, it was opposite at 35 dpi (I). Data presented as mean±SEM; n=4-5 mice/group. The 
significant differences between the groups were determined using the independent sample t-test 
for the normally distributed data. The non-normally distributed data were analysed using the 
Mann-Whitney U test (Appendix 5). The level of significance was indicated as *p≤0.05, 
**p≤0.01, and ns=non-significant. 
 
MCP-1 production however was higher in diabetic lungs at all timepoints (Figure 8.3 C). IL-6 
was initially slightly higher in diabetic but by 35 dpi was lower than controls (Figure 8.3 D). 
IFN-γ was undetectable at 1 dpi but it was significantly decreased in diabetic lungs compared 
to control lungs at 14 dpi and 35 dpi (Figure 8.3 E).  
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IL-12 concentration was slightly elevated in the lungs of diabetic mice compared to control 
mice at 1 and 14 dpi (Figure 8.3 F) but lower at 35 dpi (Figure 8.3 F). IL-10 level was higher 
at 1 dpi, similar at 14 dpi and lower at 35 dpi in lungs of diabetic mice compared to controls 
(Figure 8.3 I). IL-2 (Figure 8.3 G), IL-4 (Figure 8.3 H) and IL-17A (Appendix 5, Table A5.14) 
were undetectable in the lungs of both diabetic and control mice at all timepoints of infection.   
 Cytokine production following M. tuberculosis (H37Rv) infection 
 Cytokine production in spleen  
In M. tuberculosis (H37Rv) infection at 1 day post infection (dpi), IL-1β level in the spleen of 
both diabetic and control mice was comparable (Figure 8.4 A). The secretion of IL-1β peaked 
at 14 dpi and was 3.30 times higher in diabetic mice compared to controls. Although the 
production of this cytokine was reduced by 30 dpi in both groups, the level in diabetic spleen 
was slightly higher than controls (Figure 8.4 A). TNF-α and MCP-1 production were initially 
lower in diabetic mice but higher at later timepoints (Figure 8.4 B & C). IL-6 production was 
significantly higher in diabetic mice at 14 dpi although there were no differences in the 
production of this cytokine in both groups at 1 and 30 dpi (Figure 8.4 D). IFN-γ concentration 
was consistently lower in diabetic spleen compared to control mice at all timepoints of infection 
(Figure 8.4 E). IL-2 level in diabetics and control was similar early in infection but level in 
diabetics were significantly lower at 14 and 30 dpi (Figure 8.4 G). IL-10 concentration was 
slightly higher in diabetic at 14 dpi although a reverse trend was found in 30 dpi (Figure 8.3 I). 
IL-12 (Figure 8.4 F), IL-4 (Figure 8.4 H) and IL-17A (Appendix 6, Table A6.12) were not 
detected in any spleen supernatants.  
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Figure 8.4 Cytokine production in spleen following M. tuberculosis (H37Rv) infection  
Mice infected with M. tuberculosis (H37Rv) were assessed for cytokine production in spleen. 
Figure illustrates the kinetics of IL-1β (A), TNF-α (B), MCP-1 (C), IL-6 (D), IFN-γ (E), IL-12 
(F), IL-2 (G), IL-4 (H) and IL-10 (I) production in control and diabetic mice at 1, 14 and 30 
days post-infection (dpi). Overall, a higher production of IL-1β (A), TNF-α (B), MCP-1 (C), 
IL-6 (D) was observed in diabetic mice compared to controls at 14 and 30 dpi. Whereas the 
production of IFN-γ (E) was significantly lower in diabetic mice compared to controls at both 
1 and 14 dpi although its level did not sustain at 30 dpi. A significantly lower production of IL-
2 (G) was observed at 14 and 30 dpi although there was no difference at 1 dpi. The production 
of IL-10 (I) was higher in diabetic at 14 dpi although a reverse trend was found in 30 dpi. IL-
12 (F) and IL-4 (H) secretion was minimum throughout the infection in both groups. Data 
presented as mean±SEM; n=4-5 mice/group. The significant differences between the groups 
were determined using the independent sample t-test for the normally distributed data. The non-
normally distributed data were analysed using the Mann-Whitney U test (Appendix 6). The 
level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. 
 
 Cytokine production in liver  
Liver IL-1β level in diabetic was lower at all timepoints compared to controls following M. 
tuberculosis (H37Rv) infection (Figure 8.5 A). The TNF-α concentration was consistently 
lower in diabetic liver compared to controls at all the timepoints of infection (Figure 8.5 B). 
MCP-1 was lower in diabetic liver at 1 and 35 dpi although it was opposite at 14 dpi (Figure 
8.5 C). Secretion of IL-6 was variable during the infection (Figure 8.5 D). IFN-γ and IL-12 
concentrations in the liver of diabetic mice were lower than control mice at all the timepoints 
post infection (Figure 8.5 E & F). IL-2 level was comparable at 1 and 14 dpi, but significantly 
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decreased in diabetic mice at 30 dpi (Figure 8.5 G). IL-4 level was slightly increased in diabetic 
liver compared to controls at 1 dpi although level was minimal at 14 and 30 dpi (Figure 8.5 H). 
IL-10 secretion was found slightly higher in liver of diabetic mice compared to controls at 1 
and 14 dpi although a reverse trend was observed at 30 dpi (Figure 8.5 I). IL-17A was slightly 
higher in the liver of control mice at 1 (control, 2.03±1.27 vs diabetic, 0.97±0.77, pg/mL, 
p=0.9113) and 30 dpi (control, 4.99±2.85 vs diabetic, 0.0.38±0.0.30, pg/mL, p=0.1955) 
although it was undetectable in either group at 14 dpi.  
 
 
 
 
 
 
 
 
 
 
Figure 8.5 Cytokine production in liver following M. tuberculosis (H37Rv) infection  
Mice infected with M. tuberculosis (H37Rv) were assessed for cytokine production in liver. 
Figure illustrates the kinetics of IL-1β (A), TNF-α (B), MCP-1 (C), IL-6 (D), IFN-γ (E), IL-12 
(F), IL-2 (G), IL-4 (H) and IL-10 (I) production in control and diabetic mice at 1, 14 and 30 
days post-infection (dpi). Overall, the production of IL-1β (A), TNF-α (B), IL-6 (D), IFN-γ (E), 
IL-12 (F) and IL-2 (G) was lower in diabetic mice compared to controls. The production of 
MCP-1 (C) was significantly lower in diabetic mice compared to controls at 1 dpi although a 
reverse trend was found at 30 dpi. A slightly higher production of IL-4 (H) was observed at 1 
dpi although its level was minimum in both groups at later timepoints of infections. A slightly 
higher production of IL-10 (I) was found in diabetic mice at 1 and 14 dpi although a reverse 
trend was found at 30 dpi. Data presented as mean±SEM; n=4-5 mice/group. The significant 
differences between the groups were determined using the independent sample t-test for the 
normally distributed data. The non-normally distributed data were analysed using the Mann-
Whitney U test (Appendix 6). The level of significance was indicated as *p≤0.05, **p≤0.01, 
and ns=non-significant. 
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 Cytokine production in lungs  
One day after iv infection with M. tuberculosis (H37Rv) no IL-1β was detected in either diabetic 
and control mice (Figure 8.6 A). Later in infection, there was no difference in IL-1β level. The 
TNF-α concentration was slightly lower in diabetic mice compared to controls at all timepoints 
of infections (Figure 8.6 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6 Cytokine production in lungs following M. tuberculosis (H37Rv) infection  
Mice infected with M. tuberculosis (H37Rv) were assessed for cytokine production in lungs. 
Figure illustrates the kinetics of IL-1β (A), TNF-α (B), MCP-1 (C), IL-6 (D), IFN-γ (E), IL-12 
(F), IL-2 (G), IL-4 (H) and IL-10 (I) production in control and diabetic mice at 1, 14 and 30 
days post-infection (dpi). The production of IL-1β (A) was slightly higher in the diabetic mice 
compared to controls at 14 dpi although the level was almost same at both 1 and 30 dpi in both 
groups. The production of MCP-1 was observed lower in diabetic mice compared to controls at 
1 and 14 dpi although a reverse trend was found at 30 dpi. An overall lower production of TNF-
α (B), IL-6 (D) and IFN-γ (E) was observed in diabetic mice compared to controls. A 
significantly higher production of IL-10 was observed in diabetic mice compared to controls at 
14 dpi although an opposite trend was found at 1 and 30 dpi. The production of IL-12 (F), IL-
2 (G), IL-4 (H) was negligible or undetectable in both groups. Data presented as mean±SEM; 
n=4-5 mice/group. The significant differences between the groups were determined using the 
independent sample t-test for the normally distributed data. The non-normally distributed data 
were analysed using the Mann-Whitney U test (Appendix 6). The level of significance was 
indicated as *p≤0.05, **p≤0.01, ***p≤0.001, and ns=non-significant. 
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MCP-1 concentration was lower in diabetic lungs at 1 and 14 dpi but higher at 30 dpi (Figure 
8.6 C). IL-6 production was almost similar between groups at all timepoints (Figure 8.6 D). The 
production of IFN-γ was significantly lower in the lungs of diabetic mice compared to control 
at all the timepoints (Figure 8.6 E). It was 10, 3.20 and 1.80 times lower in the lungs of diabetic 
mice compared to controls at 1, 14 and 30 dpi, respectively (Figure 8.6 E). IL-10 concentration 
in diabetic lungs was increased significantly at 14 dpi compared to controls but decreased by 
30 dpi (Figure 8.6 I). IL-12 (Figure 8.6 F), IL-2 (Figure 8.6 G), IL-4 (Figure 8.6 H) and IL-17A 
(Appendix 6, Table A6.14) were low or undetectable. 
 Discussion 
Increased bacillary loads (Chapter 6) and increased tissue inflammation (Chapter 7) in diabetic 
mice suggest defective and/or dysregulated immune responses in these hosts. Furthermore, we 
have demonstrated that cellular function and cytokine secretion in mycobacteria-activated 
diabetic macrophages is abnormal (Chapter 5). To further investigate these phenomena, we 
measured tissue cytokines secreted in response to different mycobacterial infections.  
The roles of specific pro- and anti-inflammatory cytokines in mycobacterial infections have 
been widely studied and reviewed (Orme and Cooper, 1999, Cooper et al., 2011, Orme and 
Ordway, 2014). In both tuberculous and NTM infections, previous studies have shown that 
mice lacking TNF-α promptly succumb to infections (Appelberg et al., 1994b, Parti et al., 2005, 
Benoit et al., 2008) by failure to activate macrophages and neutrophils (Orme and Cooper, 1999, 
Tsenova et al., 1999, Gan et al., 2005), leading to higher organ bacterial loads (Flynn et al., 
1995) and ineffective granuloma formation (Kindler et al., 1989, Flynn et al., 1995, Senaldi et 
al., 1996). Mice with defective IL-1 signalling showed decreased IFN-γ and IL-6 production 
during M. tuberculosis infection, leading to defective granuloma formation (Toossi et al., 1990, 
Juffermans et al., 2000). MCP- 1 (also called CCL2) is essential for recruitment of various 
immune cells and activated T cells into tissues (Kipnis et al., 2003). Kipnis and colleagues 
(2003) reported fewer macrophages in lungs, an increased bacterial load and failure to recruit 
antigen-specific T lymphocytes into the lungs of CCL2 knockout mice.  
In the current study, we measured less IL-1β and TNF-α in the liver and lungs of diabetic mice 
compared to controls following both M. bovis (BCG) and M. tuberculosis (H37Rv) infections 
although the opposite trend was observed in the spleen (Figure 8.1-8.6 A & B). In M. fortuitum 
infection studies, we reported a trend for decreased TNF-α in liver, lungs and spleen of diabetic 
mice compared to controls (Table 8.1-8.3). MCP-1 concentration in spleen, liver and lungs of 
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the diabetic mice tended to be higher than controls in M. bovis infection (Figure 8.1-8.3 C). In 
M. tuberculosis (H37Rv) infection, overall MCP-1 production in spleen, liver and lungs was 
lower at the earliest timepoint of infection although an opposite trend was observed at later 
timepoint of infection in diabetics compared to controls (Figure 8.4-8.6 C). In M. fortuitum 
infection (low-dose), there was no significance difference in the secretion of MCP-1 in spleen 
and lungs of both diabetic and control mice although it was lower in the liver of diabetic mice 
(Table 8.1-8.3).  
Previous studies examining TNF-α, IL-1β and MCP-1 levels in different animal models have 
produced conflicting results. A recent investigation demonstrated significantly lower TNF-α 
levels in the lungs of STZ+NA-induced diabetic mice compared to non-diabetic controls 1 
month pi although by 6-month pi TNF-α levels was far in excess of both 1 month levels and 
non-diabetic controls (Cheekatla et al., 2016). Martens and co-workers (2007) reported an 
increased level of IL-1β and TNF-α in the lungs of chronic diabetic mice (>16 weeks) compared 
to controls. Cytokine gene expression analysis showed lungs TNF-α and IL-1β mRNA 
expression was delayed in M. tuberculosis infected diabetic rats compared to control rats with 
decreased expression at 3-5 weeks post-infection (pi) but increased expression by 12 weeks pi 
(Sugawara et al., 2004). Sugawara and colleagues (2008) found increased expression of the 
TNF-α genes in the lungs of T2D rat compared to controls at 7 weeks pi in M. tuberculosis 
infection. In a guinea pig model of TB-diabetes co-morbidity, TNF-α and MCP-1 were more 
highly expressed in the spleen of diabetic guinea pigs 30 days after aerosol M. tuberculosis 
infection compared to controls (Podell et al., 2014). They also reported higher expression of 
IL-1β and MCP-1 and decreased expression of TNF-α in infected diabetic Guinea pig lungs 
compared to controls.  
Our data i.e. decreased IL-1β, TNF-α, MCP-1 concentrations early in M. tuberculosis (H37Rv) 
infection in diabetics is in general agreement with those studies that have used acute diabetic 
animal models infected. Collectively, the data indicate that IL-1β, TNF-α, MCP-1 are crucial 
in acute infections. These data suggested that an overall lower production of TNF-α, IL-1β and 
MCP-1 at the earliest time of infection in diabetic mice failed to activate and recruit 
macrophages to secrete bactericidal compounds such as ROS and iNOS. Although it was 
beyond the scope of the current study to measure these compounds, previous studies report that 
decreased production of such compounds in diabetic mice during mycobacterial infections leads 
to higher bacterial burdens and increased inflammation in infected organs (Yamashiro et al., 
2005, Vallerskog et al., 2010). Moreover, a higher production of MCP-1 in diabetic organs at 
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later timepoints of this study further suggested failure to control bacterial loads (as seen in 
Chapter 6) resulting in more tissue inflammation as observed in other diabetic animal models 
(Vallerskog et al., 2010, Podell et al., 2014, Cheekatla et al., 2016).  
The role of IL-6 in TB defence is conflicting (Nagabhushanam et al., 2003, Cooper et al., 2011, 
Dutta et al., 2012, Martinez et al., 2013, Singh and Goyal, 2013). In the current study, we 
observed slightly reduced IL-6 levels in organs of diabetic mice compared to controls infected 
with M fortuitum (Table 8.1-8.3), M. bovis (BCG) and M. tuberculosis (H37Rv) (Figure 8.1-
8.6 D). In the STZ+NA-induced mouse model, Cheekatla and co-workers (2016) demonstrated 
a significantly reduced production of IL-6 in the lungs of diabetic mice compared to controls 
during acute M. tuberculosis infection (1 month), whereas the reverse was true in chronic 
infections (6 months). These investigators suggested that IL-6 was responsible for driving 
inflammation in the lungs of chronically infected diabetic mice. When they treated chronically 
infected diabetic mice with anti-IL-6 antibodies, the expression of all pro-inflammatory 
cytokines (IFN-γ, TNF-α, IL-1β and MCP-1) was abolished in lungs compared to controls, 
suggesting that IL-6 has a primary role in driving the expression of many pro-inflammatory 
cytokines. The findings of the current study suggested that IL-6 has a protective role in acute 
infection to control the infections by inducing increase expression of pro-inflammatory 
cytokines. It would be interesting to evaluate the effect of IL-6 in this T2D model during chronic 
mycobacterial infections.  
Th1 cell responses are crucial in developing resistance and protective immunity in 
mycobacterial infections which is driven by IL-12 (Cooper et al., 1995, Cooper, 2009, 
Jasenosky et al., 2015). In the current investigation, we observed decreased concentrations of 
IL-12 in organs of diabetic mice compared to controls during M. fortuitum (Table 8.1-8.3), M. 
bovis (BCG) (Figure 8.1-8.3 F) and M. tuberculosis (H37Rv) infections (Figure 8.4-8.6 F). 
Previous studies observed a decreased expression of IL-12 in the lungs of diabetic rats 
compared to controls(Sugawara et al., 2004, Sugawara and Mizuno, 2008). Reduced IL-12 
production was observed in peritoneal exudate cells stimulated with M. bovis (Yamashiro et al., 
2005). These authors demonstrated decreased production of both IL-12 in the spleen, liver and 
lungs of STZ-induced diabetic mice compared to controls infected intravenously with M. 
tuberculosis. Reduced secretion of IL-12 in diabetic mice of this study suggests poor antigen 
presentation and Th1 cells differentiation resulting in higher mycobacterial susceptibility.  
Another key cytokine for TB protection is IFN-γ which is secreted by Th1 cell-mediated 
responses (Cooper, 2009). In the current study, we have observed an overall reduced production 
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of IFN-γ in organs of diabetic mice compared to controls during M. fortuitum (Table 8.1-8.3), 
M. bovis (BCG) (Figure 8.1-8.3 E) and M. tuberculosis (H37Rv) infections (Figure 8.4-8.6 E). 
The necessity for IFN-γ and its role in at the earliest timepoints after M. tuberculosis infection 
in hyperglycaemic mice was described by Martens and co-workers (2007). These authors 
observed decreased production of IFN-γ in lung lysates collected from hyperglycaemic mice at 
7, 14 and 21 dpi. A lower production of IFN-γ was recoded in spleen, liver and lungs of STZ-
induced diabetic mice (Yamashiro et al., 2005). Vallerskog and colleagues (2010) showed 
delayed priming of T cell responses in diabetic mice following aerosol M. tuberculosis infection 
compared to controls due to delayed appearance of IFN-γ producing T cells in the lungs and 
draining lymph nodes of diabetic mice. Other investigators have shown a marked reduction in 
IFN-γ secretion by spleen cells of diabetic mice stimulated with PPD (purified protein 
derivatives) and CFP (culture filtrate proteins) and ESAT-6 (early secretory antigenic target-6) 
antigens (Yamashiro et al., 2005). Our data are in agreement with the above studies suggesting 
an impaired or delayed Th1 cell responses in diabetic mice leading to higher susceptibility to 
mycobacterial infections. This study did not examine IFN-γ producing T cells in lungs and other 
organs, however, future studies could determine the contribution of these cells in TB-diabetes 
co-morbid infections and how the observed lack of IFN-γ in these diabetic mice influences 
infection outcome. 
In the current study, we observed minor decreases in IL-2 in the spleen and liver of diabetic 
mice compared to controls during M. bovis (BCG) and M. tuberculosis (H37Rv) infections 
(Figure 8.1, 8.2, 8.4 and 8.5 G). IL-2 has an important role in the activation and expansion of T 
cells (Johnson et al., 2003). This cytokine has been shown to reduce bacterial replication by its 
effects on IFN-γ mediated macrophage activation and in the expansion of cytotoxic T cells 
(Toossi et al., 1986, Jeevan and Asherson, 1988). Deficits in IL-2 induced cell proliferation are 
common in TB patients (Toossi et al., 1986). In diabetic rats infected with M. tuberculosis 
decreased IL-2 gene expression was observed at 3-5 weeks pi although expression was 
increased by 12 weeks pi (Sugawara et al., 2004). The differences in the secretion of IL-2 in 
the diabetic and control mice of this study further suggested the possibility of diminished or 
delayed T cell expansion and IFN-γ-producing effector T cell differentiation.  
In this investigation, we observed minor increases in IL-4 in the liver of diabetic mice early in 
infections (Figure 8.2 and 8.5 H) suggesting the possibility of immune responses (innate and 
adaptive) skewed to a type 2 response. Although type 2 cytokines can increase host resistance 
to some specific pathogens (e.g. Leishmania, Cryptococcus) (Kopf et al., 1996, Blackstock et 
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al., 1999), alterations in the Th1/Th2 balance toward a Th2- dominant response has been linked 
to adverse disease outcomes (Heinzel et al., 1989, Heinzel et al., 1995). Yamashiro and co-
workers (2005) observed increased IL-4 in the lungs and liver of STZ-induced ICR mice 
compared to controls infected intravenously with M. tuberculosis. This finding suggested that 
M. tuberculosis immune responses in diabetics may be skewed to IL-4 driven Th2 responses 
rather than the protective IL-12/IFN-γ driven Th1 responses. However, the role of this cytokine 
is still controversial and whether elevated tissue IL-4 skews immune responses in mycobacterial 
(and other) infections is far from clear (Hernandez-Pando et al., 1996, North, 1998, Flynn and 
Chan, 2001a, Jung et al., 2002, Hernandez-Pando et al., 2004).  
There was no constant trend for IL-10 production in the organs of diabetic mice compared to 
controls during mycobacterial infections (Table 8.1-8.3, Figure 8.1-8.6 I). Although we 
observed minor increases in IL-10 in the organs of diabetic mice compared to controls at the 
earliest timepoint of M. bovis (BCG) and M. tuberculosis (H37Rv) infection. In line with the 
findings of the current investigation, higher IL-10 production was observed in lungs of STZ-
induced diabetic mice during M. tuberculosis infection at 4 weeks pi although an opposite trend 
was found at 24 weeks pi (Cheekatla et al., 2016). IL-10 plays an important role in limiting 
potentially harmful inflammatory immune responses during mycobacterial infections 
(Bermudez and Champsi, 1993, Murray and Young, 1999, Jacobs et al., 2000, Roque et al., 
2007). Increased production of this cytokine in the current study suggested a decrease 
production of pro-inflammatory cytokines (e.g. TNF-α, IFN-γ) as observed in TB research 
(Gong et al., 1996, Fulton et al., 1998, Hirsch et al., 1999a) and diabetic animal model research 
(Cheekatla et al., 2016). Future research can be directed to determine the role of IL-10 in TB-
diabetes co-morbid study in IL-10 knockout diabetic mice.  
In the current investigation, the dysregulation of several pro-inflammatory cytokines (TNF-α, 
IL-1β, IL-6, IFN-γ, IL-12, IL-2) in organs from diabetic mice during acute infection with M. 
fortuitum, M. bovis and M. tuberculosis is likely to contribute to dysregulated immune 
responses. Some of the cytokine data presented here shows discrepancies with data from 
chronic mycobacterial infection models discussed above. The current research focused 
primarily on comparing early inflammatory responses (i.e. 4-5 weeks) in diabetic and non-
diabetic hosts following intravenous infections. Many of the aforementioned diabetic animal 
models are chronic infection model, often using an aerosol infection route. Future studies could 
investigate the immune status of diabetics in chronic mycobacterial infections considering both 
routes of infection (aerosol and iv) 
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9 CHAPTER 9  
GENERAL DISCUSSION 
 
Type 2 diabetes (T2D) is considered to be one of the most significant risk factors for increased 
Tuberculosis (TB) susceptibility or its reactivation leading to higher mortality (Jeon and 
Murray, 2008, Martinez and Kornfeld, 2014, Hodgson et al., 2015). Understanding TB-T2D 
co-morbid infection has become a global public health issue. Whilst M. tuberculosis contributes 
to the majority of mycobacterial infections, there are more than 150 non-tuberculous 
mycobacterial (NTM) species which are capable of causing a wide spectrum of human diseases 
(Orme and Ordway, 2014). Epidemiological studies indicate a rising incidence in pulmonary 
and skin and soft tissue infections caused by NTM (e.g. M. fortuitum) (De Groote and Huitt, 
2006, Jackson et al., 2007, Hoefsloot et al., 2013) particularly in patients with AIDS and 
diabetes (Tortoli et al., 1995, Piersimoni et al., 1997, Gholizadeh et al., 1998, Uslan et al., 2006, 
Orme and Ordway, 2014, Bridson et al., 2016, Xu et al., 2016). The precise mechanisms 
underlying this increased susceptibility of diabetics to TB or NTM infections are unclear and 
many critical questions remain to be answered. The studies presented in this thesis contribute 
to our understanding of some key differences between diabetics and non-diabetics in their 
respective responses to mycobacterial infections, identifying deficits in macrophage function 
and an inability to regulate tissue inflammation as potential reasons for increased susceptibility. 
 
To date, relatively few studies have been done in either humans (Kumar Nathella and Babu, 
2017) or animal models (Saiki et al., 1980, Sugawara et al., 2004, Yamashiro et al., 2005, 
Martens et al., 2007, Vallerskog et al., 2010, Podell et al., 2014, Cheekatla et al., 2016) to dissect 
the pathobiology in TB-T2D comorbid infections. Mimicking the key features of the pathology 
of human T2D in animal models has proven challenging with numerous models evaluated over 
many years, often producing contradictory results. Whilst diverse animal models of T2D exist, 
animal models used to investigate TB-diabetes have primarily utilised administration of high-
dose of cytotoxic streptozotocin (STZ)/STZ+NA (Nicotinamide) to induce a T1D (type 1 
diabetes)-like disease. Despite the rapid onset of hyperglycaemia in these models, they do no 
accurately model the chronic vascular and inflammatory complications associated with T2D. 
Although these studies have provided substantial information as to how hyperglycaemia affects 
active TB disease, the influence of diet, a key driver of human T2D had not been modelled, 
thereby limiting the utility of these models to investigate the pathogenesis of increased 
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mycobacterial susceptibility in diabetics (Gilbert et al., 2011, Hodgson et al., 2013a). To 
address this need, we first characterised a diet-induced murine model of T2D that mimics the 
overt signs of chronic T2D of human patients. We then assessed macrophage function, the 
kinetics of infection and inflammation and mortality in diabetic and non-diabetic animals 
infected with three different mycobacteria species. We showed that antimycobacterial activity 
in diabetics is significantly compromised.   
 
In this thesis, we describe a detailed metabolic and biochemical characterisation of a diet-
induced murine model of T2D for evaluating mycobacterial susceptibility. An energy-dense 
diet (EDD); a combination of refined carbohydrate with a moderate amount of fat was used to 
induced diabetes. Other researchers used a traditional high-fat diet (60% of energy from fat) 
which markedly exceed the typical dietary intake in developed nations (34% energy) (Harika 
et al., 2013). A sole source of energy from the high-fat diet does not represent the global dietary 
pattern. A range of parameters was evaluated after EDD intervention, as high consumption of 
EDD has been linked to high energy intake and excess weight gain (Hodgson et al., 2013a). 
The specially formulated EDD influenced glucose metabolism and resulted in obesity induced 
T2D in mice which are reflected through the higher body weight gain (almost double the weight 
of control mice). Hyperglycaemia and insulin resistance is one of the pathognomonic clinical 
features of T2D in human (ADA., 2010). Comparison of hyperglycaemic status in mice 
indicated that EDD fed mice suffered from chronic hyperglycaemia as they become more 
glucose intolerant due to insulin resistance. Chronic hyperglycaemia imposes glucose toxicity 
on numerous cell types (e.g. pancreatic β-cells and vascular endothelial cells) and correlates 
with many diabetes-related complications. Chronic hyperglycaemia (glucose toxicity) and 
insulin resistance; characteristics features of T2D in human patients (ADA., 2010, Quan et al., 
2013), was observed in the mouse model we developed including elevated levels of HbA1c and 
hyperplasia of the pancreatic islets. Moreover, an overall adiposity in EDD fed mice also 
suggested dyslipidaemia although we didn’t determine the relevant parameters such as 
triglyceride, High- (HDL) and Low-Density Lipoprotein (LDL)-cholesterol concentration in 
blood. As dyslipidaemia is associated with T2D and forms part of the diagnostic criteria for 
metabolic syndrome (Mullarkey et al., 1990, Sacks et al., 2002, Abraira et al., 2003), additional 
studies are required to assess the parameters related to dyslipidaemia.  
 
We also determined the impact of EDD on renal function. Diabetic kidney disease is one of the 
most prevalent complications of T2D and is now the leading cause of end-stage renal disease 
(ESRD) in developed countries (Ghaderian et al., 2015). The pathogenesis of diabetic kidney 
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disease is multifactorial, with the interaction of both genetic and environmental factors that 
trigger a complex network of pathophysiological events. The main criteria to diagnose diabetic 
kidney disease is the presence of an increased urinary albumin excretion (microalbuminuria and 
macroalbuminuria), which is associated with an increased risk of decline in glomerular filtration 
rate and a high risk of kidney failure (Gross et al., 2005, Fowler, 2008, Dabla, 2010). Energy- 
dense diet fed mice showed microalbuminuria and higher urinary albumin creatinine ratio 
(ACR) than non-diabetic animals, indicating some level of glomerular damage. Furthermore, 
lower levels of urinary creatinine in EDD fed mice also suggested kidneys were unable to 
function properly to filter circulating creatinine. The current study did not measure plasma 
creatinine concentrations, therefore further studies are required to accurately determine 
creatinine clearance. The urine biochemical parameters together with observed changes in 
kidney structure (mesangial thickening in the glomeruli and glomerular hypertrophy) have 
demonstrated a prolonged EDD intervention can result in significant kidney damages.  
 
Subclinical chronic inflammation is a hallmark of T2D and its associated vascular 
complications characterised by oxidative stress, elevated levels of acute phase proteins (e.g. C-
reactive protein), accumulation of advanced glycation end products, inflammatory cytokines 
and changing the proportion of immune cell subsets and their functions (Jagannathan-Bogdan 
et al., 2011, Morris et al., 2016). Future studies can also be directed to determine these 
parameters in this T2D model to better understand the pathophysiology of T2D and 
interpretation of co-morbid infections.   
 
Susceptibility to M. fortuitum, M. bovis (BCG) and M. tuberculosis (H37Rv) infections was 
determined using this T2D model (Chapter 5, 6, 7 and 8). To our knowledge, this was the first 
study to investigate host-M. fortuitum and M. bovis (BCG) interactions in diet-induced diabetic 
animal model. When the mice were challenged with high-doses of all species, increased 
mortality was observed in diabetic mice (Chapter 6). The lower survival of diabetic mice 
infected with all mycobacteria species indicated defective antimycobacterial immunity. In host-
mycobacterial infections, the primary encounter is mediated by the macrophages, particularly 
the alveolar macrophages (Tascon et al., 2000, Gonzalez-Juarrero et al., 2001, Dheda et al., 
2010). The primary function of the macrophage is phagocytosis (uptake and killing) of the 
bacilli (Henderson et al., 1997, Thurnher et al., 1997) followed by the production of the myriad 
of pro- and anti-inflammatory cytokines required for mounting an effective immune response. 
Assessment of the uptake and killing capability of alveolar (AM) and resident peritoneal 
macrophages (RPM) revealed decreased uptake and killing of all mycobacteria species by 
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diabetic macrophages (Chapter 5). Further, the uptake of mycolic acid coated beads by both 
diabetic AM and RPM was also reduced compared to uncoated beads suggestive of modulation 
of phagocytic uptake mediated, at least in part, by components of mycolic acid. The higher 
bacterial burden in the organs of mycobacteria-infected diabetic mice also suggested that 
macrophage phagocytic functions were impaired in diabetes (Figure 9.1). Although the precise 
mechanisms underlying this decreased phagocytic function in diabetic macrophages remains 
unclear, previous studies have suggested the following as possible reasons: (i) impairment of 
pattern recognition receptors (PRRs) signalling; (ii) lower expression of scavenging receptors 
(e.g. macrophage receptors with collagenase structure; MARCO, mannose, mincle receptors); 
(iii) reduced activation of co-stimulatory molecules (e.g. major histocompatibility complex 
Class II, CD14); (iv) reduced association (attachment), alteration of complement (C3b) and 
complement receptors (CR1 and CR3) with macrophages; (v) differentiation and reduction of 
macrophage number and; (vi) impaired cytokine production. It is also possible that a 
combination of these processes contributes to the defective immune responses in diabetics. In 
TB defence, host recognition by the different PRRs (mannosylated lipoarabinomannan, 
ManLAM, toll like receptors 2; TLR-2, C-type lectin) is a primary immune event that not only 
activates innate immune mechanisms, but also assists in the development of antigen specific 
adaptive immunity (Ahmad, 2011). In this host recognition process, many scavenging receptors 
are involved in phagocytosis of the bacilli, with one of the major receptors, being MARCO. 
Bowdish and colleagues (2009) demonstrated that phagocytosis by macrophages is reduced due 
to lower expression of MARCO receptors and CD14, a co-stimulatory molecule that acts with 
MARCO in the recognition of the mycobacterial cell wall components (e.g. trehalose 6,6′-
dimycolate). Amongst the receptors that mediate phagocytosis, complement receptors 1 and 3 
(CR1 and CR3) are essential, with 80% of M. tuberculosis phagocytosis being associated with 
CR3. Future studies could be directed to explore the roles of these different PRRs, scavenging 
receptors and co-stimulatory molecules in diabetic animal models to better understand their 
respective roles in host recognition, mycobacterial uptake and killing.  
 
In our study, an overall decreased production of pro-inflammatory cytokines (TNF-α, MCP-1 
and IL-6, IL-1β) by diabetic macrophages was associated with impaired killing of mycobacteria 
(Figure 9.1). Among these cytokines, TNF-α enables macrophages to secrete more 
antimycobacterial compounds (e.g. ROS and iNOS) to kill internalised bacteria (Schlesinger et 
al., 1990, Ahmad, 2011). The production of IL-1β and IL-6 further enhances the production of 
TNF-α (also IFN-γ) from macrophages (Saunders et al., 2000, Cooper, 2009, Cooper et al., 
2011). Decreased production of these cytokines in this study suggested that lower secretion of 
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antimycobacterial compounds by the mycobacteria infected macrophages leading to higher 
bacterial burden in the diabetic host. Future studies could determine whether the production of 
specific antimicrobial compounds is impaired in diabetic macrophages in vivo. Abnormal 
differentiation and egress of macrophage precursors from bone marrow have been observed in 
diabetic animals (Nikolic et al., 2004, Ma et al., 2008). Consistent with these findings, we 
observed decreased numbers of macrophages in peritoneal exudates and broncho-alveolar fluid 
from diabetic mice; potentially contributing to the impaired phagocytosis observed in diabetes.  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 9.1 Impairment of macrophage functions in type 2 diabetes-mycobacterial co-
morbid infections  
In M. tuberculosis infection, the transition from innate immune to adaptive responses requires 
phagocytic antigen presenting cells (dendritic cells and macrophages) to deliver peptides of the 
bacilli from the alveolar space to lung-draining lymph nodes for naïve T cell priming (Cooper, 
2009). Although the current study used an intravenous route of infections and didn’t determine 
the function of antigen presenting cells per se, our results suggest that antigen presentation may 
be delayed, followed by delayed or impaired T cell priming. IL-12 is a crucial cytokine (signal 
3) associated with antigen presentation and Th1 cells differentiation from naïve CD4 T cells. 
IL-2 enhances Th1 cell clonal expansion. IFN-γ is a key cytokine secreted mostly by activated 
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Th1 cells and involved in the macrophage-activating effector function (Cooper, 2009, Cooper 
et al., 2011). The central role of Th1 cells in the defence against TB has been attributed to the 
ability of Th1 cell-derived IFN-γ to activate macrophages and stimulate phagocytosis, 
phagosome maturation, production of antimycobacterial compouds, killing of bacteria and 
antigen presentation. Th1 cells secrete IFN-γ to promote macrophage M1 polarisation and 
enhance its pro-inflammatory functions by inducing the release of IL-1β, IL-6 and TNF-α. In 
the absence of effective IFN-γ signalling, increased TB susceptibility as a result of reduced 
production of antimycobacterial compounds by the macrophages and failure to restrict the 
growth of the bacilli was observed (Cooper et al., 1993, Flynn et al., 1993). We observed 
decreased levels of IFN-γ in diabetic animals in response to mycobacterial infections suggesting 
impaired/delayed Th1 cell responses in early infection. This result may be further explained by 
the decreased production of IL-12 and the lower production of IL-2 that could further reduce, 
or at least, delayed Th1 cell differentiation and expansion in acute TB-T2D co-morbid 
infections (Cooper, 2009, Cooper et al., 2011). However, some prior studies demonstrated a 
high pro-inflammatory responses (e.g. TNF-α, IL-6, MCP-1, IFN-γ) in chronic TB-diabetes co-
morbid patients (Kumar Nathella and Babu, 2017), although there are also conflicting reports 
(Tsukaguchi et al., 1992, Tsukaguchi et al., 1997, Tsukaguchi et al., 2002, Kumar et al., 2014). 
The possible explanations of these paradoxical findings in chronic TB-diabetes suggested by 
the previous research are (i) persistent higher bacterial burden (ii) alteration of downstream 
signal transduction and regulation (iii) inactivity of the cytokines (iv) an increased half-life of 
cytokine due to delayed proteolysis. All these events are resulted in with the accumulation of 
AGEs in diabetes (Greenhalgh and Hilton, 2001, Tamarat et al., 2003, Restrepo et al., 2008a, 
Uribarri et al., 2010) and mechanisms need to be addressed by future studies.  
Our findings also suggested the possibility of a shift of the immune system towards Th2 cell 
responses in diabetics (Figure 9.1). We observed increases in the Th2 cell associated cytokine 
IL-4 in response to early mycobacterial infections. IL-4 may induce macrophages to take on an 
M2 phenotype in order to resolve inflammation (Cooper, 2009, Cooper et al., 2011). 
Furthermore, IL-4 down-regulates Th1 responses by inhibiting Th1 cell differentiation and 
inducing a reversion of developing Th1 cells to the Th2 lineage and further influencing the 
transcription of the IFN- gene in Th1 effector cells (Wurtz et al. 2004). 
To overcome the limitation of these studies, future studies can be directed towards evaluating: 
(i) whether delayed antigen presenting cell trafficking from the alveolar airspace to regional 
lymph nodes impairs/delays antigen presentation; (ii) macrophage differentiation (pro or anti-
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inflammatory) and (iii) T cell differentiation and phenotypes (iv) and cytokine gene expression 
in diabetics infected with mycobacteria in both acute and chronic mycobacterial infections. 
Such studies will widen our understanding of T cell mediated responses in diabetic individuals. 
The current study highlighted the diminished antimycobacterial functions during acute 
mycobacterial infections. It would however be interesting to determine whether our findings 
would be replicated using chronic infection models (e.g. aerosol infections). 
The granuloma is considered a hallmark of TB infection. The granuloma is a type IV 
hypersensitivity reaction characterised by (i) infiltration of leucocytes; (ii) tissue destruction 
induced by persistent organisms or inflammatory cells and (iii) attempted healing by connective 
tissue replacement of damaged tissue and fibrosis. It contains live bacilli and prevents bacterial 
dissemination and reactivation of disease (Saunders and Cooper, 2000, Ehlers, 2009). 
Formation of the granuloma is one of the important outcomes of TB defence but its 
effectiveness in containing live microorganisms relies on appropriate innate and adaptive 
immune responses involved in its formation (Korbel et al., 2008). Macrophages are the principal 
cells found in the TB granuloma (Jo et al., 2007, Cooper et al., 2011). The granuloma is mainly 
composed of centrally infected macrophages surrounded by epithelioid cells, foamy 
macrophages, multinucleated giant cells of the Langhans type which are peripherally 
surrounded by CD4+ and CD8+ T cells (Gonzalez-Juarrero and Orme, 2001, Puissegur et al., 
2004). A mature granuloma is compact, highly stratified, becomes vascularised and develops a 
fibrotic capsule (Russell, 2007). However, the granuloma-associated cells aggregate in response 
to different cytokines (e.g. TNF-α, IL-12, IFN-γ) and chemokines (e.g. MCP-1) during host-
mycobacterial interactions (Saunders and Cooper, 2000, Saunders et al., 2005, Guirado and 
Schlesinger, 2013). Our findings suggest that there is defective or delayed formation of the 
granuloma/inflammatory foci possibly due to impaired macrophage antimycobacterial 
functions and Th1 cell responses. In diabetic mice infected with mycobacteria, inflammatory 
foci in liver were more diffuse with loosely associated cells containing higher numbers of 
bacilli. The presence of bacilli scattered throughout liver parenchyma rather than being 
contained within inflammatory foci, suggests that leucocyte recruitment in response to higher 
numbers of bacteria may also be impaired. Consequently, bacilli were diffusely spread and 
poorly confined within the tissue which was indicative of poor granuloma formation in diabetic 
mice. In contrast, the granulomas of non-diabetic mice were more compact with a lower number 
of bacteria. Previous research has shown that granulomas are larger in size, rich in activated 
macrophages and with few surrounding lymphocytes in immunodeficient patients with TB, 
whereas they are small, compact with more IFN-γ producing CD4 T cell in immunocompetent 
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individuals with TB infection (Ulrichs et al., 2005). Although this study didn’t determine the 
involvement of specific cells in the formation of granuloma, it would be interesting to explore 
cell phenotypes in future research.  
The current study also suggested another possibility: the breakdown of this defective granuloma 
increases the risk of reactivation of disease. Understanding the cellular basis of latent TB 
infection (LTBI) is an area of research that requires special attention as an estimated one third 
of the world population (approximately 2.5 billion) is currently considered to be latently 
infected with TB. Due to the increase in T2D and an ageing population, a considerable 
proportion of those cases could reactivate presenting a major worldwide public health crisis 
(Martinez and Kornfeld, 2014). The development of a good, tractable LTBI model is a 
prerequisite to investigate how T2D influences the risk to reactivation of latent disease. The use 
of the EDD animal model described in this study combined with novel LTBI animal models 
will certainly enhance our understanding of the true risk that T2D poses in infected people 
throughout the world. As highlighted throughout this thesis TB-T2D coinfection has the 
potential to become a major public health problem. Research into the immune mechanisms of 
TB-T2D coinfection should pave the way for the development of effective treatment and 
preventive options that reach the world’s most vulnerable populations.  
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APPENDIX 1 
 
A1.1 General solutions and media 
A1.1.1 Single strength culture medium  50 mL  
RPMI 1640 (87%)   43.50 mL 
L- glutamine (1%)   0.5 mL  
HI-FBS (10%)    5 mL 
HEPES (2%)    1 mL  
Penicillin/streptomycin  500 µL 
 
A1.1.1.1 L-glutamine stock solution 
Aliquot 200 mL (GibcoTM 200 mL bottle, 200 mM), into 5 mL tubes and store at -20°C. 
 
A1.1.1.2 Heat-inactivated foetal bovine serum (HI-FBS) 
Defrost Fetal Bovine Serum (GibcoTM, 500 mL bottle, storage -5 to -200C), then, heat 500 mL 
of Fetal Bovine Serum (FBS) at 560C for 25 minutes. Cool to room temperature (RT) and 
aliquot into 10 mL plastic tubes followed by storage at -200C until use.  
 
A1.1.1.3 Penicillin and Streptomycin 
GibcoTM Pen Strep, 100 mL bottle. This solution contains 10,000 units/mL (i.e 100 U/mL) of 
Penicillin and 10,000 µg/mL of Streptomycin. Defrost a bottle and aliquot into 5 mL tube, 
storage -5°C to -20°C. Add 1 mL GibcoTM Pen Strep in 100 mL RPMI/or 5 mL Gibco Pen Strep 
in 500 mL of RPMI 1640. 
 
A1.1.2 Amikacin sulfate salt (1300 µg/mL) 
Amikacin sulfate salt (cat. no A2324-5G, sigma) 13 mg 
Distilled water (autoclaved)    10 mL 
 
A1.1.3 Phosphate/ Dulbecco’s phosphate-buffered saline/ 1x Cold harvest medium 
Sodium chloride (NaCl)     8 g 
Sodium dihydrogen orthophosphate (NaH2PO4) 0.64 g 
Potassium chloride (KCl)    0.2 g 
Potassium dihydrogen orthophosphate (KH2PO4) 0.16 g 
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Make up to 950 mL with single distilled water and adjust pH to 7.2 before bringing the final 
volume to 1000 mL. Autoclave at 1210C for 15 minutes. 
 
A1.1.4 Trypan blue (0.4%) (w/v) (for 10 mL) 
Trypan blue      0.04 g 
Distilled water     10 mL 
 
A1.1.5 Ethanol (30%) 
Absolute ethanol     30 mL 
Distilled water      70 mL 
 
A1.1.6 Ethanol (1%) 
Absolute ethanol     1 mL 
Distilled water     99 mL 
 
A1.1.7 F68 buffer (0.1%)  
F68 buffer stock (10x) (cat. no. P566, Sigma) 1 mL 
Distilled water     99 mL 
 
A1.1.8 EDTA (ethylenediaaminetraacetic acid), 0.5 M (pH 8.0)  
Disodium EDTA dehydrate     186.1 g     
Distilled water     700 mL     
 
Adjust pH to 8.0 with 10 M NaOH. Add water to make 1 litre and autoclave 
 
A1.1.9 10 mM EDTA 
EDTA stock 0.5 M     1 mL 
1x PBS (autoclaved)     49 mL 
 
A1.1.10 Triton 100x (0.1%)  
Triton X-100 (cat. no. X100-100 mL, Sigma) 0.5 mL 
Distilled water     500 mL  
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A1.1.11 Azide buffer  
PBS (pH 7.2)       1000 mL 
HI-FBS (1%)      10 mL 
Sodium Azide (0.1%)         1mL 
 
A1.1.12 Brewer’s thioglycollate medium (3%) (w/v)  
Brewer’s thioglycollate medium   1.5 g  
Distilled water     50 mL 
 
A1.1.13 Broncho-alveolar buffer  
PBS        500 mL 
BSA fraction V (culture graded, Sigma A-2153) 1 g 
EDTA (0.25 M)      400 µL 
Filter sterilise by 63 µm filter unit 
 
A1.1.14 RBC lysis buffer (1x)  
RBC lysis buffer stock     2 mL 
(cat no. 004300, eBioscience, 10x) 
Distilled water     18 mL 
 
A1.1.15 Middlebrook 7H9 liquid medium 
Middlebrook 7H9 powder     4.7 g  
(cat. no. DF0713-17-9, BD Biosciences) 
Glycerol (50%, w/v)      10 mL  
Tween 80 (20%) 2.5 mL 
Distilled water  up to 900 mL 
 
Autoclave it and cool on bench for 30 minutes with stirring 
OADC medium (cat. no. 212240, BD Biosciences)  100 mL 
 
A1.1.16 Middlebrook 7H11 solid medium 
Middlebrook 7H11 powder  21 g 
(cat. no. DF0838-17-9, BD Biosciences) 
Glycerol (50%, w/v)  10 mL 
 
Autoclave it and cool on bench for 30 minutes with stirring 
 OADC medium (add before use)   100 mL 
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A1.1.17 Storage medium for mycobacteria 
Middlebrook 7H9 powder    0.47 g  
Glycerol (50%, w/v)      90 mL 
Tween 80 (20%)  0.25 mL 
 
Autoclave it and cool on bench for 30 minutes  
OADC medium (add before use)   10 mL 
 
A1.1.18 Tween 80, 20% (v/v) 
Tween 80       20 mL 
Distilled water      80 mL 
 
A1.1.19 Carbonate-bicarbonate buffer (100 mL) 
Buffer capsule  (cat. no. C3041, Sigma)  1 
Deionised water      100 mL 
 
A1.1.20 Chloroform: methanol solution (100 mL) 
Chloroform      10 mL 
Methanol      90 mL 
 
A1.1.21 Neutral buffered formalin (10%) 
Formalin (37-40% stock solution)    100 mL 
Water        900 mL 
NaCl       9 g 
Na2HPO4 (dibasic/anhydrous)   12 g 
 
A1.1.22 Lithium-heparin stock  
Lithium-heparin (1.5 mg/mL or 210 IU/mL)  150 mg 
PBS       100 mL  
 
A1.1.23 BD IMag™ buffer (1x working solution) 
BD IMag™ buffer       2 mL 
(cat. no. 55236, BD Biosciences, 10x) 
Deionised water     18 mL 
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A1.2 Staining methods and reagents 
A1.2.1 Haematoxylin and Eosin staining  
Procedure: Paraffin sections were dewaxed in two changes of xylene (2 minutes each), three 
changes of graded ethanol (descending concentration; 100 to 70% v/v; 2 minutes, 1 minute and 
1 minute) and washed in running tap water (1 minute). The sections were stained with Mayer’s 
haematoxylin (8 minutes) followed by washing in running tap water for 30 seconds, Scott’s tap 
water for 30 seconds and again running tap water for 2 minutes. Slides were then stained with 
eosin (4 minutes) and washed in running tap water (5 dips). The stained slides were dehydrated 
through a series of graded ethanol (70 to 100%) and xylene. Slides were mounted in DPX. 
 
A1.2.1.1 Mayer’s hamatoxilin 
Haematoxylin      2 g 
Sodium idodate      4 g 
Aluminium sluphate     100 g 
Citric acid      2 g 
Chlorol hydrate     100 g 
 
Combine ingredients with 2 litres of distilled water 
 
A1.2.1.2 Eosin 
Eosin       15 g 
Erythrosin      5 g 
Calcium chloride     5 g 
 
Combine ingredients with 2 litres of distilled water 
 
A1.2.1.3 Scott’s tap water 
Sodium carbonate     8.75 g 
Magnesium sulphate     50 g 
Combine ingredients with 2.5 litres of distilled water 
 
A1.2.2 Modified Herxheimer’s staining  
Procedure: Frozen sections were stained with Herxheimer’s solution (8 minutes) and followed 
by rinsing with ethanol (70%) and water (2 minutes). Slides were then rinsed in Scott’s tap 
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water substitute for 30 seconds and water. The stained slides were mounded on aqueous 
mounting media.  
 
A1.2.2.1 Herxheimer’s solution 
Acetone (saturated with oil Red O and Sudan IV0) 50 mL 
Ethanol (70%)      50 mL   
 
A1.2.3 Periodic Acid Schiff’s staining  
Procedure: Paraffin sections were dewaxed and oxidised in periodic acid (2 minutes) followed 
by washing in running tap water (5 minutes) and distilled water (twice). Sections were then 
placed in Schiff’s reagent for 10 minutes. Slides were washed again with distilled water (once) 
and running tap water to stain with Mayer’s hematoxylin (30 seconds). After rinsing the 
sections in water, they were dehydrated through a series of graded ethanol and xylene. The 
stained slides were mounted in DPX.  
 
A1.2.3.1 Periodic Acid (1%) 
Periodic Acid       1 g 
Distilled water      100 mL 
 
A1.2.3.2 Schiff’s reagent 
Basic Fuschin      1 g 
Distilled water      200 mL 
1 N HCl      20 mL 
Sodium metabisulfite     1 g 
 
Dissolve Basic Fuchsin and metabisulfite in HCl and add 200 mL of water. Store in the dark 
18-24 hours. Add 2 g of activated charcoal and shake for 1 minute. Remove charcoal by 
filtration and store the solution in the dark at 0-4°C. 
 
A1.2.4 Ziehl-Neelsen staining 
Procedure: Paraffin sections were dewaxed in two changes of xylene (2 minutes each), three 
changes of graded ethanol (descending concentration; 100 to 70% v/v; 2 minutes, 1 minute and 
1 minute) and washed in running tap water (1 minute). The sections were stained in Carbol 
fuschin. Heat was applied until streaming and left the slide for 5 minutes.  The slides were 
then decolorise using acid alcohol for 10-15 seconds. After washing with tap water, counter 
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staining was done using 0.5% Methylene blue for 5-10 seconds. The stained slides were 
dehydrated through a series of graded ethanol (70 to 100%) and xylene. Slides were mounted 
in DPX. 
 
A1.2.4.1 Carbol fuschin solution  
Basic fuschsin      0.3 g  
Ethanol (95%, v/v)     10 mL  
Phenol (heat-melted crystals)    5 mL  
Distilled water      95 mL  
 
A1.2.4.2 Acid Alcohol  
Ethanol (95%, v/v)     97 mL  
HCl (concentrated)     3 mL 
 
A1.2.4.3 Methylene blue solution (0.5%) 
Methylene blue     0.5 g 
Distilled water     100 mL 
 
A1.3 Miscellaneous methods and reagents 
A1.3.1 Preparation of glucose solution for glucose tolerance test 
Method: Glucose solution should be prepared in advance prior (usually before the test day) to 
the glucose tolerance test (GTT). An appropriate amount of the D-glucose (Ajax Chemicals D-
glucose) was measured based on the lean body weight of mice (70 and 90% of the total body 
mass of mice on energy-dense diet and standard rodent diet; respectively). The required amount 
of glucose for each mouse is usually delivered through 100 µL of PBS. The total volume of 
PBS based on total number of animals was calculated. The required amount of D-glucose and 
PBS was taken into a 70 mL container and mixed until fully dissolved. The fluid was then 
filtered through a 2 µm syringe filter unit (Millex-GP Syringe Filter Unit). One mL syringes 
were filled, labelled appropriately and kept in 40C until use. For injection, an appropriate sized 
needle (TERUMO® needle 27G x ½ (#NN+2713R) were used. 
 
D-Glucose Solution 
Ajax Chemicals D-glucose (CH2OH.CH.(CHOH)4.O), 2 g/kg lean body mass 
PBS (pH 7.2)       10 mL  
TERUMO® syringes (#SS+01T; 1 per cage)   1 cc/mL 
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TERUMO® needle 27 G x ½ (#NN+2713R; 1 per cage)  
Millex-GP Syringe Filter Unit, 0.2 µm (SLGP033RS) 
Sarstedt 70 mL container 
 
A1.3.2 Beckman Coulter AU480 methods of analysis 
A1.3.2.1 Beckman Coulter AU480 reagents for whole blood and urine analysis 
 Glucose reagent 1 and 2 (OSR6121) 
 HbA1c reagent 1 and 2 (OSR6192) 
 Total haemoglobin reagent (OSR6192)   
 Haemoglobin denaturant (OSR0004)  
 Microalbumin reagent 1 and 2 (OSR6167) 
 Creatinine reagent 1 and 2 (OSR6178) 
 Control serum 1 and 2 (ODC0003, ODC0004) 
 Thermo Scientific MAS Diabetes 1 and 2 (DBCL-MP) 
 Thermo Scientific MAS Omni•CORE™ (OCR-101) 
 Bio-Rad Liquichek® Urine Chemistry Control 1 and 2  
 System calibrator (ODC66300) 
 Urine calibrator (ODC0025) 
 HbA1c calibrator (ODR3032) 
 Microalbumin calibrator (ODR3024) 
 Beckman Coulter 0.5 mL sample cups (#651412) 
Cartel Cobas Cups (#2940-04) 
 
Method: Daily maintenance and calibration were done according to the manufacturer’s 
instructions. Samples were analysed if quality control samples were within the acceptable 
ranges. Test samples were distributed into Beckman Coulter sample cups (#651412) or Cartel 
Cobas Cups (#2940-04) depending on the volume available and into appropriate racks (blood 
or urine sample racks) in order from rack 1 to 20. 
 
A1.3.3 Sterilisation of mycobacterial samples 
Method: The mycobacterial cultures (1.5x107 CFU/ 100 µL for M. tuberculosis H37Rv and 
3.5x106 CFU/100 µL for M. bovis BCG) were treated with paraformaldehyde (PFA) solution 
(3.33%). A 100 µL of the mycobacterial culture was treated with 500 µL of the PFA for 0, 30, 
40 and 50 minutes. In the control groups, PBS was used instead of the PFA. Immediately after 
the end of timepoint, the PFA and PBS treated culture tubes were washed with PBS and 
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resuspended into the initial volume. Then, 200 µL of the treated bacterial culture from each 
tube were plated on 7H11 agar plates. The plates were checked for the growth of the bacteria 
following incubation at 370C for 3-4 weeks. The untreated bacterial cultures were also plated 
to confirm the presence of the mycobacteria in the suspension as positive control (Figure A1.1). 
 
 
 
Figure A1.1 Sterility checking of the pure culture of M. tuberculosis (H37Rv) after 
paraformaldehyde treatment 
The pure culture of M. tuberculosis (H37Rv) was treated with 3.33% paraformaldehyde (PFA) 
and phosphate buffer saline (PBS). There was no mycobacterial growth in PFA treated culture 
(clear agar plates), whereas numerous bacterial growth was observed in the PBS treated culture 
(deep white/cream colour on the agar plates). The photographs illustrate the pure culture 
without any treatment (A), pure culture in PBS (B), culture treated with PBS versus (vs) PFA 
at 30 minutes (C vs D), 40 minutes (E vs F) and 50 minutes (G vs H) post treatment. 
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APPENDIX 2 
 
Supplementary data from mouse model characterisation study (Chapter 4) 
 
Table A2.1 Feed intake by JCU bred mice (week 1 to 30) on standard rodent diet and 
energy-dense diet  
Week 
 
JCU bred mice, feed intake/mouse/day 
 
SRD EDD   
No. 
cages 
Mean(g)±SEM No. cages Mean(g)±SEM p-value 
Level of 
significance 
1 7 3.90±0.00 8 2.95±0.04 0.1158 ns 
2 7 3.90±0.00 8 3.34±0.34 0.9359 ns 
3 7 3.90±0.00 8 2.98±0.13 0.1535 ns 
4 7 3.52±0.21 8 3.10±0.15 0.9984 ns 
5 7 3.85±0.03 8 3.57±0.29 >0.9999 ns 
6 7 3.75±0.08 8 3.55±0.41 >0.9999 ns 
7 7 3.76±0.08 8 3.07±0.19 0.6630 ns 
8 7 3.70±0.06 8 3.07±0.21 0.8261 ns 
9 7 3.66±0.08 8 3.98±0.59 >0.9999 ns 
10 7 3.49±0.14 8 3.33±0.13 >0.9999 ns 
11 7 3.85±0.05 8 4.34±0.76 0.9872 ns 
12 7 4.57±0.28 8 3.27±0.22 0.0027 ** 
13 7 3.90±0.00 8 3.68±0.21 >0.9999 ns 
14 7 4.37±0.13 8 3.54±0.13 0.3178 ns 
15 7 3.95±0.11 8 4.41±0.74 0.9957 ns 
16 7 4.00±0.10 8 3.98±0.36 >0.9999 ns 
17 7 4.06±0.09 8 3.67±0.17 0.9998 ns 
18 7 4.30±0.08 8 3.24±0.07 0.0397 * 
19 7 4.15±0.09 8 3.41±0.20 0.5341 ns 
20 7 4.11±0.13 8 3.66±0.09 0.9975 ns 
21 7 4.21±0.14 8 3.79±0.25 0.9990 ns 
22 7 4.31±0.07 8 3.24±0.16 0.0371 * 
23 7 4.22±0.11 8 3.98±0.32 >0.9999 ns 
24 7 4.42±0.04 8 3.30±0.11 0.0212 * 
25 7 3.97±0.04 8 3.57±0.12 0.9995 ns 
26 7 4.14±0.11 8 3.25±0.05 0.1947 ns 
27 7 4.38±0.09 8 3.57±0.12 0.3364 ns 
28 7 4.28±0.08 8 3.63±0.08 0.8006 ns 
29 7 3.91±0.14 8 3.19±0.10 0.6101 ns 
30 7 3.91±0.14 8 3.19±0.10 0.6101 ns 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. In the table, SRD; Standard 
rodent diet, EDD; Energy-dese diet. Each mouse cage contains 5 mice. 
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Table A2.2 Energy intake by JCU bred mice (week 1 to 30) on standard rodent diet and 
energy-dense diet  
Week 
 
JCU bred mice, energy intake/mouse/day 
 
SRD EDD   
No. 
cages 
Mean(kcal) 
±SEM 
No. cages 
Mean (kcal 
)±SEM 
p-value 
Level of  
significance 
1 7 11.97±0.00 8 14.08±0.19 0.9961 ns 
2 7 11.97±0.00 8 15.94±1.00 0.2588 ns 
3 7 11.50±0.33 8 14.25±0.63 0.9001 ns 
4 7 10.82±0.66 8 14.79±0.72 0.2576 ns 
5 7 11.81±0.09 8 17.07±1.37 0.0198 * 
6 7 11.52±0.24 8 16.97±1.94 0.0126 * 
7 7 11.55±0.25 8 14.65±0.89 0.7398 ns 
8 7 11.37±0.18 8 14.69±1.00 0.6121 ns 
9 7 11.24±0.25 8 19.01±2.82 <0.0001 **** 
10 7 10.70±0.44 8 15.89±0.63 0.0229 * 
11 7 11.82±0.15 8 20.76±3.65 <0.0001 **** 
12 7 14.02±0.88 8 15.60±1.06 >0.9999 ns 
13 7 11.97±0.00 8 17.58±0.99 0.0086 ** 
14 7 13.47±0.35 8 16.93±0.63 0.5251 ns 
15 7 12.12±0.34 8 21.06±3.52 <0.0001 **** 
16 7 12.28±0.32 8 19.01±1.74 0.0004 *** 
17 7 12.46±0.28 8 17.56±0.81 0.0285 * 
18 7 13.20±0.23 8 15.46±0.34 0.9896 ns 
19 7 12.75±0.29 8 16.30±0.96 0.4670 ns 
20 7 12.61±0.39 8 17.51±0.45 0.0432 * 
21 7 12.93±0.43 8 18.12±1.18 0.0229 * 
22 7 13.24±0.23 8 15.49±0.74 0.9901 ns 
23 7 12.97±0.34 8 19.03±1.53 0.0027 ** 
24 7 13.58±0.12 8 15.77±0.51 0.9935 ns 
25 7 12.19±0.12 8 17.06±0.60 0.0470 * 
26 7 12.71±0.35 8 15.53±0.25 0.8737 ns 
27 7 13.46±0.27 8 17.04±0.55 0.4541 ns 
28 7 13.13±0.25 8 17.37±0.37 0.1632 ns 
29 7 11.99±0.44 8 15.26±0.46 0.6430 ns 
30 7 11.99±0.44 8 15.26±0.46 0.6430 ns 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-significant. In 
the table, SRD; Standard rodent diet, EDD; Energy-dese diet. Each mouse cage contains 5 mice. 
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Table A2.3 Body weight of JCU bred mice (week 1 to 30) on standard rodent diet and 
energy-dense diet 
Week 
JCU bred mice, body weight 
SRD EDD   
Number Mean(g)±SEM Number 
Mean 
(g)±SEM 
p-
value 
Level of 
significance 
0 35 15.49±0.29 35 15.03±0.43 >0.9999 ns 
1 35 18.00±0.22 35 20.14±0.32 0.0398 * 
2 35 18.81±0.24 35 22.62±0.28 <0.0001 **** 
3 35 19.22±0.23 35 24.54±0.31 <0.0001 **** 
4 35 21.18±0.24 35 25.82±0.32 <0.0001 **** 
5 35 21.93±0.21 35 27.43±0.36 <0.0001 **** 
6 35 21.39±0.32 35 28.53±0.40 <0.0001 **** 
7 35 21.84±0.35 35 29.40±0.45 <0.0001 **** 
8 35 23.15±0.28 35 29.84±0.56 <0.0001 **** 
9 34 23.69±0.30 35 31.05±0.53 <0.0001 **** 
10 34 23.79±0.33 35 31.91±0.64 <0.0001 **** 
11 34 23.96±0.26 35 32.82±0.64 <0.0001 **** 
12 34 25.53±0.25 35 33.33±0.65 <0.0001 **** 
13 34 25.87±0.21 35 34.12±0.67 <0.0001 **** 
14 34 26.07±0.23 35 34.99±0.68 <0.0001 **** 
15 34 25.91±0.25 35 36.63±0.74 <0.0001 **** 
16 34 26.33±0.25 35 37.99±0.77 <0.0001 **** 
17 34 26.61±0.25 35 38.74±0.77 <0.0001 **** 
18 34 27.18±0.25 35 39.91±0.81 <0.0001 **** 
19 34 26.93±0.25 35 41.13±0.81 <0.0001 **** 
20 34 27.07±0.23 35 42.05±0.76 <0.0001 **** 
21 34 27.45±0.24 35 42.80±0.72 <0.0001 **** 
22 34 27.42±0.29 35 42.99±0.72 <0.0001 **** 
23 34 28.31±0.29 35 44.24±0.68 <0.0001 **** 
24 34 27.61±0.26 35 44.43±0.67 <0.0001 **** 
25 34 27.75±0.26 35 44.41±0.65 <0.0001 **** 
26 34 28.14±0.28 35 43.44±0.67 <0.0001 **** 
27 34 27.65±0.31 35 44.53±0.70 <0.0001 **** 
29 34 28.04±0.26 35 45.90±0.70 <0.0001 **** 
30 34 27.86±0.29 35 46.31±0.69 <0.0001 **** 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as *p≤0.05, ****p≤0.0001 and ns=non-significant. In the table, SRD; Standard 
rodent diet, EDD; Energy-dese diet.   
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Table A2.4 Glucose tolerance test of JCU and ARC bred mice on standard rodent diet 
and energy-dense diet at 25th and 30th week of diet intervention 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. Data 
presented as mean±SEM. The level of significance was indicated as **p≤0.01, ***p≤0.001, ****p≤0.0001 and 
ns=non-significant. In the table, SRD; Standard rodent diet, EDD; Energy-dese diet.   
 
JCU bred mice, 25th week,  
Time (minutes) Number 
SRD 
(mmol/L) 
Number 
EDD 
(mmol/L) 
p-value 
Level of 
significance 
Baseline 35 7.83±0.27 34 9.09±0.34 0.5138 ns 
15 35 21.12±0.81 34 20.60±0.63 0.9780 ns 
30 35 17.75±0.75 34 20.73±0.82 0.0021 ** 
60 35 12.44±0.62 34 16.81±0.64 <0.0001 **** 
120 35 8.34±0.32 34 11.16±0.34 0.0041 ** 
JCU bred mice, 30th week 
Baseline 35 8.50±0.25 34 8.80±0.25 0.9905 ns 
15 35 17.33±0.48 34 19.41±0.58 0.0017 ** 
30 35 12.95±0.40 34 17.89±0.67 <0.0001 **** 
60 35 11.04±0.29 34 13.21±0.42 0.0010 *** 
120 35 8.72±0.22 34 10.10±0.24 0.0821 ns 
ARC bred mice, 25th week 
Baseline 40 7.70±0.15 39 9.02±0.17 0.0767 ns 
15 40 17.31±0.55 39 20.47±0.45 <0.0001 **** 
30 40 12.19±0.43 39 17.95±0.55 <0.0001 **** 
60 40 10.37±0.34 39 14.96±0.46 <0.0001 **** 
120 40 7.48±0.24 39 10.57±0.22 <0.0001 **** 
ARC bred mice, 30th week 
Baseline 40 8.67±0.23 39 9.34±0.23 0.7998 ns 
15 40 17.99±0.52 39 18.91±0.47 0.5204 ns 
30 40 13.65±0.48 39 17.01±0.64 <0.0001 **** 
60 40 10.83±0.34 39 15.57±0.59 <0.0001 **** 
120 40 8.46±0.22 39 11.73±0.42 <0.0001 **** 
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Table A2.5 Histological features of JCU bred mice on standard rodent diet and energy-
dense diet at 30th week of the diet intervention 
Repli
cate 
Herxheimer’s 
stained area in 
liver (%) 
Adipocyte size 
(µm2) 
Islet area on 
pancreatic 
area (%) 
PAS+ stained 
area in kidney 
(%) 
Glomerular area 
(µm2) 
SRD EDD SRD EDD SRD EDD SRD EDD SRD EDD 
R1 0 40.6 585.94 1157.15 0.91 0.76 19.12 18.49 986.57 2612.7 
R2 0 15.64 547.23 1331.55 0.38 1.38 15.79 27.87 1067.44 1867.84 
R3 0.04 42.56 420.64 1027.86 1 1.74 27.89 26.08 1448.69 2252.97 
R4 0.02 30.74 615.48 1956.56 0.73 1.97 16.1 31.31 1213.88 2228.16 
R5 0.02 16.34 333.75 2415.48 0.55 3.25 15.17 18.28 1474.63 1990.05 
R6 0.12 32.11 343.42 1586.15 0.25 1.13 10.51 26.72 1402.71 2088.95 
R7 0.02 28.64 966.21 1773.49 0.67 1.27 13.3 19.89 1680.93 2860.31 
R8 0.12 26.06 113.85 1862.63 1.23 2.42 23.28 24.02 1291.99 2400.42 
R9 0.02 27.2 283.55 2135.93 1.11 0.97 18.77 21.15 1706.08 2701.74 
R10 1.9 30.9 817.6 2655.52 0.81 1.33 14.02 27.22 1616.6 2111.81 
R11 0.6 34.62 513.83 2104.62 1.28 1.42 14.62 19.24 1157.9 2531.65 
R12 0.44 33.52 412.92 2326.75 0.29 2.11  33.12 1887.93 2110.03 
R13 0.2 36.92 561.63 1826.38 0.21 0.89  23.69 1131.61 2143.98 
R14 0 13.18 327.11 1936.27 0.38 0.59  34.27 1885.41 2638.28 
R15 0 21.6 604.39 2138.69 0.49 1.05  27.03  1592.28 
R16 0.18 21.6  2227.89 0.42 1.42     
R17 0   3188.6 0.55 2.06     
R18 0.08    0.65 0.96     
R19 0.1    1.16 2.41     
R20 0.08    0.37 0.7     
R21 0.06    0.93 1.01     
R22     0.45      
R23     0.21      
R24     0.54      
R25     0.2      
R26     0.72      
R27     0.21      
Mean
± 
SEM 
0.19±
0.19 
28.26±
2.20 
496.50±
55.54 
1979.50
±130.0 
0.62±
0.06 
1.47±
0.14 
17.14±
1.48 
25.23±
1.34 
1425.17
±79.52 
2275.41
±89.27 
p-
value 
**** <0.0001♦ ***** <0.0001 **** <0.0001 *** <0.0005 ***** <0.0001 
Statistical analysis: Data were checked for normality using Shapiro-Wilk’s test. Data passed the test if p≥0.05. 
The normality distributed data were compared between groups using the unpaired t-test with Welch’s correction. 
The non-normally distributed data (♦) were compared between groups using Mann-Whitney U test. Data presented 
as mean±SEM. The level of significance was indicated as ***p≤0.0001 and ****p≤0.0001. In the table, SRD; 
Standard rodent diet, EDD; Energy-dese diet.   
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Table A2.6 Calculation of percentage of diabetic mice based on baseline fasting blood 
glucose in JCU and ARC bred mice on energy-dense diet at 25th and 30th week of diet 
intervention 
Baseline fasting blood glucose level (mmol/L) 
25th week 30th week 
JCU bred mice,  
Upper 99% CI of mean 
>9.86 
ARC bred mice,  
Upper 99% CI of mean 
>9.57 
JCU bred mice,  
Upper 99% CI of 
mean >9.35 
ARC bred mice,  
Upper 99% CI of 
mean >10.11 
SRD EDD SRD EDD SRD EDD SRD EDD 
6.8 11.7 11 9.9 7.3 15.5 12.4 14.4 
9 9 9.5 12 9 6.9 11.7 12.3 
11.5 13.9 9.2 12.9 8.8 13.9 8.7 15.8 
9.5 11.4 11 8.6 7 13.5 12 12.8 
10.4 5.8 11.9 12.9 9.4 7.6 7.9 12.9 
8.9 8.4 8.2 12.1 8.9 10.5 8 10.9 
8.4 14.5 9.4 11.9 11.3 14.4 11.2 13 
9.1 8.4 6.9 14.4 10.8 12.1 11.1 9.7 
8.9 7.5 10.6 10.5 11.3 10.6 8.2 12.4 
13.5 9.2 9.5 7.2 10.3 11.9 11.3 10.8 
9.8 9.8 10.4 12.2 10.7 7.7 9.9 12.2 
9.7 10 8.9 10.3 8.7 10.8 10.4 14.2 
8.3 13.1 9.7 11.6 8.9 13.3 11.4 13.7 
10.9 10.2 11.5 11.8 8.5 7.4 8.2 8.2 
9 10.2 9.7 12 8.7 7.5 7.5 10.5 
9.7 11.4 6.6 8.2 9 13.4 8.1 9.4 
8.2 8.3 8.6 10.8 8.7 10 11.3 9.3 
7.3 8 7.8 7.1 8.9 7.5 10 9.7 
8.9 11 8.7 8.7 6.9 12.5 11.5 9.4 
10.6 13.3 7.1 7.9 7 12.2 11.5 10.8 
8 11 7.7 12.6 7.4 11.2 6.5 12.7 
10.7 9.4 6.9 11.9 5.7 10.3 7.7 14.8 
8.2 15.1 7.3 11.4 5.4 14.5 8.8 13.2 
7.7 9.7 5.9 13 10 13.9 8.2 10.7 
12.3 10.4 7.1 13.4 6.3 6.8 6.5 13.4 
6.5 9.9 10.3 14 8.4 9.3 10.9 11.3 
5.8 12.4 10.2 13.9 9.5 12.1 7.1 13.8 
9.5 13.2 9.5 9.8 8.9 12.5 8.8 13.8 
7.5 10.6 6 14.7 7.5 9.8 9.5 9.6 
9.9 10.4 11.2 13.4 9.3 12.9 9.2 10.9 
8.1 10.3 8.7 7 8.5 13.2 9.5 10.6 
7.8 10.2 8.1 13.2  13.5 10.1 12.6 
10.5 8.4 10.9 8.7  11.8 7.5 10.5 
10 9.9 8.2 10.6  9.4 6.4 14.7 
8.3  8 10.1   8 13.7 
  9.3 13.5   6.4 14.1 
  8.6 12.9   10.1 8.6 
  8.9 13.2   6.8 8.8 
  9.5    11.7  
  8.1    11.2  
% diabetic 
 67.64% 
 (23/34) 
 
78.94%  
(30/38) 
 
76.47% 
(26/34) 
 
 
76.31% 
(29/38) 
Note: Mice on EDD considered T2D if they demonstrated a raised fasting blood glucose at levels higher the 
upper 99% confidence interval (CI) for the mean of age-matched control group fed on a standard rodent diet. 
SRD; Standard rodent diet, EDD; Energy-dese diet.   
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Table A2.7 Calculation of percentage of diabetic mice based HbA1c in JCU and ARC bred 
mice on energy-dense diet at 25th and 30th weeks of diet intervention 
 HbA1c (%) 
25th week 30th week 
JCU bred mice,  
Upper 99% CI of mean 
>2.76 
ARC bred mice,  
Upper 99% CI of mean 
>2.85 
JCU bred mice,  
Upper 99% CI of 
mean >2.56 
ARC bred mice,  
Upper 99% CI of 
mean >2.72 
SRD EDD SRD EDD SRD EDD SRD EDD 
1.65 2.81 2.69 3.39 2.15 3.09 2.49 3.46 
2.34 2.11 2.7 2.81 2.7 2.47 2.53 2.71 
2.27 2.4 2.44 3.46 2.48 2.09 2.6 3.47 
2.44 3.14 3.07 2 1.14 3.01 1.37 3.01 
2.4 3.33 2.14 2.79 2.64 3.09 2.19 3.18 
2.81 2.75 3.33 2.95 2.58 2.71 2.49 2.87 
2.93 2.77 2.55 2.62 2.39 2.69 2.77 2.58 
3.14 2.68 3.16 3.08 2.23 2.78 2.44 2.98 
2.8 3.03 3.13 3.01 2.97 2.72 2.99 2.93 
2.67 2.94 3.53 2.67 2.9 2.28 2.91 2.55 
2.95 1.67 3.06 2.88 2.88 3.19 2.67 3.29 
3.05 2.61 2.61 3.43 2.7 2.48 2.66 2.8 
2.74 3.01 2.98 3.04 2.58 2.82 2.29 3.32 
2.82 2.7 3.05 3.12 1.84 2.78 3.07 3.08 
3.03 2.81 1.9 2.88 1.72 2.6 2.95 3.12 
2.77 2.51 2.38 3.08 2.74 2.74 2.91 2.88 
2.49 2.81 2.5 3.22 1.97 2.55 3.29 2.95 
2.86 2.85 3.06 2.73 1.87 2.54 2.59 1.74 
3.09 3.02 2.72 3.04 2.47 3.13 2.4 2.89 
2.18 3.62 2.56 3.23 2.27 2.73 1.88 2.49 
2.16 3.08 2.87 2.96 2.37 2.82 2.87 2.53 
1.88 3.1 1.79 3 1.67 2.99 1.56 2.68 
2.02 3.29 2.63 3.01 2.12 2.76 2.47 3.09 
2.85 3.2 2.52 3.15 2.54 2.38 2.37 2.82 
1.55 2.79 1.92 2.84 2.67 2.65 1.42 2.86 
2.5 2.17 3.34 2.74 2.23 2.63 2.34 2.93 
3.15 2.75 2.99 2.99 2.34 2.51 2.4 2.99 
2.32 2.73 2.85 2.61 2.4 2.71 1.9 1.89 
2.68 2.91 2.2 2.92  2.96 2.61 2.85 
1.8 3.07 3 1.92  2.05 2.85 2.79 
2.47 3.07 2.88 2.91   2.53 2.15 
 3.37 2.38 3.31   1.5 3.06 
 2.46 3.09 2.02   2.77 3.03 
 2.77 1.94 2.98   2.19 2.82 
  2.56 2.92   2.61 3.12 
  2.59 2.85   2.91 2.75 
  2.36 2.92   3.45 2.78 
  2.56 2.7   2.29 2.75 
  2.28    2.96  
  2.72    2.98  
% diabetic 
64.70% 
(22/34) 
 
68.42% 
(26/38) 
 
73.33% 
(22/30%) 
 
76.31% 
(29/38) 
Note: Mice on EDD considered T2D if they demonstrated a raised HbA1c at levels higher the upper 99% 
confidence interval (CI) for the mean of age-matched control group fed on a standard rodent diet.  
In the table, SRD; Standard rodent diet, EDD; Energy-dese diet.  
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Table A2.8 Calculation of percentage of diabetic mice based on area under the curve in 
JCU and ARC bred mice on energy-dense diet at 25th and 30th weeks of diet intervention 
GTT (AUC) 
25th week 30th week 
JCU bred mice,  
Upper 99% CI of mean 
>1757 
ARC bred mice,  
Upper 99% CI of mean 
>1381 
JCU bred mice,  
Upper 99% CI of 
mean >1454 
ARC bred mice,  
Upper 99% CI of 
mean >1481 
SRD EDD SRD EDD SRD EDD SRD EDD 
1178 1826 1445 1799 1144 1453 1486 1787 
1429 1334 1516 1488 1277 1364 1449 2226 
1919 1712 1237 1697 1101 1965 1897 2771 
1871 1900 1652 1695 1352 1742 1461 1888 
1556 1724 1745 1622 1469 1594 1435 2363 
1784 1627 1103 1787 990 1692 1447 1637 
1526 1728 1219 1895 1440 2157 1568 1870 
2429 1460 1129 1656 1451 1540 976.5 1790 
1987 2315 1203 1694 1447 1571 1043 1895 
1961 1991 1196 1802 1552 1367 1626 1421 
1512 2047 1444 1737 1460 1490 1491 1393 
1775 1868 1414 2027 1732 1463 1671 1409 
1078 2151 1319 1829 1536 1929 1274 2006 
1706 1703 1447 2111 1384 1365 1467 1534 
2345 1527 1590 1188 1163 1646 1830 1666 
1829 1770 923.3 1752 1341 1352 1265 1620 
1514 1318 744 2032 1402 1139 1220 2086 
1787 1912 1055 2504 1497 1443 1494 1349 
1934 1998 870.8 1256 1409 1905 1505 1402 
1004 2488 953.3 1750 1552 1831 1410 1746 
1893 2135 1058 1709 1217 1850 1020 1635 
1713 2618 1019 1738 1550 1406 1097 1395 
1643 2655 1152 1770 1294 2183 1268 1490 
1840 2297 1257 1827 1020 1646 1222 2263 
1487 1943 894 2282 1551 1859 955.5 1721 
591.8 1713 1582 1517 1188 1482 1499 2082 
1218 2252 1406 1478 1081 1954 1112 2171 
1389 1987 1465 1696 1487 1691 1334 1996 
1507 2001 1183 1861 1238 1873 1265 1925 
1673 2676 1243 1835 1469 1625 1190 2105 
1245 2054 1316 1745 1481 1668 1617 1686 
1256 1722 1433 1724 1397 1983 1254 2261 
1236 1642 1589 2066 1414 1674 1835 1933 
1359 1695 1327 1577 1393 1432 1191 1856 
1292  1487 2043 1595  1433 1476 
  1449 1922   1307 1499 
  1278 1581   1599 1300 
  1424 1578   1302 1331 
  1256 1718   1487  
  1272    1329  
% diabetic 
64.70% 
(22/34) 
 
94.43% 
(37/39) 
 
76.64% 
(26/34) 
 
78.94% 
(30/38) 
Note: Mice on EDD considered T2D if they demonstrated a raised glucose tolerance test-Area under the 
curve (GTT-AUC) at levels higher the upper 99% confidence interval (CI) for the mean of age-matched 
control group fed on a standard rodent.  
In the table, SRD; Standard rodent diet, EDD; Energy-dese diet.   
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Table A2.9 Calculation of percentage of diabetic mice based fasting blood glucose (2 hours 
post-glucose challenge) in JCU and ARC bred mice on energy-dense diet at 25th and 30th 
weeks of diet intervention 
 
FBG (2 hours post-glucose challenge, mmol/L) 
25th week 30th week 
JCU bred mice,  
Upper 99% CI of mean 
>9.22 
ARC bred mice, 
Upper 99% CI of mean 
>8.13 
JCU bred mice, 
Upper 99% CI of mean 
>9.32 
ARC bred mice, 
Upper 99% CI of mean 
>9.05 
SRD EDD SRD EDD SRD EDD SRD EDD 
6.4 11.7 8.2 9.8 6.7 10.7 9.5 11.3 
7 8.5 9.9 9.2 7.9 9.4 8.5 17.1 
8.9 11 8.1 9.3 7.4 11.4 10.1 18.8 
8.6 14 10.3 10 9.1 8.9 9.1 14 
10.2 8.4 8.2 7.6 11 7.4 8.5 14.2 
10.2 10.7 7.4 11 7.8 10.5 9.2 10.7 
8.5 9.9 7.4 11.4 10.1 11.3 9.4 9.4 
13.2 9.7 7.2 9.7 10.1 9 7.5 12 
11.6 11.9 7.4 11.3 9.8 9.6 8.3 12.2 
9.7 11.2 6.4 10.9 10.3 8.8 8.6 9.9 
8 12 7.3 12.2 8.6 9.8 8.6 9.4 
10 11.2 7.7 10 11.5 9 9.9 8.9 
7.4 12.5 6.8 9.7 9.5 10.8 7.7 11.8 
9.5 8 8.2 11.9 7 8.3 8.7 10.7 
10.6 8.9 8.4 8.1 9.3 11.7 11 9.8 
7.1 9.2 5.3 10.8 8.5 8.9 7.9 10.4 
7 7.5 5.3 12 7.9 8 8.1 13.1 
9.7 11.7 5.3 9.7 9.2 8.7 8.1 8.5 
9.5 11.5 4.9 7.4 7.4 10.7 9.5 8 
6.5 14.1 4.7 11.7 8.2 11.7 8.7 12.7 
9.6 14.2 5.2 10.8 7.7 10.8 5.7 8.4 
8.8 13.7 5.5 10.4 9.8 9.8 6.9 8.3 
7.5 13.9 5.9 11.8 8.2 12.8 5.6 10 
9.2 12.5 6.9 13.9 6.5 10.1 7 15.4 
8.9 9.9 4.6 12.9 10.6 9 4.9 12.8 
2.8 12.7 9.4 10.1 7.9 11.3 8.9 15.4 
7.8 13.7 9 10 5.4 12.5 7.3 15.2 
7.7 13.5 8.3 9.8 9.3 9.2 8.5 14.3 
7.3 11.4 6.8 11.7 9 11.1 7.4 13.2 
10 11.8 7.6 10.3 8.8 10.2 8 13.1 
6.5 11.3 9.2 11.9 8.9 9.4 10.9 10.4 
6 10.3 7.3 9.7 8.6 13.3 7.8 13.7 
6.7 8.2 9.2 12.9 9 8.8 11.7 12.8 
7 8.7 7.4 11.4 8.7 10.4 7.8 11.9 
6.4  10.1 11.2 9.4  8.8 9.8 
  9.2 10.5   9.1 9.9 
  8.4 9.8   9.1 9.4 
  8 9.1   7.4 8.7 
  8 10.4   9.4  
  8.6    9.3  
% diabetic 
76.47% 
(26/34) 
 
97.43% 
(38/39) 
 
67.64% 
(23/34) 
 
84.21% 
(32/38) 
Note: Mice on EDD considered T2D if they demonstrated a raised FBG (2 hours post-glucose challenge) 
levels higher the upper 99% confidence interval (CI) for the mean of age-matched control group fed on a 
SRD. 
In the table, SRD; Standard rodent diet, EDD; Energy-dese diet, FBG; Fasting blood glucose 
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Table A2.10 Calculation of percentage of diabetes mice based on histological findings at 
30 weeks of the energy-dense diet intervention of JCU bred mice 
 
ACR, 
Upper 99% CI 
of mean >1.30 
 
Islet area on pancreas 
(%),  
Upper 99% CI of mean 
>0.80 
 
% PAS+ stain on kidney,  
Upper 99% CI of mean 
>21.84 
Glomerular area (µm2), 
Upper 99% CI of mean 
>1665 
SRD EDD SRD EDD SRD EDD SRD EDD 
0.22 3.48  0.76 19.12    
0.62 2.13 0.91 1.38 15.79 18.49 986.57 2612.7 
1.00 3.63 0.38 1.74 27.89 27.87 1067.44 1867.84 
1.27 2.87 1 1.97 16.1 26.08 1448.69 2252.97 
5.12 1.44 0.73 3.25 15.17 31.31 1213.88 2228.16 
0.8 2.11 0.55 1.13 10.51 18.28 1474.63 1990.05 
1.48 1.97 0.25 1.27 13.3 26.72 1402.71 2088.95 
0.7 0.71 0.67 2.42 23.28 19.89 1680.93 2860.31 
1.12 1.21 1.23 0.97 18.77 24.02 1291.99 2400.42 
0.96 1.1 1.11 1.33 14.02 21.15 1706.08 2701.74 
0.97 3.05 0.81 1.42 14.62 27.22 1616.6 2111.81 
0.68 22.69 1.28 2.11  19.24 1157.9 2531.65 
0.87 1.91 0.29 0.89  33.12 1887.93 2110.03 
0.66 3.43 0.21 0.59  23.69 1131.61 2143.98 
0.75 0.52 0.38 1.05  34.27 1885.41 2638.28 
0.88 3.79 0.49 1.42  27.03  1592.28 
1.23 4.5 0.42 2.06     
1.05 1.33 0.55 0.96     
1 3.05 0.65 2.41     
0.64 5.26 1.16 0.7     
0.46 2.99 0.37 1.01     
0.56 1.32 0.93      
0.55 3.03 0.45      
0.37 3.7 0.21      
0.5 2.61 0.54      
0.89 3.19 0.2      
0.29 3.69 0.72      
0.84 3.49 0.21      
1.07 4.1       
0.21 0.87       
1.03 4.11       
0.66        
0.43        
% 
diabeti
c 
83.87
% 
(26/31
) 
 
85.71% 
(18/21) 
 
73.33% 
(11/15) 
 
93.33% 
(14/15) 
Note: Mice on EDD considered T2D if they demonstrated a raised parameter (e.g. ACR) levels higher the upper 
99% confidence interval (CI) for the mean of age-matched control group fed on a standard rodent diet. 
SRD; Standard rodent diet, EDD; Energy-dese diet., ACR; albumin creatinine ratio, PAS; periodic acid Schiff 
 293 
All supplementary photographs and figure from mouse model characterisation study 
(Chapter 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2.1 The representative photographs (one photo/mouse) of liver sections of JCU 
bred mice (n=21) on standard rodent diet (SRD) for a period of 30 weeks. All the 
photographs were taken at 200x magnification after Modified Herxheimer’s staining. 
Photographs represent the deposition of lipid in liver (red colour indicates lipid).  
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Figure A2.2 The representative photographs (one photo/mouse) of liver sections of JCU 
bred mice (n=16) on energy-dense diet (EDD) for a period of 30 weeks. All the 
photographs were taken at 200x magnification after Modified Herxheimer’s staining. 
Photographs represent the deposition of lipid in liver (red colour indicates lipid).  
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Figure A2.3 The representative photographs (one photo/mouse) of visceral adipose tissue 
sections of JCU bred mice (n=15) on standard rodent diet (SRD) for a period of 30 weeks. 
All the photographs were taken at 200x magnification after H&E staining. Photographs 
represent the size of the adipocyte in visceral adipose tissue after diet intervention period.  
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Figure A2.4 The representative photographs (one photo/mouse) of visceral adipose tissue 
sections of JCU bred mice (n=17) on energy-dense diet (EDD) for a period of 30 weeks. 
All the photographs were taken at 200x magnification after H&E staining. Photographs 
represent the size of the adipocyte in visceral adipose tissue after diet intervention period. 
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Figure A2.5 The representative photographs (one photo/mouse) of kidney section of JCU 
bred mice (n=14) on standard rodent diet (SRD) for a period of 30 weeks. All the 
photographs were taken at 200x magnification after periodic acid Schiff’s (PAS) staining. 
Photographs represent the size of the glomerulus after the diet intervention period.  
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Figure A2.6 The representative photographs (one photo/mouse) of kidney section of JCU 
bred mice (n=15) on energy-dense diet (EDD) for a period of 30 weeks. All the 
photographs were taken at 200x magnification after PAS staining. Photographs represent 
the size of the glomerulus after diet intervention period.  
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Figure A2.7 The representative photographs (one photo/mouse) of pancreatic sections of 
JCU bred mice (n=27) on standard rodent diet (SRD) for a period of 30 weeks. All the 
photographs were taken at 200x magnification after H&E staining. Photographs 
represent the size of the pancreatic islet after diet intervention. 
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Figure A2.8 The representative photographs (one photo/mouse) of pancreatic sections of 
JCU bred mice (n=21) on energy-dense diet for a period of 30 weeks. All the photographs 
were taken at 200x magnification after H&E staining. Photographs represent the size of 
the pancreatic islet area after diet intervention period. 
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APPENDIX 3 
 
All supplementary data from Chapter 5 (mycobacterial uptake, killing and cytokine 
production by macrophages) 
 
Table A3.1 Bead phagocytosis assay using peritoneal exudate macrophages (elicited) and 
resident peritoneal exudate macrophages (non-elicited) at a multiplicity of infection 1:1 
and 1:10  
 Control (%, n=3),  Diabetic (%, n=3) p-value Level of significance 
Peritoneal exudate macrophages (PEM, elicited), MOI 1:1, 4 hours incubation 
FB 8.42±0.08 7.33±0.25 0.0151 * 
MACB 4.78±0.31 5.79±0.49 0.1568 ns 
CB 4.75±0.12 6.91±0.80 0.0567 ns 
Peritoneal exudate macrophages (PEM), MOI 1:10, 4 hours incubation 
FB 10.84±0.38 5.75±0.14 0.0002 *** 
MACB 11.60±0.46 7.43±1.00 0.0193 * 
CB♦ 12.45±0.76 8.33±0.44 0.0495 * 
Resident peritoneal macrophages (RPM, non-elicited), MOI 1:1, 4 hours incubation 
FB 4.28±0. 20 2.23±0.26 0.0033 ** 
MACB 2.36±0.12 1.93±0.56 0.4938 ns 
CB 3.20±1.15 2.59±0.20 0.6260 ns 
Resident peritoneal macrophages (RPM, non-elicited), MOI 1:10, 4 hours incubation 
FB 9.44±0.17 4.66±0.40 0.0004 *** 
MACB 12.11±0.31 5.33±0.94 0.0024 ** 
CB♦ 11.33±0.65 6.98±0.57 0.0495 * 
Statistical analysis: Data were checked for normality using Shapiro-Wilk’s test. Data passed the test if p≥0.05. 
The normally distributed data were compared between the groups using independent sample t-test. The non-
normally distributed data (♦) were compared between the groups using Mann-Whitney U test. Data presented as 
mean (%)±SEM. The level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and ns=non-
significant. In the table, FB; fresh beads, MACB; mycolic acid coated beads and CB; control beads, MOI; 
multiplicity of infection.  
 
Table A3.2 Bead phagocytosis by alveolar macrophages and resident peritoneal 
macrophages from the same group of control and diabetic mice at a multiplicity of 
infection 1:10  
 Control (%, n=4-5) Diabetic (%, n=4-5) p-value Level of significance 
Alveolar macrophages (AM), MOI 1:10, 4 hours incubation 
CB 22.96±0.74 19.84±0.79 0.0260 * 
MACB 13.49±0.39 9.69±0.82 0.0057 ** 
TDMCB 12.58±0.89 8.92±0.11 0.0148 * 
Resident peritoneal macrophages (RPM, non-elicited), MOI 1:10, 4 hours incubation 
CB 28.96±1.10 23±1.66 0.0285 * 
MACB 5.56±0.34 3.84±0.32 0.0107 ** 
TDMCB 2.86±0.12 1.87±0.11 0.0005 *** 
Statistical analysis: Data were compared between the groups using independence sample t-test as they passed the 
test of normality (Shapiro-Wilk’s test, p≥0.05). Data presented as mean (%)±SEM. The level of significance was 
indicated as *p≤0.05, **p≤0.01 and ***p≤0.001 and ns=non-significant. In the table, CB; controls beads, MACB; 
mycolic acid coated beads and TDMCB; trehalose 6, 6′ dimycolate coated beads; MOI; multiplicity of infection. 
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Table A3.3 Cytokine production by alveolar leucocytes and resident peritoneal exudate 
cells from control and diabetic mice during co-culture with mycolic acid coated beads  
Alveolar leucocytes (AL): Beads, 4 hours incubation 
Category 
Control 
(pg/mL, n=3-5) 
Diabetic 
(pg/mL, n=3-5) 
p-value 
Level of  
significance 
TNF-α 
Cell (AL) 417.89±97.35 213.68±9.88 0.0063 ** 
AL:CB 307.19±5.06 223.75±13.36 0.0051 ** 
AL:MACB 272.27±23.16 186.23±8.54 0.0039 ** 
AL:TDMCB 318.55±10.05 161.72±13.56 <0.0001 **** 
IL-6 
Cell (AL) 3.83±0.28 16.7±3.15 <0.0001 **** 
AL:CB 10.81±0.59 3.03±0.54 <0.0001 **** 
AL:MACB 9.96±1.39 2.72±0.18 0.0003 *** 
AL:TDMCB 13.40 1.26 <0.0001 **** 
Resident peritoneal exudate cells (RPEC): Beads, 4 hours incubation 
 
Control 
(n=3-5) 
Diabetic 
(n=3-5) 
p-value 
Level of  
significance 
TNF-α 
Cell (RPEC) 4.32±3.00 2.43±2.43 >0.9999 ns 
RPEC:CB 6.61±1.06 2.40±2.40 >0.9999 ns 
RPEC:MACB 7.74±0. 2.40±1.77 0.8411 ns 
RPEC:TDMCB 8.31±0.97 1.10±0.77 0.1972 ns 
IL-6♦ 
Cell (RPC) 132.46±5.12 65.27±4.73 <0.0001 **** 
RPEC:CB 125.12±5.22 53.57±4.71 <0.0001 **** 
RPEC:MACB 129.66±7.50 54.63±3.92 <0.0001 **** 
RPEC:TDMCB 134.66±4.04 51.60±1.90 <0.0001 **** 
     
Statistical analysis: The normally distributed data were compared among the groups using the ordinary one-way 
ANOVA with Holm Sidak’s multiple comparisons test. The non-normally distributed data (♦) were compared 
among the groups using the Kruskal-Wallis test with Dunn’s multiple comparisons test. Data presented as mean 
(pg/mL)±SEM. The level of significance was indicated as **p≤0.01, ***p≤0.001 and ****p≤0.0001. In the table, 
CB; controls beads, MACB; mycolic acid coated beads and TDMCB; trehalose 6, 6′ dimycolate coated beads.  
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Table A3.4 Uptake by resident peritoneal exudate cells (RPEC) and its-associated 
Mycobacterium fortuitum and killing of M. fortuitum by RPEC from control and diabetic 
mice at a multiplicity of infection 1:1 and 1:10 
Category Replicate 
Control Diabetic p- 
value 
Level of 
significance 
Mean (%)±SEM  
Peritoneal exudate cells (RPEC): M. fortuitum, MOI: 1:1 
4 hours uptake and cell 
associated bacteria 
3 29.32±6.03 25.17±4.05 0.6023 ns 
24 hours killing 3 58.08±6.48 38.30±4.15 0.0725 ns 
Peritoneal exudate cells (RPEC): M. fortuitum, MOI: 1:10 
4 hours uptake and cell 
associated bacteria 
3 21.95±1.36 16.20±2.61 0.1448 ns 
24 hours killing 3 43.29±5.88 28.93±2.98 0.1185 ns 
Statistical analysis: Data were compared between groups using the Unpaired t-test with Welch’s correction as 
data sets passed the test of normality (Shapiro-Wilk’s test, p≥0.05). The level of significance was indicated and 
ns=non-significant (p≥0.05). In the table, MOI; multiplicity of infection. 
 
Table A3.5 Percent uptake and killing of M. fortuitum by alveolar macrophages and 
resident peritoneal macrophages from control and diabetic mice  
Category 
Replicate  
(C, D) 
Control Diabetic 
p-value 
Level of 
 significance Mean (%)±SEM 
CD11c+ cells as alveolar macrophage (AM): M. fortuitum, MOI 1:10 
4 hours uptake 3, 3 6.94±0.25 4.17±0.07 0.0052 ** 
24 hours killing 3, 2 64.56±0.92 44.24±4.58 0.0099 ** 
CD11b+ cells as resident peritoneal macrophage (RPM): M. fortuitum, MOI 1:10 
4 hours uptake 3, 3 4.46±0.82 2.39±0.09 0.1268 ns 
24 hours killing 3, 3 53.91±5.32 31.66±2.36 0.0365 * 
Statistical analysis: Data were compared between groups using the Unpaired t-test with Welch’s correction as 
data sets passed the test of normality (Shapiro-Wilk’s test, p≥0.05). The level of significance was indicated as 
*p≤0.05, **p≤0.01 and ns=non-significant. In the table, C; control and D; diabetic, MOI; multiplicity of infection. 
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Table A3.6 Cytokine production by alveolar macrophages from control and diabetic mice infected with M. fortuitum for 4 and 24 hours 
 AM (cell), 4 hr, n=2-4 AM:Mft, 4 hr, n=4-6 AM (cell), 24 hr, n=2 AM:Mft, 24 hr, n=3-4 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
TNF-α 
Control 22.92±1.00 ns 
0.4757 
219.7±14.83 **** 
<0.0001 
13.85±0.85 ns 
0.0995 
2309±69.67 **** 
<0.0001 Diabetic 7.12±2.44 40.47±1.56 5.61±0.47 169.4±20.36 
MCP-1 
Control 2.52±1.51 ns 
0.9511 
0.00±0.00 
0.4251 
0.00±0.00 
- 
96.83±6.62 *** 
0.001♦ Diabetic 2.36±1.64 4.67±2.76 0.00±0.00 10.56±3.71 
IL-6 
Control 3.39±0.96 ns 
0.6028 
15.60±4.76 ** 
0.0016 
1.99±0.44 ns 
0.9909 
613.4±81.08 **** 
0.0001 Diabetic 0.00±0.00 3.57±0.73 1.10±1.10 31.27±3.17 
IL-12p70 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IFN-γ 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IL-10 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Statistical analysis: The normally distributed data were compared among the groups using the ordinary one-way ANOVA with Holm Sidak’s multiple comparisons test. The normally 
distributed data (♦) were compared between the groups using the Unpaired t-test with Welch’s correction. The level of significance was indicated as **p≤0.01, ***p≤0.001, 
****p≤0.0001 and ns=non-significant. In the table, AM; alveolar macrophages, hr; hour, Mft; Mycobacterium fortuitum. 
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Table A3.7 Cytokine production by resident peritoneal macrophages from control and diabetic mice infected with M. fortuitum for 4 and 24 
hours 
 RPM (cell), 4 hr, n=4 RP:Mft, 4 hr, n=4-6 RPM (cell), 24 hr, n=4 RPM:Mft, 24 hr, n=3 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
TNF-α 
Control 0.00±0.00 
- 
124.0±6.56 **** 
0.0001♦ 
9.70±5.50 ns 
0.5670 
150.2±21.36 * 
0.0311 Diabetic 0.00±0.00 69.93±3.04 1.68±1.14 104.7±9.62 
MCP-1 
Control 2.71±2.71 ns 
>0.9999▪ 
6.15±2.24 ns 
>0.9999▪ 
2.57±1.84 ns 
0.8959 
257.0±10.1 **** 
<0.0001 Diabetic 4.99±3.13 5.74±1.48 3.67±2.18 151.5±10.30 
IL-6 
Control 5.95±1.04 ns 
0.5474 
148.4±6.70 **** 
<0.0001 
13.96±4.75 ns 
0.8820 
1063±108.1 **** 
0.0001 Diabetic 1.63±0.94 77.45±2.65 4.24±1.86 587.32±43.22 
IL-12p70 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IFN-γ 
Control 0.00±0.00 
- 
0.00±0.00 
-- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IL-10 
Control 0.00±0.00 
- 
36.45±1.41 *** 
0.0003♦ 
0.00±0.00 
- 
7.66±1.72 
>0.9999□ 
Diabetic 0.00±0.00 26.78±1.01 0.00±0.00 7.30±1.40 
Statistical analysis: The normally distributed data were compared among the groups using the ordinary one-way ANOVA with Holm Sidak’s multiple comparison test. The normally 
distributed data (♦) were compared between the groups using the Unpaired t-test with Welch’s correction. The non-normally distributed data (▪) were compared among the groups 
using Kruskal-Wallis test with Dunn’s multiple comparisons test. The non-normally distributed data (□) were compared between groups using Mann-Whitney U test. The level of 
significance was indicated as *p≤0.05, ***p≤0.001, ****p≤0.0001 and ns=non-significant. In the table, RPM; resident peritoneal macrophages, hr; hour, Mft; Mycobacterium fortuitum. 
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Table A3.8 Uptake and killing of M. bovis (BCG) by alveolar macrophages and resident 
peritoneal macrophages from control and diabetic mice  
Category 
Replicate  
(C, D) 
Control Diabetic 
p-value 
Level of  
significance Mean (%)±SEM 
CD11c+ cells as alveolar macrophages (AM): M. bovis, MOI 1:10 
4 hours uptake 3, 4 4.56±0.31 3.37±0.23 0.0378 * 
24 hours killing 3, 4 93.77±0.13 89.97±0.79 0.0156 * 
CD11b+ cells as resident peritoneal macrophages (RPM): M. bovis, MOI 1:10 
4 hours uptake 5, 5 3.84±0.28 2.54±0.21 0.0070 ** 
24 hours killing 5, 5 90.93±1.03 87.41±0.75 0.0272 * 
48 hours killing 5, 5 95.51±0.70 93.92±0.61 0.1266 ns 
Statistical analysis: Data were compared between the groups using the Unpaired t-test with Welch’s correction 
as data sets passed the test of normality (Shapiro-Wilk’s test, p≥0.05). The level of significance was indicated as 
*p≤0.05, **p≤0.010 and ns=non-significant. In the table, C; control and D; diabetic, MOI; multiplicity of infection. 
 
 
 
 
 308 
Table A3.9 Cytokine production by alveolar macrophage from control and diabetic mice infected with M. bovis (BCG) for 4 and 24 hours 
 AM (cell), 4 hr, n=2-3 AM: M. bovis, 4 hr, n=3 AM (cell), 24 hr, n=2-3 AM: M. bovis, 24 hr, n=3-4 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
TNF-α 
Control 37.08±17.09 ns 
0.2275 
69.76±0.57 ns 
0.1062 
7.18±0.69 ns 
0.9195 
319.79±52.04 ** 
0.0041 Diabetic 18.96±3.50 44.41±6.14 2.72±0.34 140.18±10.37 
MCP-1 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IL-6 
Control 0.15±0.15 ns 
0.9401 
4.00±3.15 ** 
0.0096 
0.00±0.00 
- 
5.25±0.33 **** 
<0.0001 Diabetic 0.41±0.06 17.64±2.29 0.00±0.00 17.13±0.82 
IL-1β 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 ns 
>0.9999 Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.23±0.17 
IL-12p70 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 ns 
0.4000□ 
0.05±0.00 
>0.9999□ 
Diabetic 0.49±0.20 0.00±0.00 0.05±0.05 0.00±0.00 
IFN-γ 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IL-10 
Control 8.31±0.28 
0.4183 
10.04±2.48 
0.2892 
12.70±2.43 ns 
0.9989 
9.10±1.34 ns 
0.7844 Diabetic 5.30±1.00 13.88±0.63 12.58±2.32 12.98±2.32 
Statistical analysis: The normally distributed data were compared among the groups using the ordinary one-way ANOVA with Holm Sidak’s multiple comparisons test. The non-
normally distributed data (□) were compared between the groups using the Mann-Whitney U test. The level of significance was indicated as **p≤0.01, ****p≤0.0001 and ns=non-
significant. In the table, AM; alveolar macrophages, hr; hour. 
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Table A3.10 Cytokine production by resident peritoneal macrophages from control and diabetic mice infected with M. bovis (BCG) for 4 and 
24 hours 
 RPM (cell), 4 hr, n=3 RPM: M. bovis, 4 hr, n=4 RPM (cell), 24 hr, n=3 RPM: M. bovis, 24 hr, n=4 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
TNF-α 
Control 2.84±0.68 ns 
0.8695 
129.36±16.54 *** 
0.0005 
5.92±1.80 ns 
0.9859 
289.43±63.91 ns 
0.9859 Diabetic 0.21±0.18 47.50±5.45 1.54±1.09 281.26±25.15 
MCP-1 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
149.90±27.91 ** 
0.0081♦ Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 47.00±15.89 
IL-6 
Control 38.09±3.39 ns 
0.6446 
601.26±58.55 **** 
<0.0001 
2.08±0.68 ns 
0.9877 
467.54±105.94 ns 
0.0751 Diabetic 9.73±1.64 168.77±31.78 0.42±0.35 213.81±51.21 
IL-1β 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
8.55±2.02 
0.0530♦ 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 2.64±1.00 
IL-12p70 
Control 0.00±0.00 
0.4000□ 
0.00±0.00 
- 
0.19±0.19 
0.9685 
0.30±0.30 
0.9784 
Diabetic 0.08±0.04 0.00±0.00 0.01±0.01 0.24±0.13 
IFN-γ 
Control 0.00±0.00 
- 
0.00±0.00 
-- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IL-10 
Control 30.89±1.28 ns 
0.4296 
171.63±10.78 **** 
<0.0001 
15.08±3.32 ns 
0.9895 
57.24±5.00 ** 
0.0044 Diabetic 21.19±4.02 95.70±6.96 15.01±1.94 38.10±2.06 
Statistical analysis: The normally distributed data were compared among the groups using the ordinary one-way ANOVA with Holm Sidak’s multiple comparisons test. The normally 
distributed data (♦) were compared between the groups using the Unpaired t-test with Welch’s correction. The non-normally distributed data (□) were compared between the groups 
using the Mann-Whitney U test. The level of significance was indicated as **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-significant. In the  table, RPM; resident peritoneal 
macrophages, hr; hour.
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Table A3.11 Uptake and killing of M. tuberculosis (H37Rv) by alveolar macrophages and 
resident peritoneal macrophages from control and diabetic mice  
Category 
Replicate 
 (C, D) 
Control Diabetic 
p-value 
Level of 
 significance Mean (%)±SEM 
CD11c+ cells as alveolar macrophages (AM): M. tuberculosis, MOI 1:10 
4 hours uptake 4, 5 5.17±0.41 3.56±0.35 0.0232 * 
24 hours killing 4, 5 91.73±0.33 85.41±1.96 0.0308 * 
CD11b+ cells as resident peritoneal macrophages (RPM): M. tuberculosis, MOI 1:10 
4 hours uptake 2, 4 4.20±0.07 2.56±0.36 0.0892 ns 
24 hours killing 2, 4 88.83±0.34 75.61±3.01 0.0212 * 
Statistical analysis: Data were compared between groups using the Unpaired t-test with Welch’s correction as 
data sets passed the test of normality (Shapiro-Wilk’s test, p≥0.05). The level of significance was indicated as 
*p≤0.05 and ns=non-significant. In the table, MOI; multiplicity of infection.  
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Table A3.12 Cytokine production by alveolar macrophages from control and diabetic mice infected with M. tuberculosis (H37Rv) for 4 and 24 
hours 
 AM (cell), 4 hr, n=1 AM: Mtb, 4 hr, n=4-5 AM (cell), 24 hr, n=2 AM: Mtb, 24 hr, n=4 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
TNF-α 
Control 12.16 ns 
0.8927 
128.79±4.06 **** 
<0.0001 
10.52±3.34 ns 
0.9620 
1586.14±105.36 **** 
<0.0001 Diabetic 13.46 38.56±2.33 4.17±1.45 91.46±6.03 
MCP-1 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
 
85.49±6.84 *** 
0.0006♦ Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IL-6 
Control 0.33 ns 
>0.9999 
11.85±1.05 **** 
0.0001 
1.00±1.00 ns 
0.9946 
581.19±52.42 **** 
<0.0001 Diabetic 0.33 2.46±0.15 0.55±0.55 19.10±1.22 
IL-1β 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
3.67±0.74 ** 
0.0042♦ Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 179.36±22.20 
IL-12p70 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IFN-γ 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IL-10 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Statistical analysis: The normally distributed data were compared among the groups using the ordinary one-way ANOVA with Holm Sidak’s multiple comparisons test. The normally 
distributed data (♦) were compared between groups using the Unpaired t-test with Welch’s corrections. The level of significance was indicated as **p≤0.01, ***p≤0.001, ****p≤0.0001 
and ns=non-significant. In the table, AM; alveolar macrophages, hr; hour. 
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Table A3.13 Cytokines production by resident peritoneal macrophages from control and diabetic mice infected with M. tuberculosis (H37Rv) 
for 4 and 24 hours 
 RPM (cell), 4 hr, n=1 RP:Mtb, 4 hr, n=4 RPM (cell), 24 hr, n=2 RPM:Mtb, 24 hr, n=2-4 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
TNF-α 
Control 0.00±0.00 
- 
60.22±7.28 * 
0.0202♦ 
3.80±2.12 ns 
0.6386 
68.49±3.92 *** 
0.0002 Diabetic 0.00±0.00 27.62±0.70 5.62±4.08 35.97±0.83 
MCP-1 
Control 0.00±0.00 
- 
0.00±0.00 
- 
1.84±1.84 ns 
0.9683 
248.52±3.05 **** 
0.0001 Diabetic 0.00±0.00 0.00±0.00 1.29±1.29 135.65±9.25 
IL-6 
Control 3.68 ns 
0.8911 
93.66±10.40 ** 
0.0080 
8.02±5.94 
 
780.51±36.60 **** 
0.0001 Diabetic 0.70 39.26±0.79 2.33±1.91 372.54±26.81 
IL-1β 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
43.69±5.22 ns 
0.1333□ Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 21.14±4.42 
IL-12p70 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IFN-γ 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
IL-10 
Control 0.00±0.00 
- 
1.70±0.170 ns 
>0.9999□ 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Statistical analysis: The normally distributed data were compared among the groups using the ordinary one-way ANOVA with Holm Sidak’s multiple comparison test. The normally 
distributed data (♦) were compared between the groups using the Unpaired t-test with Welch’s corrections. The non-normally distributed data (□) were compared between the groups 
using Mann-Whitney U test. The level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-significant. In the table, Mtb; Mycobacterium 
tuberculosis (H37Rv), RPM; resident peritoneal macrophages, hr; hour. 
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APPENDIX 4 
 
All supplementary data of M. fortuitum infection study (Chapter 6-8) 
Dose: 1x107 CFU/mouse (low-dose) and 3x108 CFU/mouse (high-dose) 
 
Table A4.1 Body weight and area under the curve of mice on standard rodent diet and 
energy-dense diet 
 
Parameters Mouse Number Mean±SEM p-value 
Level of 
significance 
Body weight 
(0 week; g) ♦ 
SRD 33 18.81±0.32 
>0.9999 ns 
EDD 33 19.97±0.30 
Body weight 
(30th week; g) ♦ 
SRD 33 29.76±0.28 
0.0050 ** EDD 33 48.54±0.86 
EDD 33 9.12±0.20 
Area under the curve 
(AUC) 
SRD 33 1030.88±21.26 
0.0000 **** 
EDD 33 1677.39±37.25 
Statistical analysis: Data were checked for normal distribution using Shaprio-Wilk’s test. Data passed the test if 
p≥0.05. The non-normally distributed data (♦) were compared among the groups using the Kruskal-Wallis test 
with Dunn’s multiple comparisons test. The area under the curve was compared between the groups using the 
Mann-Whitney U test as data set didn’t pass the test of normality. The level of significance was indicated as 
**p≤0.01, ****p≤0.0001 and ns=non-significant. In the table, SRD; standard rodent diet, EDD; energy-dense diet. 
 
Table A4.2: Glucose tolerance test after 30 weeks of standard rodent diet and energy-
dense diet intervention 
Time (minutes) 
SRD 
(mmol/L, n=33) 
EDD 
(mmol/L, n=33) 
p-value 
Level of 
significance 
0 6.65±0.13 9.12±0.20 <0.0001 **** 
15 13.66±0.39 18.80±0.44 <0.0001 **** 
30 9.65±0.28 16.69±0.54 <0.0001 **** 
120 5.99±0.12 10.01±0.25 <0.0001 **** 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. Data 
presented as mean±SEM. The level of significance was indicated as ****p≤0.0001. In the table, SRD; standard 
rodent diet, EDD; energy-dense diet.  
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Table A4.3 Percentage of diabetic mice after 30 weeks of energy-dense diet intervention 
based on fasting blood glucose and area under the curve-glucose tolerance test  
Column statistics: Baseline fasting blood glucose (FBG) Area under the curve (AUC) 
 
 
 
 
Mice on EDD  Diabetic Mice on EDD  Diabetic 
Baseline FBG (mmol/L) Upper 99% CI of mean 
(>7mmol/L) (Yes/No) 
AUC-GTT Upper 99% CI of mean 
(>1089) (Yes/No) 
8.2 Yes 1628.00 Yes 
7.4 Yes 1319.00 Yes 
10 Yes 1792.00 Yes 
8.1 Yes 1812.00 Yes 
10.7 Yes 1761.00 Yes 
10.7 Yes 1764.00 Yes 
9.8 Yes 2099.00 Yes 
7.2 Yes 1621.00 Yes 
8.2 Yes 1458.00 Yes 
10.5 Yes 2404.00 Yes 
10.7 Yes 1488.00 Yes 
6.4 NO 1453.00 Yes 
8.4 Yes 1557.00 Yes 
10 Yes 1699.00 Yes 
8.4 Yes 1711.00 Yes 
8.7 Yes 1417.00 Yes 
9.9 Yes 1679.00 Yes 
10.2 Yes 1793.00 Yes 
8.3 Yes 1598.00 Yes 
9.5 Yes 2052.00 Yes 
11.1 Yes 1748.00 Yes 
9.6 Yes 1607.00 Yes 
9 Yes 1673.00 Yes 
9.9 Yes 1866.00 Yes 
9.6 Yes 1700.00 Yes 
8.7 Yes 1378.00 Yes 
10 Yes 1705.00 Yes 
8.6 Yes 1472.00 Yes 
8.4 Yes 1654.00 Yes 
9.1 Yes 1664.00 Yes 
8.8 Yes 1564.00 Yes 
7.6 Yes 1608.00 Yes 
9.2 Yes 1610.00 Yes 
% diabetic 96.97% (32/33) % diabetic  100 (33/33) 
Note: Mice were considered type 2 diabetes if they demonstrated a raised baseline FBG and AUG-GTT with 
evidence of glucose intolerance at levels higher the upper 99% confidence interval (CI) for the mean of age-
matched control group fed on a standard rodent diet. 
FBG; fasting blood glucose, EDD; energy-dense diet, AUC-GTT; area under the curve-glucose tolerance test 
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Table A4.4 Daily feed intake by mice following M. fortuitum infection 
Week Mouse Cage no. 
Feed intake 
(g/mouse/day) p-value 
Level of  
significance 
Mean±SEM 
Low-dose (1x107 CFU/mouse) 
0 (baseline) 
Control 3 4.50±0.00 
0.3235 ns 
Diabetic 3 3.50 ±.00 
1 
Control 5 4.14±0.11 
0.1593 ns 
Diabetic 5 2.94±0.57 
2 
Control 3 4.43±0.04 
0.1802 ns 
Diabetic 4 3.01±0.11 
3 
Control 3 4.19±0.20 
>0.9999 ns 
Diabetic 4 4.31±0.94 
4 
Control 3 4.56±0.06 
0.9924 ns 
Diabetic 4 4.88±1.31 
High-dose (3x108 CFU/mouse) 
0 (baseline) 
Control 3 4.50±0.00 
0.4227 ns 
Diabetic 3 3.50 ±.00 
1 
Control 3 3.44±0.20 
0.0792 ns 
Diabetic 2 1.60±0.01 
2 
Control 3 3.00±0.52 
0.0351 * 
Diabetic 2 0.74±0.01 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as *p≤0.05 and ns=non-significant. Each cage contains 1-5 mice. 
 
Table A4.5 Energy intake by mice following M. fortuitum infection 
Week Mouse Number 
Energy intake 
(kcal/mouse/day) p-value 
Level of 
significance 
Mean±SEM 
Low-dose (1x107 CFU/mouse) 
0 (baseline) 
Control 3 13.82±0.00 
0.7876 ns 
Diabetic 3 16.73±0.00 
1 
Control 5 12.73±0.34 
0.7876 
ns 
 Diabetic 5 14.05±2.71 
2 
Control 3 13.59±0.13 
0.9909 
ns 
 Diabetic 4 14.40±0.52 
3 
Control 3 12.86±0.61 
0.9996 
ns 
 Diabetic 4 20.60±4.50 
4 
Control 3 14.00±0.18 
0.0257 ^ 
Diabetic 4 23.33±6.26 
High-dose (3x108 CFU/mouse) 
0 (baseline) 
Control 3 13.82±0.00 
0.1196 ns 
Diabetic 3 16.73±0.00 
1 
Control 3 10.56±0.06 
0.3130 ns 
Diabetic 2 7.58+0.00 
2 
Control 3 9.21±1.58 
0.0285 * 
Diabetic 2 3.51±0.03 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as *p≤0.05 and ns=non-significant. Each cage contains 1-5 mice. 
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Table A4.6 Body weight of mice following M. fortuitum infection  
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as ***p≤0.001, ****p≤0.0001 and ns=non-significant. 
Table A4.7 Blood glucose level of mice following M. fortuitum infection 
Week Mouse Number 
Body glucose 
(mmol/L) p-value 
Level of 
significance 
Mean±SEM 
Low-dose (1x107 CFU/mouse) 
0 (baseline) 
Control 33 6.65±0.13 
<0.0001 **** 
Diabetic 30 9.23±0.20 
1 
Control 27 6.10±0.19 
<0.0001 **** 
Diabetic 24 10.42±0.42 
2 
Control 17 8.54±0.19 
0.9980 ns 
Diabetic 14 8.36±0.49 
3 
Control 17 8.33±0.35 
0.0577 ns 
Diabetic 14 7.12±0.32 
4 
Control 17 7.70±0.36 
0.0000 **** 
Diabetic 14 11.07±0.54 
High-dose (3x108 CFU/mouse) 
0 (baseline) 
Control 8, 3 7.60±0.28 
0.0685 ns 
Diabetic 8, 3 9.85±1.55 
1 
Control 8, 3 5.86±0.50 0.8789 
 
ns 
 Diabetic 8, 3 5.22±0.94 
2 
Control 8, 3 6.86±0.30 
0.1629 ns 
Diabetic 8, 3 5.00±0.51 
 Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as ****p≤0.0001 and ns=non-significant. 
 
Week Mouse Number 
Body weight (g) 
p-value 
Level of  
significance Mean±SEM 
Low-dose (1x107 CFU/mouse) 
0 (baseline) 
Control 33 27.62±0.30 
<0.0001 **** 
Diabetic 30 46.97±0.53 
1 
Control 27 29.61±0.31 
<0.0001 **** 
Diabetic 24 43.65±0.75 
2 
Control 27 29.22±0.32 
<0.0001 **** 
Diabetic 24 42.09±0.90 
3 
Control 17 30.50±0.52 
<0.0001 **** 
Diabetic 14 39.60±1.66 
4 
Control 17 31.13±0.52 
<0.0001 **** 
Diabetic 14 39.00±1.60 
5 
Control 17 30.00±0.45 
<0.0001 **** 
Diabetic 14 38.63±1.55 
High-dose (3x108 CFU/mouse) 
0 (baseline) 
Control 8 26.78±1.62 
<0.0001 **** 
Diabetic 3 52.83±2.49 
1 
Control 8 24.22±0.91 
0.0002 
*** 
 Diabetic 3 42.10±1.89 
2 
Control 8 23.61±1.03 
0.5953 ns 
Diabetic 3 28.45±7.85 
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Table A4.8 Organ weight of mice following M. fortuitum infection  
Organs DPI 
Number 
/group 
or (C, D)  
Control Diabetic 
p-value 
Level of  
significance 
Mean (g)±SEM 
Low-dose (1x107 CFU/mouse) 
 
Spleen 
 
1 6 0.09±0.01 0.14±.01 0.0046 ** 
14 ♦ 10 0.14±0.02 0.19±0.02 0.0405 * 
35 9 0.28±0.04 0.36±0.03 0.1347 ns 
 
Liver 
 
1 6 1.42±0.09 2.52±0.20 0.0004 *** 
14 10 1.70±0.11 2.68±0.17 0.0001 **** 
35 9 1.90±0.10 2.98±0.19 0.0001 **** 
Lungs 
1 6 0.24±0.01 0.27±0.03 0.4963 ns 
14 10 0.26±0.02 0.26±0.02 0.8129 ns 
35 ♦ 9 0.27±0.01 0.29±0.02 0.0921 ns 
Kidney 
(left) 
14 ♦ 10 0.21±0.01 0.31±0.02 0.0080 ** 
35 ♦ 10 0.23±0.01 0.35±0.02 0.0003 *** 
High-dose (3x108 CFU/mouse) 
Spleen 14 4, 6 0.41±0.03 0.43±0.10 0.8337 ns 
Liver 14♦ 4, 6 2.19±0.12 2.85±0.49 0.5224 ns 
Lungs 14 4, 6 0.33±0.02 0.30±0.05 0.5938 ns 
Kidney 
(left) 
14 4, 6 0.23±0.01 0.38±0.04 0.0063 ** 
Statistical analysis: Data were checked for normality using Shapiro-Wilk’s test. Data passed the test if p≥0.05. 
The normally distributed data were compared between the groups using the independent sample t-test. The non-
normally distributed data (♦) were compared between the groups using the Mann-Whitney U test. The level of 
significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-significant. In the table, 
DPI; days post-infection, C; control and D; diabetic. 
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Table A4.9 Organ bacterial kinetics of mice following M. fortuitum infection 
Organs DPI 
Number 
/group 
or (C, D)  
Control Diabetic 
p- 
value 
Level of 
significance Mean (log10 CFU) ±SEM 
Low-dose (1x107 CFU/mouse) 
Spleen 
1 3 2.43E+05±5.65E+04 3.24E+05±5.14E+04 0.3468 ns 
14 5 1.64E+05±5.77E+03 1.19E+05±2.26E+04 0.0905 ns 
35 5 3.37E+04±3.67E+03 6.02E+04±1.08E+04 0.0484 * 
Liver 
1 3 1.10E+06±3.99E+05 1.17E+06±5.14E+05 0.9179 ns 
14♦ 4, 5 2.53E+06±4.42E+05 5.06E+06±1.02E+06 0.0500 * 
35 5, 4 9.14E+05±9.22E+04 2.21E+06±2.78E+05 0.0141 * 
Lungs 
1 3 3.52E+04±6.40E+03 3.95E+04±2.97E+03 0.5359 ns 
14 2, 5 5.00E+03±1.00E+03 2.13E+04±7.43E+03 0.0336 * 
35 5, 4 4.88E+03±1.59E+03 1.80E+04±3.53E+03 0.0081 ** 
14 5 3.37E+04±4.18E+03 9.89E+04±3.87E+04 0.0283 * 
35 5, 4 3.88E+04±9.80E+03 2.06E+05±3.48E+04 0.0013 ** 
Kidneys 
14♦ 5,5 3.37E+04±4.18E+03 9.89E+04±3.87E+04 0.0283 * 
35 5,4 3.88E+04±9.80E+03 2.06E+05±3.48E+04 0.0013 ** 
High-dose (3x108 CFU/mouse) 
Spleen 14 3, 2 1.95E+05±1.68E+05 1.27E+06±1.90E+05 0.0255 * 
Liver 14 3, 2 5.34E+05±2.27E+05 9.05E+06±4.25E+06 0.0752 ns 
Lungs 14 3, 2 1.21E+05±6.06E+04 1.79E+06±2.25E+05 0.0029 ** 
Kidneys 14 3, 2 5.31E+05±1.59E+05 2.01E+06±2.30E+05 0.1160 ns 
Statistical analysis: The normally distributed data were compared between groups using the independent sample 
t-test. The non-normally distributed data (♦) were compared between the groups using Mann-Whitney U test. The 
level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. In the table, DPI; days post-
infection, C; control and D; diabetic. 
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Table A4.10 Liver lesions of M. fortuitum infected mice 
Parameter DPI 
Control Diabetic p-
value 
Level of 
significance Mean±SEM, n=5/group 
Low-dose (1x107 CFU/mouse) 
Inflamed area on liver (%) 
14  
2.51±0.49 6.97±1.38 0.0163 * 
Number of foci on liver/ 
200x) 
3.47±0.56 7.68±0.74 0.0021 ** 
Mean area of each 
inflammatory focus (µm2) 
1071.34±89.57 1295.24±158.1 0.2528 ns 
Inflamed area on liver (%) 
35 
10.75±0.36 16.77±1.61 0.0163 * 
Number of inflammatory 
foci on liver/200x) 
7.97±0.20 11.36±0.71 0.0069 ** 
Mean area of each 
inflammatory focus (µm2) 
1985.95±72.48 2165.38±123.68 0.2460 ns 
Acid-fast 
bacilli/inflammatory focus 
35♦ 
 
5.66±0.61 9.91±1.50 0.0079 ** 
High-dose (3x108 CFU/mouse) n=3 control and 2 diabetic mice  
Inflamed area on liver (%) 
14 
18.69±1.68 35.99±6.22 0.2002 ns 
Number of foci on 
liver/200x 
15.33±0.73 32.20±2.80 0.0872 ns 
Mean area of each 
inflammatory focus (µm2) 
1686.99±67.38 1611.07±75.12 0.5162 ns 
Acid-fast 
bacilli/inflammatory focus 
87.3±4.60 102.15±16.65 0.4806 ns 
Statistical analysis: The normally distributed data were compared between the groups using the independent 
sample t-test. The non-normally distributed data (♦) were compared between the groups using the Mann-Whitney 
U test. The level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. 
 
Table A4.11 Lungs lesions of M. fortuitum infected mice 
Parameter DPI 
Control Diabetic p-
value 
Level of 
significance Mean (%)±SEM, n=5/group 
Low-dose (1x107 CFU/mouse) 
Inflamed area in lungs 
14 16.16±1.24 22.24±2.83 0.0846 ns 
35 20.53±0.87 24.80±0.79 0.0080 ** 
High-dose (3x108 CFU/mouse) n=3 control and 2 diabetic mice  
Inflamed area in lungs 14 40.23±2.51 52.04±1.31 0.0398 * 
Statistical analysis: Data were compared between the groups using the independent sample t-test as they passed 
the test of normality (Shapiro-Wilk’s test). The level of significance was indicated as *p≤0.05, **p≤0.01, and 
ns=non-significant. In the table, DPI; days post-infection 
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Supplementary figures and photographs from M. fortuitum study (Chapter 6-7) 
Dose: 1x107 (low-dose) and 3x108 CFU/mouse (high-dose) 
 
M. fortuitum infection (low-dose) 
 
 
 
  
  
  
  
 
 
 
 
Figure A4.1 Daily feed intake by each mouse following a low-dose of M. fortuitum infection 
Mice were infected with low-dose of M. fortuitum (1x107 CFU/mouse). Daily feed intake by 
each mouse was monitored for a period of 4 weeks. The feed intake by the diabetic mice 
dropped at first 2 weeks of infection. Then, the feed intake rose gradually in the same group of 
mice at later few weeks of infection. In contrast, there was a fluctuation of feed intake in the 
control group throughout the infection. Data presented as mean±SEM. The significant 
difference between the groups was determined using the two-way ANOVA with Sidak’s 
multiple comparisons test. The level of significance was indicated as ns=non-significant.  
 
 
 
 
 
 
 
  
 
 
 
 
Figure A4.2 Survival of mice following a low-dose of M. fortuitum infection 
Diabetic and control mice were infected with low-dose of M. fortuitum (1x107 CFU/mouse) 
intravenously to determine the kinetics of infection and their survival after 60 days post-
infection (dpi). There was no mortality observed in both diabetic and control groups. The 
Kaplan Meier survival curves with Log-rank (Mantel-Cox) tests were used to compare the 
susceptibility between the groups. The level of significance was indicated as ns=non-
significant. 
Days post-infection 
ns 
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Figure A4.3 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. fortuitum. All the photographs were taken 
at 200x magnification after the Hematoxylin and Eosin (H&E) staining of the liver 
sections at 1 day post-infection. In both diabetic and control mice, a diffuse inflammation 
was observed at this timepoint of infection.  
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Figure A4.4 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. fortuitum. All the photographs were taken 
at 200x magnification after the H&E staining to quantify the inflamed area over the liver 
at 14 days post-infection. In both diabetic and control mice, foci of 
inflammation/granuloma formation were evident at this timepoint of infection. 
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Figure A4.5 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. fortuitum. All the photographs were taken 
at 200x magnification after H&E staining to quantify the inflamed area in the liver at 35 
days post-infection. In both diabetic and control mice, more foci of 
inflammation/granuloma formation were evident at this timepoint of infection.  
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Figure A4.6 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. fortuitum. All the photographs were taken 
at 1000x magnification after Ziehl-Neelsen staining to quantify the number of acid-fast 
bacilli (magenta) in each inflammatory focus /granuloma.  
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Figure A4.7 The representative photographs (one photo/mouse) of lung sections of control 
and diabetic mice infected with low-dose of M. fortuitum. All the photographs were taken 
at 40x magnification after H&E staining of lung sections at 1 day post-infection. In both 
diabetic and control mice, a diffuse inflammation was observed at this timepoint of 
infection.  
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Figure A4.8 The representative photographs (one photo/mouse) of lung sections of control 
and diabetic mice infected with low-dose of M. fortuitum. All the photographs were taken 
at 40x magnification after H&E staining to quantify the total area of the lungs at 14 days 
post-infection. The inflamed area over the total area of lungs was measured on the 
photographs taken at 100x magnification (not shown here).  
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Figure A4.9 The representative photographs (one photo/mouse) of lung sections of control 
and diabetic mice infected with low-dose of M. fortuitum. All the photographs were taken 
at 40x magnification after H&E staining to quantify the total area of the lungs at 35 days 
post-infection. The inflamed area over the total area of lungs was measured on the 
photographs taken at 100x magnification (not shown here). 
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M. fortuitum infection (high-dose) 
 
 
 
 
 
 
 
 
 
Figure A4.10 Daily feed intake by each mouse following a high-dose of M. fortuitum 
infection 
Mice were infected with a high-dose of M. fortuitum (3x108 CFU/mouse). Daily feed intake by 
each mouse was monitored for a period of 2 weeks (until the death of the mice). There was a 
dramatic fall in the daily feed intake by each mouse in both control and diabetic group following 
infection. Data presented as mean±SEM. The significant difference between groups was 
determined using the two-way ANOVA with Sidak’s multiple comparisons test. The level of 
significance indicated as *p≤0.05 and ns=non-significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4.11 The representative photographs (one photo/mouse) of liver sections of 
control and diabetic mice infected with high-dose of M. fortuitum. All the photographs 
were taken at 200x magnification after H&E staining to quantify the inflamed area over 
the liver at 14 days post-infection. In both diabetic and control mice, more foci of 
inflammation/granuloma formation were evident at this timepoint of infection.  
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Figure A4.12 The representative photographs (one photo/mouse) of liver sections of 
control and diabetic mice infected with M. fortuitum. All the photographs were taken at 
100x magnification after Ziehl-Neelsen staining to quantify the number of acid-fast bacilli 
(magenta) in each inflammatory focus/granuloma.  
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Figure A4.13 The representative photographs (one photo/mouse) of lung sections of 
control and diabetic mice infected with high-dose M. fortuitum. All the photographs were 
taken at 40x magnification after H&E staining to quantify the total area of the lungs at 14 
days post-infection. The Inflamed area over the total area of lungs was measured on the 
photographs taken at 100x magnification (not shown here). 
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APPENDIX 5  
 
All supplementary data from M. bovis (BCG) infection study (Chapter 6-8) 
Dose: 1x106 CFU/mouse (low-dose) and 2x106/mouse (high-dose) 
 
 
Table A5.1 Body weight and area under the curve of mice on standard rodent diet and 
energy-dense diet  
Parameters Mouse Number Mean±SEM p-value 
Level of 
significance 
Body weight 
(0 week; g) ♦ 
SRD 32 25.18±0.30 0.9849 
 
ns 
EDD 34 25.17±0.30 
Body weight 
(30th week; g) ♦ 
SRD 31 27.44±0.26 
<0.0001 **** 
EDD 33 46.19±0.65 
Area under the 
curve (AUC) 
SRD 31 1199.86±31.11 
0.0000 **** 
EDD 33 1963.36±47.16 
Statistical analysis: Data were checked for normal distribution using Shaprio-Wilk’s test. Data passed the test if 
p≥0.05. The non-normally distributed data (♦) were compared among the groups using the Kruskal-Wallis test 
with Dunn’s multiple comparisons test. Area under the curve was compared between the groups using the Mann-
Whitney U test as data set didn’t pass the test of normality. The level of significance was indicated as 
****p≤0.0001 and ns=non-significant. In the table, EDD; energy-dense diet, SRD; standard rodent diet. 
 
Table A5.2 Glucose tolerance test after 30 weeks of energy-dense diet and standard rodent 
diet intervention 
Time (minutes) 
SRD 
(mmol/L, n=31) 
EDD 
(mmol/L, n=33) 
p-value 
Level of 
significance 
0 9.83±0.20 6.07±0.14 <0.0001  **** 
15 19.58±0.50 15.06±0.42 <0.0001  **** 
30 20.22±0.63 12.69±0.48 <0.0001  **** 
120 11.88±0.37 5.83±0.12 <0.0001  **** 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. Data 
presented as mean±SEM. The level of significance was indicated as ****p≤0.0001 and ns=non-significant. In the 
table, EDD; energy-dense diet, SRD; standard rodent diet. 
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Table A5.3 Percentage of diabetic mice after 30 weeks of energy-dense diet intervention 
based on baseline fasting blood glucose and area under the curve 
 
Column statistics: Baseline fasting blood glucose           Area under the curve  
  
 
 
 
 
 
 
Mice on EDD Diabetic Mice on EDD Diabetic 
Baseline FBG (mmol/L) Upper 99% CI of mean 
(>6.47 mmol/L) (Yes/No) 
AUC-GTT Upper 99% CI of mean 
(>1285) (Yes/No) 
10 Yes 2090 Yes 
11 Yes 2489 Yes 
8.3 Yes 1688 Yes 
9.2 Yes 2132 Yes 
10.5 Yes 2234 Yes 
10.1 Yes 1687 Yes 
11 Yes 1984 Yes 
8.8 Yes 2337 Yes 
10.8 Yes 2282 Yes 
10.2 Yes 1988 Yes 
11.3 Yes 2027 Yes 
8.2 Yes 1661 Yes 
9.3 Yes 1646 Yes 
10.2 Yes 1853 Yes 
7.3 Yes 2000 Yes 
10.8 Yes 1822 Yes 
10.8 Yes 1889 Yes 
9.7 Yes 1883 Yes 
9.2 Yes 2297 Yes 
9.5 Yes 1379 Yes 
9.5 Yes 2318 Yes 
10.7 Yes 2159 Yes 
12.3 Yes 2263 Yes 
10.8 Yes 2032 Yes 
9.3 Yes 1979 Yes 
11 Yes 2039 Yes 
7.7 Yes 1865 Yes 
10.6 Yes 1744 Yes 
7.9 Yes 1228 NO 
8.5 Yes 1973 Yes 
9.8 Yes 1912 Yes 
9.2 Yes 1950 Yes 
10.8 Yes 1961 Yes 
% diabetic 100% (33/33) % diabetic  96.97 (32/33) 
Note: Mice were considered type 2 diabetes if they demonstrated a raised baseline FBG and AUG-GTT with 
evidence of glucose intolerance at levels higher the upper 99% confidence interval (CI) for the mean of age-
matched control group fed on a standard rodent diet. 
FBG; fasting blood glucose, AUC; area under the curve; AUC-GTT; area under the curve, EDD; energy-dense 
diet 
  
333 
Table A5.4 Daily feed intake by mice following M. bovis (BCG) infection 
Week Mouse 
Cage 
no. 
Feed intake 
(g/mouse/day) p-value 
Level of 
significance 
Mean±SEM 
Low-dose (1x106 CFU/mouse) 
0 (baseline) 
Control 3 4.50±0.00 
<0.0001 **** 
Diabetic 3 3.50±0.00 
1 
Control 6 2.94±0.04 0.0703 
 
ns 
Diabetic 4 3.22±0.11 
2 
Control 6 2.54±0.10 
0.1488 ns 
Diabetic 4 2.81±0.14 
3 
Control 4 3.01±0.24 0.6257 
 
ns 
Diabetic 3 2.81±0.31 
4 
Control 4 3.88±0.20 
0.0075 ** 
Diabetic 3 3.13±0.17 
High-dose (2x106 CFU/mouse) 
0 (baseline) 
Control 3 4.50±0.00 
0.2383 ns 
Diabetic 3 3.50±0.00 
1 
Control 2 4.73±0.51 <0.0001 
 
**** 
Diabetic 2 1.83±0.50 
2 
Control 2 5.43±0.25 
<0.0001 **** 
Diabetic 2 2.48±0.17 
3 
Control 2 4.16±0.01 
0.0009 *** 
Diabetic 2 1.97±0.02 
4 
Control 2 4.16±0.02 
0.0998 ns 
Diabetic 2 2.96±0.58 
5 
Control 2 4.60±0.39 
0.9997 ns 
Diabetic 2 4.39±0.44 
6 
Control 2 4.10±0.30 
0.9995 ns 
Diabetic 2 4.32±0.17 
7 
Control 2 4.17±0.27 
0.8439 ns 
Diabetic 2 3.60±0.02 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-significant. Each cage 
contains 1-5 mice. 
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Table A5.5 Daily energy intake by mice following M. bovis (BCG) infection 
Week Mouse 
Cage 
no. 
Energy intake 
(kcal/mouse/day) p-value 
Level of 
significance 
Mean±SEM 
Low-dose (1x106 CFU/mouse) 
0 (baseline) 
Control 3 13.82±0.00 
0.0013 ** 
Diabetic 3 16.73±0.00 
1 
Control 6 9.02±0.13 <0.0001 
 
**** 
 Diabetic 4 15.38±0.50 
2 
Control 6 7.80±0.30 <0.0001 
 
**** 
 Diabetic 4 13.42±0.68 
3 
Control 4 9.23±0.74 0.0001 
 
*** 
 Diabetic 3 13.42±1.50 
4 
Control 4 11.91±0.62 
0.0056 ** 
Diabetic 3 14.98±0.81 
High-dose (2x106 CFU/mouse) 
0 (baseline) 
Control 3 13.82±0.00 
0.4923 ns 
Diabetic 3 16.73±0.00 
1 
Control 2 14.53±1.57 
0.0286 * 
Diabetic 2 8.73±2.37 
2 
Control 2 16.66±0.77 
0.0955 ns 
Diabetic 2 11.86±0.83 
3 
Control 2 12.79±0.03 
0.4296 ns 
Diabetic 2 9.43±0.12 
4 
Control 2 12.78±0.06 
0.9896 ns 
Diabetic 2 14.16±2.78 
5 
Control 2 14.11±1.20 
0.0073 ** 
Diabetic 2 21.00±2.10 
6 
Control 2 12.58±0.81 
0.0017 ** 
Diabetic 2 17.20±0.09 
7 
Control 2 12.80±0.84 
0.1509 ns 
Diabetic 2 17.20±0.09 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-significant. 
Each cage contains 1-5 mice. 
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Table A5.6 Body weight of mice following M. bovis (BCG) infection  
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as ****p≤0.0001. 
 
 
Week Mouse Number 
Body weight  
p-value 
Level of 
significance Mean(g)±SEM 
Low-dose (1x106 CFU/mouse) 
0 (baseline) 
Control 32 27.08±0.86 
0.0000 **** 
Diabetic 29 46.44±0.80 
1 
Control 26 27.36±0.32 
0.0000 **** 
Diabetic 19 45.52±1.14 
2 
Control 26 26.34±0.80 
0.0000 **** 
Diabetic 23 45.22±1.23 
3 
Control 16 27.50±0.40 
0.0000 **** 
Diabetic 13 41.27±2.13 
4 
Control 16 27.00±0.37 
0.0000 **** 
Diabetic 13 40.47±2.28 
5 
Control 16 26.75±0.46 
0.0000 **** 
Diabetic 13 36.92±2.07 
High-dose (2x106 CFU/mouse) 
0 (baseline) 
Control 12 28.75±0.59 
<0.0001 **** 
Diabetic 9 50.47±1.40 
1 
Control 12 28.40±0.59 
<0.0001 **** 
Diabetic 9 50.12±1.40 
2 
Control 12 28.65±0.48 
<0.0001 **** 
Diabetic 9 44.08±2.09 
3 
Control 11 28.19±0.66 
<0.0001 **** 
Diabetic 9 36.79±1.95 
4 
Control 11 28.24±0.52 
<0.0001 **** 
Diabetic 7 37.02±1.90 
5 
Control 11 28.24±0.55 
<0.0001 **** 
Diabetic 7 36.77±1.79 
6 
Control 11 27.22±0.42 
<0.0001 **** 
Diabetic 7 35.05±1.56 
7 
Control 10 27.41±0.50 
<0.0001 **** 
Diabetic 7 35.61±1.68 
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Table A5.7 Blood glucose level following M. bovis (BCG) infection  
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. 
 
Week Mouse Number 
Blood glucose 
p-value 
Level of 
significance Mean(mmol/L)±SEM 
Low-dose (1x106 CFU/mouse) 
0 (baseline) 
Control 32 7.35±0.20 
0.0012 ** 
Diabetic 29 8.54±0.29 
1 
Control 26 8.12±0.23 
0.9929 ns 
Diabetic 19 8.13±0.29 
2 
Control 25 8.11±0.17 
0.0809 ns 
Diabetic 22 8.59±0.24 
3 
Control 16 7.72±0.20 
0.3089 ns 
Diabetic 13 8.22±0.47 
4 
Control 16 7.74±0.28 
0.2980 ns 
Diabetic 13 8.29±0.47 
5 
Control 16 8.39±0.22 
0.2632 ns 
Diabetic 13 9.01±0.53 
High-dose (2x106 CFU/mouse) 
0 (baseline) 
Control 11 7.40±0.22 
0.0095 ** 
Diabetic 9 9.57±0.77 
1 
Control 12 7.02±0.25 
0.1233 ns 
Diabetic 9 8.58±0.39 
2 
Control 12 6.02±0.26 
0.4532 ns 
Diabetic 9 7.18±0.45 
3 
Control 11 5.50±0.15 
0.0184 * 
Diabetic 8 7.60±0.35 
4 
Control 11 6.25±0.31 
0.0811 ns 
Diabetic 7 8.07±0.37 
5 
Control 11 7.07±0.37 
0.1426 ns 
Diabetic 7 8.74±0.66 
6 
Control 11 8.23±0.48 
0.0757 ns 
Diabetic 7 10.07±1.13 
7 
Control 11 7.65±0.37 
0.0102 * 
Diabetic 7 9.13±0.50 
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 Table A5.8 Organ weight of mice following M. bovis (BCG) infection  
Organs DPI 
Number 
/group 
Control Diabetic p-
value 
Level of 
significance Mean(g)±SEM 
Low-dose (1x106 CFU/mouse) 
 
Spleen 
1 8 0.09±0.01 0.15±0.03 0.0476 * 
14 10 0.15±0.02 0.38±0.04 0.0002 *** 
35 4 0.20±0.03 0.35±0.02 0.0064 ** 
 
Liver 
1 8 1.57±0.07 2.9±0.35 0.0069 ** 
14 10 1.90±0.07 3.37±0.15 0.0000 **** 
35 4 2.44±0.14 3.81±0.10 0.0002 *** 
Lungs 
1 8 0.23±0.02 0.30±0.02 0.0230 * 
14♦ 10 0.24±0.02 0.29±0.03 0.1304 ns 
35 4 0.38±0.04 0.45±0.03 0.1884 ns 
Statistical analysis: Data were checked for normality using Shapiro-Wilk’s test. Data passed the test if p≥0.05. 
The normally distributed data were compared between the groups using the independent sample t-test. The non-
normally distributed data (♦) were compared between the groups using the Mann-Whitney U test. The level of 
significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-significant. In the table, 
DPI; days post-infection. 
 
Table A5.9 Organ bacterial kinetics of mice following M. bovis (BCG) infection 
Organs DPI 
Number 
/group 
Control Diabetic p- 
value 
Level of 
significance Mean(log10 CFU)±SEM 
Low-dose (1x106 CFU/mouse) 
Spleen 
1 4 1.36E+04±1.81E+03 1.68E+04±4.01E+03 0.4976 ns 
14♦ 5 1.10E+05±1.89E+04 2.80E+05±5.68E+04 0.1161 ns 
35 5 1.97E+04±3.04E+03 3.57E+04±5.87E+03 0.0419 * 
Liver 
1♦ 4 1.05E+05±1.64E+04 2.57E+05±1.45E+05 0.5637 ns 
14 5 3.70E+06±5.13E+05 1.26E+07±2.77E+06 0.0306 * 
35 5 1.50E+05±3.78E+04 9.15E+05±2.37E+05 0.0311 * 
Lungs 
1 4 6.63E+03±9.87E+02 8.75E+03±3.66E+02 0.0901 ns 
14 3 3.60E+04±4.41E+03 8.04E+04±6.43E+03 0.0029 ** 
35 5 1.92E+03±2.87E+02 5.54E+03±4.69E+02 0.0002 *** 
Statistical analysis: The normally distributed data were compared between the groups using the independent 
sample t-test. The non-normally distributed data (♦) were compared between the groups using Mann-Whitney U 
test. The level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and ns=non-significant. In the 
table, DPI; days post-infection. 
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Table A5.10 Liver lesions of M. bovis (BCG) infected mice 
Parameter DPI 
Control Diabetic p-
value 
Level of 
significance Mean±SEM, n=5/group 
Low-dose (1x106 CFU/mouse) 
Inflamed area on liver 
(%) 
14  
4.49±0.44 8.23±0.82 0.0038 ** 
Number of 
inflammatory foci on 
liver/ 200x) 
4.40±0.43 6.68±0.44 0.0059 ** 
Mean area of each 
inflammatory focus 
(µm2) 
3598.80±135.85 4322.06±301.32 0.0601 ns 
Inflamed area on liver 
(%) 
35 
9.05±0.39 12.19±0.80 0.0075 ** 
Number of 
inflammatory foci on 
liver/ 200x) 
6.82±0.46 8.08±0.78 0.2010 ns 
Mean area of each 
inflammatory (µm2) 
4766.06±416.05 5436.45±485.25 0.3249 ns 
Acid-fast 
bacilli/inflammatory 
focus 
14 
 
13.00±1.08 17.56±3.96 0.2985 ns 
35 17.59±2.09 23.25±5.01 0.2940 
ns 
 
Statistical analysis: Data were compared between the groups using the independent sample t-test as they passed 
the test of normality (Shapiro-Wilk’s test, p≥0.05). The level of significance was indicated as *p≤0.05, **p≤0.01 
and ns=non-significant. In the table, DPI; days post-infection. 
 
Table A5.11 Lung lesions in M. bovis (BCG) infected mice 
Parameter DPI 
Control Diabetic p-
value 
Level of 
significance Mean (%)±SEM, n=5/group 
Low-dose (1x106 CFU/mouse) 
Inflamed area in lungs 
14 11.28±1.00 18.61±3.06 0.0524 * 
35 22.74±0.74 25.47±0.69 0.0274 * 
Statistical analysis: Data were compared between the groups using the independent sample t-test as they passed 
the test of normality (Shapiro-Wilk’s test). The level of significance was indicated as *p≤0.05. In the table, DPI; 
days post-infection. 
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 Table A5.12 Cytokine production in spleen following M. bovis (BCG) infection (low-dose) 
Spleen  
Days-post infection, n=4-5 mice/group 
1 14 35 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p- value 
Mean±SEM 
(pg/mL) 
p-value 
IL-1β 
Control 3.93±0.69 ns 
0.0576 
75.06±7.69 ns 
0.1954 
20.12±4.97 * 
0.0546 Diabetic 8.96±2.03 98.09±14.37 41.04±7.86 
TNF-α 
Control 39.16±4.95 ns 
0.0810 
 
196.40±18.25 ns 
0.8415 
 
52.72±1.98 ns 
0.1478 
 Diabetic 28.21±2.36 203.47±26.50 46.84±3.09 
MCP-1 
Control 6.48±3.75 ns 
0.1445 
 
172.32±30.31 ns 
0.2601 
 
25.59±3.48 ** 
0.0056 
 Diabetic 21.58±8.47 214.64±17.34 54.50±6.86 
IL-6 
Control 6.22±0.63 * 
0.0350 
15.01±2.81 ns 
0.1131 
7.13±1.96 ns 
0.1271 Diabetic 3.56±0.84 21.22±2.08 3.65±0.60 
IFN-γ 
Control 1.88±0.62 ns 
0.7150 
 
49.17±16.87 ns 
0.5321 
 
11.10±1.57 * 
0.0343 
 Diabetic 2.28±0.84 35.78±11.67 6.68±0.74 
IL-12p70 
Control 0.23±0.13 ns 
0.7457♦ 
 
0.47±0.43 ns 
0.2812 
 
2.25±1.69 ns 
0.8877♦ Diabetic 1.09±1.07 2.33±1.47 1.97±0.91 
IL-2 
Control 8.37±0.98 ns 
0.3475 
9.76±4.06 * 
0.0245♦ 
8.02±2.14 * 
0.0380 Diabetic 6.56±1.49 1.75±0.30 2.21±0.96 
IL-4 
Control 0.76±0.76 ns 
0.3173 
 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 
IL-10 
Control 30.21±5.27 ns 
0.1745♦ 
 
22.22±4.40 ns 
0.5097 
 
26.18±6.90 ns 
0.6952 
 Diabetic 24.46±3.88 18.86±2.08 23.19±2.57 
IL-17A 
Control 0.00±0.00 ns 
0.3173♦ 
0.04±0.04 ns 
0.3173♦ 
0.00±0.00 ns 
0.1360♦ Diabetic 0.20±0.20 0.00±0.00 0.21±0.13 
Statistical analysis: The normally distributed data were compared between the groups using the independent 
sample t-test. The non-normally distributed data (♦) were compared between the groups using the Mann-Whitney 
U test. The level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. 
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Table A5.13 Cytokine production in liver following M. bovis (BCG) infection (low-dose) 
Liver  
Days-post infection, n=4-5 mice/group 
1 14 35 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
IL-1β 
Control 3.55±1.22 ** 
0.0057 
61.50±14.74 ns 
0.1148 
46.43±18.27 ns 
0.6132 Diabetic 11.86±1.51 30.78±9.17 32.67±18.73 
TNF-α 
Control 21.78±4.88 ns 
0.0999 
 
72.25±7.78 * 
0.0163♦ 
 
45.47±3.69 *** 
0.0008 
 Diabetic 33.06±2.50 48.92±3.83 19.51±2.06 
MCP-1 
Control 48.23±5.48 * 
0.0358 
 
125.16±23.14 ns 
0.2813 
 
41.46±8.15 ns 
0.3127 
 Diabetic 69.21±5.90 162.22±22.22 52.89±6.40 
IL-6 
Control 20.10±3.72 ns 
0.7768 
24.91±6.93 ns 
0.6683 
23.39±7.87 * 
0.0563 Diabetic 22.63±8.52 31.77±13.76 4.63±1.08 
IFN-γ 
Control 2.09±0.54 ns 
0.0630 
 
27.53±1.42 * 
0.0301 
 
6.70±0.48 *** 
0.0008 
 Diabetic 3.56±0.29 21.69±1.69 3.23±0.28 
IL-12p70 
Control 16.31±3.60 0.2149 
 
9.90±2.12 ns 
0.3962 
 
15.48±4.23 ns 
0.1889 
 Diabetic 33.96±11.12 13.80±4.04 7.45±3.39 
IL-2 
Control 15.41±5.28 
0.8855 
15.36±5.88 ns 
0.1638 
8.49±3.68 ns 
0.2669 Diabetic 16.28±2.37 28.43±6.17 14.94±3.97 
IL-4 
Control 2.28±1.53 * 
0.0198 
2.29±1.82 * 
0.0300 
0.75±0.49 ns 
0.6107♦ Diabetic 7.85±0.89 14.96±4.45 0.45±0.26 
IL-10 
Control 33.27±4.00 ns 
0.2369 
 
18.34±2.22 ns 
0.0871 
 
36.19±1.98 ns 
0.1409 Diabetic 39.80±2.53 29.29±4.81 27.27±4.87 
IL-17A 
Control 0.15±0.15 ns 
0.0907♦ 
0.27±0.27 ns 
0.1389 
0.05±0.05 ns 
0.1955♦ Diabetic 1.12±0.44 1.28±0.53 0.45±0.26 
Statistical analysis: The normally distributed data were compared between the groups using the independent 
sample t-test. The non-normally distributed data (♦) were compared between the groups using the Mann-Whitney 
U test. The level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and ns=non-significant. 
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Table A5.14 Cytokine production in lungs following M. bovis (BCG) infection (low-dose) 
Lungs 
Days-post infection, n=4-5 mice/group 
1 14 35 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-
value 
Mean±SEM 
(pg/mL) 
p value 
Mean±SEM 
(pg/mL) 
p 
value 
IL-1β 
Control 6.44±3.40 ns 
0.0800 
4.81±0.83 ns 
0.8222 
14.41±7.36 ns 
0.3193 Diabetic 17.69±6.40 4.08±3.05 5.56±3.32 
TNF-α 
Control 22.31±6.30 ns 
0.0947 
 
38.89±1.39 * 
0.0374 
 
66.40±28.49 ns 
0.1102♦ 
 Diabetic 34.44±1.17 29.41±3.54 27.59±7.58 
MCP-1 
Control 85.58±17.83 ns 
0.2627 
 
120.15±13.34 * 
0.0541 
 
39.34±16.94 ns 
0.3493 Diabetic 133.23±35.30 167.11±15.99 65.64±19.61 
IL-6 
Control 17.38±7.54 ns 
0.1610 
5.81±0.85 ns 
0.9430 
18.88±7.55 ns 
0.0907♦ Diabetic 44.11±15.56 5.92±1.16 3.59±0.76 
IFN-γ 
Control 0.05±0.04 ns 
0.7231♦ 
 
14.85±3.41 * 
0.0330 
 
6.17±0.95 ** 
0.0026 
 Diabetic 0.10±0.06 4.84±1.90 1.11±0.38 
IL-12p70 
Control 2.54±1.39 ns 
0.7600♦ 
 
0.47±0.32 ns 
0.1900♦ 
 
2.86±0.75 * 
0.0181 
 Diabetic 3.18±1.46 1.76±0.85 0.29±0.29 
IL-2 
Control 0.00±0.00 
- 
0.00±0.00 ns 
0.3739 
3.76±1.93 ns 
0.1306♦ Diabetic 0.00±0.00 0.70±0.70 1.34±1.34 
IL-10 
Control 17.08±2.57 ** 
0.0070 
 
21.87±2.53 ns 
0.9638 
 
28.16±5.17 ns 
0.0829 
 Diabetic 34.20±4.05 21.49±7.71 11.56±6.09 
IL-4 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 
IL-17A 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 
Statistical analysis: The normally distributed data were compared between groups using the independent sample 
t-test. The non-normally distributed data (♦) were compared between the groups using the Mann-Whitney U test. 
The level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. 
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All supplementary figures and photographs from M. bovis (BCG) infection study 
(Chapter 6-7) 
Dose: 1x106 (low-dose) and 2x106 (high-dose) 
 
M. bovis (BCG) infection (low-dose) 
 
 
   
   
 
 
 
 
 
 
 
Figure A5.1 Daily feed intake by each mouse following low-dose of M. bovis (BCG) 
infection 
Mice were infected with low-dose of M. bovis (1x106 CFU/mouse). Daily feed intake by each 
mouse was monitored for a period of 4 weeks. The feed intake by the diabetic mice dropped 
gradually followed by a slight increased at last 2 weeks of infection. In control group, there was 
a sharp reduction of the daily feed intake by each mouse at first 2 weeks of infection followed 
by a rapid raise at last few weeks of infection. Data presented as mean±SEM. The significance 
difference was determined using the two-way ANOVA with Sidak’s multiple comparisons test. 
The level of significance was indicated as **p≤0.01 and ***** p≤0.0001 and ns=non-
significant.  
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Figure A5.2 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. bovis (BCG). All the photographs were 
taken at 200x magnification after Hematoxylin and Eosin (H&E) staining of the liver 
sections at 1 day post-infection. In both diabetic and control mice, a diffuse inflammation 
was observed at this timepoint of infection.  
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Figure A5.3 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. bovis (BCG). All the photographs were 
taken at 200x magnification after H&E staining to quantify the inflamed area in liver at 
14 days post-infection. In both diabetic and control mice, foci of inflammation/granuloma 
formation were evident at this timepoint of infection.  
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Figure A5.4 The representative photographs (one photo/mouse) of livers section of control 
and diabetic mice infected with low-dose of M. bovis (BCG). All the photographs were 
taken at 200x magnification after H&E staining to quantify the inflamed area in liver at 
35 days post-infection. In both diabetic and control mice, more foci of 
inflammation/granuloma formation were evident at this timepoint of infection.  
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Figure A5.5 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. bovis (BCG). All the photographs were 
taken at 1000x magnification after Ziehl-Neelsen staining to quantify the number of acid-
fast bacilli (magenta) in each inflammatory foci/granuloma at 14 days-post infection.  
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Figure A5.6 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. bovis (BCG). All the photographs were 
taken at 1000x magnification after Ziehl-Neelsen staining to quantify the number of acid-
fast bacilli (magenta) in inflammatory foci/granuloma at 35 days-post infection.  
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Figure A5.7 The representative photographs (one photo/mouse) of lung sections of control 
and diabetic mice infected with low-dose of M. bovis (BCG). All the photographs were 
taken at 40x magnification after H&E staining of the lung sections at 1 day post-infection. 
In both diabetic and control mice, a diffuse inflammation was observed at this timepoint 
of infection.  
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Figure A5.8 The representative photographs (one photo/mouse) of lung sections of control 
and diabetic mice infected with low-dose of M. bovis (BCG). All the photographs were 
taken at 40x magnification after H&E staining to quantify the total area of the lungs at 14 
days post-infection. The Inflamed area over the total area of the lungs was measured on 
the photographs taken at 100x magnification (not shown here).  
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Figure A5.9 The representative photographs (one photo/mouse) of lung sections of control 
and diabetic mice infected with low-dose of M. bovis (BCG). All the photographs were 
taken at 40x magnification after H&E staining to quantify the total area of the lungs at 35 
days post-infection. The Inflamed area over the total area of the lungs was measured on 
the photographs taken at 100x magnification (not shown here). 
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M. bovis (BCG) infection (high-dose) 
 
 
  
 
  
  
 
 
 
 
 
Figure A5.10 Daily feed intake by each mouse following high-dose of M. bovis (BCG) 
infection 
Mice were infected with high-dose of M. bovis (BCG, 2x106 CFU/mouse). Daily feed intake 
by each mouse was monitored for a period of 7 weeks. A reduction of the daily feed intake by 
each diabetic mouse at first 3 weeks of infection was observed although an opposite trend was 
observed in later weeks. In control group, there was a fluctuation of daily feed intake by each 
mouse throughout the infection. Data presented as mean±SEM. The significant difference 
between the groups was determined using the two-way ANOVA with Sidak’s multiple 
comparisons test. The level of significance was indicated as ***p≤0.001, ****p≤0.0001 and 
ns=non-significant. 
Week post-infection 
Fe
ed
 in
ta
ke
/m
ou
se
 (
g)
 
  
352 
APPENDIX 6  
 
All supplementary data from M. tuberculosis (H37Rv) infection study (Chapter 6-8) 
Dose: 4x106 CFU/mouse (low-dose) and 2x107/mouse (high-dose) 
 
 
Table A6.1 Body weight and area under the curve of mice on standard rodent diet and 
energy-dense diet 
 
Parameters Mouse Number Mean±SEM p-value 
Level of 
significance 
Body weight 
(0 week, g) ♦ 
SRD 39 20.91±0.34 
0.4536 ns 
EDD 40 21.44±0.30 
Body weight 
(30th week, g) ♦ 
SRD 39 28.39±0.28 0.0000 **** 
EDD 40 50.97±0.55 
Area under the 
curve (AUC) 
SRD 39 1379.43±48.72 0.0000 **** 
EDD 40 2074.73±51.86 
Statistical analysis: Data were checked for normal distribution using Shaprio Wilk’s test. Data passed the test if 
p≥0.05. The non-normally distributed data (♦) were compared among the groups using the Kruskal-Wallis test 
with Dunn’s multiple comparisons test. The area under the curve was compared between the groups using the 
independent sample t-test as the data sets passed the test of normality. The level of significance was indicated as 
****p≤0.0001 and ns=non-significant. In the table, EDD; energy-dense diet, SRD; standard rodent diet. 
 
Table A6.2 Glucose tolerance test after 30 weeks of energy-dense diet and standard rodent 
diet intervention 
Time (minutes) 
SRD 
(mmol/L, n=39) 
EDD 
(mmol/L, n=40) 
p-value 
Level of 
significance 
0 7.87±1.98 10.16±0.24 0.2057 ns 
15 18.96±0.57 24.60±0.57 <0.0001 **** 
30 14.35±0.66 21.69±0.75 <0.0001 **** 
120 6.27±0.20 10.89±0.26 0.0005 *** 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. Data 
were mean±SEM. The level of significance was indicated as ***p≤0.001, ****p≤0.0001 and ns=non-significant. 
In the table, EDD; energy-dense diet, SRD; standard rodent diet. 
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Table A6.3 Percentage of diabetic mice after 30 weeks of energy-dense-diet intervention 
based on fasting blood glucose and area under the curve  
Column statistics: Baseline fasting blood glucose      Area under the curve 
  
 
 
 
 
 
 
 
 
Mice on EDD Diabetic Mice on EDD Diabetic 
Baseline FBG  
(mmol/L) 
Upper 99% CI of mean (>6.27 
mmol/L) (Yes/No) 
AUC-GTT Upper 99% CI of mean 
(>1512) (Yes/No) 
9 YES 1757 YES 
9.8 YES 2082 YES 
7.9 YES 1931 YES 
7.1 YES 1726 YES 
7.9 YES 1553 YES 
10.9 YES 1980 YES 
10.8 YES 2157 YES 
8.2 YES 1897 YES 
11.7 YES 2258 YES 
10.1 YES 1812 YES 
10.6 YES 1968 YES 
11.4 YES 2211 YES 
11.7 YES 1712 YES 
10.7 YES 2516 YES 
10.4 YES 1812 YES 
11.8 YES 2268 YES 
9.7 YES 2196 YES 
9.8 YES 1974 YES 
7.4 YES 1849 YES 
11.3 YES 2557 YES 
8.3 YES 1889 YES 
9.6 YES 2037 YES 
8.8 YES 1582 YES 
11.2 YES 1823 YES 
7.8 YES 1616 YES 
10.9 YES 2801 YES 
10.3 YES 2021 YES 
12.9 YES 2602 YES 
10.4 YES 2082 YES 
11.4 YES 1969 YES 
12.3 YES 2028 YES 
12.3 YES 2684 YES 
10.8 YES 2163 YES 
10.7 YES 2306 YES 
10.6 YES 2594 YES 
8.1 YES 1714 YES 
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10.2 YES 2323 YES 
10.6 YES 2723 YES 
12.5 YES 1904 YES 
8.3 YES 1872 YES 
% diabetic 100% (40/40) % diabetic  100 (40/40) 
Note: Mice were considered type 2 diabetes if they demonstrated a raised baseline FBG and AUG-GTT with 
evidence of glucose intolerance at levels higher the upper 99% confidence interval (CI) for the mean of age-
matched control group fed on a standard rodent diet. 
FBG; fasting blood glucose, AUC; area under the curve; AUC-GTT; area under the curve, EDD; energy-dense 
diet 
 
Table A6.4 Daily feed intake by mice following M. tuberculosis (H37Rv) infection 
Week Mouse 
Cage 
no. 
Feed intake 
(g/mouse/day) p-value 
Level of 
significance 
Mean±SEM 
Low-dose (4x106 CFU/mouse) 
0 (baseline) 
Control 5 4.50±0.00 
0.3270 ns 
Diabetic 5 3.50±0.00 
1 
Control 6 5.06±0.20 
0.0011 ** 
Diabetic 4 2.73±0.68 
2 
Control 6 4.93±0.26 
0.0002 *** 
Diabetic 4 1.99±0.15 
3 
Control 4 5.84±0.90 
<0.0001 **** 
Diabetic 3 2.27±0.35 
4 
Control 4 6.14±0.89 
0.0008 *** 
Diabetic 3 3.36±0.70 
High-dose (2x107 CFU/mouse) 
0 (baseline) 
Control 2 4.50±0.00 0.0209 * 
Diabetic 2 3.50±0.00 
1 
Control 2 5.53±0.04 <0.0001 **** 
Diabetic 2 2.62±0.16 
2 
Control 2 4.15±0.06 <0.0001 **** 
Diabetic 2 0.69±0.23 
3 
Control 2 4.24±0.34 <0.0001 **** 
Diabetic 2 1.80±0.07 
4 
Control 2 5.19±0.14 <0.0001 **** 
Diabetic 2 2.88±0.84 
5 
Control 2 6.02±0.04 <0.0001 **** 
Diabetic 2 3.07±0.26 
6 
Control 2 5.18±0.17 <0.0001 **** 
Diabetic 2 2.06±0.26 
7 
Control 2 5.60±0.17 <0.0001 **** 
Diabetic 2 2.57±0.01 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. 
The level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 and ns=non-
significant. Each cage contains 1-5 mice. 
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Table A6.5 Daily energy intake by mice following M. tuberculosis (H37Rv) infection 
Week Mouse 
Cage 
no. 
Energy intake 
(kcal/mouse/day) p-value 
Level of 
significance 
Mean±SEM 
Low-dose (4x106 CFU/mouse) 
0 (baseline) 
Control 5 13.82±0.00 
0.5556 ns 
Diabetic 5 16.73±0.00 
1 
Control 6 15.52±0.62 
0.7107 ns 
Diabetic 4 13.06±0.39 
2 
Control 6 15.13±0.80 
0.0663 ns 
Diabetic 4 9.52±0.73 
3 
Control 4 17.91±2.77 
0.0222 * 
Diabetic 3 10.85±1.68 
4 
Control 4 18.16±2.75 
0.7212 ns 
Diabetic 3 16.05±3.33 
High-dose (2x107 CFU/mouse) 
0 (baseline) 
Control 2 13.82±0.00 0.2660 
ns 
Diabetic 2 16.73±0.00 
1 
Control 2 16.97±0.14 0.0925 
ns 
Diabetic 2 12.53±0.78 
2 
Control 2 12.73±0.19 0.0001 
*** 
Diabetic 2 3.32±1.08 
3 
Control 2 13.01±1.05 0.0987 
ns 
Diabetic 2 8.61±0.34 
4 
Control 2 15.94±0.42 0.8081 
ns 
Diabetic 2 13.76±4.00 
5 
Control 2 18.47±0.13 0.2084 
ns 
Diabetic 2 14.69±1.22 
6 
Control 2 15.90±0.52 0.0102 
** 
Diabetic 2 9.84±1.24 
7 
Control 2 17.19±0.51 0.0508 
* 
Diabetic 2 12.29±0.07 
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated as *p≤0.05, **p≤0.01and ns=non-significant. Each cage contains 1-5 mice. 
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Table A6.6 Body weight of mice following M. tuberculosis (H37Rv) infection  
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. The 
level of significance was indicated ****p≤0.0001 and ns=non-significant. 
Week Mouse Number 
Body weight 
p-value 
Level of 
significance Mean(g)±SEM 
Low-dose (4x106 CFU/mouse) 
0 (baseline) 
Control 23 28.29±0.35 
<0.0001 **** 
Diabetic 23 50.41±0.83 
1 
Control 16 28.90±0.42 
<0.0001 **** 
Diabetic 18 47.48±0.96 
2 
Control 16 29.23±0.41 
<0.0001 **** 
Diabetic 18 43.11±0.95 
3 
Control 11 28.48±0.57 
<0.0001 **** 
Diabetic 13 40.21±1.26 
4 
Control 11 28.29±0.56 
<0.0001 **** 
Diabetic 13 39.80±1.44 
High-dose (2x107 CFU/mouse) 
0 (baseline) 
Control 9 26.08±0.49 <0.0001 
 
**** 
Diabetic 10 48.91±0.93 
1 
Control 9 26.24±0.45 <0.0001 
 
**** 
Diabetic 9 42.08±0.89 
2 
Control 9 24.48±0.96 <0.0001 
 
**** 
Diabetic 9 32.68±0.80 
3 
Control 7 24.01±1.50 0.9385 
 
ns 
Diabetic 7 25.81±1.66 
4 
Control 6 24.67±1.08 >0.9999 
 
ns 
Diabetic 5 25.07±2.55 
5 
Control 6 24.60±1.29 0.9747 
 
ns 
Diabetic 4 26.47±2.29 
6 
Control 6 24.17±0.97 0.9898 
 
ns 
Diabetic 4 25.11±2.34 
7 
Control 6 23.03±0.92 >0.09999 
 
ns 
Diabetic 4 23.20±2.73 
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Table A 6.7 Blood glucose level of mice following M. tuberculosis (H37Rv) infection  
Statistical analysis: Data were analysed using the two-way ANOVA with Sidak’s multiple comparisons test. 
The level of significance was indicated as ****p≤0.0001 and ns=non-significant. 
 
 
Week Mouse Number 
Blood glucose 
(mmol/L) p-value 
Level of 
significance 
Mean±SEM 
Low-dose (4x106 CFU/mouse) 
0 (baseline) 
Control 23 5.68±0.17 
0.0000 **** 
Diabetic 23 9.78±0.30 
1 
Control 16 8.80±0.19 
0.3425 ns 
Diabetic 18 8.11±0.43 
2 
Control 16 8.02±0.17 
0.9636 ns 
Diabetic 18 7.74±0.28 
3 
Control 11 8.95±0.22 
0.1458 ns 
Diabetic 13 7.94±0.28 
4 
Control 11 8.90±0.28 
0.7843 ns 
Diabetic 13 8.38±0.29 
High-dose (2x107 CFU/mouse) 
0 (baseline) 
Control 10 6.82±0.24 
<0.0001 **** 
Diabetic 10 12.80±0.62 
1 
Control 9 6.96±0.22 
0.9964 ns 
Diabetic 9 6.47±0.17 
2 
Control 6 5.52±0.30 
0.9925 ns 
Diabetic 7 6.07±0.62 
3 
Control 6 5.32±0.74 
>0.9999 ns 
Diabetic 5 5.63±0.47 
4 
Control 6 7.40±0.52 
0.6503 ns 
Diabetic 4 5.94±0.90 
5 
Control 6 7.23±0.53 
0.6863 ns 
Diabetic 4 5.73±0.73 
6 
Control 6 8.18±0.49 
0.6488 ns 
Diabetic 4 6.63±1.35 
7 
Control 6 7.13±0.53 
0.9374 ns 
Diabetic 4 6.08±1.30 
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Table A6.8 Organ weight of mice following M. tuberculosis (H37Rv) infection  
Organs DPI 
Number 
/group 
Control Diabetic p-
value 
Level of 
significance Mean±SEM 
Low-dose (4x106 CFU/mouse) 
 
Spleen 
 
1♦ 5 0.11±0.01 0.29±0.13 0.0147 * 
14 5 0.55±0.02 0.77±0.06 0.0151 * 
30 5 0.26±0.03 0.55±0.07 0.0087 ** 
 
Liver 
 
1 5 1.33±0.10 2.36±0.14 0.0003 *** 
14 5 2.74±0.13 3.31±0.19 0.0405 * 
30 5 1.80±0.06 3.36±0.25 0.0003 *** 
Lungs 
1♦ 5 0.23±0.02 0.26±0.02 0.1150 ns 
14 5 0.31±0.01 0.81±0.50 0.3723 ns 
30 5 0.31±0.01 0.35±0.04 0.4265 ns 
Statistical analysis: Data were checked for normality using Shapiro-Wilk’s test. Data passed the test if p≥0.05. 
The normally distributed data were compared between the groups using the independent sample t-test. The non-
normally distributed data (♦) were compared between the groups using the Mann-Whitney U test. The level of 
significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and ns=non-significant. In the table, DPI; days post-
infection. 
 
Table A6.9 Organ bacterial kinetics of mice following M. tuberculosis (H37Rv) infection 
Organs DPI Number 
/group 
Control Diabetic p- 
value 
Level of 
significance 
Mean (log10 CFU)±SEM 
Low-dose (4x106 CFU/mouse) 
Spleen 
1 5 2.29E+05±2.86E+04 2.21E+05±4.88E+04 0.8856 ns 
14 5 3.89E+06±7.77E+05 1.26E+07±2.16E+06 0.0053 ** 
30♦ 5 1.89E+06±2.55E+05 9.37E+06±3.11E+06 0.0431 * 
Liver 
1 5 1.10E+06±8.08E+04 1.11E+06±7.14E+04 0.9598 ns 
14 5 4.02E+06±4.00E+05 7.21E+06±1.09E+06 0.0254 * 
30 5 2.30E+06±1.17E+05 6.03E+06±6.71E+05 0.0045 ** 
Lungs 
1 5 3.19E+04±3.31E+03 2.54E+04±2.65E+03 0.1628 ns 
14♦ 5 3.69E+05±7.08E+04 1.29E+06±3.51E+05 0.0331 * 
30 5 9.93E+05±2.58E+05 1.95E+06±5.59E+05 0.1576 ns 
Statistical analysis: The normally distributed data were compared between the groups using the independent 
sample t-test. The non-normally distributed data (♦) were compared between groups using the Mann-Whitney U 
test. The level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. 
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Table A6.10 Liver lesions of M. tuberculosis (H37Rv) infected mice 
Parameter DPI 
Control Diabetic p-
value 
Level of 
significance Mean±SEM, n=5/group 
Low-dose (1x106 CFU/mouse) 
Inflamed area on liver 
(%) 
14  
10.76±0.50 14.83±1.49 0.0325 * 
Number of 
inflammatory foci on 
liver/ 200x) 
7.68±0.61 7.31±1.32 0.8083 ns 
Mean area of each 
inflammatory focus 
(µm2) ♦ 
4991.50±260.66 8658.03±2552.10 0.0283 * 
Inflamed area on liver 
(%) 
30 
12.87±0.60 16.96±1.54 0.0388 * 
Number of 
inflammatory foci on 
liver/ 200x) 
7.22±0.17 7.96±0.77 0.3763 ns 
Mean area of each 
focus (µm2) ♦ 
6594.02±104.22 6594.02±104.22 0.1172 ns 
Acid-fast 
bacilli/inflammatory 
focus 
(n=4-5 mouse/group at 
14 dpi♦) 
 
14 
21.74±3.27 28.08±6.74 1.000 ns 
30 32.78±1.77 45.07±5.08 0.0714 ns 
Statistical analysis: The normally distributed data were compared between the groups using the independent 
sample t-test. The non-normally distributed data (♦) were analysed using Mann-Whitney U test. The level of 
significance was indicated as *p≤0.05 and ns=non-significant. 
 
Table A6.11 Lungs lesions in M. tuberculosis (H37Rv) infected mice 
Parameter DPI 
Control Diabetic p-
value 
Level of 
significance Mean (%)±SEM, n=5/group 
Low-dose (4x106 CFU/mouse) 
Inflamed area in lungs 
14 15.34±0.72 22.06±1.91 0.0109 ** 
30 23.80±1.67 31.39±2.40 0.0317 * 
Statistical analysis: Data were compared between the groups using the independent sample t-test as they passed 
the test of normality (Shapiro-Wilk’s test, p≥0.05). The level of significance was indicated as *p≤0.05, 
**p≤0.01and ns=non-significant. 
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Table A6.12 Cytokine production in spleen following M. tuberculosis (H37Rv) infection 
(low-dose) 
Spleen 
Days post-infection, n=4-5 mouse/group 
1 14 30 
Cytokine 
Mouse 
 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
IL-1β 
Control 10.30±1.84 ns 
0.4098 
325.18±38.21 * 
0.0283♦ 
106.59±18.46 ns 
0.1745♦ Diabetic 13.65±3.37 1075.05±323.77 212.24±51.40 
TNF-α 
Control 42.79±6.41 ns 
0.0894 
 
174.77±22.60 * 
0.0265 
72.78±4.54 * 
0.0363 Diabetic 28.96±3.18 262.46±23.08 110.96±12.67 
MCP-1 
Control 73.42±12.15 * 
0.0163♦ 
98.15±7.10 * 
0.0256 
45.05±2.16 * 
0.0758♦ Diabetic 30.72±1.28 125.45±7.01 61.37±7.77 
IL-6 
Control 4.73±0.70 ns 
0.7220 
10.04±1.05 * 
0.0476 
6.53±0.23 ns 
0.2248 Diabetic 4.37±0.70 13.72±1.17 7.65±0.77 
IFN-γ 
Control 64.04±14.38 ** 
0.0090♦ 
107.68±6.53 * 
0.0359 
44.82±5.59 ns 
0.1197 Diabetic 15.42±3.00 87.99±4.30 32.81±4.04 
IL-12p70 
Control 0.00±0.00 ns 
0.3466 
0.00±0.00 ns 
0.1547 
0.17±0.17 ns 
0.3466 Diabetic 0.12±0.12 0.59±0.37 0.00±0.00 
IL-2 
Control 5.42±2.32 ns 
0.9748 
12.03±2.22 * 
0.0149 
11.54±1.80 ** 
0.0042 Diabetic 5.52±2.28 5.38±0.63 4.00±0.62 
IL-10 
Control 24.09±4.39 ns 
0.9049 
 
17.48±1.21 ns 
0.0622 
 
29.76±1.27 ns 
0.1032 Diabetic 23.43±3.05 21.78±1.57 24.56±5.16 
IL-4 
Control 0.00±0.00 
- 
0.08±0.08 ns 
0.3882 
 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.97±0.97 0.00±0.00 
IL-17A 
Control 0.04±0.04 ns 
0.4777 
0.27±0.14 ns 
0.1021 
0.56±0.34 ns 
0.1418 Diabetic 0.14±0.13 0.00±0.00 0.00±0.00 
Statistical analysis: The normally distributed data were compared between the groups using the independent 
sample t-test. The non-normally distributed data (♦) were compared between the groups using the Mann-Whitney 
U test. The level of significance was indicated as *p≤0.05, **p≤0.01 and ns=non-significant. 
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Table A6.13 Cytokine production in liver following M. tuberculosis  (H37Rv) infection 
(low-dose) 
Liver 
Days post-infection, n=4-5 mouse/group 
1 14 30 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
IL-1β 
Control 21.04±3.59 ns 
0.1754 
203.08±39.03 ns 
0.6881 
71.76±14.54 ns 
0.2606 Diabetic 13.12±3.94 177.30±48.06 50.64±9.63 
TNF-α 
Control 81.11±20.69 * 
0.0472♦ 
 
115.26±10.81 * 
0.0120 
 
68.17±6.58 *** 
0.0006 
 Diabetic 39.90±6.04 77.02±4.79 29.93±2.28 
MCP-1 
Control 341.84±93.28 * 
0.0213♦ 
89.74±9.49 ns 
0.0902 
92.51±20.87 ns 
0.4647♦ Diabetic 72.94±13.10 122.40±14.05 68.24±5.65 
IL-6 
Control 29.78±11.87 ns 
0.3472♦ 
8.16±1.37 ns 
0.6015♦ 
13.13±4.44 ns 
0.0758♦ Diabetic 13.34±3.37 15.62±7.80 6.04±0.84 
IFN-γ 
Control 97.59±23.83 * 
0.0174♦ 
 
75.81±6.06 ns 
0.2595 
 
21.86±1.70 * 
0.0256 Diabetic 24.99±4.67 62.55±9.09 16.22±0.83 
IL-12p70 
Control 53.81±22.75 ns 
0.1172♦ 
 
4.03±1.68 ns 
0.9107 
 
17.62±4.37 * 
0.0160♦ Diabetic 19.79±6.15 3.80±1.16 6.56±1.29 
IL-2 
Control 18.87±6.32 ns 
0.8433 
2.20±0.85 * 
0.0170♦ 
17.45±3.04 * 
0.0134 Diabetic 16.93±7.09 0.17±0.17 5.41±2.30 
IL-10 
Control 45.85±7.73 ns 
0.8130 
24.32±3.44 ns 
0.3108 
47.74±5.70 * 
0.0134 Diabetic 48.30±6.40 29.04±2.70 34.72±4.20 
IL-4 
Control 3.80±2.03 ns 
0.6752♦ 
0.00±0.00 ns 
0.3466 
1.82±0.81 ns 
0.1564 Diabetic 7.29±4.50 0.21±0.21 0.39±0.24 
IL-17A 
Control 2.03±1.27 ns 
0.9113♦ 
0.00±0.00 
- 
4.99±2.85 ns 
0.1955♦ Diabetic 0.97±0.77 0.00±0.00 0.38±0.38 
Statistical analysis: The normally distributed data were compared between the groups using the independent 
sample t-test. The non-normally distributed data (♦) were compared between the groups using the Mann-Whitney 
U test. The level of significance was indicated as *p≤0.05, ***p≤0.001 and ns=non-significant. 
 
 
 
  
362 
Table A6.14 Cytokine production in lungs following M. tuberculosis (H37Rv) infection 
(low-dose) 
Lungs 
Days post-infection, n=4-5 mouse/group 
1 14 30 
Cytokine Mouse 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
Mean±SEM 
(pg/mL) 
p-value 
IL-1β 
Control 0.00±0.00 ns 
0.1484 
20.08±10.76 ns 
0.4094 
16.66±4.94 ns 
0.9814 Diabetic 0.60±0.38 31.90±8.27 16.42±8.87 
TNF-α 
Control 12.56±0.73 ns 
0.0772 
 
62.55±6.48 ns 
0.2506♦ 
 
54.54±9.88 ns 
0.5226 
 Diabetic 7.78±2.03 59.05±18.07 45.67±8.86 
MCP-1 
Control 98.59±8.54 *** 
0.0007 
 
98.49±8.08 ns 
0.3573 
 
28.19±2.41 ** 
0.0095 
 Diabetic 34.67±3.92 77.97±19.40 45.85±4.62 
IL-6 
Control 4.39±0.45 ns 
0.1713 
23.07±2.10 ns 
0.7269 
6.85±2.05 ns 
0.2506♦ Diabetic 3.14±0.70 20.44±6.79 4.25±0.36 
IFN-γ 
Control 7.00±2.68 * 
0.0157♦ 
128.70±26.82 * 
0.0163♦ 
17.89±2.27 * 
0.0293 Diabetic 0.70±0.55 40.14±4.00 9.93±1.94 
IL-12p70 
Control 0.12±0.12 ns 
0.3466 
 
0.00±0.00 
- 
0.16±0.11 ns 
0.2014 
 Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 
IL-10 
Control 20.22±2.43 ns 
0.4211 
 
14.19±1.39 ns 
0.0445 
 
27.16±4.70 ns 
0.0927♦ 
 Diabetic 16.80±3.22 22.62±2.97 19.36±2.55 
IL-2 
Control 0.00±0.00 ns 
0.3466 
0.09±0.09 ns 
0.3466 
0.24±0.24 ns 
0.4386♦ Diabetic 1.34±1.34 0.00±0.00 1.93±1.64 
IL-4 
Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 
IL-17A Control 0.00±0.00 
- 
0.00±0.00 
- 
0.00±0.00 
- 
 Diabetic 0.00±0.00 0.00±0.00 0.00±0.00 
Statistical analysis: The normally distributed data were compared between the groups using the independent 
sample t-test. The non-normally distributed data (♦) were compared between the groups using the Mann-Whitney 
U test. The level of significance was indicated as *p≤0.05, **p≤0.01, ***p≤0.001 and ns=non-significant. 
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All supplementary figures and photographs from M. tuberculosis (H37Rv) study 
(Chapter 6-7) 
Dose: 4x106 CFU/mouse (low-dose) and 2x107 CFU/mouse (high-dose) 
 
M. tuberculosis (H37Rv) infection (low-dose) 
 
 
   
   
  
  
 
 
 
 
Figure A6.1 Daily feed intake by each mouse following low-dose of M. tuberculosis 
(H37Rv) infection 
Mice were infected with low-dose of M. tuberculosis (H37Rv, 4x106 CFU/mouse). The daily 
feed intake by each mouse were monitored for a period of 4 weeks. The daily feed intake by 
the diabetic mice reduced gradually followed by a slight increase at last 2 weeks of infection. 
In control group, there was a gradual rise of the feed intake by each mouse until the end of the 
infection. Data presented as mean±SEM. The significant difference between groups was 
determined using the two-way ANOVA with Sidak’s multiple comparisons test. The level of 
significance was indicated as **p≤0.01, ***p≤0.01 and ***0p≤0.0001 and ns=non-significant.  
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Figure A6.2 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. tuberculosis (H37Rv). All the photographs 
were taken at 100x magnification after the H&E staining of liver sections at 1-day post-
infection. In both diabetic and control mice, a diffuse inflammation was observed at this 
timepoint of infection.  
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Figure A6.3 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. tuberculosis (H37Rv). All the photographs 
were taken at 100x magnification after H&E staining to quantify the inflamed area in 
liver at 14 day post-infection. In both diabetic and control mice, foci of 
inflammation/granuloma formation were evident at this timepoint of infection.  
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Figure A6.4 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. tuberculosis (H37Rv). All the photographs 
were taken at 100x magnification after H&E staining to quantify the inflamed area in 
liver at 30 days post-infection. In both diabetic and control mice, more foci of 
inflammation/granuloma formation were evident at this timepoint of infection.  
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Figure A6.5 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. tuberculosis (H37Rv). All the photographs 
were taken at 1000x magnification after Ziehl-Neelsen staining to quantify the number of 
acid-fast bacilli (magenta) in each of inflammatory focus/granuloma at 14 days post 
infection.  
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Figure A6.6 The representative photographs (one photo/mouse) of liver sections of control 
and diabetic mice infected with low-dose of M. tuberculosis (H37Rv). All the photographs 
were taken at 1000x magnification after the Ziehl-Neelsen staining to quantify the number 
of acid-fast bacilli (magenta) in each of inflammatory focus/granuloma at 30 days post 
infection.  
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Figure A6.7 The representative photographs (one photo/mouse) of lung sections of control 
and diabetic mice infected with low-dose of M. tuberculosis (H37Rv). All the photographs 
were taken at 40x magnification after H&E staining of the lung sections at 1 day post-
infection. In both diabetic and control mice, a diffuse inflammation was observed at this 
timepoint of infection.  
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Figure A6.8 The representative photographs (one photo/mouse) of lung sections of control 
and diabetic mice infected with low-dose of M. tuberculosis (H37Rv). All the photographs 
were taken at 40x magnification after H&E staining to quantify the total area of the lung 
at 14 days post-infection. The Inflamed area over the total area of lungs was measured on 
the photographs taken at 100x magnification (not shown here).  
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Figure A6.9 The representative photographs (one photo/mouse) of lung sections of control 
and diabetic mice infected with low-dose of M. tuberculosis (H37Rv). All the photographs 
were taken at 40x magnification after H&E staining to quantify the total area of lungs at 
30 days post-infection. The Inflamed area over the total area of the lung was measured on 
the photographs taken at 100x magnification (not shown here). 
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M. tuberculosis (H37Rv) infection (high-dose) 
Liver lesions of M. tuberculosis (H37Rv) infected mice  
 
 
 
 
 
 
 
 
 
 
Figure A6.10 Daily feed intake by each mouse following high-dose of M. tuberculosis 
(H37Rv) infection 
Mice were infected with high-dose of M. tuberculosis (H37Rv, 2x107 CFU/mouse). Daily feed 
intake by each mouse was monitored for a period of 7 weeks. A dramatic fall of the daily feed 
was observed in diabetic mice until the second week of infection. Whereas a progressive 
reduction of feed was observed in control mice at the same timepoint of infection compared to 
their pre-infection period (0 week). After the second week of infection, feed intake rose 
gradually in both control and diabetic mice although some fluctuation was noticed at last 3 
weeks of infection. Data presented as mean±SEM. The significant difference between the 
groups was determined using the two-way ANOVA with Sidak’s multiple comparisons test. 
The level of significance was indicated as *p≤0.05 and ****p≤0.0001.  
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APPENDIX 7 
 
Publication resulting from this thesis 
 
ALIM, M. A., SIKDER, S., BRIDSON, T. L., RUSH, C. M., GOVAN, B. L. & KETHEESAN, 
N. 2017. Anti-mycobacterial function of macrophages is impaired in a diet induced model of 
type 2 diabetes. Tuberculosis (Edinb), 102, 47-54. 
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